FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Chen, J Zhu, JM Cho, HH Cui, KM Li, FH Zhou, XB Rogers, JT Wong, STC Huang, XD AF Chen, Jian Zhu, Jinmin Cho, Hyun-Hee Cui, Kemi Li, Fuhai Zhou, Xiaobo Rogers, Jack T. Wong, Stephen T. C. Huang, Xudong TI Differential cytotoxicity of metal oxide nanoparticles SO JOURNAL OF EXPERIMENTAL NANOSCIENCE LA English DT Article DE metal oxide nanoparticles; cytotoxicity; high-content cell imaging; SH-SY5Y neuroblastoma cell; H4 neuroglioma cell ID DIESEL EXHAUST PARTICLES; AIRWAY EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; BRAIN; EXPOSURE; IRON AB Concerns about the potential health hazards of nanomaterials are growing. To determine the potential toxicity of metal oxide nanoparticles, human SH-SY5Y neuroblastoma and H4 neuroglioma cells were exposed to Fe(2)O(3), CuO and ZnO nanoparticles and their metal ion counterparts (Fe(3+), Cu(2+) and Zn(2+)) at a concentration range of 0.01-100 mu M for 48 h, under the cell culture conditions: 95% O(2), 5% CO(2), 85% humidity, 37 degrees C. Their ensemble cell viability was determined by MTS cell proliferation assay. A live/dead cell assay was also performed, and cellular images were acquired by a high-content fluorescence microscope and quantified by a novel computerised image analysis protocol. Our data indicated that exposure of these nanoparticles induced differential toxic effects in both SH-SY5Y and H4 cells, and the cells had dose-dependent toxic responses to the CuO nanoparticle insult. In conclusion, the toxic responses of the nanoparticles are complex, and they warrant further in vivo studies. However, it remains to be determined if these nanopartilces have synergistically enhancing or cancelling toxic effects upon both SH-SY5Y and H4 cells. C1 [Chen, Jian; Zhu, Jinmin; Cui, Kemi; Li, Fuhai; Zhou, Xiaobo; Wong, Stephen T. C.; Huang, Xudong] Brigham & Womens Hosp, Dept Radiol, Funct & Mol Imaging Ctr, Boston, MA 02115 USA. [Chen, Jian; Zhu, Jinmin; Cui, Kemi; Li, Fuhai; Zhou, Xiaobo; Wong, Stephen T. C.; Huang, Xudong] Harvard Univ, Sch Med, Boston, MA USA. [Cho, Hyun-Hee; Rogers, Jack T.] Massachusetts Gen Hosp, Neurochem Lab, Dept Psychiat, Charlestown, MA USA. [Cho, Hyun-Hee; Rogers, Jack T.] Harvard Univ, Sch Med, Charlestown, MA USA. RP Wong, STC (reprint author), Brigham & Womens Hosp, Dept Radiol, Funct & Mol Imaging Ctr, 75 Francis St, Boston, MA 02115 USA. EM swong5@partners.org; xhuang3@partners.org FU NIH [5K01MH002001]; Radiology Department of Brigham and Women's Hospital; Harvard Center for Neurodegeneration Repair; K12 training grant [5K12MH069281] FX This work was supported by a NIH Career Development grant (X. Huang, 5K01MH002001) and funds from Radiology Department of Brigham and Women's Hospital, the Center for Bioinformatics Program Grant (S. T. C. Wong) of Harvard Center for Neurodegeneration & Repair. J. Zhu is a recipient of a K12 training grant (D. N. Kennedy, 5K12MH069281). NR 23 TC 7 Z9 7 U1 1 U2 14 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1745-8080 J9 J EXP NANOSCI JI J. Exp. Nanosci. PY 2008 VL 3 IS 4 BP 321 EP 328 DI 10.1080/17458080802235765 PG 8 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 513TT UT WOS:000271347200007 ER PT J AU Mizoguchi, A Mizoguch, E AF Mizoguchi, Atsushi Mizoguch, Emiko TI Inflammatory bowel disease, past, present and future: lessons from animal models SO JOURNAL OF GASTROENTEROLOGY LA English DT Review DE antigen sampling; autophagy; IBD; Breg; mucin; NOD2; Th17; TLRs ID REGULATORY T-CELLS; NF-KAPPA-B; CHRONIC INTESTINAL INFLAMMATION; SODIUM-INDUCED COLITIS; TOLL-LIKE RECEPTORS; ALPHA MUTANT MICE; PROINFLAMMATORY GENE-EXPRESSION; MUCOSAL DENDRITIC CELLS; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM AB Accumulating data from animal models indicate that inflammatory bowel disease (IBD) is mediated by a much more complicated mechanism than previously predicted. For example, the role of an individual molecule in the pathogenesis of IBD distinctly differs depending on several factors, including the fundamental mechanism of induction of the disease, the target cell type, the phase of disease, and the environment. Therefore, it has been difficult in the past to fully explain the complicated mechanism. Novel concepts have recently been proposed to further explain the complicated mechanism of IBD. In this review, we introduce past, current, and possible future concepts for IBD models regarding T helper (Th) 1, Th2, and Th17, antigen sampling and presentation, regulatory cell networks, NOD2, Toll-like receptors, bacteria/epithelia interaction, stem cells, autophagy, microRNAs, and glycoimmunology, and we also discuss the relevance of these new concepts, developed at the bench (in animal models), to the bedside. C1 [Mizoguchi, Atsushi] Massachusetts Gen Hosp, Dept Pathol Expt Pathol, Boston, MA 02114 USA. [Mizoguchi, Atsushi; Mizoguch, Emiko] Harvard Univ, Massachusetts Gen Hosp, Ctr Study Inflammat Bowel Dis, Sch Med, Boston, MA USA. [Mizoguch, Emiko] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. RP Mizoguchi, A (reprint author), Massachusetts Gen Hosp, Dept Pathol Expt Pathol, 185 Cambridge St, Boston, MA 02114 USA. FU NIDDK NIH HHS [DK74454, DK43351, DK64351, DK64289] NR 224 TC 106 Z9 111 U1 2 U2 14 PU SPRINGER TOKYO PI TOKYO PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PY 2008 VL 43 IS 1 BP 1 EP 17 DI 10.1007/s00535-007-2111-3 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 263BW UT WOS:000253193600001 PM 18297430 ER PT J AU Sahani, DV Shah, ZK Catalano, OA Boland, GW Brugge, WR AF Sahani, Dushyant V. Shah, Zarine K. Catalano, Onofrio A. Boland, Giles W. Brugge, William R. TI Radiology of pancreatic adenocarcinoma: Current status of imaging SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Review DE adenocarcinoma; endoscopic ultrasound; multidetector computed tomography; pancreas; positron emission tomography; computed tomography ID NEEDLE-ASPIRATION BIOPSY; DYNAMIC MR PANCREATOGRAPHY; SECTION HELICAL CT; ENDOSCOPIC ULTRASOUND; SECRETIN STIMULATION; DIFFERENTIATING TUMOR; COMPUTED-TOMOGRAPHY; VASCULAR INVASION; CANCER; DIAGNOSIS AB Pancreatic adenocarcinoma is one of the leading causes of cancer death in the West, with a poor overall 5-year survival rate of only 4%. Late clinical presentation with an advanced disease results in a low rate of surgical intervention. Tumor serum marker CA 19-9 is sensitive, although not specific for the diagnosis of adenocarcinomas of the pancreas. The treatment approach is based on whether the tumor is resectable or non-resectable at presentation. Therefore, imaging plays a crucial role in the management of this disease. Many modalities are available to image the pancreas. They include non-invasive techniques, like ultrasound, contrast-enhanced multidetector computed tomography, magnetic resonance imaging and integrated positron emission tomography/computed tomography, and invasive techniques, like endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. Each of these modalities has its peculiar strengths and weaknesses. C1 [Sahani, Dushyant V.; Catalano, Onofrio A.; Boland, Giles W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Brugge, William R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. [Shah, Zarine K.] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA. RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent, White 270,55 Fruit St, Boston, MA 02114 USA. EM dsahani@partners.org RI Shah, Zarine/E-4064-2011 OI Shah, Zarine/0000-0002-0354-9678 NR 66 TC 67 Z9 73 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD JAN PY 2008 VL 23 IS 1 BP 23 EP 33 DI 10.1111/j.1440-1746.2007.05117.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 241QN UT WOS:000251671000006 PM 18171340 ER PT J AU Chang, EY Li, X Jerosch-Herold, M Priest, RA Enestvedt, CK Xu, J Springer, CS Jobe, BA AF Chang, Eugene Y. Li, Xin Jerosch-Herold, Michael Priest, Ryan A. Enestvedt, C. Kristian Xu, Jingang Springer, Charles S., Jr. Jobe, Blair A. TI The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 20th World Congress of International-Society-for-Digestive-Surgery CY NOV 29-DEC 02, 2006 CL Rome, ITALY SP Int Soc Digest Surg DE esophageal adenocarcinoma; dynamic contrast-enhanced magnetic resonance imaging; neoadjuvant chemoradiation ID POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; TRANSCYTOLEMMAL WATER EXCHANGE; CR BOLUS-TRACKING; NEOADJUVANT CHEMORADIOTHERAPY; BARRETTS-ESOPHAGUS; SHUTTER-SPEED; PREOPERATIVE CHEMORADIATION; ENDOSCOPIC ULTRASONOGRAPHY; INDUCTION CHEMORADIATION AB Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role. This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with esophageal adenocarcinoma and control subjects underwent scanning. Patients treated with neoadjuvant therapy underwent pre- and postchemoradiation scans. Parameters were extracted for each pixel were K-trans (equilibrium rate for transfer of contrast reagent across the vascular wall), v(e) (volume fraction of interstitial space), and tau(i) (mean intracellular water lifetime). Five esophageal adenocarcinoma patients and two tumor-free control subjects underwent scanning. The mean K-trans value was 5.7 times greater in esophageal adenocarcinoma, and tau(i) is 2.0 times smaller, than in the control subjects. K-trans decreased by 11.4-fold after chemoradiation. Parametric maps qualitatively demonstrate a difference in K-trans. DCE MRI of the esophagus is feasible. K-trans, a parameter that has demonstrated discriminative ability in other malignancies, also shows promise in differentiating esophageal adenocarcinoma from benign tissue. The determination of K-trans represents an in vivo assay for endothelial permeability and thus may serve as a quantitative measure of response to induction chemoradiation. C1 [Chang, Eugene Y.; Priest, Ryan A.; Enestvedt, C. Kristian; Jobe, Blair A.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. [Li, Xin; Jerosch-Herold, Michael; Xu, Jingang; Springer, Charles S., Jr.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA. [Jobe, Blair A.] Portland VA Med Ctr, Dept Surg, Portland, OR USA. RP Jobe, BA (reprint author), Oregon Hlth & Sci Univ, Dept Surg, Mail Code L223,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM jobeb@ohsu.edu RI Jerosch-Herold, Michael/F-2496-2010; OI Springer, Charles/0000-0002-5966-2135 FU NIBIB NIH HHS [R01 EB00422]; NINDS NIH HHS [R01 NS40801] NR 58 TC 15 Z9 17 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN PY 2008 VL 12 IS 1 BP 166 EP 175 DI 10.1007/s11605-007-0253-5 PG 10 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 250JW UT WOS:000252297100027 PM 17768665 ER PT J AU Plomondon, MLE Magid, DJ Mosoudi, FA Jones, PG Barry, LC Havronek, E Peterson, ED Krumholz, HM Spertus, JA Rumsfeld, JS AF Plomondon, Mary E. Magid, David J. Mosoudi, Frederick A. Jones, Philip G. Barry, Liso C. Havronek, Edward Peterson, Eric D. Krumholz, Harlon M. Spertus, John A. Rumsfeld, John S. CA PREMIER Investigators TI Association between angina and treatment satisfaction after myocardial infarction SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE angina; treatment satisfaction; myocardial infarction ID QUALITY-OF-LIFE; ACUTE CORONARY SYNDROMES; STABLE ANGINA; FUNCTIONAL STATUS; ARTERY DISEASE; MANAGED CARE; IMPACT; QUESTIONNAIRE; PERFORMANCE; DEPRESSION AB BACKGROUND: Patient satisfaction is increasingly recognized as a quality indicator and important outcome of care. Little is known about the clinical factors associated with satisfaction after myocardial infarction (MI). OBJECTIVE: To assess the hypothesis that angina after MI is independently associated with lower treatment satisfaction. METHODS: We evaluated 1,815 MI patients from 19 U.S. centers. Angina was measured at I and 6 months after MI using the Seattle Angina Questionnaire (SAQ). Treatment satisfaction was measured using the SAQ at 6 months. Multivariable regression was used to evaluate the association between 1- and 6-month angina and 6-month treatment satisfaction. RESULTS: Sixty-two percent of patients had no angina at 1 and 6 months after MI, 14% had transient angina (angina at 1 month, no angina at 6 months), 11% had new angina (angina at 6 months only), and 13% had persistent angina (angina at both 1 and 6 months). In unadjusted analysis, the presence of angina at 6 months, whether new or persistent, was associated with lower treatment satisfaction (p < 0.001). In multivariable analysis, angina was associated with lower treatment satisfaction [relative risk (RR) 2.9, 95%confidence interval (Cl) 2.4-3.5 patients with new angina; RR 3.1, 95%CI 2.5-3.9 patients with persistent angina, vs patients with no angina]. CONCLUSION: In conclusion, angina in the 6 months following MI is present in almost 1 in 4 patients and is strongly associated with lower treatment satisfaction. This suggests the importance of angina surveillance and management after MI as a possible target to improve treatment satisfaction and, thereby, quality of care. C1 [Plomondon, Mary E.; Rumsfeld, John S.] Denver VA Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Magid, David J.] Colorado Kaiser Permanente, Aurora, CO USA. [Mosoudi, Frederick A.; Havronek, Edward] Denver Hlth Med Ctr, Denver, CO USA. [Jones, Philip G.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Barry, Liso C.; Krumholz, Harlon M.] Yale Univ, Med Ctr, New Haven, CT USA. [Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC USA. RP Plomondon, MLE (reprint author), Denver VA Med Ctr, Eastern Colorado Hlth Care Syst, 1055 Clermont St 111B, Denver, CO 80220 USA. EM Meg.Plomondon@va.gov FU AHRQ HHS [R-01 HS11282-01, R01 HS011282]; NIA NIH HHS [T32AG019134, T32 AG019134] NR 32 TC 11 Z9 11 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 IS 1 BP 1 EP 6 DI 10.1007/s11606-007-0430-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 256GM UT WOS:000252715700001 PM 17955303 ER PT J AU Goldstein, NE Mehta, D Teitelbaum, E Bradley, EH Morrison, RS AF Goldstein, Nathon E. Mehta, Dovendra Teitelbaum, Ezra Bradley, Elizabeth H. Morrison, R. Sean TI "It's Like Crossing a Bridge" complexities preventing physicians from discussing deactivation of implantable defibrillators at the end of life SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 27-29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med DE palliative care; advanced technology; communicatiom; patient-physician relationship; implantable cardioverter defibrillator ID INTENSIVE-CARE-UNIT; CARDIOVERTER-DEFIBRILLATOR; SUSTAINING TREATMENTS; OF-LIFE; HOSPITALIZED ADULTS; ADVANCE DIRECTIVES; PALLIATIVE CARE; SERIOUSLY ILL; HEART-FAILURE; DECISIONS AB OBJECTIVE: To understand potential barriers to physician-initiated discussions about Implantable Cardioverter Defibrillator (ICD) deactivation in patients with advanced illness. DESIGN. Qualitative one-on-one interviews. PARTICIPANTS: Four electrophysiologists, 4 cardiologists, and 4 generalists (internists and geriatricians) from 3 states. APPROACH: Clinicians were interviewed using open-ended questions to elicit their past experiences with discussing deactivating ICDs and to determine what barriers might impede these discussions. Transcripts of these interviews were analyzed using the qualitative method of constant comparison. RESULTS: Although many physicians believed that conversations about deactivating ICDs should be included in advance care planning discussions, they acknowledged that they rarely did this. Physicians indicated that there was something intrinsic to the nature of these devices that makes it inherently difficult to think of them in the same context as other management decisions at the end of a patient's life. Other explanations physicians gave as to why they did not engage in conversations included: the small internal nature of these devices and hence absence of a physical reminder to discuss the ICD, the absence of an established relationship with the patient, and their own general concerns relating to withdrawing care. CONCLUSION: Whereas some of the barriers to discussing ICD deactivation are common to all forms of advance care planning, ICDs have unique characteristics that make these conversations more difficult. Future educational interventions will need to be designed to teach physicians how to improve communication with patients about the management of ICDs at the end of life. C1 [Goldstein, Nathon E.; Teitelbaum, Ezra; Morrison, R. Sean] Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. [Goldstein, Nathon E.; Morrison, R. Sean] James J Vet Affairs Hlth Syst, Geriatr Res Educ & Clin Care Ctr, Bronx, NY USA. [Mehta, Dovendra] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bradley, Elizabeth H.] Yale Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT USA. [Bradley, Elizabeth H.] Yale Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. RP Goldstein, NE (reprint author), Mt Sinai Sch Med, Dept Geriatr, 1 Gustave Levy Pl,Box 1070, New York, NY 10029 USA. EM Nathan.Goldstein@mssm.edu FU NIA NIH HHS [K24 AG022345, K23 AG025933, 1K24AG22345-01, 1 K23 AG025933-01A1] NR 40 TC 46 Z9 46 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 SU 1 BP 2 EP 6 DI 10.1007/s11606-007-0237-x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 249FG UT WOS:000252212300002 PM 18095036 ER PT J AU Keating, NL Landrum, MB Guodognoli, E Winer, EP Ayanion, JZ AF Keating, Noncy L. Landrum, Mory Beth Guodognoli, Edword Winer, Eric P. Ayanion, John Z. TI Care in the months before death and hospice enrollment among older women with advanced breast cancer SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med DE end-of-life care; breast cancer; outpatient care ID MEDICARE MANAGED CARE; OF-LIFE-CARE; NATIONAL HOSPICE; TERMINAL CARE; UNITED-STATES; CLAIMS DATA; LAST YEAR; END; MINORITIES; PATTERNS AB BACKGROUND: Variations in hospice use are not well understood. OBJECTIVE: Assess whether care before death, including the types of physicians seen, number of outpatient visits, and hospitalizations, was associated with hospice use and the timing of enrollment. DESIGN/SETTING: Observational study of a population-based sample of advanced breast cancer patients included in the Surveillance, Epidemiology, and End Results-Medicare database. PATIENTS: There were 4,455 women aged >= 65 diagnosed with stage III/IV breast cancer during 1992-1999 who died before the end of 2001. MEASUREMENTS: Hospice use and, among enrollees, enrollment within 2 weeks of death. Independent variables of interest included hospitalizations, outpatient visits, and physicians seen before death. RESULTS: Adjusted hospice use rates were higher for hospitalized patients (45% if hospitalized for 1-7 days, 46% if 8-20 days, 35% if 21 days) than those not hospitalized (31%, P < 0.001). Adjusted rates were also higher among patients seeing a cancer specialist and primary care provider (PCP; 41%) and those seeing a cancer specialist and no PCP (38%) than among those seeing; a PCP and no cancer specialist (30%) or neither type of physician (22%; P < 0.001). Hospice use also increased with increasing frequency of outpatient visits (P < 0.001). Hospitalizations, physicians seen, and visits were not associated with referral within 2 weeks of death (all P >= 0.10). DISCUSSION: Care before death is associated with hospice use among older women with advanced breast cancer. Additional research is needed to understand better how differences in patient characteristics and disease status influence cancer care before death and the role of various types of physicians in hospice referrals. C1 [Keating, Noncy L.; Landrum, Mory Beth; Guodognoli, Edword; Ayanion, John Z.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Keating, Noncy L.; Ayanion, John Z.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA. [Winer, Eric P.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM keating@ftcp.med.harvard.edu NR 47 TC 13 Z9 14 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 IS 1 BP 11 EP 18 DI 10.1007/s11606-007-0422-y PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 256GM UT WOS:000252715700003 PM 17939006 ER PT J AU Zickmund, SL Hess, R Bryce, CL McTigue, K Olshansky, E Fitzgerald, K Fischer, GS AF Zickmund, Susan L. Hess, Rachel Bryce, Cindy L. McTigue, Kathleen Olshansky, Ellen Fitzgerald, Katharine Fischer, Gary S. TI Interest in the use of computerized patient portals: We of the provider-patient relationship SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 27-29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med DE patient portal; bioinformatics; provider-patient communication; diabetes; e-mail communication ID CONGESTIVE-HEART-FAILURE; PRIMARY-CARE; E-MAIL; CONTROLLED-TRIAL; DIGITAL DIVIDE; COMMUNICATION; PHYSICIANS; DISEASE; ACCESS; RECORD AB BACKGROUND: Bioinformatics experts are developing interactive patient portals to help those living with diabetes and other chronic diseases to better manage their conditions. However, little is known about what influences patients' desires to use this technology. OBJECTIVE: To discern the impact of the provider-patient relationship on interest in using a web-based patient portal. DESIGN: Qualitative analysis of focus groups. PARTICIPANTS: Ten focus groups involving 39 patients (range 2-7) recruited from four primary care practices. APPROACH: A qualitative approach was used, which involved reading transcribed texts until a consensus was reached on data interpretation. An intercoder reliability kappa score (0.89) was determined by comparing the provider-patient relationship talk selected by the two coders. A conceptual framework was developed, which involved the development and refinement of a codebook and the application of it to the transcripts. RESULTS: Interest in the portal was linked to dissatisfaction with the provider-patient relationship, including dissatisfaction with provider communication/ responsiveness, the inability to obtain medical information, and logistical problems with the office. Disinterest in the portal was linked to satisfaction with the provider-patient relationship, including provider communication/responsiveness, difficulty in using the portal, and fear of losing relationships and e-mail contact with the provider. No patient identified encrypted e-mail communication through the portal as an advantage. CONCLUSIONS: Promoting the use of computerized portals requires patient-based adaptations. These should include ease of use, direct provider e-mail, and reassurances that access and interpersonal relationships will not be lost. Education is needed about privacy concerns regarding traditional e-mail communication. C1 [Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Zickmund, Susan L.; Hess, Rachel; Bryce, Cindy L.; McTigue, Kathleen; Fischer, Gary S.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Zickmund, Susan L.; Hess, Rachel; Bryce, Cindy L.; McTigue, Kathleen; Fitzgerald, Katharine] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Bryce, Cindy L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. [McTigue, Kathleen] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Olshansky, Ellen] Univ Calif Irvine, Program Nursing Sci, Irvine, CA USA. [Fitzgerald, Katharine] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Dept Commun, Pittsburgh, PA USA. RP Zickmund, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM Susan.Zickmund@rned.va.gov FU NCATS NIH HHS [UL1 TR000005] NR 49 TC 36 Z9 36 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 SU 1 BP 20 EP 26 DI 10.1007/s11606-007-0273-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 249FG UT WOS:000252212300005 PM 18095039 ER PT J AU Nuckols, TK Lim, YW Wynn, BO Mattke, S Maclean, CH Harber, P Brook, RH Wallace, P Garland, RH Asch, S AF Nuckols, Teryl K. Lim, Yee-Wei Wynn, Barbara O. Mattke, Soeren Maclean, Catherine H. Harber, Philip Brook, Robert H. Wallace, Peggy Garland, Reno H. Asch, Steven TI Rigorous development does not ensure that guidelines are acceptable to a panel of knowledgeable providers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE practice guidelines; quality assurance; health care; evidence-based medicine; attitude of health personnel; evaluation ID CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE; METHODOLOGICAL QUALITY; APPROPRIATENESS METHOD; PHYSICIAN AWARENESS; GENERAL-PRACTICE; VALIDITY; ADHERENCE; ATTITUDES; BARRIERS AB BACKGROUND: Rigorous guideline development methods are designed to produce recommendations that are relevant to common clinical situations and consistent with evidence and expert understanding, thereby promoting guidelines' acceptability to providers. No studies have examined whether this technical quality consistently leads to acceptability. OBJECTIVE: To examine the clinical acceptability of guidelines having excellent technical quality. DESIGN AND MEASUREMENTS: We selected guidelines covering several musculoskeletal disorders and meeting 5 basic technical quality criteria, then used the widely accepted AGREE Instrument to evaluate technical quality. Adapting an established modified Delphi method, we assembled a multidisciplinary panel of providers recommended by their specialty societies as leaders in the field. Panelists rated acceptability, including "perceived comprehensiveness" (perceived relevance to common clinical situations) and "perceived validity" (consistency with their understanding of existing evidence and opinions), for ten common condition/therapy pairs pertaining to Surgery, physical therapy, and chiropractic manipulation for lumbar spine, shoulder, and carpal tunnel disorders. RESULTS: Five guidelines met selection criteria. Their AGREE scores were generally high indicating excellent technical quality. However, panelists found 4 guidelines to be only moderately comprehensive and valid, and a fifth guideline to be invalid overall. Of the topics covered by each guideline, panelists rated 50% to 69% as "comprehensive" and 6% to 50% as "valid". CONCLUSION. Despite very rigorous development methods compared with guidelines assessed in prior studies, experts felt that these guidelines omitted common clinical situations and contained much content of uncertain validity. Guideline acceptability should be independently and formally evaluated before dissemination. C1 [Nuckols, Teryl K.; Lim, Yee-Wei; Wynn, Barbara O.; Mattke, Soeren; Brook, Robert H.; Garland, Reno H.; Asch, Steven] RAND Corp, Santa Monica, CA 90407 USA. [Nuckols, Teryl K.; Brook, Robert H.; Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Maclean, Catherine H.] WellPoint Inc, Thousand Oaks, CA USA. [Harber, Philip] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Div Occupat & Environm Med, Los Angeles, CA USA. [Wallace, Peggy] ACS Healthcare Solut Inc, Playa Del Rey, CA USA. [Asch, Steven] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. RP Nuckols, TK (reprint author), RAND Corp, 1776 Main St,PO Box 2138, Santa Monica, CA 90407 USA. EM teryl@rand.org NR 44 TC 22 Z9 22 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 IS 1 BP 37 EP 44 DI 10.1007/s11606-007-0440-9 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 256GM UT WOS:000252715700006 PM 18030541 ER PT J AU Berz, JPB Orlander, JD AF Berz, Jonathan P. B. Orlander, Jay D. TI Prolonged cerebellar ataxia: An unusual complication of hypoglycemia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hypoglycemia; ataxia; diabetes mellitus AB A 51-year-old male with a history of insulin-dependent diabetes and polysubstance abuse presented after overdose on insulin. Soon after resuscitation, he displayed a severe ataxia in all 4 limbs and was unable to walk; all of which persisted for at least 5 days. Laboratory testing was unrevealing, including relatively normal brain magnetic resonance imaging. He had recovered full neurologic function 3 months after the event. This report describes a case of reversible cerebellar ataxia as a rare complication of severe hypoglycemia that may occur in patients with abnormal cerebellar glucose metabolism. Thus, this phenomenon should be included in the differential diagnosis of patients with a history of hypoglycemia who present with ataxia. In this context, the differential diagnosis of cerebellar ataxia is discussed, as is the proposed mechanism for hypoglycemia-induced cerebellar dysfunction. C1 [Berz, Jonathan P. B.] Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA. [Berz, Jonathan P. B.; Orlander, Jay D.] Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA. [Orlander, Jay D.] VA Boston HealthCare Syst, Boston, MA USA. RP Berz, JPB (reprint author), Boston Univ, Med Ctr, Dept Med, 91 E Concord St,MAT 2, Boston, MA 02118 USA. EM Jonathan.Berz@bmc.org OI Orlander, Jay/0000-0003-0204-8449 NR 9 TC 4 Z9 4 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2008 VL 23 IS 1 BP 103 EP 105 DI 10.1007/s11606-007-0407-x PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 256GM UT WOS:000252715700016 PM 18000716 ER PT J AU Viswanath, K Blake, K Meissner, H Saiontz, NG Mull, C Freeman, C Hesse, B Croyle, R AF Viswanath, K. Blake, Kelly D. Meissner, Helen I. Saiontz, Nicole Gottlieb Mull, Corey Freeman, Carol S. Hesse, Bradford Croyle, Robert T. TI Occupational Practices and the Making of Health News: A National Survey of US Health and Medical Science Journalists SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID CANCER CONTROL; BREAST-CANCER; MASS-MEDIA; PROFESSIONALS; INFORMATION; COVERAGE; PRESS; WOMEN AB News media coverage of health topics can frame and heighten the salience of health-related issues, thus influencing the public's beliefs, attitudes, and behaviors. Through their routine coverage of scientific developments, news media are a critical intermediary in translating research for the public, patients, practitioners, and policymakers. Until now, little was known about how health and medical science reporters and editors initiate, prioritize, and develop news stories related to health and medicine. We surveyed 468 reporters and editors representing 463 local and national broadcast and print media outlets to characterize individual characteristics and occupational practices leading to the development of health and medical science news. Our survey revealed that 70% of respondents had bachelor's degrees; 8% were life sciences majors in college. Minorities are underrepresented in health journalism; 97% of respondents were non-Hispanic and 93% were White. Overall, initial ideas for stories come from a news source followed by press conferences or press releases. Regarding newsworthiness criteria, the potential for public impact and new information or development are the major criteria cited, followed by ability to provide a human angle and ability to provide a local angle. Significant differences were seen between responses from reporters vs. editors and print vs. broadcast outlets. C1 [Viswanath, K.; Blake, Kelly D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Meissner, Helen I.] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. [Saiontz, Nicole Gottlieb; Hesse, Bradford; Croyle, Robert T.] NCI, Bethesda, MD 20892 USA. [Mull, Corey; Freeman, Carol S.] ORC Macro Int Inc, Calverton, MD USA. RP Viswanath, K (reprint author), 44 Binney St,LW703, Boston, MA 02115 USA. EM vish_viswanath@dfci.harvard.edu OI Hesse, Bradford/0000-0003-1142-1161 NR 41 TC 42 Z9 43 U1 4 U2 29 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2008 VL 13 IS 8 BP 759 EP 777 AR PII 906253738 DI 10.1080/10810730802487430 PG 19 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 378QK UT WOS:000261338800004 PM 19051112 ER PT J AU Vagefi, PA Cosimi, AB Ginns, LC Kotton, CN AF Vagefi, Parsia A. Cosimi, A. Benedict Ginns, Leo C. Kotton, Camille N. TI Cutaneous Aspergillus ustus in a lung transplant recipient: Emergence of a new opportunistic fungal pathogen SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article ID INVASIVE ASPERGILLOSIS; INFECTION; VORICONAZOLE; CASPOFUNGIN; DIAGNOSIS; THERAPY; ASSAY; GALACTOMANNAN; SPECTRUM AB Opportunistic fungal infections remain a significant complication in immunosuppressed patients, especially those having undergone solid-organ transplantation-We report a 39-year-old patient who represents the second case of cutaneous Aspergillus ustus infection in a solid-organ transplant recipient, and the first documented case after lung transplantation. The patient's cutaneous lower extremity aspergillosis responded to a combination of intravenous liposomal amphotericin B, caspofungin and topical terbinafine cream, with a concomitant reduction in immunosuppression. A ustus is an emerging opportunistic fungal pathogen in transplant recipients. C1 [Kotton, Camille N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Vagefi, Parsia A.; Cosimi, A. Benedict] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02114 USA. [Ginns, Leo C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lung Transplant Program,Pulm Crit Care Unit, Boston, MA 02114 USA. RP Kotton, CN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Cox 5,55 Fruit St, Boston, MA 02114 USA. EM ckotton@partners.org NR 18 TC 20 Z9 21 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD JAN PY 2008 VL 27 IS 1 BP 131 EP 134 DI 10.1016/j.healun.2007.09-020 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 253IW UT WOS:000252512900021 PM 18187099 ER PT J AU Butt, AA Kahloon, A Skanderson, M McGinnis, KA AF Butt, A. A. Kahloon, A. Skanderson, M. McGinnis, K. A. TI Medical, psychiatric and substance use comorbidities in HCV and HCV-HIV coinfected persons SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [Butt, A. A.; Kahloon, A.] Univ Pittsburgh, Pittsburgh, PA USA. [Butt, A. A.; Skanderson, M.; McGinnis, K. A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM bufta@dom.pitt.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 642 BP S239 EP S239 DI 10.1016/S0168-8278(08)60644-3 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683201133 ER PT J AU Chiang, DY Villanueva, A Hoshida, Y Peix, J Newell, P Minguez, B Thung, S Sole, M Tovar, V Alsinet, C Roayaie, S Schwartz, M Bruix, J Battiston, C Mazzaferro, V Friedman, SL Meyerson, M Llovet, JM AF Chiang, D. Y. Villanueva, A. Hoshida, Y. Peix, J. Newell, P. Minguez, B. Thung, S. Sole, M. Tovar, V. Alsinet, C. Roayaie, S. Schwartz, M. Bruix, J. Battiston, C. Mazzaferro, V. Friedman, S. L. Meyerson, M. Llovet, J. M. TI A novel molecular classification of HCV-related hepatocellular carcinoma (HCC) based on integrative genomic analysis SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [Chiang, D. Y.; Meyerson, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Chiang, D. Y.; Meyerson, M.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Chiang, D. Y.; Hoshida, Y.; Meyerson, M.] Harvard Univ, Broad Inst, Canc Program, Cambridge, MA 02138 USA. [Villanueva, A.; Peix, J.; Newell, P.; Minguez, B.; Thung, S.; Roayaie, S.; Schwartz, M.; Friedman, S. L.; Llovet, J. M.] Mt Sinai Sch Med, Mt Sinai Liver Canc Program, New York, NY USA. [Hoshida, Y.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [Sole, M.; Tovar, V.; Alsinet, C.; Bruix, J.; Llovet, J. M.] Hosp Clin Barcelona, CIBERehd, IDIBAPS, HCC Translat Res Lab,BCLC Grp, Barcelona, Spain. [Battiston, C.; Mazzaferro, V.] Natl Canc Inst, Gastroenterol Surg & Liver Transplantat Unit, I-20133 Milan, Italy. EM augusto.villanueva@mssm.edu RI Meyerson, Matthew/E-7123-2012; Minguez, Beatriz/N-4456-2014 OI Minguez, Beatriz/0000-0002-7276-9666 NR 0 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 24 BP S12 EP S12 DI 10.1016/S0168-8278(08)60026-4 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683200025 ER PT J AU DiBisceglie, AM Hassanein, TI Jeffers, LJ Hamzeh, FM Lindsay, KL Chung, RT AF DiBisceglie, A. M. Hassanein, T. I. Jeffers, L. J. Hamzeh, F. M. Lindsay, K. L. Chung, R. T. TI Association of pretreatment and on-treatment factors with null response in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [DiBisceglie, A. M.] St Louis Univ, Sch Med, St Louis, MO USA. [Hassanein, T. I.] Univ Calif San Diego, San Diego, CA 92103 USA. [Jeffers, L. J.] Univ Miami, Miami, FL USA. [Hamzeh, F. M.] Roche Labs, Nutley, NJ USA. [Lindsay, K. L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Chung, R. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM dibiscam@slu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 783 BP S292 EP S292 DI 10.1016/S0168-8278(08)60785-0 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683201274 ER PT J AU Nevzorova, YA Moro, N Gassler, N Sicinski, P Trautwein, C Liedtke, C AF Nevzorova, Y. A. Moro, N. Gassler, N. Sicinski, P. Trautwein, C. Liedtke, C. TI The role of E-type cyclins and G1-S phase transition in hepatic fibrogenesis SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [Sicinski, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gassler, N.] Univ Hosp Aachen, Inst Pathol, Aachen, Germany. [Nevzorova, Y. A.; Moro, N.; Trautwein, C.; Liedtke, C.] Univ Hosp Aachen, Dept Med 3, Aachen, Germany. EM nevzorovaj@googlemail.com NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 52 BP S22 EP S22 DI 10.1016/S0168-8278(08)60054-9 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683200053 ER PT J AU Shiffman, ML Chumg, RT Hamzeh, FM AF Shiffman, M. L. Chumg, R. T. Hamzeh, F. M. TI Time to HCV RNA undetectability supersedes baseline factors in predicting SVR in patients with HCV genotype 1 SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [Shiffman, M. L.] Virginia Commonwealth Univ, Richmond, VA USA. [Chumg, R. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hamzeh, F. M.] Roche Labs, Nutley, NJ USA. EM mshiffma@vcu.edu NR 0 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 835 BP S313 EP S313 DI 10.1016/S0168-8278(08)60837-5 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683201326 ER PT J AU Shiffman, ML Morishima, C Lindsay, KL Hoefs, JC Dienstag, JL Szabo, G Lee, WM Wright, EC AF Shiffman, M. L. Morishima, C. Lindsay, K. L. Hoefs, J. C. Dienstag, J. L. Szabo, G. Lee, W. M. Wright, E. C. CA HALT-C Trial Grp TI Suppression of serum HCV RNA levels during maintenance peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [Shiffman, M. L.] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA. [Morishima, C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Lindsay, K. L.] Univ So Calif, Div Gastroenterol & Liver Dis, Los Angeles, CA USA. [Hoefs, J. C.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA. [Dienstag, J. L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02115 USA. [Szabo, G.] Univ Massachusetts, Sch Med, Ctr Liver, Worcester, MA 01605 USA. [Lee, W. M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Wright, E. C.] NIDDK, Dept Hlth & Human Serv, Bethesda, MD USA. EM mshiffma@vcu.edu NR 0 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 144 BP S62 EP S62 DI 10.1016/S0168-8278(08)60146-4 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683200145 ER PT J AU Wiesch, JS Listgarden, J Li, B Nawar, H Kasprowicz, V Nolan, B Bium, J Lewis-Ximenez, L McGovern, B Kuntzen, T Kwok, B Allen, T Sette, A Lohse, A Walker, B Chung, R Kim, A Lauer, G AF zur Wiesch, J. Schulze Listgarden, J. Li, B. Nawar, H. Kasprowicz, V. Nolan, B. Bium, J. Lewis-Ximenez, L. McGovern, B. Kuntzen, T. Kwok, B. Allen, T. Sette, A. Lohse, A. Walker, B. Chung, R. Kim, A. Lauer, G. TI Comprehensive assessment of HCVCD4+epitopes through conventional mapping combined with computational analysis SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 23-27, 2008 CL Milan, ITALY SP European Assoc Study Liver C1 [zur Wiesch, J. Schulze; Lohse, A.] Univ Klin Hamburg Eppendorf, Med Klin 1, Hamburg, Germany. [zur Wiesch, J. Schulze; Li, B.; Nawar, H.; Kasprowicz, V.; Nolan, B.; Bium, J.; Allen, T.; Walker, B.; Kim, A.; Lauer, G.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA. [Chung, R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Listgarden, J.] Microsoft Res, Redmond, WA USA. [Sette, A.] La Jolla Inst Allergy & Immunol, Boston, MA USA. [McGovern, B.] Tufts Univ, Lemuel Shattuck Hosp, Boston, MA 02111 USA. [Kwok, B.] Benaroya Res Inst, Seattle, WA USA. [Lewis-Ximenez, L.] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2008 VL 48 SU 2 MA 622 BP S231 EP S232 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 312PL UT WOS:000256683201113 ER PT J AU Johnson, CV Mimiaga, MJ Bradford, J AF Johnson, Carey V. Mimiaga, Matthew J. Bradford, Judith TI Health care issues among lesbian, gay, bisexuall transgender and intersex (LGBTI) populations in the united states: Introduction SO JOURNAL OF HOMOSEXUALITY LA English DT Editorial Material DE gay; lesbian; bisexual; transgender; intersex; sexual minorities; ethics in public health; health disparities; HIV/AIDS ID SEXUAL ORIENTATION; WOMEN; RISK AB This supplemental issue of the Journal of Homosexuality presents research that explores a variety of health care issues encountered by lesbian, gay, bisexual, transgender and intersex (LGBTI) population groups in the United States over the 10-year period from 1993 to 2002. Topics include access to health care, utilization of care, training of medical and mental health providers, and the appropriate preparation of clinical offices and waiting areas. Authors used a variety of community-based public health research methods, including participant and provider surveys and retrospective chart reviews of patients, to develop this body of research, providing a recent-historical perspective on the complex health care and health-related needs of sexual and gender minorities. Particularly for transgender and intersex populations, the state of research describing their health care needs is in its infancy, and much remains to be done to design effective medical and mental health programs and interventions. C1 [Johnson, Carey V.; Mimiaga, Matthew J.; Bradford, Judith] Fenway Community Hlth, Fenway Inst, Boston, MA 02115 USA. [Mimiaga, Matthew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Bradford, Judith] Virginia Commonwealth Univ, Richmond, VA USA. RP Johnson, CV (reprint author), Fenway Community Hlth, Fenway Inst, 7 Haviland St, Boston, MA 02115 USA. EM cjohnson@fenwayhealth.org NR 33 TC 14 Z9 14 U1 5 U2 19 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0091-8369 J9 J HOMOSEXUAL JI J. Homosex. PY 2008 VL 54 IS 3 BP 213 EP 224 DI 10.1080/00918360801982025 PG 12 WC Psychology, Multidisciplinary; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA 315CT UT WOS:000256856200001 PM 18825859 ER PT J AU Berg, MB Mimiaga, MJ Safren, SA AF Berg, Michael B. Mimiaga, Matthew J. Safren, Steven A. TI Mental health concerns of gay and bisexual men seeking mental health services SO JOURNAL OF HOMOSEXUALITY LA English DT Article DE mental health services; gay and bisexual men; chart review ID NATIONAL-COMORBIDITY-SURVEY; SEX SEXUAL PARTNERS; UNITED-STATES; PSYCHIATRIC-DISORDERS; EATING DISORDERS; ORIENTATION; PREVALENCE; ADULTS; SUICIDALITY; POPULATION AB Little data exist about the mental health needs of gay and bisexual men. This is due to limitations of existing studies such as small and nonrepresentative samples, failure to assess sexual orientation, and concerns about stigmatization, possibly causing sexual minority individuals to be reluctant to disclose their sexual orientation to researchers. Fenway Community Health is a large urban health center that serves the LGBT community. The large number of gay and bisexual men who present for mental health treatment allows for a unique opportunity to gain insight into mental health, prevention, and intervention needs for this group. The current study is a review of the mental health information from all of the gay and bisexual men who reported that they were HIV-negative during their mental health intake over a six-month period at Fenway Community Health (January to June 2000; N = 92). The most frequent presenting problems were depression, anxiety, and relationship issues. Additionally, presenting problems included current or past abuse, substance abuse, finance and employment, recent loss, and family issues. The most frequent diagnoses were depression, anxiety disorders, and adjustment disorders. These findings support the notion that presenting problems and mental health concerns among gay and bisexual men are similar to those frequently reported by individuals in other mental health facilities, however, specific psychosocial stressors are unique to this population. C1 [Mimiaga, Matthew J.; Safren, Steven A.] Fenway Community Hlth, Res & Evaluat Dept, Boston, MA 02115 USA. [Berg, Michael B.] Wheaton Coll, Wheaton, IL 60187 USA. [Mimiaga, Matthew J.; Safren, Steven A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Safren, SA (reprint author), Fenway Community Hlth, Res & Evaluat Dept, 7 Haviland St, Boston, MA 02115 USA. EM ssafren@partners.org FU NIMH NIH HHS [MH 66660, R21 MH066660] NR 26 TC 23 Z9 26 U1 1 U2 11 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0091-8369 J9 J HOMOSEXUAL JI J. Homosex. PY 2008 VL 54 IS 3 BP 293 EP 306 DI 10.1080/00918360801982215 PG 14 WC Psychology, Multidisciplinary; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA 315CT UT WOS:000256856200008 PM 18825866 ER PT J AU Kwan, DM Dhaliwal, G Baudendistel, TE AF Kwan, Damon M. Dhaliwal, Gurpreet Baudendistel, Thomas E. TI Thinking inside the box SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID CONSTRICTIVE PERICARDITIS; PORTAL-HYPERTENSION; MODERN-ERA C1 [Kwan, Damon M.; Baudendistel, Thomas E.] Calif Pacific Med Ctr, Kanbar Cardiac Ctr, Dept Med, San Francisco, CA 94115 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kwan, DM (reprint author), Calif Pacific Med Ctr, Kanbar Cardiac Ctr, Dept Med, 2333 Buchanan St,Room 1-109, San Francisco, CA 94115 USA. EM amgine18@yahoo.com NR 18 TC 2 Z9 2 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN-FEB PY 2008 VL 3 IS 1 BP 71 EP 76 DI 10.1002/jhm.267 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 292IB UT WOS:000255258600012 PM 18257049 ER PT J AU Zhou, J Matsuoka, M Cantor, H Homer, R Enelow, RI AF Zhou, Jing Matsuoka, Mitsuo Cantor, Harvey Homer, Robert Enelow, Richard I. TI Cutting edge: Engagement of NKG2A on CD8(+) effector T Cells limits immunopathology in influenza pneumonia SO JOURNAL OF IMMUNOLOGY LA English DT Article ID VIRUS-INFECTION; CD94/NKG2A EXPRESSION; CD94-NKG2A RECEPTORS; LUNG INJURY; A H5N1; LYMPHOCYTES; RESPONSES; IMMUNITY; QA-1(B); ALPHA AB Influenza pneumonia results in considerable lung injury, a significant component of which is mediated by CD8(+) T cell Ag recognition in the distal airways and alveoli. TNF-alpha produced by Ag-specific CD8(+) T cells appears primarily responsible for this immunopatbologv, and we have examined the negative regulation of CD8(+) TNF production by CD94/NKG2A engagement with its receptor, Qa-1b. TNF production by antiviral CD8(+) T cells was significantly enhanced by NKG2A blockade in vitro, and mice deficient in the NKG2A ligand, Qa-1b, manifested significantly greater pulmonary pathologv upon CD8(+) T cell-mediated clearance in influenza pneumonia. Furthermore, blockade of NKG2A ligation resulted in the enhancement of lung injuiy induced by CD8(+) effect or cell recognition of alveolar Ag in vivo in the absence of infectious virus. These data demonstrate that CD94/NKG2A transduces a biologically important signal in vivo to activated CD8(+) T cells that limits immunopathology in severe influenza infection. C1 [Zhou, Jing; Matsuoka, Mitsuo; Enelow, Richard I.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Homer, Robert] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Homer, Robert; Enelow, Richard I.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Cantor, Harvey] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Enelow, RI (reprint author), Dartmouth Med Sch, Dept Med, Lebanon, NH 03756 USA. EM richard.i.enelow@dartmouth.edu FU NIAID NIH HHS [AI069360] NR 24 TC 31 Z9 31 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2008 VL 180 IS 1 BP 25 EP 29 PG 5 WC Immunology SC Immunology GA 248OF UT WOS:000252162700004 PM 18096998 ER PT J AU Napimoga, MH Vieira, SM Dal-Secco, D Freitas, A Souto, FO Mestriner, FL Alves, JC Grespan, R Kawai, T Ferreira, SH Cunha, FQ AF Napimoga, Marcelo H. Vieira, Silvio M. Dal-Secco, Daniela Freitas, Andressa Souto, Fabricio O. Mestriner, Fabiola L. Alves-Filho, Jose C. Grespan, Renata Kawai, Toshihisa Ferreira, Sergio H. Cunha, Fernando Q. TI Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta A(12,14)-prostaglandin J(2), reduces neutrophil migration via a nitric oxide pathway SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ENDOTHELIAL ADHESION MOLECULES; SOLUBLE GUANYLATE-CYCLASE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ISCHEMIA/REPERFUSION INJURY; ANTIINFLAMMATORY ACTIVITY; LEUKOCYTE MIGRATION; DOWN-REGULATION; INFLAMMATION; ROSIGLITAZONE AB Ligands for peroxisome proliferator-activated receptor gamma (PPAR-gamma), such as 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) have been implicated as a new class of anti-inflammatory compounds with possible clinical applications. Based on this concept, this investigation was designed to determine the effect of 15d-PGJ(2)-mediated activation of PPAR-gamma ligand on neutrophil migration after an inflammatory stimulus and clarify the underlying molecular mechanisms using a mouse model of peritonitis. Our results demonstrated that 15d-PGJ(2) administration decreases leukocyte rolling and adhesion to the inflammated mesenteric tissues by a mechanism dependent on NO. Specifically, pharmacological inhibitors of NO synthase remarkably abrogated the 15d-PGJ(2)-mediated suppression of neutrophil migration to the inflammatory site. Moreover, inducible NOS(-/-) mice were not susceptible to 15d-PGJ(2)-mediated suppression of neutrophil migration to the inflammatory sites when compared with their wild type. In addition, 15d-PGJ(2)-mediated suppression of neutrophil migration appeared to be independent of the production of cytokines and chemokines, since their production were not significantly affected in the carrageenan-injected peritoneal cavities. Finally, up-regulation of carrageenan-triggered ICAM-I expression in the mesenteric microcirculation vessels was abrogated by pretreatment of wild-type mice with 15d-PGJ(2), whereas 15d-PGJ(2) inhibited F-actin rearrangement process in neutrophils. Taken together these findings demonstrated that 15d-PGJ(2) suppresses inflammation-initiated neutrophil migration in a mechanism dependent on NO production in mesenteric tissues. C1 [Napimoga, Marcelo H.] Univ Uberaba, Mol Biol Lab, BR-38055500 Uberaba, MG, Brazil. [Napimoga, Marcelo H.; Vieira, Silvio M.; Dal-Secco, Daniela; Freitas, Andressa; Mestriner, Fabiola L.; Alves-Filho, Jose C.; Grespan, Renata; Ferreira, Sergio H.; Cunha, Fernando Q.] Univ Sao Paulo, Fac Med Riberap Preto, Dept Pharmacol, Sao Paulo, Brazil. [Souto, Fabricio O.] Univ Sao Paulo, Fac Med Riberap Preto, Dept Surg & Anat, Sao Paulo, Brazil. [Vieira, Silvio M.] Natl Inst Res Amazon, Pharmacol Lab, Manaus, Amazonas, Brazil. [Kawai, Toshihisa] Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Napimoga, MH (reprint author), Univ Uberaba, Mol Biol Lab, Ave Nene Sabino 1801, BR-38055500 Uberaba, MG, Brazil. EM marcelo.napimoga@uniube.br RI Freitas, Andressa/B-7264-2012; Napimoga, Marcelo/F-8789-2011; Souto, Fabricio/I-3071-2013; Alves-Filho, Jose Carlos/B-5814-2008; Cunha, Fernando/M-3090-2014; Manfredo Vieira, Silvio/J-3980-2015 OI Freitas, Andressa/0000-0003-4552-2606; Napimoga, Marcelo/0000-0003-4472-365X; Souto, Fabricio/0000-0002-2392-8499; Alves-Filho, Jose Carlos/0000-0002-9918-8714; Manfredo Vieira, Silvio/0000-0001-8036-4223 FU NIDCR NIH HHS [DE 18310] NR 54 TC 37 Z9 41 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2008 VL 180 IS 1 BP 609 EP 617 PG 9 WC Immunology SC Immunology GA 248OF UT WOS:000252162700069 PM 18097063 ER PT J AU Smyk-Pearson, S Golden-Mason, L Klarquist, J Burton, JR Tester, IA Wang, CC Culbertson, N Vandenbark, AA Rosen, HR AF Smyk-Pearson, Susan Golden-Mason, Lucy Klarquist, Jared Burton, James R., Jr. Tester, Ian A. Wang, Chia C. Culbertson, Nicole Vandenbark, Arthur A. Rosen, Hugo R. TI Functional suppression by FoxP3(+)CD4(+)CD25(high) regulatory T cells during acute hepatitis C virus infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 11-15, 2005 CL San Francisco, CA SP Amer Assoc Study Liver Dis ID IN-VITRO PROLIFERATION; MULTIPLE-SCLEROSIS; DENDRITIC CELLS; IMMUNE-RESPONSE; VIRAL CLEARANCE; CORE PROTEIN; FOXP3; LYMPHOCYTES; DYSFUNCTION; ACTIVATION AB Background. Infection with hepatitis C virus (HCV) is characterized by impairment of viral effector T cell responses and a high propensity for viral persistence. Previous studies have demonstrated that chronic HCV infection is associated with an increased frequency of regulatory T (T-reg) cells, compared with that in persons whose infection resolved and in healthy persons. However, all patients in prior analyses had exposures in the distant past, precluding the ability to determine whether Treg cells play a causal role in establishing persistence during the earliest stages of infection or whether they are expanded because of viral persistence. Methods. For the first time, we longitudinally analyzed T-reg cells in patients with acute HCV infection (n = 27). We used a multiparameter approach, including fluorescence-activated cell sorting analysis of cell-surface and intracellular antigens, coculture experiments with highly purified CD4(+) CD25(high) regulatory and CD4(+)CD25(-) responder cell populations, and multiplex analysis of secreted cytokines. Results. Forkhead transcription factor 3 (FoxP3) expression and Treg cell suppression were greater in patients with acute HCV infection than in healthy control subjects but were not different at the first time point among patients who subsequently developed persistence or resolved HCV infection spontaneously; however, 6 months later, the resolution of disease was associated with a relative loss of functional suppression. Conclusions. Collectively, these data indicate that patients with acute HCV infection who develop chronicity versus spontaneous resolution exhibit temporal changes in T-reg cell function. It is possible that repetitive viral antigenic stimulation alters the function of T-reg cells over time. C1 [Smyk-Pearson, Susan; Golden-Mason, Lucy; Klarquist, Jared; Burton, James R., Jr.; Tester, Ian A.; Rosen, Hugo R.] Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, GI Div,Hepatitis C Ctr, Denver, CO 80262 USA. [Smyk-Pearson, Susan; Golden-Mason, Lucy; Klarquist, Jared; Burton, James R., Jr.; Tester, Ian A.; Rosen, Hugo R.] Univ Colorado, Hlth Sci Ctr, Integrated Program Immunol, Denver, CO 80262 USA. [Smyk-Pearson, Susan; Golden-Mason, Lucy; Klarquist, Jared; Burton, James R., Jr.; Tester, Ian A.; Rosen, Hugo R.] Natl Jewish Med & Res Ctr, Denver, CO USA. [Wang, Chia C.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Culbertson, Nicole; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Culbertson, Nicole; Vandenbark, Arthur A.] Portland VA Med Ctr, Portland, ME USA. RP Rosen, HR (reprint author), Univ Colorado, Hlth Sci Ctr, Div Gastroenterol & Hepatol, GI Div,Hepatitis C Ctr, 4200 E 9th Ave,B-158, Denver, CO 80262 USA. EM Hugo.Rosen@UCHSC.edu FU NIDDK NIH HHS [R01 DK060590]; PHS HHS [U19 A 1066328-01] NR 31 TC 60 Z9 64 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 1 PY 2008 VL 197 IS 1 BP 46 EP 57 DI 10.1086/523651 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 251TV UT WOS:000252399000009 PM 18171284 ER PT J AU Kawakami, A Sakane, F Imai, SI Yasuda, S Kai, M Kanoh, H Jin, HY Hirosaki, K Yamashita, T Fisher, DE Jimbow, K AF Kawakami, Akinori Sakane, Fumio Imai, Shin-Ichi Yasuda, Satoshi Kai, Masahiro Kanoh, Hideo Jin, Hai-Ying Hirosaki, Kuninori Yamashita, Toshiharu Fisher, David E. Jimbow, Kowichi TI Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID TYROSINASE-RELATED PROTEIN-1; GTP-BINDING-PROTEINS; INTRACELLULAR-TRANSPORT; ENDOCYTIC COMPARTMENTS; LATE ENDOSOMES; LYSOSOMES; MEMBRANE; LOCALIZATION; MELANOCYTES; BIOGENESIS AB Melanosome biogenesis consists of multistep processes that involve synthesis of melanosomal protein, which is followed by vesicle transport/fusion and post-translational modifications such as glycosylation, proteolysis, and oligomerization. Because of its complexity, the details of the molecular mechanism of melanosome biogenesis are not yet fully understood. Here, we report that, in MMAc melanoma cells, wild-type (WT) Rab7 and its dominant-active mutant (Rab7-Q67L), but not its dominant-negative mutant (Rab7-T22N), were colocalized in the perinuclear region with granules containing Stage I melanosomes, where the full-length, immature gp100/Pmel17/Silv was present. It was also found that overexpression of Rab7-Q67L and, to a lesser extent, Rab7-WT increased the amount of proteolytically processed, mature gp100. However, Rab7-T22N did not show such an effect. Moreover, siRNA-mediated Rab7 knockdown considerably inhibited gp100 maturation. These results collectively suggest that the GTP-bound form of Rab7 promotes melanogenesis through the regulation of gp100 maturation in melanoma cells. C1 [Kawakami, Akinori; Jin, Hai-Ying; Hirosaki, Kuninori; Yamashita, Toshiharu; Jimbow, Kowichi] Sapporo Med Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan. [Sakane, Fumio; Imai, Shin-Ichi; Yasuda, Satoshi; Kai, Masahiro; Kanoh, Hideo] Sapporo Med Univ, Sch Med, Dept Biochem, Sect II, Sapporo, Hokkaido, Japan. [Fisher, David E.] Childrens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Hematol Oncol,Melanoma Program, Boston, MA USA. [Jimbow, Kowichi] Inst Dermatol & Cutaneous Sci, Sapporo, Hokkaido, Japan. RP Jimbow, K (reprint author), Sapporo Med Univ, Sch Med, Dept Dermatol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan. EM jimbow@sapmed.ac.jp OI Sakane, Fumio/0000-0003-0857-0377 NR 36 TC 9 Z9 11 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2008 VL 128 IS 1 BP 143 EP 150 DI 10.1038/sj.jid.5700964 PG 8 WC Dermatology SC Dermatology GA 240UL UT WOS:000251613600019 PM 17625594 ER PT J AU Valencia, A Kochevar, IE AF Valencia, Antonio Kochevar, Irene E. TI Nox1-based NADPH oxidase is the major source of UVA-Induced reactive oxygen species in human keratinocytes SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID INDUCED OXIDATIVE STRESS; CULTURED HUMAN-FIBROBLASTS; LEMLI-OPITZ-SYNDROME; SINGLET OXYGEN; ENDOTHELIAL-CELLS; SEQUENTIAL ACTIVATION; HUMAN-SKIN; MITOCHONDRIA; ULTRAVIOLET; RADIATION AB UVA radiation is a major environmental stress on skin, causing acute and chronic photodamage. These responses are mediated by reactive oxygen species (ROS), although the cellular source of these ROS is unknown. We tested the hypotheses that UVA-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is required for ROS generation in human keratinocytes (HK) and that these ROS initiate rapid prostaglandin E(2) (PGE(2)) synthesis. Treatment of HK with a non-toxic dose of UVA rapidly increased NADPH oxidase activity and intracellular ROS, which were partially blocked by an inhibitor of NADPH oxidase and by a mitochondria-selective antioxidant. Depleting the Nox1 isoform of the catalytic subunit of NADPH oxidase using small interfering RNA (siRNA) blocked the UVA-induced ROS increase, indicating that ROS produced by mitochondria or other sources are downstream from Nox1. Nox1 siRNA also blocked UVA-initiated PGE2 synthesis. The mechanism for activation of Nox1 is mediated by an increase in intracellular calcium. Ceramide, which has been proposed to mediate responses to UVA in HK, also activated NADPH oxidase. These results indicate that UVA activates Nox1-based NADPH oxidase to produce ROS that stimulate PGE2 synthesis, and that Nox1 may be an appropriate target for agents designed to block UVA-induced skin injury. C1 [Valencia, Antonio; Kochevar, Irene E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Kochevar, IE (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Thier 224,55 Fruit St, Boston, MA 02114 USA. EM kochevar@helix.mgh.harvard.edu FU NIGMS NIH HHS [GM 30955] NR 53 TC 89 Z9 94 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2008 VL 128 IS 1 BP 214 EP 222 DI 10.1038/sj.jid.5700960 PG 9 WC Dermatology SC Dermatology GA 240UL UT WOS:000251613600026 PM 17611574 ER PT J AU Nguyen, MK Chan, AM Shimazaki, K Moniz, R Kelly, K Gordon, LK Braun, J AF Nguyen, M. K. Chan, A. M. Shimazaki, K. Moniz, R. Kelly, K. Gordon, L. K. Braun, J. TI Role of epithelial membrane protein (EMP2) in Chlamydia infectivity in vivo SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 30-FEB 02, 2008 CL Carmel, CA SP Amer Federat Med Res C1 [Nguyen, M. K.; Chan, A. M.; Shimazaki, K.; Moniz, R.; Kelly, K.; Braun, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Chan, A. M.; Shimazaki, K.; Gordon, L. K.] Jules Stein Eye Inst, Los Angeles, CA USA. [Gordon, L. K.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 17 BP 108 EP 108 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793300027 ER PT J AU Nguyen, MK Chan, AM Shimazaki, K Moniz, R Kelly, K Gordon, LK Braun, J AF Nguyen, M. K. Chan, A. M. Shimazaki, K. Moniz, R. Kelly, K. Gordon, L. K. Braun, J. TI Role of epithelial membrane protein (EMP2) in Chlamydia infectivity in vivo SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 30-FEB 02, 2008 CL Carmel, CA SP Amer Federat Med Res C1 [Nguyen, M. K.; Chan, A. M.; Shimazaki, K.; Moniz, R.; Kelly, K.; Braun, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Chan, A. M.; Shimazaki, K.; Gordon, L. K.] Jules Stein Eye Inst, Los Angeles, CA USA. [Gordon, L. K.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 253 BP 187 EP 187 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793300264 ER PT J AU Pereira, RI Leitner, J Draznin, B AF Pereira, R. I. Leitner, J. Draznin, B. TI Pioglitazone stimulates adiponectin secretion from 3T3-L1 adipocytes via activation of the phosphatidylinositol 3 '-kinase SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 30-FEB 02, 2008 CL Carmel, CA SP Amer Federat Med Res C1 [Pereira, R. I.; Leitner, J.; Draznin, B.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Pereira, R. I.; Draznin, B.] UCHSC, Aurora, CO USA. [Pereira, R. I.] Denver Hlth, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 268 BP 192 EP 193 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793300279 ER PT J AU Parikh, R Patel, D Rebello, G Kattapuram, S AF Parikh, R. Patel, D. Rebello, G. Kattapuram, S. TI The ligament of wrisberg, lateral discoid menisci, and associated findings: A study utilizing imaging and arthroscopy SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 30-FEB 02, 2008 CL Carmel, CA SP Amer Federat Med Res C1 [Parikh, R.; Patel, D.; Rebello, G.; Kattapuram, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Parikh, R.] SUNY Brooklyn, Brooklyn, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 323 BP 211 EP 211 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793300334 ER PT J AU Duclekula, A Kulig, C Trotter, J Everson, G AF Duclekula, A. Kulig, C. Trotter, J. Everson, G. TI Five year experience with Tenofovir for lamivudine resistant hepatitis B virus SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 30-FEB 02, 2008 CL Carmel, CA SP Amer Federat Med Res C1 [Duclekula, A.; Kulig, C.; Trotter, J.; Everson, G.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Kulig, C.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 353 BP 221 EP 221 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301013 ER PT J AU Baker, D Obeid, L Gilkeson, G AF Baker, D. Obeid, L. Gilkeson, G. TI Role of sphingosine kinase I in a mouse model of chronic inflammation SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Baker, D.; Obeid, L.; Gilkeson, G.] Med Univ S Carolina, Charleston, SC USA. [Baker, D.; Obeid, L.; Gilkeson, G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 39 BP 356 EP 356 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301189 ER PT J AU Campbell, R Cooper, GS Gilkeson, GS AF Campbell, R. Cooper, G. S. Gilkeson, G. S. TI The economic burden of systemic lupus erythematosus among patients of the carolina lupus study early in the course of disease SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Campbell, R.; Gilkeson, G. S.] Med Univ S Carolina, Charleston, SC USA. [Cooper, G. S.] US EPA, Washington, DC USA. [Gilkeson, G. S.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 142 BP 390 EP 390 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301292 ER PT J AU Bryan, AC Parker, TM Bruner, GR Harley, JB Gilkeson, GS Kamen, DL AF Bryan, A. C. Parker, T. M. Bruner, G. R. Harley, J. B. Gilkeson, G. S. Kamen, D. L. TI Relationship between smoking and autoantibody positivity among female African American lupus patients SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Bryan, A. C.; Parker, T. M.; Gilkeson, G. S.; Kamen, D. L.] Med Univ S Carolina, Charleston, SC USA. [Gilkeson, G. S.] Ralph H Johnson VAMC, Charleston, SC USA. [Bruner, G. R.; Harley, J. B.] OMRF, Oklahoma City, OK USA. [Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Harley, J. B.] Oklahoma City VAMC, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 262 BP 429 EP 430 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301410 ER PT J AU Markland, AD Richter, HE Burgio, KL Wheeler, TL Malone, MP Goode, PS AF Markland, A. D. Richter, H. E. Burgio, K. L. Wheeler, T. L., III Malone, M. P. Goode, P. S. TI Outcomes of combination treatment of fecal incontinence in women SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Markland, A. D.; Richter, H. E.; Wheeler, T. L., III; Malone, M. P.; Goode, P. S.] Univ Alabama, Birmingham, AL USA. [Markland, A. D.; Burgio, K. L.; Goode, P. S.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 283 BP 436 EP 437 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301430 ER PT J AU Snyder, E Farless, L Cherrington, A Estrada, C Bryan, T Boobaker, E AF Snyder, E. Farless, L. Cherrington, A. Estrada, C. Bryan, T. Boobaker, E. TI An objective evaluation of Women's Health Track curriculum utilizing the American College of Physicians In-Training Examination SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Snyder, E.; Farless, L.; Cherrington, A.; Estrada, C.; Bryan, T.; Boobaker, E.] Univ Alabama, Birmingham, AL USA. [Snyder, E.; Estrada, C.; Bryan, T.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 421 BP 484 EP 484 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301568 ER PT J AU Willett, LL Paranjape, A Estrada, C AF Willett, L. L. Paranjape, A. Estrada, C. TI Identifying key components for an effective poster presentation: An observational study SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2008 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Willett, L. L.] Univ Alabama, Birmingham, AL USA. [Paranjape, A.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Estrada, C.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2008 VL 56 IS 1 MA 442 BP 491 EP 491 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 257IV UT WOS:000252793301589 ER PT J AU Jain, S Lee, SH Korneszczuk, K Culberson, CR Southard, JH Berthiaume, F Zhang, JX Clemens, MG Lee, CY AF Jain, Shailendra Lee, Sang Ho Korneszczuk, Katarzyna Culberson, Catherine R. Southard, James H. Berthiaume, Francois Zhang, Jian X. Clemens, Mark G. Lee, Charles Y. TI Improved preservation of warm ischemic livers by hypothermic machine perfusion with supplemented University of Wisconsin solution SO JOURNAL OF INVESTIGATIVE SURGERY LA English DT Article DE donation after cardiac death; hypothermic machine perfusion; liver preservation; preservation solution; simple cold storage ID DONOR RAT LIVERS; REPERFUSION INJURY; HEPATIC ISCHEMIA; ANOXIC INJURY; CARDIAC DEATH; TRANSPLANTATION; HEPATOCYTES; CALCIUM; THROMBOXANE; MECHANISMS AB Hypothermic machine perfusion (HMP) has the potential to improve recovery and preservation of Donation after Cardiac Death (DCD) livers, including uncontrolled DCD livers. However, current perfusion solutions lack the needed substrates to improve energy recovery and minimize hepatic injury, if warm ischemic time (WIT) is extended. This proof-of-concept study tested the hypothesis that the University of Wisconsin (UW) solution supplemented with anaplerotic substrates, calcium chloride, thromboxane A(2) inhibitor, and antioxidants could improve HMP preservation and minimize reperfusion injury of warm ischemic livers. Preflushed rat livers subjected to 60 min WIT were preserved for 5 h with standard UW or supplemented UW (SUW) solution. Post preservation hepatic functions and viability were assessed during isolated perfusion with Krebs -Henseleit solution. Livers preserved with SUW showed significantly (p < .001) improved recovery of tissue ATP levels (mu mol/g liver), 2.06 +/- 0.10 (mean +/- SE), as compared to the UW group, 0.70 +/- 0.10, and the level was 80% of that of fresh control livers (2.60 +/- 0.13). At the end of 1 h of rewarming, lactate dehydrogenase (U/L) in the perfusate was significantly (p < .05) lower in the SUW group (429 +/- 58) as compared to ischemia -reperfusion (IR) (781 +/- 12) and the UW group (1151 +/- 83). Bile production (mu/min/g liver) was significantly (p < .05) higher in the SUW group (280 +/- 13) as compared to the IR (224 +/- 24) and the UW group (114 +/- 14). The tissue edema formation assessed by tissue wet -dry ratio was significantly (p < .05) higher in UW group. Histology showed well-preserved hepatic structure in the SUW group. In conclusion, this study suggests that HMP with SUW solution has the potential to restore and preserve livers with extended WIT. C1 [Jain, Shailendra; Clemens, Mark G.; Lee, Charles Y.] Univ N Carolina, Dept Mech Engn & Engn Sci, Charlotte, NC 28223 USA. [Lee, Sang Ho; Korneszczuk, Katarzyna; Culberson, Catherine R.; Zhang, Jian X.; Clemens, Mark G.] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA. [Southard, James H.] Univ Wisconsin, Dept Surg, Madison Med Ctr, Madison, WI USA. [Berthiaume, Francois] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Cambridge, MA 02138 USA. [Clemens, Mark G.; Lee, Charles Y.] HepatoSys Inc, Cornelius, NC USA. RP Lee, CY (reprint author), Univ N Carolina, Dept Mech Engn & Engn Sci, 481B Woodward Hall,9201 Univ City Blvd, Charlotte, NC 28223 USA. EM cyclee@uncc.edu NR 31 TC 11 Z9 11 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0894-1939 J9 J INVEST SURG JI J. Invest. Surg. PY 2008 VL 21 IS 2 BP 83 EP 91 DI 10.1080/08941930701883657 PG 9 WC Surgery SC Surgery GA 275JO UT WOS:000254067900007 PM 18340625 ER PT J AU Wilmanski, JM Petnicki-Ocwieja, T Kobayashi, KS AF Wilmanski, Jeanette M. Petnicki-Ocwieja, Tanja Kobayashi, Koichi S. TI NLR proteins: integral members of innate immunity and mediators of inflammatory diseases SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Review DE NACHT; host-pathogen interaction; Nod2; Crohn's disease ID NF-KAPPA-B; FAMILIAL MEDITERRANEAN FEVER; INTESTINAL EPITHELIAL-CELLS; CASPASE RECRUITMENT DOMAIN; BARE LYMPHOCYTE SYNDROME; TOLL-LIKE RECEPTORS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; LEGIONELLA-PNEUMOPHILA INFECTION; TRANSPORTS MURAMYL DIPEPTIDE; NOD2 3020INSC MUTATION AB The innate immune system is the first line of defense against microorganisms and is conserved in plants and animals. The nucleotide-binding domain, leucine rich containing (NLR) protein family is a recent addition to the members of innate immunity effector molecules. These proteins are characterized by a central oligomerization domain, termed nucleotide-binding domain (NBD) and a protein interaction domain, leucine-rich repeats (LRRs) at the C terminus. It has been shown that NLR proteins are localized to the cytoplasm and recognize microbial products. To date, it is known that Nod1 and Nod2 detect bacterial cell wall components, whereas Ipaf and Naip detect bacterial flagellin, and NACHT/LRR/Pyrin 1 has been shown to detect anthrax lethal toxin. NLR proteins comprise a diverse protein family ( over 20 in humans), indicating that NLRs have evolved to acquire specificity to various pathogenic microorganisms, thereby controlling host-pathogen interactions. Activation of NLR proteins results in inflammatory responses mediated by NF-kappa B, MAPK, or Caspase-1 activation, accompanied by subsequent secretion of proinflammatory cytokines. Mutations in several members of the NLR protein family have been linked to inflammatory diseases, suggesting these molecules play important roles in maintaining host-pathogen interactions and inflammatory responses. Therefore, understanding NLR signaling is important for the therapeutic intervention of various infectious and inflammatory diseases. C1 [Wilmanski, Jeanette M.; Petnicki-Ocwieja, Tanja; Kobayashi, Koichi S.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Wilmanski, Jeanette M.; Petnicki-Ocwieja, Tanja; Kobayashi, Koichi S.] Harvard Med Sch, Dept Pathol, Boston, MA USA. [Wilmanski, Jeanette M.] St Peters Coll, Dept Biol, Jersey City, NJ USA. RP Kobayashi, KS (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Dana 1420A,44 Binney St, Boston, MA 02115 USA. EM Koichi_Kobayashi@dfci.harvard.edu FU NIDDK NIH HHS [R01 DK074738-05, DK074738-01A1, R01 DK074738] NR 225 TC 107 Z9 114 U1 1 U2 6 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JAN PY 2008 VL 83 IS 1 BP 13 EP 30 DI 10.1189/jlb.0607402 PG 18 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 243YV UT WOS:000251834100002 PM 17875812 ER PT J AU Bennett, SM Litz, BT Maguen, S Ehrenreich, JT AF Bennett, Shannon M. Litz, Brett T. Maguen, Shira Ehrenreich, Jill T. TI An Exploratory Study of the Psychological Impact and Clinical Care of Perinatal Loss SO JOURNAL OF LOSS & TRAUMA LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COMPLICATED GRIEF; PREGNANCY LOSS; NEONATAL DEATH; MISCARRIAGE; STILLBIRTH; SUPPORT; SCALE; SATISFACTION; BEREAVEMENT AB Perinatal loss is a unique and potentially traumatizing experience that can leave bereaved parents struggling with a host of mental health difficulties. In this exploratory study of the predictors and mental health outcomes associated with perinatal loss, we examined a cohort of women who experienced a perinatal loss within the previous 5 years. Results suggest perinatal loss is associated with considerable distress and impairment for some women, with greater severity primarily predicted by maladaptive coping skills, low social support, and intense emotionality following the loss. The majority of women in this sample were satisfied with the care they received in the hospital after their loss, including their engagement in reportedly contentious bereavement rituals in the medical setting. Limitations of this research are noted, and suggestions for future research and clinical care are provided. C1 [Bennett, Shannon M.; Litz, Brett T.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Litz, Brett T.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. [Litz, Brett T.] VA Boston Hlth Care Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Ehrenreich, Jill T.] Univ Miami, Child & Adolescent Anxiety & Depress Treatment Pr, Miami, FL USA. RP Bennett, SM (reprint author), Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02215 USA. EM smbennet@bu.edu NR 44 TC 24 Z9 25 U1 3 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1532-5024 J9 J LOSS TRAUMA JI J. Loss Trauma PY 2008 VL 13 IS 6 BP 485 EP 510 AR PII 905533993 DI 10.1080/15325020802171268 PG 26 WC Psychology, Social SC Psychology GA 372OK UT WOS:000260910700001 ER PT J AU Ford, ME Kallen, M Richardson, P Matthiesen, E Cox, V Teng, EJ Cook, KF Petersen, NJ AF Ford, M. E. Kallen, M. Richardson, P. Matthiesen, E. Cox, V. Teng, E. J. Cook, K. F. Petersen, N. J. TI Effect of social support on informed consent in older adults with Parkinson disease and their caregivers SO JOURNAL OF MEDICAL ETHICS LA English DT Article ID MULTIPLE-SCLEROSIS AB PURPOSE: To evaluate the effects of social support on comprehension and recall of consent form information in a study of Parkinson disease patients and their caregivers. DESIGN and METHODS: Comparison of comprehension and recall outcomes among participants who read and signed the consent form accompanied by a family member/friend versus those of participants who read and signed the consent form unaccompanied. Comprehension and recall of consent form information were measured at one week and one month respectively, using Part A of the Quality of Informed Consent Questionnaire (QuIC). RESULTS: The mean age of the sample of 143 participants was 71 years (SD = 8.6 years). Analysis of covariance was used to compare QuIC scores between the intervention group (n = 70) and control group (n = 73). In the 1-week model, no statistically significant intervention effect was found (p = 0.860). However, the intervention status by patient status interaction was statistically significant (p = 0.012). In the 1-month model, no statistically significant intervention effect was found (p = 0.480). Again, however, the intervention status by patient status interaction was statistically significant (p = 0.040). At both time periods, intervention group patients scored higher (better) on the QuIC than did intervention group caregivers, and control group patients scored lower (worse) on the QuIC than did control group caregivers. IMPLICATIONS: Social support played a significant role in enhancing comprehension and recall of consent form information among patients. C1 [Ford, M. E.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Kallen, M.; Richardson, P.; Matthiesen, E.; Cox, V.; Petersen, N. J.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr 152, Houston, TX 77030 USA. [Kallen, M.; Richardson, P.; Matthiesen, E.; Cox, V.; Petersen, N. J.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Teng, E. J.] Michael E DeBakey Vet Affairs Med Ctr 152, Houston, TX USA. [Cook, K. F.] Baylor Coll Med, Dept Neurol, PADRECC, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Ford, ME (reprint author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, 135 Cannon St,Suite 303,POB 250835, Charleston, SC 29425 USA. EM fordmar@musc.edu FU NCI NIH HHS [N01-CN-25512]; NIA NIH HHS [I P30 AG 21677]; NIMHD NIH HHS [RFA-MD-04-0] NR 15 TC 8 Z9 8 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-6800 J9 J MED ETHICS JI J. Med. Ethics PD JAN 1 PY 2008 VL 34 IS 1 BP 41 EP 47 DI 10.1136/jme.2006.018192 PG 7 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 243ZO UT WOS:000251836000013 PM 18156521 ER PT J AU Houston, TK Richman, JS Ray, MN Allison, JJ Gilbert, GH Shewchuk, RM Kohler, CL Kiefe, CI AF Houston, Thomas K. Richman, Joshua S. Ray, Midge N. Allison, Jeroan J. Gilbert, Gregg H. Shewchuk, Richard M. Kohler, Connie L. Kiefe, Catarina I. CA DPBRN Collaborative Grp TI Internet Delivered Support for Tobacco Control in Dental Practice: Randomized Controlled Trial SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE Smoking cessation; Internet; general practice; dental; randomized controlled trial; health services research ID ECOLOGICAL MOMENTARY ASSESSMENT; CONTINUING MEDICAL-EDUCATION; SMOKING-CESSATION; HEALTH-CARE; INTERVENTION; PHYSICIANS; DENTISTS; PROGRAM; USERS; BIOTERRORISM AB Background: The dental visit is a unique opportunity for tobacco control. Despite evidence of effectiveness in dental settings, brief provider-delivered cessation advice is underutilized. Objective: To evaluate an Internet-delivered intervention designed to increase implementation of brief provider advice for tobacco cessation in dental practice settings. Methods: Dental practices (N = 190) were randomized to the intervention website or wait-list control. Pre-intervention and after 8 months of follow-up, each practice distributed exit cards (brief patient surveys assessing provider performance, completed immediately after the dental visit) to 100 patients. Based on these exit cards, we assessed: whether patients were asked about tobacco use (ASK) and, among tobacco users, whether they were advised to quit tobacco (ADVISE). All intervention practices with follow-tip exit card data were analyzed as randomized regardless of whether they participated in the Internet-delivered intervention. Results: Of the 190 practices randomized, 143 (75%) dental practices provided follow-up data. Intervention practices' mean performance improved post-intenention by 4% on ASK (29% baseline, adjusted odds ratio = 1.29 [95% CI 1.17-1.42]), and by 11% on ADVISE (44% baseline, OR = 1.55 [95% CI 1.28-1.87]). Control practices improved by 3% on ASK (Adj. OR I. 18 [95% CI 1.07-1.29]) and did not significantly improve in ADVISE. A significant group-by-time interaction effect indicated that intervention practices improved more over the study period than control practices for ADVISE (P = 0.042) but not for ASK. Conclusion: This low-intensity, easily disseminated intervention was successful in improving provider performance on advice to quit. C1 [Houston, Thomas K.; Allison, Jeroan J.] Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. [Houston, Thomas K.] Birmingham VA Med Ctr, Surg & Med Acute Care & Adv Illness Res & Transit, VA HSR&D REAP, Birmingham, AL USA. [Houston, Thomas K.; Richman, Joshua S.; Ray, Midge N.; Allison, Jeroan J.; Gilbert, Gregg H.; Shewchuk, Richard M.; Kiefe, Catarina I.] Univ Alabama, Ctr Outcomes & Effectiveness Res, Birmingham, AL 35294 USA. [Richman, Joshua S.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Alabama, Div Prevent Med, Birmingham, AL 35294 USA. [Ray, Midge N.; Shewchuk, Richard M.] Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL 35294 USA. [Gilbert, Gregg H.] Univ Alabama, Sch Dent, Dept Diagnost Sci, Birmingham, AL 35294 USA. [Kohler, Connie L.] Univ Alabama, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA. [DPBRN Collaborative Grp] Dent PBRN Org, Birmingham, AL USA. RP Houston, TK (reprint author), Univ Alabama, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM thouston@uab.edu RI Houston, Thomas/F-2469-2013; OI Allison, Jeroan/0000-0003-4472-2112 FU National Institute on Drug Abuse (NIDA) [R01-DA-17971]; Translational Research In Dental Practice-Based Tobacco Control Interventions [RFA DE-03-007]; National Institute of Dental and Craniofacial Research (NIDCR) [U01-DE-16747, U01-DE-16746]; National Institute of Dental and Craniofacial Research (NIDCR); National Institutes of Health FX We would like to thank Dr. Sharina Person, Biostatistician, Jackie Causey, Data Base Analyst, and Jessica Williams and Heather Coley, Research Assistants, for their contributions. We are grateful for their invaluable assistance with the study. This project was supported by grants R01-DA-17971 from the National Institute on Drug Abuse (NIDA) funded through RFA DE-03-007 "Translational Research In Dental Practice-Based Tobacco Control Interventions", and grants U01-DE-16747, and U01-DE-16746 from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health. The investigators were independent of the funding agency in terms of study design, intervention development, data collection and analyses, and interpretation. NR 57 TC 19 Z9 19 U1 1 U2 4 PU JOURNAL MEDICAL INTERNET RESEARCH PI TORONTO PA TORONTO GENERAL HOSPITAL, R FRASER ELLIOTT BLDG, 4TH FL, R 4S435, 190 ELIZABETH ST, TORONTO, ON M5G 2C4, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PY 2008 VL 10 IS 5 AR e38 DI 10.2196/jmir.1095 PG 12 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 405HW UT WOS:000263214800006 PM 18984559 ER PT J AU Nannini, A Lazar, J Berg, C Tomashek, K Cabral, H Barger, M Barfield, W Kotelchuck, M AF Nannini, Angela Lazar, Jane Berg, Cynthia Tomashek, Kay Cabral, Howard Barger, Maly Barfield, Wanda Kotelchuck, Milton TI Injury: A major cause of pregnancy-associated morbidity in Massachusetts SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Article DE assault; falls; injury; motor vehicle crash; postpartum; pregnancy; women's health ID MOTOR-VEHICLE CRASHES; INTIMATE PARTNER VIOLENCE; SEAT-BELT USE; PRENATAL-CARE; HOSPITALIZED INJURIES; WASHINGTON-STATE; MATERNAL DEATHS; FETAL OUTCOMES; NORTH-CAROLINA; UNITED-STATES AB Hospital visits (inpatient, observation, and emergency department) for injury occurring during pregnancy and 1 year postpartum (the pregnancy-associated period) were examined to determine groups at risk for injuries. The dataset included maternally linked vital records and hospital visit data for a population-based cohort of women residing in Massachusetts who delivered between 2002 and 2003 (n = 100,051). Injury morbidity (injury visits with International Classification of Diseases, Ninth Revision, Clinical Modification codes 800-999.99 or selected E-codes) was evaluated by individual woman- and visit-based analyses. Overall, one in seven women sought hospital care for pregnancy-associated injuries, and rates were as high as one in four for some subgroups. Most pregnancy-associated injury visits (91%) occurred in emergency departments. More than 4% of women had a motor vehicle collision, which was the leading cause of injury. The risk for injury was significantly higher among women who were adolescents (relative risk [RR] = 1.88; 95% confidence interval [CI], 1.78-1.98), black non-Hispanic (RR = 1.88; 95% CI, 1.80-1.97), those who had public insurance (RR = 2.50; 95% CI, 2.41-2.56), or those who had less than a high school education (RR = 2.48; 95% CI, 2.39-2.58) when compared with referent groups. Clinical guidelines for preconception and pregnancy-associated periods should include recommendations for injury history assessment and preventative counseling for women. J Midwifery Womens Health 2008;53:3-10 (c) 2008 by the American College of Nurse-Midwives. C1 [Nannini, Angela; Lazar, Jane] Northeastern Univ, Bouve Coll Hlth Sci, Sch Nursing, Boston, MA 02115 USA. [Lazar, Jane] Beth Israel Deaconess Med Ctr Labor & Delivery, Boston, MA USA. [Berg, Cynthia] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Reprod Hlth, Bethesda, MD 20892 USA. [Tomashek, Kay] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. CDC, Div Vector Borne Infect Dis, Dengue Branch, San Juan, PR USA. [Cabral, Howard; Barger, Maly] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Maternal & Child Hlth Epidemiol Program, Atlanta, GA USA. [Kotelchuck, Milton] Boston Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02215 USA. RP Nannini, A (reprint author), Northeastern Univ, Bouve Coll Hlth Sci, Sch Nursing, 106D Robinson Hall,360 Huntington Ave, Boston, MA 02115 USA. EM a.nannini@neu.edu OI Cabral, Howard/0000-0002-1185-8331 NR 40 TC 6 Z9 6 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1526-9523 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD JAN-FEB PY 2008 VL 53 IS 1 BP 3 EP 10 DI 10.1016/j.jmwh.2007.07.018 PG 8 WC Nursing SC Nursing GA 250WE UT WOS:000252331200002 PM 18164428 ER PT J AU Chan, SY Loscalzo, J AF Chan, Stephen Y. Loscalzo, Joseph TI Pathogenic mechanisms of pulmonary arterial hypertension SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Review DE pulmonary arterial hypertension; molecular mechanism; vasoconstriction; thrombosis; proliferation; genetic association; acquired risk; vascular effector ID SMOOTH-MUSCLE-CELLS; MORPHOGENETIC PROTEIN-RECEPTOR; NITRIC-OXIDE SYNTHASE; RHO-KINASE INHIBITOR; VASOACTIVE-INTESTINAL-PEPTIDE; CHRONICALLY HYPOXIC RATS; HEREDITARY HEMORRHAGIC TELANGIECTASIA; 5-HYDROXYTRYPTAMINE TRANSPORTER GENE; IMMUNODEFICIENCY-VIRUS-INFECTION; SARCOMA-ASSOCIATED HERPESVIRUS AB Pulmonary arterial hypertension (PAH) is a complex disease that causes significant morbidity and mortality and is clinically characterized by an increase in pulmonary vascular resistance. The histopathology is marked by vascular proliferation/fibrosis, remodeling, and vessel obstruction. Development of PAH involves the complex interaction of multiple vascular effectors at all anatomic levels of the arterial wall. Subsequent vasoconstriction, thrombosis, and inflammation ensue, leading to vessel wall remodeling and cellular hyperproliferation as the hallmarks of severe disease. These processes are influenced by genetic predisposition as well as diverse endogenous and exogenous stimuli. Recent studies have provided a glimpse at certain molecular pathways that contribute to pathogenesis; these have led to the identification of attractive targets for therapeutic intervention. We will review our current understanding of the mechanistic underpinnings of the genetic and exogenous/acquired triggers of PAH. The resulting imbalance of vascular effectors provoking pathogenic vascular changes will also be discussed, with an emphasis on common and overarching regulatory pathways that may relate to the primary triggers of disease. The current conceptual framework should allow for future studies to refine our understanding of the molecular pathogenesis of PAH and improve the therapeutic regimen for this disease. (C) 2007 Elsevier Inc. All rights reserved. C1 [Chan, Stephen Y.; Loscalzo, Joseph] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA. [Chan, Stephen Y.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA. RP Loscalzo, J (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA. EM jloscalzo@partners.org FU NHLBI NIH HHS [R01 HL061795, HL61795, HL81587, HV28718, N01 HV028178, P01 HL081587, P01 HL081587-030002, R01 HL061795-10, R37 HL061795] NR 237 TC 118 Z9 133 U1 0 U2 9 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2008 VL 44 IS 1 BP 14 EP 30 DI 10.1016/j.yjmcc.2007.09.006 PG 17 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 257MR UT WOS:000252803700003 PM 17950310 ER PT J AU Greyson, CR Schwartz, GG Lu, L Ye, SY Helmke, S Xu, Y Ahmad, H AF Greyson, Clifford R. Schwartz, Gregory G. Lu, Li Ye, Shuyu Helmke, Steve Xu, Ya Ahmad, Hasan TI Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE hypertension; pulmonary; ventricular dysfunction; right; myocardial contraction; calpain; protease inhibitors; calpastatin ID RECRUITABLE STROKE WORK; RAT-HEART; PULMONARY-HYPERTENSION; TROPONIN-I; STUNNED MYOCARDIUM; SKELETAL-MUSCLE; CONSCIOUS DOGS; BRIEF ISCHEMIA; INTACT HEART; CALPASTATIN AB Right ventricular contractile failure from acute RV pressure overload is an important cause of morbidity and mortality, but the mechanism of RV failure in this setting is incompletely defined. We hypothesized that RV dysfunction from acute RV pressure overload is, in part, due to activation of calpain, and that calpain inhibition would therefore attenuate RV dysfunction. Anesthetized, open chest pigs were treated with the calpain inhibitor MDL-28170 or with inactive vehicle, and then subjected to acute RV pressure overload for 90 min. RV contractile function was assessed by the regional Frank-Starling relation. RV myocardial tissue was analyzed for evidence of calpain activation and calpain-mediated proteolysis. RV pressure overload caused severe contractile dysfunction, along with significant alterations in the endogenous calpain inhibitor calpastatin typical of calpain activation. MDL-28170 attenuated RV free wall dysfunction by more than 50%. However, there were no differences in degradation of spectrin, desmin, troponin-I or SERCA2 between SHAM operated pigs and pigs subjected to acute RV pressure overload, or between vehicle and MDL-28170 treated pigs. Acute RV pressure overload causes calpain activation, and RV contractile dysfunction from acute RV pressure overload is attenuated by the calpain inhibitor MDL-28170; however, the effect is not explained by inhibition of calpain-mediated degradation of spectrin, desmin, troponin-I or SERCA2. Because this is the first report of any agent that can directly attenuate RV contractile dysfunction in acute RV pressure overload, further investigation of the mechanism of action of MDL-28170 in this setting is warranted. (C) 2007 Elsevier Inc. All rights reserved. C1 [Greyson, Clifford R.; Schwartz, Gregory G.; Lu, Li; Ye, Shuyu; Xu, Ya; Ahmad, Hasan] Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. [Greyson, Clifford R.; Schwartz, Gregory G.; Lu, Li; Ye, Shuyu; Xu, Ya; Ahmad, Hasan] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. [Helmke, Steve] Univ Colorado, Hlth Sci Ctr, Sch Med, Div Gastroenterol & Hepatol, Denver, CO 80202 USA. RP Greyson, CR (reprint author), Denver VA Med Ctr, Cardiol Sect, Cardiol 111B,1055 Clermont St, Denver, CO 80220 USA. EM Clifford.Greyson@UCHSC.edu FU NHLBI NIH HHS [R01 HL068606, F32 HL076072, HL49944, K08 HL003475-05, R56 HL049944, HL68606, R01 HL068606-02, R01 HL068606-01A2, R01 HL068606-03, R01 HL068606-04, K08 HL003475-06, F32HL076072, R01 HL049944] NR 46 TC 17 Z9 17 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2008 VL 44 IS 1 BP 59 EP 68 DI 10.1016/j.yjmcc.2007.10.010 PG 10 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 257MR UT WOS:000252803700007 PM 18068185 ER PT J AU Spruill, LS Baicu, CF Zile, MR McDermott, PJ AF Spruill, Laura S. Baicu, Catalin F. Zile, Michael R. McDermott, Paul J. TI Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE cardiac hypertrophy; gene expression; protein biosynthesis; translation; polyribosomes; messenger RNA; 5 ' untranslated regions ID CARDIAC-HYPERTROPHY; PROTEIN-SYNTHESIS; ADULT MYOCARDIUM; GENE-EXPRESSION; HEART-FAILURE; C-JUN; INITIATION; GROWTH; MECHANISMS; MDM2 AB During pressure overload hypertrophy, selective changes in cardiac gene expression occur that regulate growth and modify the structural and functional properties of the myocardium. To determine the role of translational mechanisms, a murine model of transverse aortic constriction was used to screen a set of specified mRNAs for changes in translational activity by measuring incorporation into polysomes in response to acute pressure overload. Candidate mRNAs were selected on the basis of two main criteria: (1) the 5'-untranslated region of the mRNA contains an excessive amount of secondary structure (Delta G < -50 kCal/mol), which is postulated to regulate efficiency of translation, and (2) the protein product has been implicated in the regulation of cardiac hypeytrophy. After 24 h of transverse aortic constriction, homogenates derived from the left ventricle were layered onto 15-50% linear sucrose gradients and resolved into monosome fractions (messenger ribonucleoprotein particles) and polysome fractions by density gradient ultracentrifugation. The levels of mRNA in each fraction were quantified by real-time RT-PCR. The screen revealed that pressure overload increased translational activity of 6 candidate mRNAs as determined by a significant increase in the percentage of total mRNA incorporated into the polysome fractions. The mRNAs code for several functional classes of proteins linked to cardiac hypertrophy: the transcription factors c-myc, c-jun and MEF2D, growth factors VEGF and FGF-2 and the E3 ubiquitin ligase MDM2. These studies demonstrate that acute pressure overload alters cardiac gene expression by mechanisms that selectively regulate translational activity of specific mRNAs. (C) 2007 Elsevier Inc. All rights reserved. C1 [McDermott, Paul J.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Room303,Strom Thurmond Biomed Res Bldg,114 Dought, Charleston, SC 29403 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [P01 HL048788, P01 HL048788-150001, P01 HL048788-159006, P01 HL-48788] NR 37 TC 11 Z9 11 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2008 VL 44 IS 1 BP 69 EP 75 DI 10.1016/j.yjmcc.2007.10.011 PG 7 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 257MR UT WOS:000252803700008 PM 18036610 ER PT J AU Ogino, S Goel, A AF Ogino, Shuji Goel, Ajay TI Molecular classification and correlates in colorectal cancer SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Review ID ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE-INSTABILITY STATUS; O-6-METHYLGUANINE DNA METHYLTRANSFERASE; BEAUMONT-HOSPITAL SYMPOSIUM; MITOTIC STRESS CHECKPOINT; POPULATION-BASED SAMPLE; BETA-CATENIN MUTATIONS; II RECEPTOR GENE; CPG ISLAND; COLON-CANCER AB Molecular classification of colorectal cancer is evolving. As our understanding of colorectal carcinogenesis improves, we are incorporating new knowledge into the classification system. In particular, global genomic status [microsatellite instability (MSI) status and chromosomal instability (CIN) status] and epigenomic status [CpG island methylator phenotype (CIMP) status] play a significant role in determining clinical, pathological and biological characteristics of colorectal cancer. in this review, we discuss molecular classification and molecular correlates based on MSI status and CIMP status in colorectal cancer. Studying molecular correlates is important in cancer research because it can 1) provide clues to pathogenesis, 2) propose or support the existence of a new molecular subtype, 3) alert investigators to he aware of potential confounding factors in association studies, and 4) suggest surrogate markers in clinical or research settings. C1 [Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Goel, Ajay] Baylor Univ, Med Ctr, Dept Internal Med, Dallas, TX USA. [Ogino, Shuji] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Ogino, S (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM shuji_ogino@dfci.harvard.edu FU NCI NIH HHS [P01 CA055075, P01 CA087969, P01 CA55075, P01 CA87969] NR 128 TC 211 Z9 216 U1 3 U2 31 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD JAN PY 2008 VL 10 IS 1 BP 13 EP 27 DI 10.2353/jmoldx.2008.070082 PG 15 WC Pathology SC Pathology GA 253MB UT WOS:000252521200003 PM 18165277 ER PT J AU Copeland, LA Zeber, JE Salloum, IM Pincus, HA Fine, MJ Kilbourne, AM AF Copeland, Laurel A. Zeber, John E. Salloum, Ihsan M. Pincus, Harold A. Fine, Michael J. Kilbourne, Amy M. TI Treatment adherence and illness insight in veterans with bipolar disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE bipolar disorder; illness insight; patient acceptance of health care; patient nonadherence; veterans ID RANDOMIZED CONTROLLED-TRIAL; MEDICATION ADHERENCE; COGNITIVE THERAPY; ANTIPSYCHOTIC MEDICATIONS; RELAPSE PREVENTION; SCHIZOPHRENIA; MAINTENANCE; LITHIUM; MANIA; NONADHERENCE AB Insight into the perceived value of psychotherapy and pharmacological treatment may improve adherence to medication regimens among patients with bipolar disorder, because patients are more likely to take medication they believe will make them better. We conducted a cross-sectional survey of patients recruited into the Continuous Improvement for Veterans in Care-Mood Disorders (CIVIC-MD; July 2004-July 2006), assessing therapeutic insight and 2 measures of medication adherence: the Morisky scale of intrapersonal barriers and missing any doses the previous 4 days. Among 435 patients with bipolar disorder, 27% had poor adherence based on missed dose and 46% had poor adherence based on the Morisky. In multivariable models, greater insight into medication was negatively associated with both measures of poor adherence. Odds of poor adherence increased for women, African Americans, mania, and hazardous drinking. The association of mutable factors-hazardous drinking, manic symptoms, and insight-could represent an opportunity to improve adherence. C1 [Copeland, Laurel A.; Zeber, John E.] VERDICT, S Texas Vet Hlth Care Syst, HSR&D, San Antonio, TX 78229 USA. [Copeland, Laurel A.; Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Salloum, Ihsan M.] Univ Miami, Dept Psychiat & Behav Sci, Leonard M Miller Sch Med, Miami, FL 33152 USA. [Pincus, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Pincus, Harold A.] New York Presbyterian Hosp, New York, NY USA. [Fine, Michael J.] Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. [Kilbourne, Amy M.] Serious Mental Illness Treatment Res & Educ Ctr, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Copeland, LA (reprint author), VERDICT, S Texas Vet Hlth Care Syst, HSR&D, 7400 Merton Minter 11c6, San Antonio, TX 78229 USA. EM laurel.copeland@va.gov OI Copeland, Laurel/0000-0002-9478-0209 FU NIAID NIH HHS [5K24AI01769] NR 43 TC 37 Z9 40 U1 4 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2008 VL 196 IS 1 BP 16 EP 21 DI 10.1097/NMD.0b013e31815fa4d4 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 253IN UT WOS:000252512000003 PM 18195637 ER PT J AU Alcalay, RN Shulman, JM Plotkin, SR AF Alcalay, Roy N. Shulman, Joshua M. Plotkin, Scott R. TI Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article C1 Neurol Inst, New York, NY 10032 USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Alcalay, RN (reprint author), Neurol Inst, 710 W 168th St, New York, NY 10032 USA. EM royalcalay@gmail.com NR 3 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2008 VL 86 IS 1 BP 55 EP 56 DI 10.1007/s11060-007-9448-6 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 238ZS UT WOS:000251487800007 PM 17634859 ER PT J AU Voloschin, AD Betensky, R Wen, PY Hochberg, F Batchelor, T AF Voloschin, Alfredo D. Betensky, Rebecca Wen, Patrick Y. Hochberg, Fred Batchelor, Tracy TI Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE primary CNS lymphoma; salvage therapy; topotecan; radiographic response; survival ID PRIMARY CNS LYMPHOMA; PROSPECTIVE TRIAL; PHASE-II; CHEMOTHERAPY; METHOTREXATE; BRAIN; TEMOZOLOMIDE; RADIATION AB Treatment for patients with refractory or relapsed primary CNS lymphoma (PCNSL) remains unsatisfactory. Topotecan is an intravenous topoisomerase I inhibitor with good CSF penetration and documented efficacy in patients with relapsed systemic non-Hodgkin's lymphoma. In this study 15 patients with refractory or relapsed PCNSL were treated with intravenous topotecan (1.5 mg/m(2) stop) for five consecutive days during each 21-day cycle. All 15 patients had measurable, contrast-enhancing tumor on cranial MRI at the time of relapse. Three (20%) patients achieved a complete response after one, three and four cycles, respectively, while three (20%) patients achieved a partial response after two cycles each, for a total response proportion of 40%. Three patients had stable disease at the end of topotecan treatment. Six patients (40%) had progressive disease during treatment. Median overall survival was 981 days (95% CI: 275, NA) and median progression free survival was 60 days (95% CI: 46, 945). Three out of 15 patients had grade 3 thrombocytopenia. Six out of 15 patients had grade 3 neutropenia, while 5/15 patients had grade 4 neutropenia, and 13/15 patients received g-CSF at some point during treatment. There were no deaths directly related to treatment toxicity. Our study shows that topotecan, as a salvage therapy in patients with relapsed or refractory PCNSL, is associated with an overall response proportion of 40% and should be considered in patients who have failed prior methotrexate-based chemotherapy and/or whole brain irradiation. However, progression is frequent and early and most patients required growth factor support due to myelotoxicity. C1 Massachusetts Gen Hosp, Dept Neurol, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA. Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Dept Radiat Oncol & Neurol, Boston, MA 02114 USA. RP Batchelor, T (reprint author), Massachusetts Gen Hosp, Dept Neurol, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM tbatchelor@partners.org NR 19 TC 38 Z9 39 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2008 VL 86 IS 2 BP 211 EP 215 DI 10.1007/s11060-007-9464-6 PG 5 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 238ZU UT WOS:000251488000012 PM 17896078 ER PT J AU Vivekananda, U Johnston, C McKenna-Yasek, D Shaw, CE Leigh, PN Brown, RH Al-Chalabi, A AF Vivekananda, Umesh Johnston, Clare McKenna-Yasek, Diane Shaw, Christopher E. Leigh, P. Nigel Brown, Robert H. Al-Chalabi, Ammar TI Birth order and the genetics of amyotrophic lateral sclerosis SO JOURNAL OF NEUROLOGY LA English DT Article DE genetic; spermatogenesis; sibship; paternal age effect; birth order ID MOTOR-NEURON DISEASE; PARENTAL AGE; SPONTANEOUS MUTATION; SPORADIC ALS; IDENTIFICATION; RISK AB The cause of ALS remains largely unknown for the 90% with no known family history, but spontaneous mutation to risk alleles of as yet unidentified genes is possible. It has long been recognized that genetic diseases may be more likely to occur in the last born children of a sibship because increased paternal age is associated with an increased spontaneous point mutation rate in sperm. To test the hypothesis that such a mechanism is responsible for sporadic ALS, we have performed a retrospective analysis of birth order position. We have analyzed sibships of size greater than four using a binomial test for birth position. The 478 pedigrees studied show no birth order effect, suggesting that any genetic contributions to sporadic ALS are more likely to be through deletion in large genes or interactions of common polymorphisms, rather than frequent spontaneous point mutation. This is encouraging for the prospect of finding sporadic ALS susceptibility genes using genome-wide association mapping. C1 [Vivekananda, Umesh; Johnston, Clare; Shaw, Christopher E.; Leigh, P. Nigel; Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat, Dept Neurol, MRC Ctr Neurodegenerat Res, London SE5 8AF, England. [McKenna-Yasek, Diane; Brown, Robert H.] Massachusetts Gen Hosp, Cecil B Day Neuromuscular Lab, Boston, MA 02129 USA. [McKenna-Yasek, Diane; Brown, Robert H.] Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Al-Chalabi, A (reprint author), Kings Coll London, Inst Psychiat, Dept Neurol, MRC Ctr Neurodegenerat Res, P043, London SE5 8AF, England. EM ammar@iop.kcl.ac.uk RI Al-Chalabi, Ammar/E-5361-2010 OI Al-Chalabi, Ammar/0000-0002-4924-7712 FU Medical Research Council [, G0500289] NR 16 TC 6 Z9 6 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD JAN PY 2008 VL 255 IS 1 BP 99 EP 102 DI 10.1007/s00415-007-0709-2 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 255RD UT WOS:000252674200015 PM 18060566 ER PT J AU Yip, S Lafrate, AJ Louis, DN AF Yip, Stephen Lafrate, A. John Louis, David N. TI Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Review DE biomarkers; glioblastoma; glioma; molecular diagnostics; neuropathology; oligodendroglioma ID GROWTH-FACTOR RECEPTOR; IN-SITU HYBRIDIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; LOW-GRADE OLIGODENDROGLIOMAS; METHYLTRANSFERASE MGMT GENE; CELL LUNG-CANCER; PHASE-III TRIAL; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER HYPERMETHYLATION AB Advances in understanding the molecular underpinnings of cancer and in molecular diagnostic technologies have changed the clinical practice of oncologic pathology. The development of targeted therapies against specific molecular alterations in cancer further portends changes in the role of the pathology laboratory to guide such custom therapies. To reconcile the flood of scientific discoveries in this area, the promises of highly touted novel therapeutics, and the practicality of applying this knowledge to the day-to-day practice of clinical neuropathology, the present review highlights the operative differences between diagnostic, predictive, and prognostic markers, and discusses issues surrounding the transition of prospective biomarkers to routine laboratory implementation. This review focuses on 3 predictive molecular markers that are either in clinical use or are contemplated for use in the evaluation of malignant gliomas: assessment of 1p/19q loss in oligodendroglial tumors, examination Of O-6-methylguanine DNA methyltransferase promoter methylation status in glioblastomas, and molecular dissection of the epidermal growth factor receptor-phosphatidylinositol 3-kinase pathway in glioblastomas. Implementation of such predictive markers is not straightforward and requires critical review of the available literature and attention to practical laboratory, compliance, financial, and clinical management issues. C1 [Yip, Stephen; Lafrate, A. John; Louis, David N.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Yip, Stephen; Lafrate, A. John; Louis, David N.] Harvard Med Sch, Boston, MA 02114 USA. RP Louis, DN (reprint author), Massachusetts Gen Hosp, James Homer Wright Pathol Labs, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM dlouis@partners.org NR 123 TC 57 Z9 62 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JAN PY 2008 VL 67 IS 1 BP 1 EP 15 DI 10.1097/nen.0b013e31815f65fb PG 15 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 249AI UT WOS:000252198500001 PM 18091559 ER PT J AU Freeman, SH Spires-Jones, T Hyman, BT Growdon, JH Frosch, MP AF Freeman, Stefanie H. Spires-Jones, Tara Hyman, Bradley T. Growdon, John H. Frosch, Matthew P. TI TAR-DNA binding protein 43 in Pick disease SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE frontotemporal dementia; immunohistochemistry; neurodegeneration; Pick bodies; Pick disease; TDP-43 ID FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; TDP-43 PROTEINOPATHY; PATHOLOGY; DEMENTIA; MUTATIONS; NEUROPATHOLOGY; INCLUSIONS AB Pick disease (PiD) is a frontotemporal dementia characterized by frontal and temporal atrophy, neuronal loss, gliosis, ballooned neurons that are positive for alpha-13 crystallin and neurofilament, and the presence of tau- and ubiquitin-positive Pick bodies. TAR-DNA binding protein 43 (TDP-43) has been found to be a component of ubiquitinated inclusions in other neurodegenerative diseases, including frontotemporal lobar degeneration with ubiquitinated inclusions and amyotrophic lateral sclerosis. Fifteen cases of PiD were examined using imimmohistochemical methods, and 5 cases with both Pick bodies and smaller intracytoplasmic inclusions that showed staining for ubiquitin, tau, and TDP-43 were observed. The presence of TDP-43 inclusions in PiD suggests that TDP-43 accumulation may be an important component of many neurodegenerative diseases, and that its presence in only some cases of PiD may indicate different pathways of disease development. C1 [Freeman, Stefanie H.; Hyman, Bradley T.; Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Pathol, CS Kubik Lab Neuropathol, Boston, MA 02114 USA. [Freeman, Stefanie H.; Spires-Jones, Tara; Hyman, Bradley T.; Growdon, John H.; Frosch, Matthew P.] Massachusetts Gen Hosp, Alzheimers Res Unit, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA. [Freeman, Stefanie H.; Spires-Jones, Tara; Hyman, Bradley T.; Growdon, John H.; Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Freeman, Stefanie H.; Spires-Jones, Tara; Hyman, Bradley T.; Growdon, John H.; Frosch, Matthew P.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Freeman, Stefanie H.; Spires-Jones, Tara; Hyman, Bradley T.; Growdon, John H.; Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA USA. RP Freeman, SH (reprint author), Massachusetts Gen Hosp, Alzheimers Dis Res Unit, B114,114 16th St, Charlestown, MA 02129 USA. EM sfreeman1@partners.org FU NIA NIH HHS [AG05134] NR 18 TC 45 Z9 47 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JAN PY 2008 VL 67 IS 1 BP 62 EP 67 DI 10.1097/nen.0b013e3181609361 PG 6 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 249AI UT WOS:000252198500006 PM 18091558 ER PT J AU Elkassabany, NM Bhatia, J Deogaonkar, A Barnett, GH Lotto, M Maurtua, M Ebrahim, Z Schubert, A Ference, S Farag, E AF Elkassabany, Nabil M. Bhatia, Jasmine Deogaonkar, Anupa Barnett, Gene H. Lotto, Michelle Maurtua, Marco Ebrahim, Zeyd Schubert, Armin Ference, Sandra Farag, Ehab TI Perioperative complications of blood brain barrier disruption under general anesthesia: A retrospective review SO JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY LA English DT Review DE blood brain barrier disruption; primary central nervous system lymphoma ID ENHANCED CHEMOTHERAPY DELIVERY; INTRAARTERIAL CHEMOTHERAPY; TUMORS AB Blood brain barrier disruption enhances drug delivery in pritmary central nervous system lymphoma. In this study, we report adverse events that were encountered intraoperatively and in the postoperative period in these patients. A retrospective analysis of 17 patients documenting demographic data, pre-procedure medical history, intraoperative, and postoperative anesthetic complications was conducted between January 2002 and December 2004. Seventeen patients underwent 210 treatments under general anesthesia with a mean of 12.4 +/- 7.2 treatments per patient. Focal seizures occurred in 13% of patients. Generalized motor seizures occurred in 4 treatment sessions in 2 different patients. The incidence of seizures was significantly higher when the internal carotid artery was used for injection, as opposed to the vertebral artery (20.8% and 6.02%, respectively, P = 0.0034). Tachycardia associated with ST segment depression occurred 9 times (4.3%) in 3 patients. One patient had significant ST segment elevation (more than 1.5mm). Transient cerebral vasospasm after methotrexate injection occurred in 9% of patients. Postoperative nausea and vomiting were observed in 11.9% of patients. After emergence, lethargy and obtundation occurred in 7.6% of the cases. The incidence of postoperative headache and reversible motor deficits was 6% and 3.8%, respectively. Our review highlights the problems that were encountered during blood brain barrier disruption under anesthesia and in the postoperative period. Further prospective studies are required for comprehensive evaluation of intraprocedure and postprocedure complications that will allow development of an optimal anesthetic plan and will improve patient outcome by preventing potential complications. C1 [Lotto, Michelle; Maurtua, Marco; Ebrahim, Zeyd; Schubert, Armin; Farag, Ehab] Cleveland Clin, Dept Gen Anesthesiol, Cleveland, OH 44195 USA. [Barnett, Gene H.; Ference, Sandra] Cleveland Clin, Dept Brain Tumor, Cleveland, OH 44195 USA. [Barnett, Gene H.; Ference, Sandra] Cleveland Clin, Neurooncol Ctr, Cleveland, OH 44195 USA. [Farag, Ehab] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44195 USA. [Bhatia, Jasmine; Deogaonkar, Anupa] Cleveland Clin, Div Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA. [Lotto, Michelle; Maurtua, Marco; Schubert, Armin; Farag, Ehab] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA. [Elkassabany, Nabil M.] Univ Penn, Dept Anesthesia & Crit Care, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Farag, E (reprint author), Cleveland Clin, Dept Gen Anesthesiol, E31,9500 Euclid Ave, Cleveland, OH 44195 USA. EM farage@ccf.org RI Schubert, Armin/D-3589-2011 NR 15 TC 13 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0898-4921 J9 J NEUROSURG ANESTH JI J. Neurosurg. Anesthesiol. PD JAN PY 2008 VL 20 IS 1 BP 45 EP 48 PG 4 WC Anesthesiology; Clinical Neurology; Surgery SC Anesthesiology; Neurosciences & Neurology; Surgery GA 247VB UT WOS:000252109600008 PM 18157025 ER PT J AU Crews, L Lentz, MR Gonzalez, RG Fox, HS Masliah, E AF Crews, Leslie Lentz, Margaret R. Gonzalez, R. Gilberto Fox, Howard S. Masliah, Eliezer TI Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS SO JOURNAL OF NEUROVIROLOGY LA English DT Review DE encephalitis; gp120; HIV; macaque; SIV; transgenic ID CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; MAGNETIC-RESONANCE-SPECTROSCOPY; PLATELET-ACTIVATING-FACTOR; PROTON MR SPECTROSCOPY; COAT PROTEIN GP120; HIV-ASSOCIATED DEMENTIA; NECROSIS-FACTOR-ALPHA; ANTIRETROVIRAL THERAPY; TAT PROTEIN AB The success of antiretroviral therapy has reduced the incidence of severe neurological complication resulting from human immunodeficiency virus (HIV) infection. However, increased patient survival has been associated with an increased prevalence of protracted forms of HIV encephalitis leading to moderate cognitive impairment. NeuroAIDS remains a great challenge to patients, their families, and our society. Thus development of preclinical models that will be suitable for testing promising new compounds with neurotrophic and neuroprotective capabilities is of critical importance. The simian immunodeficiency virus (SIV)-infected macaque is the premiere model to study HIV neuropathogenesis. This model was central to the seminal work of Dr. Opendra "Bill" Narayan. Similar to patients with HIV encephalitis, in the SIV model there is injury to the synaptodendritic structure of excitatory pyramidal neurons and inhibitory calbindin-immunoreactive interneurons. This article, which is part of a special issue of the Journal of NeuroVirology in honor of Dr. Bill Narayan, discusses the most important neurodegenerative features in preclinical models of neuroAIDS and their potential for treatment development. C1 [Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Crews, Leslie; Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA. [Lentz, Margaret R.; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Div Neuroradiol, Charlestown, MA USA. [Lentz, Margaret R.; Gonzalez, R. Gilberto] AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Fox, Howard S.] Scripps Res Inst, Dept Mol & Integrat Neurosci, La Jolla, CA 92037 USA. RP Masliah, E (reprint author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM emasliah@UCSD.edu RI Crews, Leslie/B-7584-2014; OI Crews, Leslie/0000-0003-0704-0067; Fox, Howard/0000-0003-2032-374X FU NIH [NS050041, NS051129, NS34626, RR13213, MH45294, MH59745, MH58164, DA12065] FX This work was supported by NIH grants NS050041 (R. G. G.), NS051129 (M. R. L.), NS34626 (R. G. G.), RR13213 (R. G. G.), NS34626 (R. G. G.), MH45294 (E. M.), MH59745 (E. M.), MH58164 (E. M.), and DA12065 (E. M.). NR 153 TC 15 Z9 15 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2008 VL 14 IS 4 BP 327 EP 339 DI 10.1080/13550280802132840 PG 13 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 346MQ UT WOS:000259073000008 PM 18780234 ER PT J AU Kang, JX AF Kang, Jing X. TI A Transgenic Mouse Model for Gene-Nutrient Interactions SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Review DE Transgenic mouse modelcGene-nutrient interactions; Caenorhabditis elegans; Polyunsaturated fatty acids ID POLYUNSATURATED FATTY-ACIDS; FAT-1 MICE; MAMMARY-GLAND; OMEGA-3-FATTY-ACIDS; DESATURASE; NUTRITION; COLITIS; RICH AB Diets or nutritional supplements contain many nutrients and other components that may interact, which adds a layer of complexity to their evaluation. A well-controlled experimental model that can eliminate or minimize the confounding factors of diet is critical for addressing nutrient-gene interactions. The newly generated fat-1 transgenic mouse was genetically engineered to carry a gene, namely fat-1, from the round worm Caenorhabditis elegans and is capable of converting n-6 to n-3 fatty acids (which is naturally impossible in mammals), leading to an increase in n-3 fatty acid content with a balanced n-6/n-3 fatty acid ratio in all tissues, independent of diet. Recent studies using this model indicate that balancing the tissue n-6/n-3 ratio could exert a significant effect on gene expression. The fat-1 mouse model allows carefully controlled studies to be performed in the absence of restricted diets, which can create confounding factors that limit studies of this nature. Copyright (C) 2008 S. Karger AG, Basel C1 [Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA. RP Kang, JX (reprint author), Massachusetts Gen Hosp, Dept Med, 149-13th St,Room 4433, Charlestown, MA 02129 USA. EM kang.jing@mgh.harvard.edu FU American Cancer Society [RSG-03-140-01-CNE]; National Institutes of Health [R01CA-113605] FX This work was supported by grants from the American Cancer Society (RSG-03-140-01-CNE) and the National Institutes of Health (R01CA-113605). NR 16 TC 9 Z9 10 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2008 VL 1 IS 4 BP 172 EP 177 DI 10.1159/000119714 PG 6 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 494FE UT WOS:000269794800003 PM 19776625 ER PT J AU Kang, JX AF Kang, J. X. TI The Fat-1 Mouse Model and Omega-3 Research: An Overview SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Meeting Abstract C1 [Kang, J. X.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2008 VL 1 IS 6 BP 270 EP 270 PG 1 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 494FG UT WOS:000269795000006 ER PT J AU He, C Wang, J Kang, JX AF He, C. Wang, J. Kang, J. X. TI Enhanced Neurogenesis and Neuritogenesis by Docosahexaenoic Acid in Fat-1 Transgenic Mice SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Meeting Abstract C1 [He, C.; Wang, J.; Kang, J. X.] Massachusetts Gen Hosp, Dept Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2008 VL 1 IS 6 BP 271 EP 271 PG 1 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 494FG UT WOS:000269795000011 ER PT J AU Kang, JX AF Kang, J. X. TI The Fat-1 Mouse Model and Omega-3 Research: An Overview SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Meeting Abstract C1 [Kang, J. X.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2008 VL 1 IS 6 BP 279 EP 280 PG 2 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 494FG UT WOS:000269795000030 ER PT J AU Troulis, MJ Tayebaty, FT Papadaki, M Williams, WB Kaban, LB AF Troulis, Maria J. Tayebaty, Fardad T. Papadaki, Maria Williams, W. Bradford Kaban, Leonard B. TI Condylectomy and costochondral graft reconstruction for treatment of active idiopathic condylar resorption SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article; Proceedings Paper CT 87th Annual Meeting of the American-Association-of-Oral-and-Maxillofacial-Surgeons CY SEP 21-24, 2005 CL Boston, MA SP Amer Assoc Oral & Maxillofacial Surg ID VERTICAL RAMUS OSTEOTOMY; ORTHOGNATHIC SURGERY; SKELETAL SCINTIGRAPHY; MANDIBULAR CONDYLES; GROWTH; CONSTRUCTION; DIAGNOSIS; ATROPHY; UNIT; RAT AB Purpose: The purpose of this study was to evaluate the outcomes in patients with active bilateral idiopathic condylar resorption treated by condylectomy and costochondral graft (CCG) reconstruction. Patients and Methods: This was a retrospective evaluation of 15 consecutive patients treated at Massachusetts General Hospital from 1999 to 2004 who had: 1) active bilateral idiopathic condylar resorption confirmed by clinical examination, plain radiographs, and technetium-99 bone scan; 2) adequate documentation; and 3) a minimum of 12 months follow-up. Patients with an identifiable cause of condylar resorption such as rheumatoid or degenerative arthritis, trauma, or steroid use, or who had less than 12 months follow-up were excluded. Preoperative, immediate postoperative, 6-month, 12-month, and latest follow-up clinical examinations, lateral cephalograms, and panoramic radiographs were used to evaluate the Outcomes. Inferior alveolar and marginal mandibular nerve function, jaw motion, and occlusion were evaluated by history and physical examination. All patients underwent bilateral condylectomy and CCG reconstruction. Results: There were 13 female and 2 male patients with a mean age of 24 years. Mean follow-up was 34 months (range, 12 to 84). Preoperatively, all patients had Class II malocclusion: mean overjet 6.2 mm and mean anterior open bite -2.65 mm. At latest postoperative follow-up, all patients showed Class I p occlusion with no anterior open bite, a stable and reproducible occlusion, and a normal range of TMJ motion with a mean maximal incisal opening of 39 mm. Conclusion: The results of this study indicate that a stable and satisfactory outcome is achievable in patients with active idiopathic condylar resorption treated by condylectomy and CCG reconstruction. (C) 2008 American Association of Oral and Maxillofacial Surgeons. C1 [Kaban, Leonard B.] Harvard Univ, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Oral & Maxillofacial Surg Serv, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Oral & Maxillofacial Surg Serv, Boston, MA 02114 USA. [Troulis, Maria J.] Harvard Univ, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Minimally Invas Surg Program, Boston, MA 02114 USA. RP Kaban, LB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Oral & Maxillofacial Surg Serv, Warren 1201,55 Fruit St, Boston, MA 02114 USA. EM Lkaban@Partners.org FU NIDCR NIH HHS [(K23 DE 14070-01] NR 28 TC 19 Z9 20 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2008 VL 66 IS 1 BP 65 EP 72 DI 10.1016/j.joms.2007.08.030 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 245VG UT WOS:000251966300011 PM 18083417 ER PT J AU Friedlander, AH Tajima, T Kawakami, KT Wang, MB Tomlinson, J AF Friedlander, Arthur H. Tajima, Tracey Kawakami, Kyle T. Wang, Marilene B. Tomlinson, James TI The relationship between measures of nutritional status and masticatory function in untreated patients with head and neck cancer SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article; Proceedings Paper CT 89th Annual Meeting of the American-Association-of-Oral-and-Maxillofacial-Surgeons CY OCT 12, 2007 CL Honolulu, HI SP Amer Assoc Oral & Maxillofacial Surg ID QUALITY-OF-LIFE; ORAL-CANCER; ADVANCED-CARCINOMA; WEIGHT-LOSS; DENTITION; DISEASE; CACHEXIA; ALCOHOL; RISK; DIET AB Purpose: Nearly 40% of newly diagnosed patients with head and neck cancer are malnourished before treatment begins with many researchers ascribing the malnutrition to a paucity of teeth. We attempted to determine if inadequate numbers of occluding pairs of teeth, rather than mere numbers of teeth, in newly hospitalized, untreated head and neck cancer patients correlates with nutritional status parameters used to identify those at heightened risk for malnutrition-related complications. Patients and Methods: Patients and cancer-free, matched controls were evaluated for malnutrition (body mass index <= 20 [weight (kg)/height (m(2))]), serum albumin <= 2.7 g/dL, hemoglobin <= 11.9 g/dL, and total lymphocyte count <= 1,449/mu L), and inadequate numbers of occluding pairs of teeth variably defined as less than 5 "posterior pairs" of occluding teeth or less than 6 or 7 "total pairs" of occluding teeth. Results: Head and neck cancer patients had significantly lower body mass index (P =.005) and total lymphocyte count (P =.019) than controls, but there were no significant correlations between the nutritional and dental variables in either group. Conclusions: Untreated head and neck cancer patients frequently have nutritional status parameters indicating heightened risk for malnutrition-related complications but inadequate masticatory function is not a causative factor. C1 [Friedlander, Arthur H.; Tajima, Tracey; Kawakami, Kyle T.; Wang, Marilene B.; Tomlinson, James] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Tomlinson, James] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 55 TC 6 Z9 7 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2008 VL 66 IS 1 BP 85 EP 92 DI 10.1016/j.joms.2007.08.023 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 245VG UT WOS:000251966300014 PM 18083420 ER PT J AU Steinbacher, DM Upton, J Rahbar, R Ferraro, NF AF Steinbacher, Derek M. Upton, Josepb Rahbar, Reza Ferraro, Nalton F. TI Yolk sac tumor of the mandible SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID ENDODERMAL SINUS TUMOR; GERM-CELL TUMORS; NECK REGION; HEAD; CHILDREN; CANCER; ORBIT AB Malignant germ cell tumors represent 3% of neoplasms in the pediatric population. (1)Yolk sac tumors (endodermal sinus tumors) are the most common malignant germ cell tumors in this age group. In young children, the majority of these tumors affect extragonadal sites, principally the sacrococcygeal region. Adolescents and adults usually present with a gonadal primary. Only 6% of germ cell tumors involve the extracranial head and neck.(2-5) No cases have been reported involving the mandible. Here, we present the first reported case of an infant with isolated yolk sac tumor of the right mandible. C1 [Steinbacher, Derek M.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Harvard Combine Program, Boston, MA 02114 USA. [Upton, Josepb; Rahbar, Reza; Ferraro, Nalton F.] Childrens Hosp, Boston, MA 02115 USA. RP Steinbacher, DM (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Harvard Combine Program, 55 Fruit St,Wang ACC 230, Boston, MA 02114 USA. EM dereks@post.harvard.edu NR 20 TC 5 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2008 VL 66 IS 1 BP 151 EP 153 DI 10.1016/j.joms.2006.10.073 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 245VG UT WOS:000251966300026 PM 18083432 ER PT J AU Dworkin, RH Gnann, JW Oaklander, AL Raja, SN Schmader, KE Whitley, RJ AF Dworkin, Robert H. Gnann, John W., Jr. Oaklander, Anne Louise Raja, Srinivasa N. Schmader, Kenneth E. Whitley, Richard J. TI Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia SO JOURNAL OF PAIN LA English DT Article DE herpes zoster; postherpetic neuralgia; diagnosis; assessment; acute pain; chronic pain ID QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; NEUROPATHIC PAIN; CLINICAL-TRIALS; IMMPACT RECOMMENDATIONS; OUTCOME MEASURES; DOUBLE-BLIND; ACYCLOVIR; THERAPY; IMPACT AB Accurate evaluation of pain plays a critical role in identifying new interventions for the treatment and prevention of herpes zoster and postherpetic neuralgia (PHN). Different types of pain and other sensory symptoms are found in patients with herpes zoster, and these vary greatly with respect to their presence, location, duration, intensity, and quality. The results of recent studies of herpes zoster and PHN and the development of new methods for assessing neuropathic pain provide a foundation for diagnosing and assessing the pain associated with herpes zoster. We review the results of recent research to identify the essential components that must be considered in developing an evidence-based description of pain associated with herpes zoster and PHN. Perspective: Comprehensive assessments of pain are necessary for clinical research on the epidemiology, natural history, pathophysiologic mechanisms, treatment and prevention of pain in herpes zoster and PHN. (c) 2008 by the American Pain Society. C1 [Dworkin, Robert H.] Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA. [Dworkin, Robert H.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [Gnann, John W., Jr.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Gnann, John W., Jr.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Oaklander, Anne Louise] Harvard Univ, Dept Neurol, Boston, MA 02115 USA. [Raja, Srinivasa N.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA. [Schmader, Kenneth E.] Duke Univ, Durham VA Med Ctr, Dept Med, Durham, NC USA. [Whitley, Richard J.] Univ Alabama, Dept Pediat, Birmingham, AL USA. RP Dworkin, RH (reprint author), Univ Rochester, Sch Med & Dent, Dept Anesthesiol, 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA. EM robert_dworkin@urmc.rochester.edu OI Yang, Shuman/0000-0002-9638-0890 NR 55 TC 62 Z9 67 U1 1 U2 7 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD JAN PY 2008 VL 9 IS 1 SU 1 BP S37 EP S44 DI 10.1016/j.jpain.2007.10.008 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 256AK UT WOS:000252699900006 PM 18166464 ER PT J AU Gnann, JW AF Gnann, John W., Jr. TI Vaccination to prevent herpes zoster in older adults SO JOURNAL OF PAIN LA English DT Article DE herpes zoster; zoster vaccine; postherpetic neuralgia ID ATTENUATED VARICELLA VACCINE; CELL-MEDIATED-IMMUNITY; POSTHERPETIC NEURALGIA; VIRUS; RESPONSES; INFECTIONS; DECLINE; AGE AB Herpes zoster causes substantial morbidity, especially among older adults. Although the acute cutaneous manifestations can be painful and troublesome, the most important consequence of herpes zoster (shingles) is the chronic pain syndrome known as postherpetic neuralgia (PHN). Previous studies have suggested that declining varicella-zoster virus (VZV)-specific cell-mediated immune (CMI) responses account for the increased frequency of herpes zoster seen in older adults. This led to the idea that immunization designed to boost VZV-specific CMI responses might reduce the risk of herpes zoster. This hypothesis was tested in a large, randomized, placebo-controlled clinical trial called the Shingles Prevention Study (SPS). Compared with the placebo group, herpes zoster vaccine recipients had a 61.1% reduction in zoster "burden of illness" (an index incorporating incidence and severity of herpes zoster); a 66.5% reduction in the incidence of postherpetic neuralgia; and a 51.3% reduction in the incidence of herpes zoster. The incidence of serious adverse events was not different between the overall vaccine and placebo populations. The most frequently encountered adverse event among vaccine recipients was local reactogenicity, with self-limited and generally mild tenderness, warmth, or erythema occurring at the injection site in about one-half of vaccine recipients. The zoster vaccine was approved by the US Food and Drug Administration in 2006 and is indicated for prevention of herpes zoster in immunocompetent persons aged 60 years and older. Perspective: The herpes zoster vaccine provides physicians with an effective means for reducing a patient's risk for developing shingles and its attendant complications. No significant safety concerns regarding the vaccine have been identified Indications for use of the attenuated-virus vaccine in special subpopulations continue to evolve. (c) 2008 by the American Pain Society. C1 [Gnann, John W., Jr.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Gnann, John W., Jr.] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA. [Gnann, John W., Jr.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Gnann, John W., Jr.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Gnann, JW (reprint author), Univ Alabama, Dept Med, 330 Community care Bldg,908 20th St S, Birmingham, AL 35294 USA. EM jgnann@uab.edu NR 33 TC 23 Z9 26 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD JAN PY 2008 VL 9 IS 1 SU 1 BP S31 EP S36 DI 10.1016/j.jpain.2007.10.007 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 256AK UT WOS:000252699900005 PM 18166463 ER PT J AU Oaklander, AL AF Oaklander, Anne Louise TI Mechanisms of pain and itch caused by herpes zoster (shingles) SO JOURNAL OF PAIN LA English DT Article DE shingles; neuralgia; zoster; itch; pruritus; mechanisms ID SPINAL-CORD-INJURY; POSTHERPETIC NEURALGIA; NERVE INJURY; NEUROPATHIC PAIN; DORSAL-HORN; SKIN BIOPSY; CUTANEOUS INNERVATION; MYELINATED AFFERENTS; SENSORY NEUROPATHY; NEURONS AB Study of humans with shingles or postherpetic neuralgia (PHN) is providing insights into pain mechanisms. Shingles pain is a combination of normal and neuropathic pain that reflects acute tissue and neural injury. PHN pain, which lasts after tissues have healed, is caused by persistent neural injuries. Spontaneous C-nociceptor activity has been documented in painful polyneuropathies and probably occurs in shingles as well, although there are no microneurographic studies of either shingles or PHN. It is uncertain if this persists in PHN since pathological examination of PHN-affected nerves and ganglia show chronic neuronal loss and quiescent scarring without inflammation. Skin-biopsy study has correlated the presence of PHN with the severity of persistent distal nociceptive axon loss, and autopsy has correlated pain persistence with segmental atrophy of the spinal cord dorsal horn, highlighting the importance of central responses to nerve injury. Pathological studies of tissues from patients with trigeminal neuralgia suggest that brief lancinating pains reflect ephaptic neurotransmission between adjacent denuded axons. The mechanisms of chronic spontaneous pain and mechanical allodynia remain uncertain despite considerable indirect evidence from animal models. Postherpetic itch is presumably caused by unprovoked firing of the peripheral and/or central neurons that mediate itch. if it occurs in neurons innervating skin left severely deafferented from shingles ("numb"), patients can give themselves painless injuries from scratching. Further human study, by electrophysiological recording, by structural and functional imaging, and by autopsy, should continue to provide much-needed insights. Perspective: Many patients continue to have chronic pain and/or itch after shingles that is unrelieved by current treatments. Many will gladly volunteer for clinical studies, including autopsy, to try and improve understanding of these common and disabling conditions. Their prevalence makes highly powered studies feasible. Funding and organization are the current bottlenecks. (c) 2008 by the American Pain Society. C1 [Oaklander, Anne Louise] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Oaklander, Anne Louise] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Oaklander, AL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 275 Charles St Warren 310, Boston, MA 02114 USA. EM aoaklander@partners.org FU NINDS NIH HHS [R01 NS 2866] NR 64 TC 49 Z9 52 U1 1 U2 13 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD JAN PY 2008 VL 9 IS 1 SU 1 BP S10 EP S18 DI 10.1016/j.jpain.2007.10.003 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 256AK UT WOS:000252699900003 PM 18166461 ER PT J AU Casarett, D Pickard, A Bailey, FA Ritchie, CS Furman, CD Rosenfeld, K Shreve, S Shea, J AF Casarett, David Pickard, Amy Bailey, F. Amos Ritchie, Christine Seel Furman, Christian Davis Rosenfeld, Ken Shreve, Scott Shea, Judy TI A nationwide VA palliative care quality measure: The Family Assessment of Treatment at the End of Life SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ITEM RESPONSE THEORY; HOSPICE CARE; DATA SET; PERSPECTIVES; VALIDATION; MEMBERS; HEALTH; DEATH; OLDER AB Objectives: To evaluate the FATE ( Family Assessment of Treatment at End of Life) Survey for use as a nationwide quality measure in the VA health care system. Design: Nationwide telephone survey. Setting: Five VA medical centers. Participants: Eligible patients received inpatient or outpatient care from a participating VA facility in the last month of life. One respondent/patient was selected using predefined eligibility criteria and invited to participate. Measurements: The FATE survey consists of 32 items in 9 domains: Well-being and dignity (4 items), Information and communication (5 items), Respect for treatment preferences (2 items), Emotional and spiritual support (3 items), Management of symptoms (4 items), Choice of inpatient facility (1 item), Care around the time of death (6 items), Access to VA services (4 items), and Access to VA benefits after the patient's death (3 items). Results: Interviews were completed with 309 respondents. The FATE showed excellent psychometric characteristics, with good homogeneity (e.g., Cronbach (alpha = 0.91) and no evidence of significant ceiling effects. The FATE also demonstrated good discriminant validity. For instance, FATE scores varied across facilities ( range 44-72; Kruskal Wallis test p < 0.001). Patients who were seen by a palliative care service had better scores ( mean 66 versus 52; rank sum test p < 0.001), as did patients who were referred to hospice (67 versus 49; rank sum test p < 0.001). Conclusions: The FATE survey offers an important source of quality data that can be used to improve the end-of-life care of all veterans, regardless of the type of care they receive or their site of death. C1 [Casarett, David] Univ Penn, Philadelphia, PA 19104 USA. [Shreve, Scott] Lebanon VA, Lebanon, PA USA. [Rosenfeld, Ken] Greater Los Angeles VA, Los Angeles, CA USA. [Furman, Christian Davis] Univ Louisville, Dept Family & Geriatr Med, Louisville, KY 40292 USA. [Ritchie, Christine Seel] Univ Alabama, Ctr Palliat Care, Birmingham, AL USA. [Bailey, F. Amos; Ritchie, Christine Seel] Birmingham VAMC, Birmingham, AL USA. [Casarett, David; Pickard, Amy; Shea, Judy] Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Casarett, D (reprint author), Univ Penn, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu NR 21 TC 37 Z9 38 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JAN PY 2008 VL 11 IS 1 BP 68 EP 75 DI 10.1089/jpm.2007.0104 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 254AY UT WOS:000252559900014 PM 18370895 ER PT J AU Hermsen, JL Gomez, FE Maeshima, Y Sano, Y Woodae, K Kudsk, KA AF Hermsen, Joshua L. Gomez, F. Enrique Maeshima, Yoshinori Sano, Yoshifumi Kang, Woodae Kudsk, Kenneth A. TI Decreased enteral stimulation alters mucosal immune chemokines SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article ID TOTAL PARENTERAL-NUTRITION; HIGH ENDOTHELIAL VENULES; ADHESION MOLECULE-1 MADCAM-1; UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; RNA-BINDING PROTEIN; LYMPHOID-TISSUE; MESSENGER-RNA; DENDRITIC CELLS; INTRAEPITHELIAL LYMPHOCYTES AB Background: Migration of lymphocytes into and through the mucosal immune system depends upon adhesion molecules to attract circulating cells and chemokines to stimulate diapedesis into tissues. Decreased enteral stimulation significantly reduces mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) levels, an adhesion molecule critical for homing of T and B cells to Peyer's patches (PP), which reduces PP and intestinal T and B cells. We studied the effect of type and route of nutrition on tissue specific chemokines in PP (CXCL-12, -13 and CCL-19, -20 and -21), small intestine (SI; CCL-20, -25 and -28) and lung (CXCL-12, CCL-28). Methods: Intravenously cannulated male Institute of Cancer Research (ICR) mice were randomized to chow or parenteral nutrition (PN) for 5 days. PP, SI, and lung chemokine mRNA levels were measured using real-time qRT-polymerase chain reaction, and analyzed serniquantitatively by the Delta Delta Ct method. Protein levels were quantified using enzyme-linked immunosorbent assay (ELISA) techniques, and groups compared using Student's t-test. Results: PP CXCL13 protein significantly decreased, whereas CCL21 protein increased significantly in the parenterally fed group. Parenteral feeding significantly decreased SI CCL20 and CCL 25 protein levels. CCL28 decreased significantly in the SI and lung of intravenously fed animals. mRNA levels changed in the opposite direction (compared with protein) for all chemokines except CCL28. Conclusions: Decreased enteral stimulation significantly alters key mucosal immune chemokine protein levels at multiple sites. In general, PN (and concomitant lack of enteral stimulation) results in decreased levels of chemokines that control lymphocyte migration within the mucosal immune system. C1 [Hermsen, Joshua L.; Gomez, F. Enrique; Maeshima, Yoshinori; Sano, Yoshifumi; Kang, Woodae; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Kudsk, Kenneth A.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, H4-736 Clin Sci Ctr, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU PHS HHS [R01 6M53439] NR 60 TC 10 Z9 12 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JAN-FEB PY 2008 VL 32 IS 1 BP 36 EP 44 DI 10.1177/014860710803200136 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 247IO UT WOS:000252072000006 PM 18165445 ER PT J AU Gerbino, PG Zurakowski, D Soto, R Griffin, E Reig, TS Micheli, LJ AF Gerbino, Peter G. Zurakowski, David Soto, Ricardo Griffin, Elizabeth Reig, Thomas S. Micheli, Lyle J. TI Long-term functional outcome after lateral patellar retinacular release in adolescents - An observational cohort study with minimum 5-year follow-up SO JOURNAL OF PEDIATRIC ORTHOPAEDICS LA English DT Article DE knee; lateral patellar retinacular release; instability; patellar tilt; survivorship ID PATELLOFEMORAL PAIN; PROXIMAL REALIGNMENT; DISLOCATION; INSTABILITY; DISORDERS; RESPONSIVENESS; RELIABILITY; MANAGEMENT; VALIDITY; LIGAMENT AB Background: Lateral patellar retinacular release has been recommended for patients with patellar tilt, tight lateral retinaculum, patellar subluxation, patellar dislocation, and patellofemoral pain. Studies of long-term outcomes after lateral release are limited, especially for differing, indications. Hypothesis: Adolescents do well after lateral retinacular release in the 5- to 22-year time frame. Methods: Patients having undergone lateral retinacular release between the years of 1981 and 1999 were contacted. Evaluation was by the Cincinnati and Lysholm scales and by level of satisfaction and need for reoperation. Results: One hundred forty knees were studied. Mean age at operation was 15.4 years (SD, 2.7 years). Average follow-up was 8.5 (SD, 4.1 years; range, 5.2-22.5 years). Twenty-five patients had needed reoperation, indicating failure of the index operation. Kaplan-Meier survivorship was 78% at 15 years. Cincinnati and Lysholm scores indicated well-functioning knees in those not requiring reoperation. Overall satisfaction improved as time from operation increased. Comparisons were made between the group requiring reoperation and those who did not. Focus was placed on knees with patellar maltracking or tilt versus patellar instability and between males and females. No differences were found among groups for reoperation rate, level of satisfaction, average Lysholm score, or average Cincinnati score. There were no differences in demographics or outcome measures between patients with patellar instability and those with tilt. Instability patients trended toward higher reoperation rates than did tilt patients, but the difference was not significant. There were no differences between males and females. Conclusion: The majority of patients are satisfied with their knee 5 to 22 years after lateral patellar retinacular release and scored well on questions rating knee health and function. Level of Evidence: Retrospective cohort study: level 2. C1 [Gerbino, Peter G.] Monterey Joint Replacement & Sports Med, Monterey, CA USA. [Zurakowski, David] Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. [Soto, Ricardo] Dana Farber Canc Inst, Boston, MA 02115 USA. [Griffin, Elizabeth] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA. [Micheli, Lyle J.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA USA. [Micheli, Lyle J.] Childrens Hosp, Div Sports Med, Boston, MA 02115 USA. [Reig, Thomas S.] Naval Reg Med Ctr, Dept Biostat, Portsmouth, VA USA. RP Gerbino, PG (reprint author), 900 Cass St,Suite 200, Monterey, CA 93940 USA. EM peter.gerbino@gmail.com NR 41 TC 13 Z9 16 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-6798 J9 J PEDIATR ORTHOPED JI J. Pediatr. Orthop. PD JAN-FEB PY 2008 VL 28 IS 1 BP 118 EP 123 PG 6 WC Orthopedics; Pediatrics SC Orthopedics; Pediatrics GA 299PD UT WOS:000255766600020 PM 18157056 ER PT J AU Donahoe, PK AF Donahoe, Patricia K. TI The mandate for innovation in pediatric surgery; creating the environment for success, parity, and excellence SO JOURNAL OF PEDIATRIC SURGERY LA English DT Editorial Material ID MULLERIAN-INHIBITING SUBSTANCE; HUMAN OVARIAN-CANCER; II RECEPTOR; DUCT REGRESSION; GROWTH; CELLS; PURIFICATION; EXPRESSION; MIS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Res Labs,Simches Res Ctr, Boston, MA 02114 USA. RP Donahoe, PK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Res Labs,Simches Res Ctr, Boston, MA 02114 USA. EM pdonahoe@partners.org NR 22 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2008 VL 43 IS 1 BP 1 EP 7 DI 10.1016/j.jpedsurg.2007.09.008 PG 7 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 260ZL UT WOS:000253048800001 PM 18213745 ER PT J AU Hopwood, CJ Baker, KL Morey, LC AF Hopwood, Christopher J. Baker, Kay L. Morey, Leslie C. TI Extratest Validity of Selected Personality Assessment Inventory Scales and Indicators in an Inpatient Substance Abuse Setting SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID FORENSIC EVALUATION; PCL-R; INMATES; PSYCHOPATHY; PAI; ADJUSTMENT; AGGRESSION; OFFENDERS AB The purpose of this study was to extend previous findings regarding the extratest validity of the Personality Assessment Inventory (Morey, 1991, 2007) scales and indicators in forensic contexts to an inpatient substance abuse setting. The Aggression Scale, and particularly the Physical Aggression subscale, related to assault history; the Suicide Scale and Suicide Probability Index related to history of suicide attempts; Antisocial Features, and particularly the Antisocial Behaviors subscale, predicted rule infractions; and the Treatment Process Index predicted treatment completion. We discuss clinical implications in the context of extant findings. C1 [Hopwood, Christopher J.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [Baker, Kay L.] Cent Texas Treatment Ctr, Granger, TX USA. [Hopwood, Christopher J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hopwood, Christopher J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Morey, Leslie C.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA. RP Hopwood, CJ (reprint author), Michigan State Univ, Dept Psychol, 107A Psychol, E Lansing, MI 48824 USA. EM hopwood2@msu.edu RI Morey, Leslie/B-5617-2008 OI Morey, Leslie/0000-0001-7711-5568 FU NIMH NIH HHS [MH75543] NR 21 TC 18 Z9 18 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2008 VL 90 IS 6 BP 574 EP 577 DI 10.1080/00223890802388533 PG 4 WC Psychology, Clinical; Psychology, Social SC Psychology GA 365TR UT WOS:000260431500006 PM 18925498 ER PT J AU Hopwood, CJ Pincus, AL DeMoor, RM Koonce, EA AF Hopwood, Christopher J. Pincus, Aaron L. DeMoor, Rebecca M. Koonce, Elizabeth A. TI Psychometric Characteristics of the Inventory of Interpersonal Problems-Short Circumplex (IIP-SC) With College Students SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID NARCISSISTIC PERSONALITY-INVENTORY; CONSTRUCT-VALIDITY; ATTACHMENT STYLES; PSYCHOTHERAPY; CIRCLE; SCALES; MODEL AB The Inventory of Interpersonal Problems-Circumplex (IIP-C; Alden, Wiggins, & Pincus, 1990) is a commonly used measure, and the Short Circumplex Version (IIP-SC; Soldz, Budman, Demby, Merry, 1995) provides a potentially valuable and economical method for personality assessment researchers. However, despite the common use of the IIP-C with college students, the psychometric characteristics of the IIP-SC have not been established in a college student sample. This study provides reliability, structural validity, concurrent validity, and descriptive data for the IIP-SC in two samples of undergraduate students. C1 [Hopwood, Christopher J.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. [Hopwood, Christopher J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hopwood, Christopher J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Pincus, Aaron L.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA. [DeMoor, Rebecca M.] Villanova Univ, Dept Psychol, Villanova, PA 19085 USA. [Koonce, Elizabeth A.] Univ Toledo, Dept Psychol, Toledo, OH USA. RP Hopwood, CJ (reprint author), Michigan State Univ, Dept Psychol, 107A Psychol, E Lansing, MI 48824 USA. EM hopwood2@msu.edu NR 24 TC 26 Z9 26 U1 2 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2008 VL 90 IS 6 BP 615 EP 618 DI 10.1080/00223890802388665 PG 4 WC Psychology, Clinical; Psychology, Social SC Psychology GA 365TR UT WOS:000260431500012 PM 18925504 ER PT J AU Fukunaga, K Shioda, N Tokoro, T Beppu, H Hara, H Kitajima, I AF Fukunaga, Kohji Shioda, Norifumi Tokoro, Takashi Beppu, Hideyuki Hara, Hideaki Kitajima, Isao TI Mechanisms of abnormal spine formation in the psychotic disorder model mice SO JOURNAL OF PHARMACOLOGICAL SCIENCES LA English DT Meeting Abstract CT 81st Annual Meeting of the Japanese-Pharmacological-Society CY MAR 17-19, 2008 CL Yokohama, JAPAN SP Japanese Pharmacol Soc C1 [Fukunaga, Kohji; Shioda, Norifumi] Tohoku Univ, Dept Pharmacol, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan. [Fukunaga, Kohji] CRESCENDO, 21st Century COE Program, Sendai, Miyagi 9808578, Japan. [Tokoro, Takashi; Kitajima, Isao] Toyama Univ, Dept Clin Mol Pathol Med, Toyama 9300194, Japan. [Hara, Hideaki] Gifu Pharmaceut Univ, Gifu 5028585, Japan. [Beppu, Hideyuki] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JAPANESE PHARMACOLOGICAL SOC PI KYOTO PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN SN 1347-8613 J9 J PHARMACOL SCI JI J. Pharmacol. Sci. PY 2008 VL 106 SU 1 BP 39P EP 39P PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 278ED UT WOS:000254265900125 ER PT J AU Donelan, MB Garcia, JA AF Donelan, Matthias B. Garcia, Jesus A. TI Purse-string closure of scalp defects following tissue expansion: an effective aesthetic alternative SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY LA English DT Article DE purse-string closure; tissue expansion; scalp defects ID MAXIMIZING GAIN; SKIN DEFECTS; SUTURE; EXPANDERS AB Primary closure of scalp defects under tension can be complicated by scar widening and alopecia, and large defects usually require the use of local flaps, skin grafts or free flaps. Tissue expansion facilitates the use of local flaps to cover Large defects, but multiple expanders and complex flaps with extensive incisions may cause significant scars and alopecia. We describe a purse-string closure of expanded scalp tissue following excision of a Large congenital nevus sebaceous. This scalp reconstructive technique minimises iatrogenic scars and uses the predictable forces of scar contracture and skin re-draping to achieve a superior aesthetic result. (C) 2007 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. C1 [Donelan, Matthias B.] Shriners Burns Hosp, Div Plast Surg, Boston, MA 02114 USA. [Garcia, Jesus A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Donelan, MB (reprint author), Shriners Burns Hosp, Div Plast Surg, 51 Blossom St, Boston, MA 02114 USA. EM mdonelan@partners.org NR 9 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1748-6815 J9 J PLAST RECONSTR AES JI J. Plast. Reconstr. Aesthet. Surg. PY 2008 VL 61 IS 4 BP 419 EP 422 DI 10.1016/j.bjps.2007.02.002 PG 4 WC Surgery SC Surgery GA 292WK UT WOS:000255296600014 PM 17449341 ER PT J AU Harezlak, J Wu, MC Wang, M Schwartzman, A Christiani, DC Lin, XH AF Harezlak, Jaroslaw Wu, Michael C. Wang, Mike Schwartzman, Armin Christiani, David C. Lin, Xihong TI Biomarker discovery for arsenic exposure using functional data. Analysis and feature learning of mass spectrometry proteomic data SO JOURNAL OF PROTEOME RESEARCH LA English DT Article ID DRINKING-WATER; SERUM; CANCER; TOXICOLOGY; PROTEIN; SAMPLES AB Plasma biomarkers of exposure to environmental contaminants play an important role in early detection of disease. The emerging field of proteomics presents an attractive opportunity for candidate biomarker discovery, as it simultaneously measures and analyzes a large number of proteins. This article presents a case study for measuring arsenic concentrations in a population residing in an As-endemic region of Bangladesh using plasma protein expressions measured by SELDI-TOF mass spectrometry. We analyze the data using a unified statistical method based on functional learning to preprocess mass spectra and extract mass spectrometry (MS) features and to associate the selected MS features with arsenic exposure measurements. The task is challenging due to several factors, the high dimensionality of mass spectrometry data, complicated error structures, and a multiple comparison problem. We use nonparametric functional regression techniques for MS modeling, peak detection based on the significant zero-downcrossing method, and peak alignment using a warping algorithm. Our results show significant associations of arsenic exposure to either under- or overexpressions of 20 proteins. C1 [Harezlak, Jaroslaw] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Wu, Michael C.; Schwartzman, Armin; Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Wang, Mike; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Schwartzman, Armin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Harezlak, J (reprint author), Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA. EM harezlak@iupui.edu; mwu@hsph.harvard.edu RI Harezlak, Jaroslaw/P-8557-2014; OI Harezlak, Jaroslaw/0000-0002-3070-7686; Wu, Michael C./0000-0002-3357-6570; Schwartzman, Armin/0000-0001-5335-1611 FU NCI NIH HHS [R37CA76404]; NIEHS NIH HHS [ES00002, R01ES015533, R01ES011622] NR 24 TC 23 Z9 23 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD JAN PY 2008 VL 7 IS 1 BP 217 EP 224 DI 10.1021/pr070491n PG 8 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 248LG UT WOS:000252154200026 PM 18173220 ER PT J AU Oberg, AL Mahoney, DW Eckel-Passow, JE Malone, CJ Wolfinger, RD Hill, EG Cooper, LT Onuma, OK Spiro, C Therneau, TA Bergen, HR AF Oberg, Ann L. Mahoney, Douglas W. Eckel-Passow, Jeanette E. Malone, Christopher J. Wolfinger, Russell D. Hill, Elizabeth G. Cooper, Leslie T. Onuma, Oyere K. Spiro, Craig Therneau, Terry A. Bergen, H. Robert, III TI Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE proteomics; ANOVA; iTRAQ; normalization; relative labeling protocol; missing data; Gauss-Siedel; backfitting; fixed effects model; mixed effects model ID PROTEIN EXPRESSION; CANCER CELLS; PROTEOMICS; ARRAYS; MODEL; QUANTITATION; MICROARRAYS; VARIANCE; DESIGN AB Statistical tools enable unified analysis of data from multiple global proteomic experiments, producing unbiased estimates of normalization terms despite the missing data problem inherent in these studies. The modeling approach, implementation, and useful visualization tools are demonstrated via a case study of complex biological samples assessed using the iTRAQ relative labeling protocol. C1 [Oberg, Ann L.; Mahoney, Douglas W.; Eckel-Passow, Jeanette E.; Therneau, Terry A.] Mayo Clin & Mayo Fdn, Canc Ctr Stat, Dept Hlth Sci Res, Div Biostat, Rochester, MN 55905 USA. [Malone, Christopher J.] Winona State Univ, Dept Math & Stat, Winona, MN 55987 USA. [Wolfinger, Russell D.] SAS Inst Inc, Cary, NC 27513 USA. [Hill, Elizabeth G.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Cooper, Leslie T.] Mayo Clin & Mayo Fdn, Div Cardiol, Rochester, MN 55905 USA. [Onuma, Oyere K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Spiro, Craig] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. [Bergen, H. Robert, III] Mayo Clin & Mayo Fdn, Mayo Proteom Res Ctr, Rochester, MN 55905 USA. RP Oberg, AL (reprint author), Mayo Clin & Mayo Fdn, Canc Ctr Stat, Dept Hlth Sci Res, Div Biostat, 200 1st St SW, Rochester, MN 55905 USA. EM oberg.ann@mayo.edu FU NCRR NIH HHS [1 UL1 RR024150-01, UL1 RR024150, UL1 RR024150-01] NR 26 TC 64 Z9 64 U1 0 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD JAN PY 2008 VL 7 IS 1 BP 225 EP 233 DI 10.1021/pr700734f PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 248LG UT WOS:000252154200027 PM 18173221 ER PT J AU Papakostas, GI Trivedi, MH Alpert, JE Seifert, CA Krishen, A Goodale, EP Tucker, VL AF Papakostas, George I. Trivedi, Madhukar H. Alpert, Jonathan E. Seifert, Cheryl A. Krishen, Alok Goodale, Elizabeth P. Tucker, Vivian L. TI Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE anxiety; depression; bupropion; SSRIs; MDD; treatment ID VENLAFAXINE EXTENDED-RELEASE; SUSTAINED-RELEASE; ANTIDEPRESSANT EFFICACY; ANXIOUS DEPRESSION; PAROXETINE; OUTPATIENTS; FLUOXETINE; SERTRALINE; PLACEBO; MIRTAZAPINE AB The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 2.8 vs. -3.9 2.8, p = 0.130) or HAM-A score (-8.8 +/- 17.2 vs. -9.1 +/- 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score > 0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score > 7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 +/- 1.14 vs. 1.25 +/- 1.09, P = 0.569), or HAM-A scores at endpoint (3.30 +/- 12.89 vs. 3.31 +/- 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Papakostas, George I.; Alpert, Jonathan E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Krishen, Alok; Goodale, Elizabeth P.; Tucker, Vivian L.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA. RP Papakostas, GI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013; OI Papakostas, George/0000-0002-2465-5103; Alpert, Jonathan/0000-0002-4332-908X FU NIMH NIH HHS [K23 MH069629] NR 49 TC 26 Z9 27 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2008 VL 42 IS 2 BP 134 EP 140 DI 10.1016/j.jpsychires.2007.05.012 PG 7 WC Psychiatry SC Psychiatry GA 240AB UT WOS:000251558300006 PM 17631898 ER PT J AU Bohne, A Savage, CR Deckersbach, T Keuthen, NJ Wilhelm, S AF Bohne, Antje Savage, Cary R. Deckersbach, Thilo Keuthen, Nancy J. Wilhelm, Sabine TI Motor inhibition in trichotillomania and obsessive-compulsive disorder SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE trichotillomania; obsessive-compulsive disorder; information processing; motor inhibition; obsessive-compulsive spectrum ID REDUCED COGNITIVE INHIBITION; GO NOGO TASKS; NEUROPSYCHOLOGICAL PERFORMANCE; UNIPOLAR DEPRESSION; SPECTRUM DISORDERS; PREFRONTAL CORTEX; TOURETTE-SYNDROME; ERP COMPONENTS; DEFICITS; DYSFUNCTION AB We investigated motor inhibition abilities in trichotillomania (TTM) and obsessive-compulsive disorder (OCD), two disorders characterized by repetitive, intentionally performed behaviors. Performance in a GoNogo experiment of 25 TTM and 21 OCD participants was compared to the performance of 26 HC participants. In contrast to OCD and HC participants, TTM participants tended to perform either 'fast and inaccurate' (indicating poor motor inhibition) or 'slow and accurate'. TTM participants with poor motor inhibition reported a significantly earlier age of TTM onset than those TTM participants who performed well. There was no evidence for motor inhibition deficits in OCD. Based on our data, a subgroup of TTM sufferers seems to be characterized by motor inhibition deficits. (c) 2006 Elsevier Ltd. All rights reserved. C1 [Bohne, Antje; Deckersbach, Thilo; Keuthen, Nancy J.; Wilhelm, Sabine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, OCD Clin, Boston, MA 02114 USA. [Savage, Cary R.] Univ Kansas, Med Ctr, Lawrence, KS 66045 USA. RP Wilhelm, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, OCD Clin, Simches Res Bldg,2nd Floor,185 Cambridge St, Boston, MA 02114 USA. EM wilhelm@psych.mgh.harvard.edu RI Citations, TLC SAB/C-4006-2011 NR 68 TC 39 Z9 39 U1 11 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2008 VL 42 IS 2 BP 141 EP 150 DI 10.1016/j.jpsychires.2006.11.008 PG 10 WC Psychiatry SC Psychiatry GA 240AB UT WOS:000251558300007 PM 17215004 ER PT J AU Gesty-Palmer, D Luttrell, LM AF Gesty-Palmer, Diane Luttrell, Louis M. TI Heptahelical terpsichory. Who calls the tune? SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION LA English DT Article; Proceedings Paper CT Annual Meeting of the Great Lakes GPCR Retreat CY SEP 27-29, 2007 CL London, CANADA ID PROTEIN-COUPLED RECEPTOR; BETA(2) ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE PTH; NUCLEAR EXPORT SIGNAL; TERNARY COMPLEX MODEL; BETA(2)-ADRENERGIC RECEPTOR; ERK1/2 ACTIVATION; EFFECTOR PATHWAY; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION AB The discovery that arrestins can function as ligand-regulated signaling scaffolds has revealed a previously unappreciated level of complexity in G protein-coupled receptor (GPCR) signal transduction. Because arrestin-bound GPCRs are uncoupled from G proteins, arrestin binding can be viewed as switching receptors between two temporally and spatially distinct signaling modes. Recent work has established two factors that underscore this duality of GPCR signaling and suggest it may ultimately have therapeutic significance. The first is that signaling by receptor-arrestin "signalsomes" does not require heterotrimeric G protein activation. The second is that arrestin-dependent signals can be initiated by pathway-specific "biased agonists," creating the potential for drugs that selectively modulate different aspects of GPCR function. Currently, however, little is known about the physiological relevance of G protein-independent signals at the cellular or whole animal levels, and additional work is needed to determine whether arrestin pathway-selective drugs will find clinical application. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Gesty-Palmer, Diane] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Gesty-Palmer, Diane] Vet Affairs Med Ctr, Durham, NC USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA. EM luttrell@musc.edu NR 112 TC 18 Z9 19 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1079-9893 J9 J RECEPT SIG TRANSD JI J. Recept. Signal Transduct. PY 2008 VL 28 IS 1-2 BP 39 EP 58 DI 10.1080/10799890801941921 PG 20 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299JR UT WOS:000255752400005 PM 18437629 ER PT J AU Lew, HL Vanderploeg, RD Moore, DE Schwab, K Friedman, L Yesavage, J Keane, TM Warden, DL Sigford, BJ AF Lew, Henry L. Vanderploeg, Rodney D. Moore, David E. Schwab, Karen Friedman, Leah Yesavage, Jerome Keane, Terence M. Warden, Deborah L. Sigford, Barbara J. TI Overlap of mild TBI and mental health conditions in returning OIF/OEF service members and veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; IRAQ; METAANALYSIS; AFGHANISTAN; SYMPTOMS; MILITARY C1 [Lew, Henry L.] VA Palo Alto Healthcare Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA. [Lew, Henry L.; Friedman, Leah; Yesavage, Jerome] Stanford Univ, Sch Med, Stanford, CA USA. [Vanderploeg, Rodney D.] James A Haley VA Hosp, Tampa, FL USA. [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA. [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA. [Friedman, Leah; Yesavage, Jerome] VA Palo Alto Healthcare Syst, Psychiat Serv, Palo Alto, CA USA. [Keane, Terence M.] VA Boston Healthcare Syst, Boston, MA USA. [Keane, Terence M.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Sigford, Barbara J.] VA Hlth Care System, Minneapolis, MN USA. [Sigford, Barbara J.] Univ Minnesota, Minneapolis, MN USA. RP Lew, HL (reprint author), VA Palo Alto Healthcare Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA. EM henrylew@stanford.edu NR 30 TC 49 Z9 49 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP XI EP XVI DI 10.1682/JRRD.2008.05.0064 PG 6 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300002 PM 18629743 ER PT J AU Cooper, RA AF Cooper, Rory A. TI In Memoriam: Men Beyond Measure SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Biographical-Item C1 [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Serv, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Serv, Pittsburgh, PA USA. EM rcooper@pitt.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 9 BP XVII EP XVIII PG 2 WC Rehabilitation SC Rehabilitation GA 426RN UT WOS:000264725500004 ER PT J AU Kwarciak, AM Cooper, RA Fitzgerald, SG AF Kwarciak, Andrew M. Cooper, Rory A. Fitzgerald, Shirley G. TI Curb descent testing of suspension manual wheelchairs SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE acceleration; curb descent; folding frame; manual wheelchair; rehabilitation; rigid frame; suspension; vibration suppression; wheelchair use; whole-body vibrations ID WHOLE-BODY VIBRATION; LOW-BACK-PAIN; SEAT; RESPONSES; SHOCK AB Manual wheelchair users are subjected to whole-body vibrations (WBV) on a regular basis as they traverse obstacles and uneven surfaces. One way users could protect themselves from secondary injuries related to WBV is by using a suspension manual wheelchair. This study investigated the ability of suspension manual wheelchairs to reduce seat accelerations during curb descents of various heights (5, 10, and 15 cm). Sixteen manual wheelchairs (four suspension, four folding, four rigid, and four rigid titanium) were tested. Suspension wheelchairs transmitted significantly lower peak seat accelerations than folding wheelchairs during the 5 cm curb descents (p = 0.048) and significantly lower frequency-weighted peak seat accelerations during the 5 and 10 cm curb descents (p = 0.03 for both heights). However, when the suspension wheelchair Quickie XTR (Sunrise Medical; Carlsbad, California) was removed from the analysis, the suspension wheelchairs were not significantly different from the nonsuspension wheelchairs. When weight was considered, the suspension wheelchairs had significantly lower peak seat accelerations than the lighter rigid wheelchairs during 5 cm curb descents (p = 0.047). While suspension manual wheelchairs offer some reduction in WBV during curb descents, their limitations should be considered when a wheelchair is selected for everyday use. C1 [Kwarciak, Andrew M.; Cooper, Rory A.; Fitzgerald, Shirley G.] VA Pittsburgh Healthcare Syst, VA Ctr Excellence Wheelchairs & Associated Rehabi, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [Kwarciak, Andrew M.; Cooper, Rory A.; Fitzgerald, Shirley G.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Kwarciak, Andrew M.; Cooper, Rory A.] Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15261 USA. [Cooper, Rory A.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, VA Ctr Excellence Wheelchairs & Associated Rehabi, Human Engn Res Labs, Dept Vet Affairs, 151R1-H,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu NR 29 TC 4 Z9 4 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 1 BP 73 EP 84 DI 10.1682/JRRD.2006.11.0142 PG 12 WC Rehabilitation SC Rehabilitation GA 290PB UT WOS:000255133600007 PM 18566927 ER PT J AU Vasterling, JJ Schumm, J Proctor, SP Gentry, E King, DW King, LA AF Vasterling, Jennifer J. Schumm, Jeremiah Proctor, Susan P. Gentry, Elisabeth King, Daniel W. King, Lynda A. TI Posttraumatic stress disorder and health functioning in a non-treatment-seeking sample of Iraq war veterans: A prospective analysis SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE functioning; health; health risk behaviors; Iraq war; OIF; PTSD; rehabilitation; soldiers; veterans; VR-12 ID CONFIRMATORY FACTOR-ANALYSIS; REPORTED PHYSICAL HEALTH; ADMINISTERED PTSD SCALE; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; VIETNAM VETERANS; ANXIETY DISORDERS; CLINICAL-RESEARCH; SOMATIC SYMPTOMS; COMBAT EXPOSURE AB To evaluate the impact of posttraumatic stress disorder (PTSD) on health-related functioning, we assessed 800 U.S. Army soldiers before and after 1-year military deployments to Iraq. As part of the Neurocognition Deployment Health Study procedures, each soldier completed at both time points self-report indexes of PTSD symptom severity, health behaviors (smoking, alcohol use), and somatic health-related functioning. Participants also completed a health-symptom checklist at the postdeployment assessment. Structural equation modeling revealed that postdeployment PTSD severity was associated with change in somatic health-related functioning, with postdeployment health symptoms as an intermediary variable. These relationships were independent of health risk behaviors, which had little association with somatic symptoms or PTSD. Our findings highlight the functional impact of PTSD, which extends beyond psychological symptoms to health-related daily functioning. C1 [Vasterling, Jennifer J.; Gentry, Elisabeth; King, Daniel W.; King, Lynda A.] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA 02130 USA. [Vasterling, Jennifer J.; King, Daniel W.; King, Lynda A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Vasterling, Jennifer J.; King, Daniel W.; King, Lynda A.] VA Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. [Schumm, Jeremiah] VA Boston Healthcare Syst, Harvard Med Sch, Boston, MA USA. [Proctor, Susan P.] USA, Environm Med Res Inst, Natick, MA 01760 USA. [Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Vasterling, JJ (reprint author), VA Boston Healthcare Syst, Dept Vet Affairs, 150 S Huntington Ave, Boston, MA 02130 USA. EM jennifer.vasterling@va.go NR 73 TC 44 Z9 44 U1 18 U2 21 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 347 EP 358 DI 10.1682/JRRD.2007.05.0077 PG 12 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300003 PM 18629744 ER PT J AU Miller, MW Wolf, EJ Martin, E Kaloupek, DG Keane, TM AF Miller, Mark W. Wolf, Erika J. Martin, Elaine Kaloupek, Danny G. Keane, Terence M. TI Structural equation modeling of associations among combat exposure, PTSD symptom factors, and Global Assessment of Functioning SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE avoidance; combat exposure; functional impairment; Global Assessment of Functioning; hyperarousal; numbing; PTSD; reexperiencing; rehabilitation; structural equation modeling ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; INTERNALIZING SUBTYPES; VETERANS; VIETNAM; SCALE; DISASTER; HEALTH; REPLICATION; EXTENSION AB This study used structural equation modeling (SEM) to evaluate the relative strength of associations between combat exposure, four posttraumatic stress disorder (PTSD) symptom factors, and functional impairment as indexed by Global Assessment of Functioning (GAF) scores in a sample of 315 veterans assessed at a Department of Veterans Affairs PTSD clinic. Results showed that the association between combat exposure and GAF scores was fully mediated by PTSD severity. The best-fitting model included direct paths from combat exposure to reexperiencing symptoms and from avoidance and numbing symptoms to GAF. However, only 17% of variance in GAF was accounted for by PTSD. The results raise concern about the use of the GAF score as a benchmark for quantifying combat PTSD-related functional impairment. C1 Dept Vet Affairs Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02118 USA. RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 2, 150 S Huntington Ave, Boston, MA 02130 USA. EM Mark.Miller5@va.gov RI Miller, Mark/G-7322-2011 OI Miller, Mark/0000-0001-6393-8563 FU CSRD VA [I01 CX000431]; NIMH NIH HHS [F31 MH074267] NR 40 TC 14 Z9 14 U1 2 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 359 EP 369 DI 10.1682/JRRD.2007.06.0085 PG 11 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300004 PM 18629745 ER PT J AU Magruder, KM Yeager, DE AF Magruder, Kathryn M. Yeager, Derik E. TI Patient factors relating to detection of posttraumatic stress disorder in Department of Veterans Affairs primary care settings SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE detection; diagnosis; posttraumatic stress disorder; primary care; provider recognition; PTSD; rehabilitation; screening; VA; veterans ID MENTAL-HEALTH-SERVICES; TREATMENT-SEEKING; CHRONIC PAIN; PSYCHOMETRIC PROPERTIES; MUTUAL MAINTENANCE; VIETNAM VETERANS; SOMATIC SYMPTOMS; PHYSICAL HEALTH; COMBAT VETERANS; TRAUMA VICTIMS AB We examined the impact of patient-level factors on provider recognition of posttraumatic stress disorder (PTSD). Analyses were based on a random sample of 1,079 consenting patients who had an outpatient visit at any of four southeastern Department of Veterans Affairs hospitals in 1999. We collected data on PTSD symptoms, sociodemographics, functional status, medical record diagnoses, and independent PTSD diagnostic assessments for 888 patients. Complete and usable data were available for 819 patients. A total of 98 patients (12%) met criteria for PTSD, and of these, 42 (43%) were correctly classified as such by their provider. Results indicate that age (50-64), war-zone service, worse functioning on the 36-Item Short Form Health Survey role emotional subscale, a diagnosis of musculoskeletal pain, a greater percentage of persistent reexperiencing or avoidance/numbing symptoms, and a previously diagnosed substance use disorder were all independently related to provider recognition of PTSD. Knowledge of these factors may help inform. providers and direct improved screening and case finding. C1 Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Magruder, KM (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv, 109 Bee St, Charleston, SC 29401 USA. EM kathryn.magruder@va.gov NR 53 TC 10 Z9 10 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 371 EP 381 DI 10.1682/JRRD.2007.06.0091 PG 11 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300005 PM 18629746 ER PT J AU King, LA King, DW Bolton, EE Knight, JA Vogt, DS AF King, Lynda A. King, Daniel W. Bolton, Elisa E. Knight, Jeffrey A. Vogt, Dawne S. TI Risk factors for mental, physical, and functional health in Gulf War veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE anxiety; Deployment Risk and Resilience Inventory; depression; environmental agents; functional health status; Gulf War illnesses; perceived threat; posttraumatic stress disorder; rehabilitation; risk factors; veteran health ID CHRONIC MULTISYMPTOM ILLNESS; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; PSYCHOMETRIC PROPERTIES; VIETNAM VETERANS; COMBAT VETERANS; I VETERANS; INVENTORY; DEPRESSION; PTSD AB Risk factors associated with war-zone events and circumstances are implicated in the health and adjustment of military veterans. We assessed a national stratified sample of community-residing veterans of the Gulf War (N = 357) using scales from the Deployment Risk and Resilience Inventory, along with an array of mental (posttraumatic stress disorder, depression, and anxiety), physical (symptom and condition indicators especially pertinent to Gulf War illnesses), and functional (both mental and physical dimensions) health outcomes. We found that perceived threat or fear of bodily harm in the war zone and self reported or perceived exposures to environmental hazards may play a critical role in all measured aspects of health. Moreover, a synergistic effect of these two risk factors was observed in the prediction of mental health and mental health functional status. C1 [King, Lynda A.; King, Daniel W.; Knight, Jeffrey A.; Vogt, Dawne S.] Boston Univ, Sch Med, Boston, MA 02118 USA. [King, Lynda A.; King, Daniel W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Bolton, Elisa E.] Dept Vet Affairs Boston Healthcare System, Boston, MA USA. RP King, LA (reprint author), VA Boston 116B 5, Natl Ctr PTSD, 150 S Huntington Ave, Boston, MA 02130 USA. EM lking@bu.edu NR 57 TC 17 Z9 18 U1 3 U2 12 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 395 EP 407 DI 10.1682/JRRD.2007.06.0081 PG 13 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300007 PM 18629748 ER PT J AU Street, AE Stafford, J Mahan, CM Hendricks, A AF Street, Amy E. Stafford, Jane Mahan, Clare M. Hendricks, Ann TI Sexual harassment and assault experienced by reservists during military service: Prevalence and health correlates SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE mental health; military service; military sexual trauma; physical health; posttraumatic stress disorder; rehabilitation; reservists; sexual assault; Sexual Experiences Questionnaire; sexual harassment AB The current investigation identified the gender-specific prevalence of sexual harassment and assault experienced during U.S. military service and the negative mental and physical health correlates of these experiences in a sample of former reservists. We surveyed a stratified random sample of 3,946 former reservists about their experiences during military service and their current health, including depression, posttraumatic stress disorder, somatic symptoms, and medical conditions. Prevalence estimates and confidence intervals of sexual harassment and assault were calculated. A series of logistic regressions identified associations with health symptoms and conditions. Both men and women had a substantial prevalence of military sexual harassment and assault. As expected, higher proportions of female reservists reported sexual harassment (60.0% vs 27.2% for males) and sexual assault (13.1% vs 1.6% for males). For both men and women, these experiences were associated with deleterious mental and physical health conditions, with sexual assault demonstrating stronger associations than other types of sexual harassment in most cases. This investigation is the first to document high instances of these experiences among reservists. These data provide further evidence that experiences of sexual harassment and assault during military service have significant implications for the healthcare needs of military veterans. C1 [Street, Amy E.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorders, Dept Vet Affairs, Boston, MA 02130 USA. [Street, Amy E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Stafford, Jane] Univ S Carolina, Dept Psychol, Aiken, SC USA. [Mahan, Clare M.] VA Environm Epidemiol Serv, Washington, DC USA. [Hendricks, Ann] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. RP Street, AE (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 3, 150 S Huntington Ave, Boston, MA 02130 USA. EM amy.street@va.gov NR 20 TC 47 Z9 47 U1 0 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 409 EP 419 DI 10.1682/JRRD.2007.06.0088 PG 11 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300008 PM 18629749 ER PT J AU Metzger, LJ Pitman, RK Miller, GA Paige, SR Orr, SP AF Metzger, Linda J. Pitman, Roger K. Miller, Gregory A. Paige, Stephen R. Orr, Scott P. TI Intensity dependence of auditory P2 in monozygotic twins discordant for Vietnam combat: Associations with posttraumatic stress disorder SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE 5-HT; auditory intensity dependence; combat disorder; event-related potentials; posttraumatic; PTSD; rehabilitation; serotonin; stress disorders; twin studies ID DIPOLE SOURCE ACTIVITY; SEROTONIN TRANSPORTER GENE; EVOKED CORTICAL POTENTIALS; SENSATION SEEKING; ALLELIC VARIATION; MAJOR DEPRESSION; ECSTASY USERS; BEHAVING CATS; VETERANS; EXPOSURE AB Two studies have reported decreased intensity dependence of the P2 event-related potential (ERP) in male combat veterans with posttraumatic stress disorder (PTSD), a response pattern presumed to reflect central nervous system-induced protective inhibition and heightened central serotonergic activity. We used an identical twin, case-control design to investigate whether intensity dependence abnormalities reflect pretrauma vulnerability or are an acquired consequence of PTSD. ERPs were measured in male Vietnam combat veterans and their noncombat-exposed monozygotic twin brothers during a four-tone, stimulus-intensity modulation procedure. Contrary to previous findings in male veterans, the PTSD group had significantly steeper P2 amplitude intensity slopes, similar to those reported for female veterans and abused children with PTSD. Additionally, increased P2 amplitude intensity slope was associated with increased PTSD symptom severity, particularly the severity of reexperiencing symptoms. A mixed-model, random-effects analysis that included the combat-unexposed twins revealed a significant diagnosis by combat exposure interaction. Inspection of group means suggests that the observed increased P2 intensity dependence is a consequence of PTSD. Our findings further suggest that low serotonergic tone may emerge as one potential consequence of this disorder. C1 [Metzger, Linda J.; Pitman, Roger K.] Dept Vet Affairs Med Ctr, Res Serv, Manchester, NH USA. [Metzger, Linda J.; Pitman, Roger K.; Orr, Scott P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Metzger, Linda J.; Pitman, Roger K.; Orr, Scott P.] Harvard Univ, Sch Med, Boston, MA USA. [Miller, Gregory A.] Univ Illinois, Dept Psychol, Urbana, IL 61801 USA. [Paige, Stephen R.] VA Puget Sound Hlth Care Syst, Seattle Epidemilog Res & Informat Ctr, Vietnam Era Twin Registry, Seattle, WA USA. RP Orr, SP (reprint author), Manchester VA Med Ctr, Res Serv 151, 718 Smyth Rd, Manchester, NH 03104 USA. EM scott.orr@va.gov FU NIMH NIH HHS [R01 MH054636, R03 MH057386-01, MH54636] NR 48 TC 11 Z9 11 U1 5 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 437 EP 449 DI 10.1682/JRRD.2007.07.0100 PG 13 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300011 PM 18629752 ER PT J AU Woodward, SH Kaloupek, DG Schaer, M Martinez, C Eliez, S AF Woodward, Steven H. Kaloupek, Danny G. Schaer, Marie Martinez, Christelle Eliez, Stephan TI Right anterior cingulate cortical volume covaries with respiratory sinus arrhythmia magnitude in combat veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE autonomic denervation; cardiac chronotropy; gyrus cinguli; heart rate variability; insular cortex; magnetic resonance imaging; posttraumatic; respiratory sinus arrhythmia; stress disorders; vagotomy ID POSTTRAUMATIC-STRESS-DISORDER; HEART-RATE-VARIABILITY; CHILDHOOD SEXUAL-ABUSE; SMALLER HIPPOCAMPAL VOLUME; CEREBRAL-BLOOD-FLOW; PSYCHOLOGICAL TRAUMA; PERIOD VARIABILITY; VAGAL MODULATION; MATTER VOLUME; CORTEX AB Existing data suggest anterior cingulate cortex (ACC) plays a role in autonomic regulation. In persons with posttraumatic stress disorder (PTSD), autonomic regulation appears impaired and smaller mean ACC volume has been reported. This study examined relationships between ACC volume and the magnitude of respiratory sinus arrhythmia (RSA) in 77 U.S. combat veterans at rest, 40 of whom met criteria for PTSD. RSA magnitude did not differ in combat survivors with and without PTSD, which contradicts studies comparing civilians with PTSD to non-traumatized controls. RSA magnitude was positively correlated with right but not left hemisphere ACC volume. This finding was statistically independent of the presence or absence of PTSD. C1 [Woodward, Steven H.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Disseminat & Training Div, Palo Alto, CA USA. [Woodward, Steven H.] Natl Ctr Posttraumat Stress Disorder, Palo Alto, CA USA. [Kaloupek, Danny G.] VA Boston Healthcare Syst, Behav Sci Div, Natl Centerfor PTSD, Boston, MA USA. [Kaloupek, Danny G.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Schaer, Marie; Martinez, Christelle; Eliez, Stephan] Univ Geneva, Dept Psychiat, Geneva, Switzerland. [Schaer, Marie] Swiss Fed Inst Technol, Signal Proc Lab, CH-1015 Lausanne, Switzerland. [Eliez, Stephan] Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland. RP Woodward, SH (reprint author), VAPAHCS, 334 PTSD,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM steve.woodward@va.gov NR 70 TC 10 Z9 10 U1 3 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 451 EP 463 DI 10.1682/JRRD.2007.06.0082 PG 13 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300012 PM 18629753 ER PT J AU Keen, SM Kutter, CJ Niles, BL Krinsley, KE AF Keen, Stefanie M. Kutter, Catherine J. Niles, Barbara L. Krinsley, Karen E. TI Psychometric properties of PTSD Checklist in sample of male veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE Clinician-Administered PTSD scale; combat exposure scale; evaluation of lifetime stressors; mental health symtomatology; PCL; potentially traumatic event; psychometric validation; PTSD; rehabilitation; self-report measure; veterans ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; SCREENING INSTRUMENT; CIVILIAN VERSION; TRAUMATIC EVENTS; SCALE; DIAGNOSIS; SYMPTOMS; CANCER; PCL AB The psychometric properties of the PTSD Checklist (PCL) were investigated in a sample of treatment-seeking and community-dwelling male veterans. In conjunction with previous reports, results from the present study indicate that the PCL possesses strong, robust psychometric properties. The current investigation suggests a cutoff score of 60 - higher than previous investigations-related to posttraumatic stress disorder (PTSD) diagnosis derived from the Clinician-Administered PTSD Scale. This research supports the use of the PCL as a brief self-report measure of PTSD symptomatology. C1 [Keen, Stefanie M.; Kutter, Catherine J.; Niles, Barbara L.; Krinsley, Karen E.] Dept Vet Affairs Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. [Keen, Stefanie M.; Niles, Barbara L.; Krinsley, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Niles, BL (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, 150 S Huntington Ave, Boston, MA 02130 USA. EM Barbara.Niles@va.gov FU NIMH NIH HHS [2T32MH019836] NR 23 TC 119 Z9 120 U1 2 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 3 BP 465 EP 474 DI 10.1682/JRRD.2007.09.0138 PG 10 WC Rehabilitation SC Rehabilitation GA 320JU UT WOS:000257230300013 PM 18629754 ER PT J AU Dicianno, BE Aguila, ED Cooper, RA Pasquina, PF Clark, MJ Collins, DM Fitzgerald, SG Wichman, TA AF Dicianno, Brad E. Aguila, Eric D. Cooper, Rory A. Pasquina, Paul F. Clark, Mary J. Collins, Diane M. Fitzgerald, Shirley G. Wichman, Todd A. TI Acute mountain sickness in disability and adaptive sports: Preliminary data SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE altitude sickness; brain injuries; headache; military; multiple sclerosis; rehabilitation; spinal cord injuries; sports; veterans; visual impairment ID ALTITUDE ILLNESS AB Acute mountain sickness (AMS) is a frequent complication for military personnel, veterans, athletes, and travelers at high altitudes. Symptoms may occur in individuals with less cerebrospinal fluid volume and less ability to accommodate increased brain volume. No studies on AMS exist in individuals with neurological impairments. We studied 64 subjects, including active and sedentary controls and those with tetraplegia, paraplegia, multiple sclerosis, and traumatic brain injury at the 2007 National Veterans Winter Sports Clinic in Snowmass, Colorado. Subjects completed three Lake Louise Score surveys to quantify symptoms. We found a higher than expected occurrence of AMS overall (51.6%) but no differences among groups, and few participants sought treatment. Fatigue and weakness were common symptoms. High subject activity levels may explain these findings. More research is warranted on larger sample sizes and on preventative medications and treatments for AMS, especially since many military personnel with neurological impairments are returning to full active service. C1 [Dicianno, Brad E.; Cooper, Rory A.; Collins, Diane M.] Univ Pittsburgh, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Cooper, Rory A.; Collins, Diane M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Cooper, Rory A.; Collins, Diane M.] Ctr Excellence Wheelchairs & Related Technol, Dept Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Aguila, Eric D.; Pasquina, Paul F.; Wichman, Todd A.] Walter Reed Army Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20307 USA. [Clark, Mary J.] Grand Junct VA Med Ctr, Grand Junction, CO USA. [Fitzgerald, Shirley G.] James A Haley Tampa VA Med Ctr, Patient Safety Ctr Inquiry, Tampa, FL USA. RP Dicianno, BE (reprint author), Univ Pittsburgh, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, 7180 Highland Dr,Bldg 4,2nd Floor E,151R1-H, Pittsburgh, PA 15206 USA. EM diciannob@herlpitt.org OI Dicianno, Brad/0000-0003-0738-0192 NR 12 TC 3 Z9 3 U1 0 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 4 BP 479 EP 487 DI 10.1682/JRRD.2007.08.0136 PG 9 WC Rehabilitation SC Rehabilitation GA 331KX UT WOS:000258012200002 PM 18712635 ER PT J AU Rintala, DH Matamoros, R Seitz, LL AF Rintala, Diana H. Matamoros, Rebeca Seitz, Laura L. TI Effects of assistance dogs on persons with mobility or hearing impairments: A pilot study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE assistance; assistance dogs; deaf; disability; hearing; hearing dogs; independence; longitudinal; mobility impairment; rehabilitation; service dogs ID SOCIAL ACKNOWLEDGMENTS; SERVICE DOGS; RECIPIENTS; PEOPLE AB Service dogs help persons with mobility impairments by retrieving items and performing other tasks. Hearing dogs alert persons with hearing impairments to environmental sounds. We conducted a pre-post, wait list-controlled pilot study to assess the impact of the dogs on the lives of recipients. Participants were recruited through two assistance dog training organizations and completed an initial questionnaire packet. The Experimental group completed another packet 6 months after receiving a dog. The Control group completed a second packet 6 months after the initial data collection. On average, dog recipients were very satisfied with their assistance dogs. Both service and hearing dog recipients reduced their dependence on other persons. Service dog recipients reduced hours of paid assistance. No other significant change occurred in various standardized outcome measures. Assistance dogs had a major positive impact on the lives of recipients. More appropriate measurement instruments are needed to capture the impact of these dogs. C1 [Rintala, Diana H.; Matamoros, Rebeca; Seitz, Laura L.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Rintala, Diana H.; Matamoros, Rebeca] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Seitz, Laura L.] Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. RP Rintala, DH (reprint author), 5451 Indigo St, Houston, TX 77096 USA. EM drintala@bcm.tmc.edu NR 21 TC 13 Z9 14 U1 5 U2 23 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 4 BP 489 EP 503 DI 10.1682/JRRD.2007.06.0094 PG 15 WC Rehabilitation SC Rehabilitation GA 331KX UT WOS:000258012200003 PM 18712636 ER PT J AU Moy, ML Garshick, E Matthess, KR Lew, R Reilly, JJ AF Moy, Marilyn L. Garshick, Eric Matthess, Kirby R. Lew, Robert Reilly, John J. TI Accuracy of uniaxial accelerometer in chronic obstructive pulmonary disease SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accelerometer; ambulation; chronic obstructive pulmonary disease; COPD; pedometer; physical activity; rehabilitation; step count; walking speed; wearable sensor ID POPULATION-BASED COHORT; PHYSICAL-ACTIVITY; DAILY-LIFE; MOTION SENSORS; COPD; RELIABILITY; MORTALITY; VALIDITY; MODELS; RT3 AB Wearable sensors have been developed and used in nondisabled adults. Little is known about their accuracy in patients with chronic disease. We tested the ActiHealth accelerometer, which measures step counts, in subjects with chronic obstructive pulmonary disease (COPD). We determined the intra- and interdevice coefficients of variation (CVs). We assessed the accuracy of the device in 15 nondisabled males and 46 subjects with COPD. Accuracy was defined as percent step capture, (device step count divided by manual step count) times 100. Predictors of percent step capture were identified using linear regression methods. The accelerometer has an intradevice CV ranging from 0.008 to 0.025 and an interdevice CV of 0.64. In nondisabled males, median percent step capture was 96% (interquartile range 81%-98%). In subjects with COPD, median percent step capture was 86% (interquartile range 72%-96%). Usual walking speed was the most important predictor of percent step capture (p = 0.004). The ActiHealth accelerometer has acceptable intra- and interdevice CVs. It is highly accurate in nondisabled subjects. The accuracy declines in subjects with COPD based on walking speed. Prior to using the ActiHealth accelerometer, researchers and clinicians should assess walking speed and percent step capture in each subject. C1 [Moy, Marilyn L.; Garshick, Eric; Matthess, Kirby R.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. [Moy, Marilyn L.] VA Boston Healthcare Syst, Dept Vet Affairs, Vet Hlth Adm, Rehabil Res & Dev Serv, Boston, MA USA. [Moy, Marilyn L.; Reilly, John J.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Moy, Marilyn L.; Garshick, Eric; Matthess, Kirby R.; Reilly, John J.] Harvard Univ, Sch Med, Boston, MA USA. [Garshick, Eric] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA. [Lew, Robert] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. RP Moy, ML (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Sect, 1400 VFW Pkwy,111PI, W Roxbury, MA 02132 USA. EM marilyn.moy@va.gov FU NICHD NIH HHS [R01 HD42141, R01 HD042141-05, R01 HD042141] NR 25 TC 13 Z9 13 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 4 BP 611 EP 617 DI 10.1682/JRRD.2007.09.0147 PG 7 WC Rehabilitation SC Rehabilitation GA 331KX UT WOS:000258012200013 PM 18712646 ER PT J AU Bresler, L Walter, JS Jahoda, A Wheeler, JS Turk, T Wurster, RD AF Bresler, Larissa Walter, James S. Jahoda, Andrew Wheeler, John S. Turk, Thomas Wurster, Robert D. TI Effective methods of pelvic plexus nerve and bladder stimulation in anesthetized animal model SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE dog; electrical stimulation; pelvic plexus nerves; spinal cord injuries; urinary bladder; urinary incontinence; urinary retention; urinary tract physiology; urination disorders; urodynamic ID ELECTRICAL-STIMULATION; CLINICAL EXPERIENCE; ELECTRODES AB Urinary retention is a serious urological problem associated with spinal cord injuries (SCIs) and other pelvic disorders. Effective methods of pelvic nerve stimulation were investigated for this problem. Following anesthesia in five dogs, the bladder was surgically exposed. Bladder and anal sphincter pressures were recorded. Testing was first conducted with probe electrodes. Barb electrodes were then implanted with a needle near the pelvic plexus nerves and the bladder wall. We tested different electrode arrangements and stimulating parameters to induce bladder contractions without skeletal muscle stimulation. The pelvic plexus nerves near the bladder were identified, and the barb electrodes were effectively implanted. Stimulation with bipolar and bilateral electrodes induced pressures over 30 cmH(2)O without skeletal muscle activation. Common stimulation parameters were 40 pps, 400 microseconds pulse duration, and 15 to 25 mA stimulating current applied for 3 s. Effective electrode implantation methods were shown. Also identified were electrode arrangements and stimulating parameters that induced strong bladder contractions without skeletal muscle activation. However, voiding studies were not conducted. Further studies with barb electrodes are warranted, and these methods may have applications for bladder stimulation following SCI. C1 [Bresler, Larissa; Jahoda, Andrew; Wheeler, John S.; Turk, Thomas] Edward Hines Jr Dept Vet Affairs Hosp, Urol Sect, Hines, IL USA. [Bresler, Larissa; Walter, James S.; Jahoda, Andrew; Wheeler, John S.; Turk, Thomas; Wurster, Robert D.] Loyola Univ Chicago, Dept Urol, Stritch Sch Med, Maywood, IL USA. [Walter, James S.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Wurster, Robert D.] Loyola Univ Chicago, Dept Neurol Surg, Stritch Sch Med, Maywood, IL USA. [Wurster, Robert D.] Loyola Univ Chicago, Dept Physiol, Stritch Sch Med, Maywood, IL USA. RP Walter, JS (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Bldg 1,Rm C-318,151,5000 S 5th Ave, Hines, IL 60141 USA. EM james.walter@va.gov NR 30 TC 2 Z9 2 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 4 BP 627 EP 637 DI 10.1682/JRRD.2007.04.0058 PG 11 WC Rehabilitation SC Rehabilitation GA 331KX UT WOS:000258012200015 PM 18712648 ER PT J AU Orris, BG Jahoda, AE Walter, JS Nemchausky, BN Wurzel, R Homan, HD Melloy, S Wheeler, JS AF Orris, Bradley G. Jahoda, Andrew E. Walter, James S. Nemchausky, Bernard N. Wurzel, Rafael Homan, Harvey D. Melloy, Sally Wheeler, John S. TI A 24-hour feasibility study of intraurethral valved catheter for bladder management in males with spinal cord injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE catheterization; cystometry; cystoscopy; intraurethral valved catheter; neurogenic bladder; rehabilitation; spinal cord injury; urinary incontinence; urinary retention; UTI ID BENIGN PROSTATIC HYPERPLASIA; TEMPORARY; COMPLICATIONS; DYSFUNCTION; OBSTRUCTION; RISK AB This feasibility study was conducted to evaluate design features of the novel intraurethral valved catheter, Surinate (Urovalve, Inc; Newark, New Jersey). The device extends from the bladder neck to just beyond the external sphincter and contains a valve that can be activated by an external magnet for bladder emptying. Five patients were recruited from the Edward Hines Jr Department of Veterans Affairs Hospital spinal cord injury population. We conducted cystometry and cystoscopy to evaluate the lower urinary tract. Then, the device was inserted for 24 hours with careful monitoring. The catheter was removed from the first patient because he developed autonomic dysreflexia during implantation. The next four patients used the catheter overnight and tolerated it well: one with independent use and two with increased abdominal pressure. Emptying time was 208 +/- 99 s, residual was 42 +/- 33 mL, and the first-stream flow rate was 1.8 +/- 0.7 mL/s. The safety tether was used in three patients because the extraction device did not work. Results showed effective implantation and stability of the device in the urethra. However, objectives for use and extraction were not met. This feasibility study provided important information that will help guide design improvements for the intraurethral valved catheter. C1 [Orris, Bradley G.; Jahoda, Andrew E.; Wheeler, John S.] Edward Hines Jr Dept Vet Affairs Hosp, Dept Surg, Hines, IL USA. [Orris, Bradley G.; Jahoda, Andrew E.; Walter, James S.; Wheeler, John S.] Loyola Univ, Med Ctr, Dept Urol, Maywood, IL 60153 USA. [Walter, James S.; Melloy, Sally] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Res, Hines, IL 60141 USA. [Nemchausky, Bernard N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Spinal Cord Injury, Hines, IL 60141 USA. [Wurzel, Rafael; Homan, Harvey D.] Urovalve Inc, Newark, NJ USA. RP Walter, JS (reprint author), Edward Hines Jr VA Hosp 151, Res Serv, Hines, IL 60141 USA. EM james.walter@med.va.gov FU NICHD NIH HHS [5R44HD039566-03] NR 17 TC 2 Z9 2 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 4 BP 639 EP 646 DI 10.1682/JRRD.2007.07.0112 PG 8 WC Rehabilitation SC Rehabilitation GA 331KX UT WOS:000258012200016 PM 18712649 ER PT J AU Ullrich, PM Jensen, MP Loeser, JD Cardenas, DD Weaver, FM AF Ullrich, Philip M. Jensen, Mark P. Loeser, John D. Cardenas, Diana D. Weaver, Frances M. TI Pain among veterans with spinal cord injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE age; catastrophizing; chronic pain; functioning; pain; pain intensity; pain interference; rehabilitation; spinal cord injury; veterans ID COPING STRATEGIES QUESTIONNAIRE; LOW-BACK-PAIN; PSYCHOLOGICAL DISTRESS; PERCEIVED STRESS; LIFE EVENTS; INTERFERENCE; VALIDITY; AGE; INDIVIDUALS; NONVETERANS AB The Department of Veterans Affairs Veterans Health Administration cares for approximately 15% of persons with spinal cord injury (SCI) in the United States. However, the nature and characteristics of pain among veterans with SCI are not well understood. This study used a postal Survey to compare veterans with SCI and nonveterans with SCI on pain intensity; pain interference; functioning; and other pain, demographic, and medical characteristics. Veterans tended to be older than nonveterans but these groups were otherwise comparable on demographic and medical variables. Veterans were not significantly different from nonveterans on pain intensity or pain interference. Veterans reported lower levels of functioning than nonveterans and higher levels of pain-related catastrophizing. However, differences in functioning between veterans and nonveterans were attributable to age differences between the groups. In summary, differences between veterans with SCI and nonveterans with SCI were few and small in magnitude, suggesting that veterans with SCI are not at greater risk for pain and pain-related problems. However, pain-related catastrophizing may be a particular concern among veterans with SCI.prevalence of chronic pain after SCI is more than 75 percent [1-3]. Persons with SCI consistently report average pain levels between 4 and 6 in studies using the 0-10 numerical rating scale (NRS) [4-5], pain levels that are high enough to warrant comprehensive treatment and prompt follow-up in primary-care settings [6]. Pain is severe, with a strong negative impact on daily functioning, in about one-third of persons with SCI [1-2]. Of significant concern is the finding that once pain conditions following SCI emerge, they tend to persist [3-4] or worsen [2,7] over time, despite the many efforts to treat this pain. In summary, while pain is a ubiquitous, recalcitrant problem among persons with SCI, the degree to which pain has a pronounced effect on functioning is much more variable. Developing a better understanding of subgroups of persons with SCI that may be especially vulnerable to pain-related functional disruptions is critical. C1 [Ullrich, Philip M.] VA Puget Sound Healthcare Syst, SCI QUERI, Dept Vet Affairs VA, Seattle, WA USA. [Ullrich, Philip M.; Jensen, Mark P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Loeser, John D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Cardenas, Diana D.] Univ Miami, Miller Sch Med, Dept Rehabil Med, Miami, FL 33136 USA. [Weaver, Frances M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA SCI QUERI, Hines, IL 60141 USA. RP Ullrich, PM (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM philip.ullrich@va.gov FU NICHD NIH HHS [P01 HD033988-10, P01 HD033988, P01 HD33988] NR 40 TC 12 Z9 12 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 6 BP 793 EP 800 DI 10.1682/JRRD.2008.01.0005 PG 8 WC Rehabilitation SC Rehabilitation GA 372UG UT WOS:000260926900003 PM 19009466 ER PT J AU Ding, D Leister, E Cooper, RA Cooper, R Kelleher, A Fitzgerald, SG Boninger, ML AF Ding, Dan Leister, Elizabeth Cooper, Rory A. Cooper, Rosemarie Kelleher, Annmarie Fitzgerald, Shirley G. Boninger, Michael L. TI Usage of tilt-in-space, recline, and elevation seating functions in natural environment of wheelchair users SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE backrest recline; data logging; posture; pressure ulcer; rehabilitation; seat elevator; seating posture; tilt-in-space; usage pattern; wheelchair; wheelchair prescription ID SPINAL-CORD-INJURY; INTERFACE PRESSURE; RELIABILITY; DISCOMFORT; SYSTEMS; POSTURE AB This study examined the usage of powered seating functions, including tilt-in-space, backrest recline, and seat elevation, among a group of wheelchair users during their typical daily activities. Twelve individuals who used a power wheelchair with seating functions participated in the study. They drove their own wheelchair and used the seating functions as needed in their community environment for about 2 weeks while the seating function usage was recorded with a portable device. We found that Subjects occupied their wheelchair for 11.8 +/- 3.4 hours a day (all data shown as mean +/- standard deviation). While occupying their wheelchairs, they accessed tilt-in-space, backrest recline, and seat elevation 19 +/- 14 times a day for 64.1% +/- 36.8%, 12 +/- 8 times for 76.0% +/- 29.8%, and 4 +/- 4 times for 22.5% +/- 34.9%, respectively. Subjects chose to stay in tilted and reclined positions in their wheelchair for 39.3% +/- 36.5% of their time each day. They spent little time in a fully upright position. Subjects changed their seating positions every 53.6 +/- 47.0 minutes. Time spent in positions of different seating pressures varied among subjects. The information collected could enhance clinical practice of wheelchair provision, resulting in better compliance with clinical instructions and appropriate use of seating functions among wheelchair users. C1 [Ding, Dan; Leister, Elizabeth; Cooper, Rory A.; Cooper, Rosemarie; Kelleher, Annmarie; Fitzgerald, Shirley G.; Boninger, Michael L.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Ding, Dan; Leister, Elizabeth; Cooper, Rory A.; Cooper, Rosemarie; Kelleher, Annmarie; Fitzgerald, Shirley G.; Boninger, Michael L.] Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA USA. RP Ding, D (reprint author), VA Pittsburgh Healthcare Syst, HERL, 7180 Highland Dr,Bldg 4,2d Fl E,151R1-H, Pittsburgh, PA 15206 USA. EM dad5@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU Paralyzed Veterans of America Research Foundation [2264-01]; National Institute on Disability and Rehabilitation Research [H13317040006]; VA Rehabilitation Research and Development Center [B3142C] FX This material was based on work supported by the Paralyzed Veterans of America Research Foundation, grant 2264-01; National Institute on Disability and Rehabilitation Research, grant H13317040006; and VA Rehabilitation Research and Development Center, grant B3142C. NR 35 TC 28 Z9 28 U1 2 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 7 BP 973 EP 983 DI 10.1682/JRRD.2007.11.0178 PG 11 WC Rehabilitation SC Rehabilitation GA 387WI UT WOS:000261981900004 PM 19165687 ER PT J AU Liu, HY Cooper, RA Pearlman, J Cooper, R Connor, S AF Liu, Hsin-Yi Cooper, Rory A. Pearlman, Jonathan Cooper, Rosemarie Connor, Samuel TI Evaluation of titanium ultralight manual wheelchairs using ANSI/RESNA standards SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE ANSI/RESNA; durability; failure; fatigue tests; lightweight; reference standards; rehabilitation; titanium wheelchair; ultralight wheelchair; wheelchair ID ELECTRIC-POWERED WHEELCHAIRS; SPINAL-CORD-INJURY; PERFORMANCE; DURABILITY; LIFE AB Comfortable propulsion and support, light weight, and small dimensions are important features that help preserve tipper-limb integrity of manual wheelchair users and improve accessibility. The titanium wheelchair is a product developed in response to these goals, but none of the test results of titanium wheelchairs had been disclosed before this study was performed. We hypothesized that these titanium wheelchairs would be in compliance with American National Standards Institute (ANSI)/Rehabilitation Engineering and Assistive Technology Society of North America (RESNA) standards. We tested 12 ultralight titanium rigid-frame wheelchairs (4 models) using ANSI/RESNA testing procedures and compared the test results with previously tested ultralight and lightweight aluminum wheelchairs. All wheelchairs passed the forward braking effectiveness test, but eight wheelchairs tipped backward before inclining to 7 degrees in the rearward braking effectiveness test. All wheelchairs passed the impact strength tests, but six wheelchairs failed in the static strength tests. Three wheelchairs Successfully completed the fatigue tests, but the remaining wheelchairs failed prematurely. This group of titanium wheelchairs had less equivalent cycles and value than the Ultralight aluminum wheelchairs that were tested in a previous study. The failure modes revealed important design issues of each model. Our results suggest that manufacturers may need to perform more careful analyses before commercializing new products. C1 [Liu, Hsin-Yi; Cooper, Rory A.; Pearlman, Jonathan; Cooper, Rosemarie; Connor, Samuel] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, VA Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA. [Liu, Hsin-Yi; Cooper, Rory A.; Pearlman, Jonathan; Cooper, Rosemarie] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, VA Rehabil Res & Dev Serv, 151R-1HD,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 FU Department of Veterans Affairs Rehabilitation Research and Development Service [B3142C]; National Science Foundation-Integrative Graduate Education and Research Traineeship program [DGE 0333420] FX This material was based on work supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (grant B3142C) and the National Science Foundation-Integrative Graduate Education and Research Traineeship program (grant DGE 0333420). NR 23 TC 9 Z9 10 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 9 BP 1251 EP 1267 DI 10.1682/JRRD.2007.12.0204 PG 17 WC Rehabilitation SC Rehabilitation GA 426RN UT WOS:000264725500005 PM 19319751 ER PT J AU Rentschler, AJ Simpson, R Cooper, RA Boninger, ML AF Rentschler, Andrew J. Simpson, Richard Cooper, Rory A. Boninger, Michael L. TI Clinical evaluation of Guido robotic walker SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE clinical testing; mobility aid; navigation assistance; obstacle avoidance; older adults; rehabilitation; robotic walker; safety; visual impairment; walker ID MOBILITY AB The Guido is a robotic walker that provides navigation and obstacle-avoidance assistance. Engineering tests have found that the device performs adequately and presents no hazard to the user. The performance of the Guido was compared with a low-tech mobility aid, the Assistive Mobility Device (AMD) developed at the Atlanta Department of Veterans Affairs Medical Center, in trials involving older adults with Visual impairments. The purpose of this study was to determine whether the Guido Could increase the safety and mobility of elderly Visually impaired individuals in supervised care facilities. Subjects traversed all obstacle course with the Guido and the AMD. Completion time, obstacle/wall contacts, and reorientations were compared for both devices. No significant differences were found between the devices for any of the tests. The Guido did not perform better than the AMD during the trials. Revisions to the device as well as a change in Subject requirements and testing protocol may produce different results. C1 [Rentschler, Andrew J.; Simpson, Richard; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Simpson, Richard; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Rentschler, Andrew J.; Simpson, Richard; Cooper, Rory A.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, VA Rehabil Res & Dev Ctr Excellence Wheelchairs &, Pittsburgh, PA USA. RP Simpson, R (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Forbes Tower,Suite 5044, Pittsburgh, PA 15260 USA. EM ris20@pitt.edu RI Simpson, Richard/G-5683-2015; OI Simpson, Richard/0000-0002-6306-9393; Boninger, Michael/0000-0001-6966-919X FU VA Research and Development Merit Review [C2272R] FX This material was based on work supported by VA Research and Development Merit Review grant C2272R. NR 29 TC 19 Z9 21 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2008 VL 45 IS 9 BP 1281 EP 1293 DI 10.1682/JRRD.2007.10.0160 PG 13 WC Rehabilitation SC Rehabilitation GA 426RN UT WOS:000264725500007 PM 19319753 ER PT J AU Svircev, JN Wallbom, AS AF Svircev, Jelena N. Wallbom, Agnes S. TI False-negative triple-phase bone scans in spinal cord injury to detect clinically suspect heterotopic ossification: A case series SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE spinal cord injuries; heterotopic ossification; radionuclide imaging; bone scan ID RISK-FACTORS AB Background/Objective: Heterotopic ossification (HO) is a complication seen in patients after spinal cord injury (SCI). Triple-phase nuclear bone scanning is the most sensitive test for the detection of HO. This retrospective study assesses whether patients with clinically suspected HO but negative triple-phase nuclear bone scans develop delayed positive nuclear bone scans. Methods: Case series: A cohort of patients with SCI and clinically suspected HO who underwent triple phase nuclear bone scans over a period of 2 years was identified from retrospective chart review of an acute inpatient SCI rehabilitation service. A subgroup of 7 patients with initially negative but subsequently positive triple-phase nuclear bone scans was identified, and the following data were collected: date, mechanism, admission level, and admission completeness of injury as well as date, number, and results of bone scans. Laboratory studies were also collected during the time of imaging. Results: Over a 2-year period, 343 patients were admitted to the SCI rehabilitation service; 60 patients were suspected of having HO and underwent a total of 85 triple-phase nuclear bone scans. Seven patients were identified with initially negative but subsequently positive bone scans. Conclusions: In patients with clinically suspicious HO but negative bone scans, follow-up scans are indicated to identify initial false-negative studies. C1 [Wallbom, Agnes S.] David Geffen UCLA Sch Med, Dept Phys Med & Rehabil, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Svircev, Jelena N.] Puget Sound VA Hlth Care Syst, Seattle, WA USA. RP Wallbom, AS (reprint author), David Geffen UCLA Sch Med, Dept Phys Med & Rehabil, Greater Los Angeles VA Healthcare Syst, 11301 Wilshire Blvd 117, Los Angeles, CA 90073 USA. EM awallbom@ucla.edu NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2008 VL 31 IS 2 BP 194 EP 196 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 315KA UT WOS:000256876200009 PM 18581667 ER PT J AU Rajan, S McNeely, MJ Warms, C Goldstein, B AF Rajan, Suparna McNeely, Marguerite J. Warms, Catherine Goldstein, Barry TI Clinical assessment and management of obesity in individuals with spinal cord injury: A review SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE spinal cord injuries; obesity; weight control; body composition; paraplegia; tetraplegia; actigraphy; bariatric surgery; Orlistat; sibutramine ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; RESIDUAL NEUROLOGICAL DEFICIT; DAILY ENERGY-EXPENDITURE; STYLE PHYSICAL-ACTIVITY; RESTING METABOLIC-RATE; SLEEP-APNEA SYNDROME; TERM WEIGHT-LOSS; NUTRITIONAL-STATUS AB Background: Diagnosing and managing obesity in individuals with spinal cord injury (SCI) remain challenging. Methods: Literature on the epidemiology, impact, and management of obesity in individuals with SCI was reviewed. Findings: Although nearly 66% of individuals with SCI are either overweight or obese, little guidance is available to measure and monitor obesity in the clinical setting. The use of anthropometric indices and specific cut points available for able-bodied persons is limited by the body composition changes that follow SCI. Indices of upper body obesity warrant examination in SCI because they provide an index of central obesity, which is more closely linked to some obesity-related conditions than is overall obesity. Investigations into the sequelae of excess body fat and its distribution are also needed in SCI because past research in this area has been inconclusive. Although limited, evidence regarding obesity interventions in SCI may be promising. Conclusions: The best anthropometric tool to define obesity in the clinical setting remains unknown. SCI-specific assessment tools and a better understanding of the sequelae of excess body weight will lead to better targeting of prevention and treatment efforts. More research is needed on the individual components of a weight management program unique to SCI. Until then, providers are urged to use a team approach and draw on existing resources and applicable research in able-bodied individuals to facilitate weight management in individuals with SCI. C1 [Rajan, Suparna; Goldstein, Barry] VA Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, SCI QUERI, Seattle, WA 98101 USA. [McNeely, Marguerite J.; Warms, Catherine; Goldstein, Barry] Univ Washington, Seattle, WA 98195 USA. RP Rajan, S (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, SCI QUERI, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM suparna.rajan@va.gov FU VA Puget Sound Health Care System; Seattle Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle Washington. NR 122 TC 29 Z9 30 U1 1 U2 8 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2008 VL 31 IS 4 BP 361 EP 372 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 356MY UT WOS:000259783500003 PM 18959353 ER PT J AU Palmas, W Teresi, J Weinstoct, RS Shea, S AF Palmas, Walter Teresi, Jeanne Weinstoct, Ruth S. Shea, Steven TI Acceptability to primary care providers of telemedicine in diabetes case management SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID SATISFACTION; PERCEPTIONS; TRIAL; TELEDERMATOLOGY AB We studied the perceptions of primary care providers (PCPs) about the telemedicine intervention in a trial of telemedicine for management of diabetes in medically under-served areas of New York State. A survey was mailed to 206 rural and 159 urban PCPs. The response rates were 25% and 22%, respectively. Eighty percent of respondents believed that a diabetes telemedicine case management system would help their practice. An overall satisfaction score (possible range 0-80) suggested good acceptability (mean 66, SD 12). In multiple linear regression, the rural location and younger age of the PCPs were independent predictors of higher satisfaction (both P < 0.01). Within-PCP comparisons showed a higher perceived impact on patients, as compared to impact on PCP practices (P< 0.001). However, the findings should be interpreted with caution due to the low response rates. C1 [Palmas, Walter; Shea, Steven] Columbia Univ, Dept Med, New York, NY USA. [Teresi, Jeanne] Hebrew Home Aged, Div Res, Bronx, NY USA. [Weinstoct, Ruth S.] SUNY Upstate Med Univ Riverdale, Joslin Diabet Ctr, Syracuse, NY USA. [Weinstoct, Ruth S.] SUNY Upstate Med Univ Riverdale, Div Endocrinol Diabet & Metab, Syracuse, NY USA. [Weinstoct, Ruth S.] VA Med Ctr, Dept Vet Affairs, Syracuse, NY USA. [Shea, Steven] Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Shea, Steven] Columbia Univ, Dept Biomed Informat, New York, NY USA. RP Palmas, W (reprint author), Div Gen Med, 622,W 168th St,PH 9-E, New York, NY 10032 USA. EM wp56@columbio.edu FU Centers for Medicare and Medicaid Services [95-C-90998] FX This research was supported by Cooperative Agreement 95-C-90998 from the Centers for Medicare and Medicaid Services. NR 11 TC 12 Z9 12 U1 0 U2 3 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2008 VL 14 IS 6 BP 306 EP 308 DI 10.1258/jtt.2008.080410 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 359CZ UT WOS:000259965100008 PM 18776076 ER PT J AU Wilens, TE Adler, LA Adams, J Sgambati, S Rotrosen, J Sawtelle, R Utzinger, L Fusillo, S AF Wilens, Timothy E. Adler, Lenard A. Adams, Jill Sgambati, Stephanie Rotrosen, John Sawtelle, Robert Utzinger, Linsey Fusillo, Steven TI Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Review DE stimulants; misuse; abuse; diversion; illicit use ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; UNDERGRADUATE STUDENT SAMPLE; PRESCRIPTION STIMULANTS; ILLICIT USE; ORAL METHYLPHENIDATE; COLLEGE-STUDENTS; INTRANASAL ABUSE; NONMEDICAL USE; UNITED-STATES AB Recent studies have provided variable information on the frequency and context of diversion and the use of nonprescribed and prescribed stimulant medications in adolescent and young adult populations. The purpose of this systematic review of the literature is to evaluate the extent and characteristics of stimulant misuse and diversion in attention-cleficit/hyperactivity disorder (ADHD) and non-ADHD individuals. Method: We conducted a systematic review of the literature of available studies looking at misuse and diversion of prescription ADHD medications using misuse, diversion, stimulants, illicit use, and ADHD medications as key words for the search. Results: We identified 21 studies representing 113,104 subjects. The studies reported rates of past year nonprescribed stimulant use to range from 5% to 9% in grade school and high school-age children and 5% to 35% in college-age individuals. Lifetime rates of diversion ranged from 16% to 29% of students with stimulant prescriptions asked to give, sell, or trade their medications. Recent work suggests that whites, members of fraternities and sororities, individuals with lower grade point averages, use of immediate-release compared to extended-release preparations, and individuals who report ADHD symptoms are at highest risk for misusing and diverting stimulants. Reported reasons for use, misuse, and diversion of stimulants include to concentrate, improve alertness, "get high," or to experiment. Conclusions: The literature suggests that individuals both with and without ADHD misuse stimulant medications. Recent work has begun to document the context, motivation, and demographic profile of those most at risk for using, misusing, and diverting stimulants. The literature highlights the need to carefully monitor high-risk individuals for the use of nonprescribed stimulants and educate individuals with ADHD as to the pitfalls of the misuse and diversion of the stimulants. C1 [Wilens, Timothy E.; Sgambati, Stephanie; Utzinger, Linsey; Fusillo, Steven] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Cambridge, MA 02138 USA. [Adler, Lenard A.; Adams, Jill; Rotrosen, John] NYU, Sch Med, New York, NY USA. [Adler, Lenard A.; Adams, Jill; Rotrosen, John] VA New York Harbor Healthcare Syst, New York, NY USA. RP Wilens, TE (reprint author), Massachusetts Gen Hosp, 32 Fruit Str,Suite YAW 6A, Boston, MA 02114 USA. EM twilens@partners.org FU NIDA NIH HHS [K24 DA016264, R01 DA012945, U10 DA13046, U10 DA15831] NR 56 TC 284 Z9 290 U1 10 U2 74 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 2008 VL 47 IS 1 BP 21 EP 31 DI 10.1097/chi.0b01361815a56f1 PG 11 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 243WF UT WOS:000251827300005 PM 18174822 ER PT J AU Prager, LM AF Prager, Laura M. TI Book, forum: New name, new direction SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Prager, LM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM lmprager@partners.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 2008 VL 47 IS 1 BP 108 EP 109 DI 10.1097/chi.0b013e31815af9e1 PG 2 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 243WF UT WOS:000251827300015 ER PT J AU Bauer, TW Shanbhag, AS AF Bauer, Thomas W. Shanbhag, Arun S. CA Implant Wear Symposium 2007 Biolog TI Are there biological markers of wear? SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Article; Proceedings Paper CT AAOS/NIH Osteolysis and Implant Wear: Biological, Biomedical Engineering, and Surgical Principles CY SEP 09-11, 2007 CL Austin, TX SP Amer Adad Orthopaed Surg, Nat Inst Hlth ID TOTAL HIP-ARTHROPLASTY; BONE TURNOVER; PERIPROSTHETIC OSTEOLYSIS; BIOCHEMICAL MARKERS; SURFACE-AREA; IN-VITRO; CHROMIUM; COBALT; TELOPEPTIDE; PROSTHESES AB Potential systemic markers of implant wear include products of the wear process (particles and ions) and mediators of the inflammatory reaction that can be induced by wear. Ions from polymers used in arthroplasty are not specific, but high metal ion levels may help identify patients with unexpectedly high wear of metal-on-metal implants. The kinetics of ion production, transport, and excretion are complex, however, so it is currently difficult to interpret the significance of mild elevations in metal ions. Indices of bone turnover (eg, collagen fragments) and mediators involved in the inflammatory reaction to particles eg, osteoprotegerin, RANKL, interleukins) may be associated with osteolysis, but systemic disorders (eg, osteoarthritis) and the use of medications that influence bone remodeling limit the predictive value of these analytes with respect to the consequences of implant wear. Using genomic and proteomic methods to measure multiple analytes offers promise, but the challenge is to identify markers specifically associated with wear that are not elevated by other conditions that often coexist in this patient population. C1 [Bauer, Thomas W.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA. [Bauer, Thomas W.] Cleveland Clin, Dept Orthoped Surg, Cleveland, OH 44106 USA. [Bauer, Thomas W.] Cleveland Clin, Spine Ctr, Cleveland, OH 44106 USA. [Shanbhag, Arun S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. RP Bauer, TW (reprint author), Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA. NR 20 TC 6 Z9 6 U1 0 U2 1 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PY 2008 VL 16 SU 1 BP S68 EP S71 PG 4 WC Orthopedics SC Orthopedics GA 323UT UT WOS:000257474600014 PM 18612017 ER PT J AU Crowninshield, RD Muratoglu, OK AF Crowninshield, Roy D. Muratoglu, Orhun K. CA Implant Wear Symposium 2007 Engn W TI How have new sterilization techniques and new forms of polyethylene influenced wear in total joint replacement? SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Article; Proceedings Paper CT AAOS/NIH Osteolysis and Implant Wear: Biological, Biomedical Engineering, and Surgical Principles CY SEP 09-11, 2007 CL Austin, TX SP Amer Adad Orthopaed Surg, Nat Inst Hlth ID MOLECULAR-WEIGHT POLYETHYLENE; TOTAL HIP-ARTHROPLASTY; CROSS-LINKED POLYETHYLENE; ALPHA-TOCOPHEROL; MECHANICAL-PROPERTIES; ACETABULAR COMPONENTS; GAMMA-IRRADIATION; VIVO OXIDATION; VITAMIN-E; UHMWPE AB Polyethylene has undergone many changes over the past several decades, including changes in consolidation processes, resin types, sterilization methods, packaging, and the extent of cross-linking. We believe that new sterilization techniques and forms of polyethylene have generally improved wear performance. Polyethylene sterilized without the use of radiation has been shown to have relatively high rates of wear in vivo. Ram-extruded polyethylene sterilized via gamma irradiation in air has been the most commonly used bearing material in the past several decades. Recently, components molded and gamma-sterilized without oxygen as well as highly cross-linked material have found increased clinical use. Exposure of polyethylene to radiation, either to sterilize it or to intentionally cross-link it, has been shown to improve the wear performance of the material. Newer second-generation methods of cross-linking polyethylene include the use of vitamin E, which quenches free radicals and demonstrates promise in providing low wear and desirable mechanical properties. C1 [Crowninshield, Roy D.] Rush Med Coll, Dept Orthoped Surg, Chicago, IL 60612 USA. [Muratoglu, Orhun K.] Massachusetts Gen Hosp, Harris Orthoped Biomech & Biomat Lab, Boston, MA 02114 USA. [Muratoglu, Orhun K.] Harvard Univ, Sch Med, Boston, MA USA. RP Crowninshield, RD (reprint author), Rush Med Coll, Dept Orthoped Surg, Chicago, IL 60612 USA. NR 31 TC 11 Z9 11 U1 0 U2 3 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PY 2008 VL 16 SU 1 BP S80 EP S85 PG 6 WC Orthopedics SC Orthopedics GA 323UT UT WOS:000257474600017 PM 18612021 ER PT J AU Malchau, H Potter, HG AF Malchau, Henrik Potter, Hollis G. CA Implant Wear Symposium 2007 Clinic TI How are wear-related problems diagnosed and what forms of surveillance are necessary? SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Article; Proceedings Paper CT AAOS/NIH Osteolysis and Implant Wear: Biological, Biomedical Engineering, and Surgical Principles CY SEP 09-11, 2007 CL Austin, TX SP Amer Adad Orthopaed Surg, Nat Inst Hlth ID TOTAL HIP-ARTHROPLASTY; CROSS-LINKED POLYETHYLENE; ACETABULAR OSTEOLYSIS; COMPUTED-TOMOGRAPHY; RADIOGRAPHS; REPLACEMENT; PROSTHESES; COMPONENT; VALIDITY AB Prospective, randomized clinical wear studies have shown significant wear reduction when highly cross-linked, e-beamed, melted polyethylene was compared with conventional polyethylene sterilized by gamma irradiation in air. More complete assessment of wear-induced osteolysis in the general total hip arthroplasty patient population must rely on registries with follow-up of large populations of patients through radiographic evaluation of wear-related factors, such as suboptimal placement of the implant components, osteolytic defects, and aseptic loosening. Follow-up radiographs should be obtained in the early postoperative period and at 1, 5, and 10 years postoperatively, and then every 1 to 5 years, thereafter depending on radiographic findings of osteolysis and its progression. When pathologic findings are present, further examinations, such as oblique Judet views and magnetic resonance imaging (MRI) with artifact minimization should be considered to provide a better determination of the extent of the osteolysis. Because conventional radiographs underestimate the prevalence and extent of osteolysis in many instances, diagnosis and surveillance should be performed with radiographic edge detection, spiral computed tomography (CT), MRI, radiostereometric analysis, and quantitation of wear and osteolysis, including bone and soft-tissue lesions. Helical CT has demonstrated excellent specificity in identifying and quantifying the extent of osteolysis. MRI can more accurately localize both osseous and soft-tissue particulate disease, and detect granuloma and compression on adjacent nerves and vessels. C1 [Malchau, Henrik] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Malchau, Henrik] Harris Orthopaed Biomech & Biomat Lab, Boston, MA USA. [Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthopaed, Adult Reconstruct Unit, Boston, MA 02114 USA. [Potter, Hollis G.] MRI Dept, New York, NY USA. [Potter, Hollis G.] Hosp Special Surg, Dept Radiol & Imaging, New York, NY 10021 USA. [Potter, Hollis G.] Cornell Univ, Weill Med Sch, New York, NY 10021 USA. RP Malchau, H (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 24 TC 17 Z9 17 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1067-151X EI 1940-5480 J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PY 2008 VL 16 SU 1 BP S14 EP S19 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 323UT UT WOS:000257474600005 PM 18612008 ER PT J AU Wright, T Greenwald, AS Lemons, J Oral, E AF Wright, Timothy Greenwald, A. Seth Lemons, Jack Oral, Ebru CA Implant Wear Symposium 2007 Engn W TI Engineering summary SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Editorial Material C1 [Wright, Timothy] Hosp Special Surg, FM Kirby Chair Orthopaed Biomech, New York, NY 10021 USA. [Greenwald, A. Seth] Cleveland Clin Hosp, Lutheran Hosp, Orthopaed Res Labs, Cleveland, OH USA. [Lemons, Jack] Univ Alabama, Birmingham, AL USA. [Oral, Ebru] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Harris Orthopaed Biomech & Biomat Lab, Boston, MA USA. RP Wright, T (reprint author), Hosp Special Surg, FM Kirby Chair Orthopaed Biomech, 535 E 70th St, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PY 2008 VL 16 SU 1 BP S120 EP S121 PG 2 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 323UT UT WOS:000257474600023 ER PT J AU Frances, A Sreenivasan, S Weinberger, LE AF Frances, Allen Sreenivasan, Shoba Weinberger, Linda E. TI Defining mental disorder when it really counts: DSM-IV-TR and SVP/SDP statutes SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material AB Civil commitment under the sexually violent predator (SVP) statutes requires the presence of a statutorily defined diagnosed mental disorder linked to sexual offending. As a consequence of broad statutory definitions and ambiguously written court decisions, a bright line separating an SVP mental disorder from ordinary criminal behavior is difficult to draw. Some forensic evaluators reject whole categories of DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders: Text Revision) diagnoses as qualifying disorders (e.g., personality and substance abuse disorders), while others debate whether recurrent rape constitutes a paraphilic disorder. We argue that the ramifications of the SVP process, in representing both the balancing of public safety and the protection of an individual's right to liberty, demand that decisions about what is a legally defined mental disorder not be made in an arbitrary and idiosyncratic manner. Greater clarity and standardization must come from both sides: the legalists who interpret the law and the clinicians who apply and work under it. C1 [Frances, Allen] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Sreenivasan, Shoba; Weinberger, Linda E.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Sreenivasan, Shoba] Greater Los Angeles VA Med Ctr, Forens Outreach Serv, Los Angeles, CA USA. [Weinberger, Linda E.] Univ So Calif, Inst Psychiat Law & Behav Sci, Los Angeles, CA USA. RP Sreenivasan, S (reprint author), 11301 Wilshire Blvd,Bldg 258,Room 136, Los Angeles, CA 90073 USA. EM shoba.sreenivasan@med.va.gov NR 12 TC 17 Z9 17 U1 0 U2 2 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2008 VL 36 IS 3 BP 375 EP 384 PG 10 WC Law; Psychiatry SC Government & Law; Psychiatry GA 356EZ UT WOS:000259762800016 PM 18802187 ER PT J AU Covinsky, KE Lindquist, K Dunlop, DD Gill, TM Yelin, E AF Covinsky, Kenneth E. Lindquist, Karla Dunlop, Dorothy D. Gill, Thomas M. Yelin, Edward TI Effect of arthritis in middle age on older-age functioning SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE arthritis; ADL; mobility ID MUSCULOSKELETAL CONDITIONS; UNITED-STATES; DISABILITY; ADULTS; IMPACT; COMMUNITY; TRANSITIONS; MORBIDITY; LIFE; POPULATION AB OBJECTIVES: To examine whether symptomatic arthritis in middle age predicts the earlier onset of functional difficulties (difficulty with activities of daily living (ADLs) and walking) that are associated with loss of independence in older persons. DESIGN: Prospective longitudinal study. SETTING: The Health and Retirement Study, a nationally representative sample of persons aged 50 to 62 at baseline who were followed for 10 years. PARTICIPANTS: Seven thousand five hundred forty-three subjects with no difficulty in mobility or ADL function at baseline. MEASUREMENTS: Arthritis was measured at baseline according to self-report. The primary outcome was time to persistent difficulty in one of five ADLs or mobility (walking several blocks or up a flight of stairs). Difficulty with ADLs or mobility was assessed according to subject interview every 2 years. Analyses were adjusted for other comorbid conditions, body mass index, exercise, and demographic characteristics. RESULTS: Twenty-nine percent of subjects reported arthritis at baseline. Subjects with arthritis were more likely to develop persistent difficulty in mobility or ADL function over 10 years of follow-up (34% vs 18%, adjusted hazard ratio (HR)=1.63, 95% confidence interval (CI)=1.43-1.86). When each component of the primary outcome was assessed separately, arthritis was also associated with persistent difficulty in mobility (30% vs 16%, adjusted HR=1.55, 95% CI=1.41-1.71) and persistent difficulty in ADL function (13% vs 5%, adjusted HR=1.85, 95% CI=1.58-2.16). CONCLUSION: Middle-aged persons who report a history of arthritis are more likely to develop mobility and ADL difficulties as they enter old age. This finding highlights the need to develop interventions and treatments that take a life-course approach to preventing the disabling effect of arthritis. C1 [Covinsky, Kenneth E.; Lindquist, Karla; Yelin, Edward] Univ Calif San Francisco, Vet Adm Med Ctr 181G, Dept Med, San Francisco, CA 94121 USA. [Covinsky, Kenneth E.; Lindquist, Karla] Univ Calif San Francisco, Vet Adm Med Ctr 181G, Div Geriatr, San Francisco, CA 94121 USA. [Yelin, Edward] Univ Calif San Francisco, VA Med Ctr 181G, Div Rheumatol, Sch Med, San Francisco, CA 94121 USA. [Yelin, Edward] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.; Lindquist, Karla] San Francisco VA Med Ctr, San Francisco, CA USA. [Dunlop, Dorothy D.] Northwestern Univ, Feinberg Sch Med, Dept Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Gill, Thomas M.] Yale Univ, Sch Med, Dept Med, New Haven, CT USA. RP Covinsky, KE (reprint author), Univ Calif San Francisco, Vet Adm Med Ctr 181G, Dept Med, 4150 Clement, San Francisco, CA 94121 USA. EM ken.covinsky@ucsf.edu FU NIA NIH HHS [K24AG029812, U01 AG009740, K24 AG021507, K24AG021507, R01AG023626, U01AG009740, R01 AG023626, K24 AG029812]; NIAMS NIH HHS [5P60AR053308-020, P60 AR053308, P60 AR053308-01] NR 36 TC 19 Z9 19 U1 3 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 23 EP 28 DI 10.1111/j.1532-5415.2007.01511.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000004 PM 18184204 ER PT J AU Spira, AP Blackwell, T Stone, KL Redline, S Cauley, JA Ancoli-Israel, S Yaffe, K AF Spira, Adam P. Blackwell, Terri Stone, Katie L. Redline, Susan Cauley, Jane A. Ancoli-Israel, Sonia Yaffe, Kristine TI Sleep-disordered breathing and cognition in older women SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE sleep apnea; cognition; older adults; women; APOE ID JAPANESE-AMERICAN MEN; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; APNEA SYNDROME; NEUROPSYCHOLOGICAL DEFICITS; DAYTIME SLEEPINESS; APOE EPSILON-4; IMPAIRMENT; POPULATION; PERFORMANCE AB OBJECTIVES: To investigate the association between objectively measured sleep-disordered breathing (SDB) and cognitive impairment in community-dwelling older women and to determine whether the apolipoprotein E (APOE) epsilon 4 allele modifies this association. DESIGN: Cross-sectional. SETTINGS: Participants' homes and two sites of the Study of Osteoporotic Fractures (SOF). PARTICIPANTS: Four hundred forty-eight women with a mean age +/- standard deviation (SD) of 82.8 +/- 3.4. MEASUREMENTS: Participants completed the Mini-Mental State Examination (MMSE), Trail Making Test Part B (Trails B), and polysomnography (PSG). SDB indices were the apnea-hypopnea index (AHI), the central apnea index (CAI), and oxygen saturation (SaO(2)) nadir less than 80%. APOE epsilon 4 was determined for a subset of 242 women. Cognitive impairment was defined as 1.5 SDs or more from the sample mean on either cognitive test (MMSE or Trails B). RESULTS:All SDB indices were associated with cognitive impairment according to the MMSE (AHI (per SD, odds ratio (OR)=1.4, 95% confidence interval (CI)=1.03-1.9), AHI of >= 30 (OR=3.4, 95% CI=1.4-8.1), SaO(2) nadir < 80% (OR=2.7, 95% CI=1.1-6.6), and CAI (per SD, OR=1.4, 95% CI=1.1-1.7)). Weaker, nonsignificant associations emerged between SDB and Trails B. In women who completed genotyping, each SD increase in AHI was associated with 70% greater odds of cognitive impairment according to the MMSE (OR=1.7, 95% CI=1.2-2.6). Women with the epsilon 4 allele had a nearly five times greater odds of impairment (per SD, OR=4.6, 95% CI-1.0-20.7); the association was smaller and nonsignificant in women without the epsilon 4 allele (per SD, OR=1.5, 95% CI-0.9-2.4; P for interaction=.08). CONCLUSION: SDB is an important risk factor for cognitive impairment in older women, especially those with the APOE epsilon 4 allele. Mechanisms linking these disorders need to be identified. C1 [Spira, Adam P.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Spira, Adam P.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Blackwell, Terri; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Redline, Susan] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Ancoli-Israel, Sonia] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. RP Spira, AP (reprint author), 4150 Clement St 181-G, San Francisco, CA 94121 USA. EM adam.spira@ucsf.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NHLBI NIH HHS [HL40489]; NIA NIH HHS [2 R01 AG027574-22A1, AG021918, AG026720, 2 R01 AG005394-22A1, AG05394, AG05407, AG08415, R01 AG005407, R01 AG026720, R01 AG027576-22, T32 AG000212-14]; NIAMS NIH HHS [AR35582, AR35583, AR35584] NR 38 TC 66 Z9 70 U1 0 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 45 EP 50 DI 10.1111/j.1532-5415.2007.01506.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000007 PM 18047498 ER PT J AU Carey, EC Covinsky, KE Lui, LY Eng, C Sands, LP Walter, LC AF Carey, Elise C. Covinsky, Kenneth E. Lui, Li-Yung Eng, Catherine Sands, Laura P. Walter, Louise C. TI Prediction of mortality in community-living frail elderly people with long-term care needs SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE mortality; aging; frailty; functional impairment; long-term care; palliative care ID OLDER HOSPITALIZED-PATIENTS; PROGNOSTIC INDEX; RISK-ADJUSTMENT; MODEL; VALIDATION; ADULTS; LIFE; SURVIVAL; PACE; END AB OBJECTIVES: To develop and validate a prognostic index for mortality in community-living, frail elderly people. DESIGN: Cohort study of Program of All-Inclusive Care for the Elderly (PACE) participants enrolled between 1988 and 1996. SETTING: Eleven PACE sites, a community-based long-term care program that cares for frail, chronically ill elderly people who meet criteria for nursing home placement. PARTICIPANTS: Three thousand eight hundred ninety-nine PACE enrollees. The index was developed in 2,232 participants and validated in 1,667. MEASUREMENTS: Time to death was predicted using risk factors obtained from a geriatric assessment performed by the PACE interdisciplinary team at the time of enrollment. Risk factors included demographic characteristics, comorbid conditions, and functional status. RESULTS: The development cohort had a mean age of 79 (68% female, 40% white). The validation cohort had a mean age of 79 (76% female, 65% white). In the development cohort, eight independent risk factors of mortality were identified and weighted, using Cox regression, to create a risk score: male sex, 2 points; age (75-79, 2 points; 80-84, 2 points; >= 85, 3 points); dependence in toileting, 1 point; dependence in dressing (partial dependence, 1 point; full dependence, 3 points); malignant neoplasm, 2 points; congestive heart failure, 3 points; chronic obstructive pulmonary disease, 1 point; and renal insufficiency, 3 points. In the development cohort, respective 1- and 3-year mortality rates were 6% and 21% in the lowest-risk group (0-3 points), 12% and 36% in the middle-risk group (4-5 points), and 21% and 54% in the highest-risk group (> 5 points). In the validation cohort, respective 1- and 3-year mortality rates were 7% and 18% in the lowest-risk group, 11% and 36% in the middle-risk group, and 22% and 55% in the highest-risk group. The area under the receiver operating characteristic curve for the point score was 0.66 and 0.69 in the development and validation cohorts, respectively. CONCLUSION: A multidimensional prognostic index was developed and validated using age, sex, functional status, and comorbidities that effectively stratifies frail, community-living elderly people into groups at varying risk of mortality. C1 [Covinsky, Kenneth E.; Eng, Catherine; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Carey, Elise C.] Mayo Clin, Coll Med, Div Gen Internal Med, Rochester, MN USA. [Covinsky, Kenneth E.; Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lui, Li-Yung] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Eng, Catherine] On Lok Senior Hlth Serv, San Francisco, CA USA. [Sands, Laura P.] Purdue Univ, Sch Nursing, Ctr Healthcare Engn, Ctr Aging & Life Course, W Lafayette, IN 47907 USA. RP Walter, LC (reprint author), VA Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA. EM Louise.Walter@ucsf.edu RI Sands, Laura/E-8919-2015 OI Sands, Laura/0000-0003-2446-4486 FU AHRQ HHS [K02HS00006-01]; NIA NIH HHS [K24 AG029812, AG022090, R01 AG023626]; PHS HHS [1K01HP00125-01] NR 31 TC 73 Z9 75 U1 0 U2 16 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 68 EP 75 DI 10.1111/j.1532-5415.2007.01496.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000010 PM 18031487 ER PT J AU Leff, B Burton, L Mader, SL Naughton, B Burl, J Koehn, D Clark, R Greenough, WB Guido, S Steinwachs, D Burton, JR AF Leff, Bruce Burton, Lynda Mader, Scott L. Naughton, Bruce Burl, Jeffrey Koehn, Debbie Clark, Rebecca Greenough, William B., III Guido, Susan Steinwachs, Donald Burton, John R. TI Comparison of stress experienced by family members of patients treated in hospital at home with that of those receiving traditional acute hospital care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE "Hospital at Home"; caregiver; stress; aged; hospital care; acute care for the elderly ID RANDOMIZED CONTROLLED-TRIAL; BURDEN; CAREGIVERS; OUTCOMES; ILLNESS; PROGRAM; INDEX; ILL AB OBJECTIVES: To compare differences in the stress experienced by family members of patients cared for in a physician-led substitutive Hospital at Home (HaH) and those receiving traditional acute hospital care. DESIGN: Survey questionnaire completed as a component of a prospective, nonrandomized clinical trial of a substitutive HaH care model. SETTING: Three Medicare managed care health systems and a Veterans Affairs Medical Center. PARTICIPANTS: Two hundred fourteen community-dwelling elderly patients who required acute hospital admission for community-acquired pneumonia, exacerbation of chronic heart failure, exacerbation of chronic obstructive pulmonary disease, or cellulitis. INTERVENTION: Treatment in a substitutive HaH model. MEASUREMENTS: Fifteen-question survey questionnaire asking family members whether they experienced a potentially stressful situation and, if so, whether stress was associated with the situation while the patient received care. RESULTS: The mean and median number of experiences, of a possible 15, that caused stress for family members of HaH patients was significantly lower than for family members of acute care hospital patients (mean +/- standard deviation 1.7 +/- 1.8 vs 4.3 +/- 3.1, P <.001; median 1 vs 4, P <.001). HaH care was associated with lower odds of developing mean levels of family member stress (adjusted odds ratio=0.12, 95% confidence interval=0.05-0.30). CONCLUSION: HaH is associated with lower levels of family member stress than traditional acute hospital care and does not appear to shift the burden of care from hospital staff to family members. C1 [Leff, Bruce; Greenough, William B., III; Guido, Susan; Burton, John R.] Johns Hopkins Univ, Sch Med, John Hopkins Care Ctr, Div Geriatr Med,Dept Med, Baltimore, MD 21224 USA. [Leff, Bruce; Burton, Lynda; Koehn, Debbie; Clark, Rebecca; Steinwachs, Donald; Burton, John R.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21224 USA. [Mader, Scott L.] Portland VA Med Ctr, Portland, OR USA. [Mader, Scott L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Naughton, Bruce] SUNY Buffalo, Buffalo, NY USA. [Naughton, Bruce] Univera Hlth, Buffalo, NY USA. [Burl, Jeffrey] Fallon Community Hlth Plan & Fallon Clin, Worcester, MA USA. Independent Hlth, Buffalo, NY USA. RP Leff, B (reprint author), Johns Hopkins Univ, Sch Med, John Hopkins Care Ctr, Div Geriatr Med,Dept Med, 5505 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM bleff@jhmi.edu NR 29 TC 17 Z9 17 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 117 EP 123 DI 10.1111/j.1532-5415.2007.01459.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000017 PM 17979955 ER PT J AU Morss, S Shugarman, LR Lorenz, KA Mularski, RA Lynn, J AF Morss, Sydney Shugarman, Lisa R. Lorenz, Karl A. Mularski, Richard A. Lynn, Joanne CA RAND So California Evidence Based TI A systematic review of satisfaction with care at the end of life SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Review DE systematic review; satisfaction; end-of-life care; palliative care ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PALLIATIVE CARE; PATIENTS PERSPECTIVES; NURSING-HOMES; CANCER; EXPERIENCES; FAMILIES; DEATH; CAREGIVERS AB The objective of this study was to systematically review the literature to better understand the conceptualization of satisfaction with end-of-life care and the effectiveness of palliative care interventions on this outcome. Data sources included Medline and the Database of Reviews of Effects. The review included relevant qualitative studies and intervention studies using satisfaction as an outcome from 1990 to 2005. Reviewing 24,423 citations yielded 21 relevant qualitative studies, four systematic reviews, and eight additional intervention studies. The qualitative literature described the domains of accessibility and coordination; competence, including symptom management; communication and education; emotional support and personalization of care; and support of patients' decision-making. For collaboration and consultation interventions, eight of 13 studies showed a significant effect on satisfaction. A meta-analysis found that palliative care and hospice teams improved satisfaction, although most studies did not include satisfaction as an outcome. For other types of interventions, only two of six showed a significant effect. For heart failure coordination of care, only seven of 32 studies addressed this as an outcome; two of the three that compared satisfaction between groups showed a significant difference. Evaluations used many different measures, only one of which was designed for the end of life. In conclusion, researchers have conceptualized satisfaction in palliative care, and different types of palliative care interventions can improve satisfaction, but it is often not included as an outcome. More focus on these satisfaction elements might improve the effectiveness of end-of-life interventions and their evaluation. C1 [Morss, Sydney] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA. [Morss, Sydney] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. [Morss, Sydney] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Shugarman, Lisa R.; Lorenz, Karl A.; Lynn, Joanne] RAND Hlth, Santa Monica, CA USA. [Shugarman, Lisa R.; Lorenz, Karl A.; Lynn, Joanne] So California Evidence Based Practice Ctr, Santa Monica, CA USA. [Lorenz, Karl A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mularski, Richard A.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Morss, S (reprint author), Room 609,624 N Broadway, Baltimore, MD 21205 USA. EM sdy@jhsph.edu NR 40 TC 0 Z9 0 U1 5 U2 13 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 124 EP 129 DI 10.1111/j.1532-5415.2007.01507.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000018 ER PT J AU Norris, SL High, K Gill, TM Hennessy, S Kutner, JS Reuben, DB Unutzer, J Landefeld, CS AF Norris, Susan L. High, Kevin Gill, Thomas M. Hennessy, Sean Kutner, Jean S. Reuben, David B. Unuetzer, Juergen Landefeld, C. Seth TI Health care for older americans with multiple chronic conditions: A research agenda SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aging; research agenda; older adults ID RANDOMIZED CLINICAL-TRIAL; OUTPATIENT GERIATRIC EVALUATION; LEUKEMIA-GROUP-B; DEPRESSIVE SYMPTOMS; ELDERLY PERSONS; FUNCTIONAL DECLINE; FOLLOW-UP; LATE-LIFE; PROGRAM; CANCER AB In response to the substantial and increasing healthcare requirements of older adults with multiple chronic conditions and acknowledgment of major gaps in knowledge and funding, two expert meetings were convened to identify a research agenda addressing the needs of this population. Research priorities are to develop and evaluate more-effective models of health care, develop and evaluate management practices and organizational structures that lead to improved long-term care, develop and implement relevant and effective preventive health strategies, determine the most effective interventions in patients who have concurrent cognitive or emotional impairments, and determine how interventions during and after hospitalization affect the outcomes of hospitalized patients. C1 [Norris, Susan L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [High, Kevin] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA. [Gill, Thomas M.] Yale Univ, Sch Med, Dept Epidemiol & Investigat Med, New Haven, CT USA. [Hennessy, Sean] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Kutner, Jean S.] Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA. [Reuben, David B.] Univ Calif Los Angeles, David Gaffen Sch Med, Div Geriatr, Los Angeles, CA USA. [Unuetzer, Juergen] Univ Washington, Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. RP Norris, SL (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd,Mail Stop B1CC, Portland, OR 97239 USA. EM norriss@ohsu.edu NR 76 TC 47 Z9 47 U1 5 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2008 VL 56 IS 1 BP 149 EP 159 DI 10.1111/j.1532-5415.2007.01530.x PG 11 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 246CL UT WOS:000251985000023 PM 18047493 ER PT J AU Rosenbloom, ST Miller, RA Johnson, KB Elkin, PL Brown, SH AF Rosenbloom, S. Trent Miller, Randolph A. Johnson, Kevin B. Elkin, Peter L. Brown, Steven H. TI A model for evaluating interface terminologies SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID MEDICAL INFORMATICS; CLINICAL-DATA; VOCABULARIES; REPRESENTATION; SYSTEMS; CLASSIFICATIONS; AGREEMENT; FRAMEWORK; SELECTION; COVERAGE AB Objective: Evaluations of individual terminology systems should be driven in part by the intended usages of such systems. Clinical interface terminologies support interactions between healthcare providers and computer-based applications. They aid practitioners in converting clinical "free text" thoughts into the structured, formal data representations used internally by application programs. Interface terminologies also serve the important role of presenting existing stored, encoded data to end users in human-understandable and actionable formats. The authors present a model for evaluating functional utility of interface terminologies based on these intended uses. Design: Specific parameters defined in the manuscript comprise the metrics for the evaluation model. Measurements: Parameters include concept accuracy, term expressivity, degree of semantic consistency for term construction and selection, adequacy of assertional knowledge supporting concepts, degree of complexity of pre-coordinated concepts, and the "human readability" of the terminology. The fundamental metric is how well the interface terminology performs in supporting correct, complete, and efficient data encoding or review by humans. Results: Authors provide examples demonstrating performance of the proposed evaluation model in selected instances. Conclusion: A formal evaluation model will permit investigators to evaluate interface terminologies using a consistent and principled approach. Terminology developers and evaluators can apply the proposed model to identify areas for improving interface terminologies. C1 [Rosenbloom, S. Trent; Miller, Randolph A.; Johnson, Kevin B.; Brown, Steven H.] Vanderbilt Univ, Dept Biomed Informat, Nashville, TN USA. [Rosenbloom, S. Trent; Miller, Randolph A.] Vanderbilt Univ, Sch Nursing, Nashville, TN 37240 USA. [Rosenbloom, S. Trent; Johnson, Kevin B.] Vanderbilt Univ, Dept Pediat, Nashville, TN 37240 USA. [Elkin, Peter L.] Mayo Fdn Med Educ & Res, Rochester, MN USA. [Brown, Steven H.] US Dept Vet Affairs, Nashville, TN USA. RP Rosenbloom, ST (reprint author), Eskind Biomed Lib, Room 440,2209 Garland Ave, Nashville, TN 37232 USA. EM trent.rosenbloom@vanderbilt.edu FU NLM NIH HHS [5K22 LM008576-02, 5R01 LM007995, K22 LM008576, R01 LM007995]; PHITPO CDC HHS [HK00014-01, U38 HK000014]; PHPPO CDC HHS [PH000022-02, R01 PH000022] NR 64 TC 19 Z9 19 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2008 VL 15 IS 1 BP 65 EP 76 DI 10.1197/jamia.M2506 PG 12 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 250PM UT WOS:000252312500011 PM 17947616 ER PT J AU Picard, MH Popp, RL Weyman, AE AF Picard, Michael H. Popp, Richard L. Weyman, Arthnr E. TI Assessment of left ventricular function by echocardiography: A technique in evolution SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article DE left ventricular function; two-dimensional echocardiography; three-dimensional echocardiography ID TIME 3-DIMENSIONAL ECHOCARDIOGRAPHY; CROSS-SECTIONAL ECHOCARDIOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; 2-DIMENSIONAL ECHOCARDIOGRAPHY; COMPUTED-TOMOGRAPHY; NATURAL-HISTORY; WALL MOTION; ULTRASOUND; VOLUME AB One of the earliest applications of clinical echocardiography was the evaluation of left ventricular (LV) size and function. The accuracy of the determination of global and regional LV function with echocardiography has improved as the technology has matured. The following paper discusses the advances in LV function assessment starting with Inge Edler's original A-mode and M-mode observation moving through two dimensional echocardiographic methods to new three dimensional echocardiographic assessment and even new Doppler and speckle myocardial methods. During the evolution of ultrasonic assessment of LV function, each new method has overcome limitations of previous ones, resulting in better appreciation of the LV geometry and volume and improved accuracy and reproducibility for quantitation. As discussed in this report, many of the echocardiographic methods used today to assess LV systolic function were envisioned by Harvey Feigenbaum more than 25 years ago. The future will undoubtedly see a new method of clinical cardiology care but with continued evolution, echocardiographic quantitation of LV function should remain a vital part of patient care. C1 [Picard, Michael H.; Weyman, Arthnr E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Picard, Michael H.; Weyman, Arthnr E.] Harvard Univ, Sch Med, Boston, MA USA. [Popp, Richard L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Picard, MH (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 5300, Boston, MA 02114 USA. EM mhpicard@partners.org OI Picard, Michael/0000-0002-9264-3243 NR 51 TC 10 Z9 11 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD JAN PY 2008 VL 21 IS 1 BP 14 EP 21 DI 10.1016/j.echo.2007.11.007 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251FY UT WOS:000252359000004 PM 18165124 ER PT J AU Smith, GL Masoudi, FA Shlipak, MG Krumholz, HM Parikh, CR AF Smith, Grace L. Masoudi, Frederick A. Shlipak, Michael G. Krumholz, Harlan M. Parikh, Chirag R. TI Renal impairment predicts long-term mortality risk after acute myocardial infarction SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; ACUTE CORONARY SYNDROMES; HEART-FAILURE; CARDIOVASCULAR OUTCOMES; PROGNOSTIC IMPLICATIONS; SYSTOLIC DYSFUNCTION; SERUM CREATININE; TEMPORAL TRENDS; UREA NITROGEN AB Renal function predicts mortality after acute myocardial infarction (AMI), but it is unknown whether the prognostic importance of renal function persists over time. This study examined how the association between renal function and mortality changed in the 10 yr after AMI in a cohort of patients. In 118,753 patients (age >= 65 yr) from the Cooperative Cardiovascular Project, mean Cockcroft-Gault creatinine clearance was 55 +/- 24 ml/min and estimated GFR was 57 +/- 21 ml/min per 1.73 m(2) at baseline. By 10 yr, 68% of patients had died. Compared with normal renal function, even mild renal impairment increased the 10-yr risk for mortality risk by 10%. Severe renal impairment more than doubled the risk for mortality at 1 yr, and this increased risk persisted at both 5 and 10 yr. At 1 yr, the contribution of creatinine clearance to mortality risk rivaled traditional factors such as BP and systolic function; by 10yr, creatinine clearance surpassed these other risk factors, rivaled only by patient age. Associations with estimated GFR demonstrated similar trends. In conclusion, renal function in hospitalized patients with AMI is an important and consistent predictor of mortality for up to 10 yr. C1 [Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, West Haven, CT 06516 USA. [Parikh, Chirag R.] Vet Adm Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT 06516 USA. [Smith, Grace L.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Div Cardiol, Denver, CO 80202 USA. [Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA. [Masoudi, Frederick A.] Colorado Fdn Med Care, Aurora, CO USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Med Serv, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Robert Wood Johnson Clin Scholars Program, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. RP Parikh, CR (reprint author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Room 21, West Haven, CT 06516 USA. EM chirag.parikh@yale.edu FU NIDDK NIH HHS [R01 DK066488-01, R01 DK066488]; NIGMS NIH HHS [GM07205, T32 GM007205] NR 33 TC 28 Z9 30 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2008 VL 19 IS 1 BP 141 EP 150 DI 10.1681/ASN.2007050554 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 250IL UT WOS:000252293100020 PM 18003773 ER PT J AU Cohn, LH AF Cohn, Lawrence H. TI What is changing and what isn't in The Journal of Thoracic and Cardiovascular Surgery: The cardiovascular and thoracic service-line concept SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. RP Cohn, LH (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM lhcohn@bics.bwh.harvard.edu NR 0 TC 2 Z9 2 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2008 VL 135 IS 1 BP 1 EP 2 DI 10.1016/j.jtcvs.2007.10.013 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 248GC UT WOS:000252139600001 ER PT J AU McDougal, WS AF McDougal, W. Scott TI Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques - Comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 [McDougal, W. Scott] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2008 VL 179 IS 1 BP 79 EP 80 DI 10.1016/j.juro.2007.08.233 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 241IN UT WOS:000251650200020 ER PT J AU Buschemeyer, WC Hamilton, RJ Aronson, WJ Presti, JC Terris, MK Kane, CJ Amling, CL Freedland, SJ AF Buschemeyer, W. Cooper, III Hamilton, Robert J. Aronson, William J. Presti, Joseph C., Jr. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Freedland, Stephen J. TI Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH database SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostatectomy; bladder; neoplasm staging ID RADICAL PROSTATECTOMY; PATHOLOGICAL ANALYSIS; SURGICAL MARGINS; CANCER; RECURRENCE; PREDICTOR; PROGNOSIS; IMPACT; RISK AB Purpose: Positive bladder neck margins after radical prostatectomy are currently designated as pT4 lesions. However, to our knowledge the prognostic significance of a positive bladder neck margin in the prostate specific antigen era is unknown. We examined the association between positive bladder neck margins and prostate specific antigen recurrence relative to other pathological findings. Materials and Methods: We examined 1,722 men from the Shared Equal Access Research Cancer Hospital Database who were treated with radical prostatectomy without lymph node metastases. Time to prostate specific antigen recurrence was compared in men with positive vs negative bladder neck margins using Cox proportional hazards models adjusted for multiple clinical and pathological features. Results: A positive bladder neck margin in 79 patients (5%) was significantly associated with other poor prognostic features, including higher prostate specific antigen, higher pathological Gleason sum, extracapsular extension, seminal vesicle invasion and other positive margins. After adjusting for clinical and pathological characteristics positive bladder neck margins were associated with an increased risk of prostate specific antigen recurrence (HR 1.52, 95% CI 1.06-2.19, p = 0.02). Relative to organ confined margin negative disease a positive bladder neck margin associated with other positive margins showed a recurrence risk that was similar to that of seminal vesicle invasion (HR 4.14, 95% CI 2.55-6.73 and HR 4.22, 95% CI 3.08-5.78, respectively, each p <0.001). An isolated positive bladder neck margin was a rare event, noted in 15 patients (0.7%). In these men the recurrence risk was difficult to estimate due to the small number. However, the HR was similar to that in men with nonbladder neck positive margins or extracapsular extension (HR 2.65, 95% CI 0.97-7.25, p = 0.06 and HR 2.19, 95% CI 1.71-2.82, p <0.001, respectively). Conclusions: In the current study a positive bladder neck margin was frequently associated with other adverse features. When it was concomitant with other positive margins, a positive bladder neck margin was associated with a progression risk similar to that of seminal vesicle invasion (T3b disease). Although men with an isolated positive bladder neck margin had a more favorable pathological profile, there were too few of them to assess outcome reliably. However, the limited data suggest that they may best be categorized as having pT3a disease. C1 [Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol, Dept Pathol, Durham, NC 27710 USA. [Buschemeyer, W. Cooper, III; Hamilton, Robert J.; Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol Surg, Dept Surg, Durham, NC 27710 USA. [Buschemeyer, W. Cooper, III; Freedland, Stephen J.] VA Med Ctr, Surg Serv, Urol Sect, Durham, NC USA. [Hamilton, Robert J.] Univ Toronto, Dept Urol Surg, Toronto, ON, Canada. [Aronson, William J.] VA Greater Los Angeles Hlth Care Syst, Surg Serv, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Surg Serv, Urol Sect, Palo Alto, CA 94304 USA. [Kane, Christopher J.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Kane, Christopher J.] Vet Affairs Med Ctr, Surg Serv, Urol Sect, San Francisco, CA 94121 USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Freedland, Stephen J.] Univ Alabama, Div Urol, Birmingham, AL USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Dept Pathol, Box 2626 Duke Univ Med Ctr, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Hamilton, Robert/0000-0002-6715-5934; Terris, Martha/0000-0002-3843-7270 FU NCI NIH HHS [R01CA100938, P50 CA92131-01A1] NR 12 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2008 VL 179 IS 1 BP 124 EP 129 DI 10.1016/j.juro.2007.08.130 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 241IN UT WOS:000251650200035 PM 17997433 ER PT J AU Smith, MR Malkowicz, SB Chu, F Forrest, J Price, D Sieber, P Barnette, KG Rodriguez, D Steiner, MS AF Smith, M. R. Malkowicz, S. B. Chu, F. Forrest, J. Price, D. Sieber, P. Barnette, K. G. Rodriguez, D. Steiner, M. S. TI Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; gonadotropin-releasing hormone; orchiectomy; osteoporosis; androgen antagonists ID POSTMENOPAUSAL WOMEN; CONTROLLED-TRIAL; BREAST-CANCER; FRACTURE RISK; SEX STEROIDS; RALOXIFENE; TAMOXIFEN; TURNOVER; PROFILE; COHORT AB Purpose: We evaluated the effects of toremifene on bone mineral density, a surrogate for fracture risk, in men receiving androgen deprivation therapy for prostate cancer. Materials and Methods: In an ongoing, multicenter, phase 3 fracture prevention study 1,392 men 50 years or older with prostate cancer receiving androgen deprivation therapy were randomized to 80 mg toremifene per day or placebo. Bone mineral density of the lumbar spine, total hip and femoral neck was assessed using dual energy x-ray absorptiometry. In this planned interim analysis of the first 197 subjects we compared bone mineral density changes from baseline to month 12 between the placebo and toremifene groups. Results: Compared with the placebo group men in the toremifene group had significant increases in bone mineral density at each evaluated skeletal site. Lumbar spine bone mineral density decreased 0.7% in the placebo group and increased 1.6% in the toremifene group (between group comparison p <0.001). Total hip bone mineral density decreased 1.3% in the placebo group and increased 0.7% in the toremifene group (p = 0.001). Femoral neck bone mineral density decreased 1.3% in the placebo group and increased 0.2% in the toremifene group (p = 0.009). Between group differences in the change in bone mineral density from baseline to month 12 were 2.3%, 2.0% and 1.5% for the lumbar spine, total hip and femoral neck, respectively. Conclusions: Toremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer. The effect of toremifene on the fracture risk is being assessed in the ongoing randomized, controlled trial. C1 [Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Malkowicz, S. B.] Univ Penn, Philadelphia, PA 19104 USA. [Sieber, P.] Urol Associates Lancaster, Lancaster, PA USA. [Chu, F.] San Bernadino Urol Associates, San Bernardino, CA USA. [Forrest, J.] Urol Specialists Oklahoma, Tulsa, OK USA. [Price, D.] Reg Urol, Shreveport, LA USA. [Barnette, K. G.; Rodriguez, D.; Steiner, M. S.] GTx Inc, Memphis, TN USA. RP Smith, MR (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7038,55 Fruit St, Boston, MA 02114 USA. EM smith.matthew@mgh.harvard.edu FU NCI NIH HHS [K24 CA121990, K24 CA121990-02] NR 20 TC 72 Z9 73 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2008 VL 179 IS 1 BP 152 EP 155 DI 10.1016/j.juro.2007.08.137 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 241IN UT WOS:000251650200042 PM 18001802 ER PT J AU Hoppe, H Barnwell, SL Nesbit, GM Petersen, BD AF Hoppe, Hanno Barnwell, Stanley L. Nesbit, Gary M. Petersen, Bryan D. TI Stent-grafts in the treatment of emergent or urgent carotid artery disease: Review of 25 cases SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID TECHNICAL CASE-REPORT; COVERED STENT; ENDOVASCULAR TREATMENT; BLOWOUT SYNDROME; FOLLOW-UP; PSEUDOANEURYSM; ANEURYSMS; REPAIR; EXPERIENCE; MANAGEMENT AB PURPOSE: To report the authors' initial experience with carotid artery stent-grafts in a comparatively large patient series for the treatment of acute bleeding and impending rupture or the prevention of distal embolization. MATERIALS AND METHODS: This retrospective study was approved by the institutional review boards and performed according to HIPPA standards. Twenty-five patients were treated with 27 carotid artery stent-grafts (Gore Viabahn, n = 10; Bard Fluency, n = 9; polytetrafluoroethylene- covered Palmaz, n = 5; and Wallgraft, n = 3). Thirteen stent-grafts were placed in patients with carotid blow-out syndrome (including three patients with carotid-airway fistula), 12 in patients with either pseudoaneurysm (n = 9) or true aneurysm (n = 3), and two in patients with intractable high-grade bare stent restenosis. RESULTS: The technical success rate was 100% (27 of 27 cases). No acute procedural transient ischemic attacks or strokes occurred. Procedural dissections occurred in two of the 27 cases (7.4%). Short-term complications occurred in three of the 27 cases (11%) (repeat hemorrhage, n = 2; common carotid artery occlusion, n = 1). The overall patient mortality rate was 36% (nine of 25 patients, all with carotid blow-out syndrome). Six-month follow-up in 15 of the 16 living patients demonstrated widely patent stent-grafts. Two patients with pseudoaneurysm also demonstrated patent stents at 18- and 33-month follow-up. CONCLUSIONS: Stent-grafts may be useful in the treatment of carotid artery bleeding syndrome, aneurysm, and stenosis, with a high procedural success rate in selected cases. The results of mid-term follow-up are encouraging, but results of long-term follow-up must be evaluated in future studies. C1 [Hoppe, Hanno; Barnwell, Stanley L.; Nesbit, Gary M.; Petersen, Bryan D.] Oregon Hlth & Sci Univ, Dotter Intervent Inst, Portland, OR 97201 USA. [Petersen, Bryan D.] Portland VA Med Ctr, Dept Angiog, Portland, OR USA. RP Petersen, BD (reprint author), Oregon Hlth & Sci Univ, Dotter Intervent Inst, L-342,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM Bryan.Petersen@med.va.gov NR 23 TC 28 Z9 28 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2008 VL 19 IS 1 BP 31 EP 41 DI 10.1016/j.jvir.2007.08.024 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 258FG UT WOS:000252853200007 PM 18192465 ER PT J AU Cantwell, CP Gervais, DA Hahn, PF Mueller, PR AF Cantwell, Colin P. Gervais, Debra A. Hahn, Peter F. Mueller, Peter R. TI Feasibility and safety of infracolic fluoroscopically guided percutaneous radiologic gastrostomy SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID QUALITY IMPROVEMENT GUIDELINES; T-FASTENER; GASTROJEJUNOSTOMY; EXPERIENCE; GASTROPEXY AB We study the feasibility and safety of infracolic fluoroscopically guided percutaneous gastrostomy when patient anatomy prevents conventional supracolic puncture. From September 2004 to April 2007, 508 gastrostomy and gastrojejunostomy catheters were inserted in a single institution, and in six patients, the position of the transverse colon prevented conventional supracolic puncture. All were male, with a mean age of 57 years. Four patients had head and neck cancer and two had neurologic conditions. With fluoroscopic guidance, a 14-F gastrostomy tube was inserted with T-fastener gastropexy caudal to the colon. The medical records of patients treated with this technique were reviewed for demographics, indication, technique, complications, function of gastrostomy, timing of removal of the gastrostomy, and subsequent hospital admissions. All procedures were technically successful and there was no procedure-related morbidity or mortality. The mean follow-up was 16 months (range, 7-25 months) and the mean duration of therapy was 7 months. Five patients had their gastrostomy removed after clinical improvement and one of these patients had a gastrostomy reinserted cephalic to the colon after recurrence of head and neck cancer. Two patients died of disease progression and one still had the gastrostomy in position. No patient was subsequently admitted for a complication of the technique or catheter malfunction. In conclusion, infracolic percutaneous radiologic gastrostomy with gastropexy is feasible in patients without an access route cephalic to the transverse colon. C1 [Cantwell, Colin P.; Gervais, Debra A.; Hahn, Peter F.; Mueller, Peter R.] Massachusetts Gen Hosp, Div Abdominal & Intervent Radiol, Boston, MA 02114 USA. [Cantwell, Colin P.; Gervais, Debra A.; Hahn, Peter F.; Mueller, Peter R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Mueller, PR (reprint author), Massachusetts Gen Hosp, Div Abdominal & Intervent Radiol, White 270,55 Fruit St, Boston, MA 02114 USA. EM pmueller@partners.org NR 12 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2008 VL 19 IS 1 BP 129 EP 132 DI 10.1016/j.jvir.2007.08.021 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 258FG UT WOS:000252853200020 PM 18192478 ER PT J AU Jones, JA Barbour, JR Stroud, RE Bouges, S Stephens, SL Spinale, FG Ikonomidis, JS AF Jones, Jeffrey A. Barbour, John R. Stroud, Robert E. Bouges, Shenikqua Stephens, Shelly L. Spinale, Francis G. Ikonomidis, John S. TI Altered Transforming Growth Factor-Beta Signaling in a Murine Model of Thoracic Aortic Aneurysm SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE TGF-beta; Aneurysm; Signal transduction; Extracellular matrix; Remodeling ID BONE MORPHOGENETIC PROTEIN-2; MATRIX METALLOPROTEINASES; VASCULAR DISORDERS; TISSUE INHIBITOR; GENE-EXPRESSION; ANGIOGENESIS; RECEPTOR; INTERLEUKIN-6; CELLS; ACTIVATION AB Objective: Thoracic aortic aneurysms (TAAs) develop by a multifactorial process involving maladaptive signaling pathways that alter the aortic vascular environment. Transforming growth factor-beta (TGF-beta) has been implicated in regulating the structure and composition of the extracellular matrix by differential activation of various intracellular signaling pathways. However, whether and to what degree TGF-beta signaling contributes to TAA development remains unclear. Accordingly, the hypothesis that alterations in TGF-beta signaling occur during aneurysm formation was tested in a murine model of TAA. Methods: TAAs were surgically induced in mice (C57BL/6J) and aortas were analyzed at predetermined time points (1, 2, and 4 weeks post-TAA induction). Quantitative real-time PCR (QPCR) was performed to evaluate the expression of 84 relevant TGF-beta superfamily genes, and the protein levels of key signaling intermediates were measured by immunoblotting. Results were compared to unoperated reference control mice. Results: QPCR revealed increased expression of TGF-beta superfamily ligands (Gdf-2, -6, -7, Inhba), ligand inhibitors (Bmper, Chrd, Gsc), and transcriptional regulators (Dlx2, Evi1), among other genes (Cdkn2b, Igf1, IL-6). Protein levels of TGF-beta receptor(II), Smad2, Smad1/5/8, phospho-Smad1/5/8, and Smurf1 were increased from control values post-TAA induction. Both TGF-beta receptor(1) and Smad4 were decreased from control values, while ALK-1 levels remained unchanged. Conclusions: These alterations in the TGF-beta pathway suggest a mechanism by which primary signaling is switched from a TGF-beta R-1/Smad2-dependent response, to an ALK-1/Smad1/5/8 response, representing a significant change in signaling outcome, which may enhance matrix degradation. Copyright (C) 2008 S. Karger AG, Basel. C1 [Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Jones, JA (reprint author), Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Strom Thurmond Res Bldg,114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM jonesja@musc.edu FU NHLBI NIH HHS [R01 HL075488-05, R01 HL059165, R01 HL059165-07, R01 HL075488, R01 HL075488-04, R01 HL102121]; NIA NIH HHS [R01 AG036954] NR 56 TC 19 Z9 20 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2008 VL 45 IS 6 BP 457 EP 468 DI 10.1159/000127437 PG 12 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 363AQ UT WOS:000260238700001 PM 18434745 ER PT J AU Alexis, JD Pyo, RT Chereshnev, I Katz, J Rollins, BJ Charo, IF Taubman, MB AF Alexis, Jeffrey D. Pyo, Robert T. Chereshnev, Igor Katz, Jonathan Rollins, Barrett J. Charo, Israel F. Taubman, Mark B. TI Inhibition of MCP-1/CCR2 Signaling Does Not Inhibit Intimal Proliferation in a Mouse Aortic Transplant Model SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE Chemokines; Intimal hyperplasia; MCP-1; Smooth muscle cell; Transplantation ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CORONARY-ARTERY DISEASE; CARDIAC ALLOGRAFT VASCULOPATHY; SMOOTH-MUSCLE-CELLS; CHRONIC REJECTION; REDUCES ATHEROSCLEROSIS; TARGETING CCR5; DEFICIENT MICE; CHEMOKINE; ARTERIOSCLEROSIS AB Background: Transplant arteriopathy is the leading cause of long term morbidity and mortality following heart transplantation. Animal models have demonstrated that monocyte chemoattractant protein (MCP)-1 is induced early after transplant in cardiac and aortic allografts. We have previously reported that deficiency of MCP-1 or its receptor, CC chemokine receptor 2 (CCR2), is associated with a reduction in intimal proliferation in a mouse femoral artery injury model. Using knockout mice, we have now examined the role of MCP-1 and CCR2 in the development of the intimal proliferation of transplant arteriopathy. Methods: C57BI/6 CCR2 and MCP-1 wild-type and knockout mice were used in the studies and aortic transplants were performed between Balb/c mice and C57BI/6 mice. Aortas from recipient animals were harvested 8 weeks after transplant. Results: Unlike arterial injury, in an aortic transplant model inhibition of MCP-1/CCR2 signaling did not result in reduced intimal proliferation. Conclusions: Despite a pathology that appears similar, the inflammatory mediators that regulate transplant arteriopathy differ from those regulating intimal proliferation secondary to wire injury. Our results suggest that targeting MCP-1/CCR2 signaling is not sufficient to block transplant arteriopathy across a complete MHC-mismatch barrier. Copyright (C) 2008 S. Karger AG, Basel. C1 [Alexis, Jeffrey D.; Taubman, Mark B.] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY USA. [Pyo, Robert T.; Chereshnev, Igor] Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA. [Pyo, Robert T.; Chereshnev, Igor] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Rollins, Barrett J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Adult Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA. [Charo, Israel F.] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA USA. [Katz, Jonathan] Sackler Sch Med, Tel Aviv, Israel. RP Alexis, JD (reprint author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, 211 Bailey Rd, W Henrietta, NY 14586 USA. EM jeffrey_alexis@urmc.rochester.edu NR 41 TC 9 Z9 10 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2008 VL 45 IS 6 BP 538 EP 546 DI 10.1159/000129688 PG 9 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 363AQ UT WOS:000260238700009 PM 18463419 ER PT J AU Holly, JE Vrublevskis, A Carlson, LE AF Holly, Jan E. Vrublevskis, Arturs Carlson, Lindsay E. TI Whole-motion model of perception during forward- and backward-facing centrifuge runs SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE Perception; self-motion; model; centrifuge; VOR ID VERTICAL AXIS ROTATION; LINEAR ACCELERATION; SELF-MOTION; VESTIBULOOCULAR REFLEX; OCULOGRAVIC ILLUSION; ECCENTRIC ROTATION; EYE-MOVEMENTS; SPATIAL ORIENTATION; OBJECT PERCEPTION; INTERNAL-MODELS AB Illusory perceptions of motion and orientation arise during human centrifuge runs without vision. Asymmetries have been found between acceleration and deceleration, and between forward-facing and backward-facing runs. Perceived roll tilt has been studied extensively during upright fixed-carriage centrifuge runs, and other components have been studied to a lesser extent. Certain, but not all, perceptual asymmetries in acceleration-vs-deceleration and forward-vs-backward motion can be explained by existing analyses. The immediate acceleration-deceleration roll-tilt asymmetry can be explained by the three-dimensional physics of the external stimulus; in addition, longer-term data has been modeled in a standard way using physiological time constants. However, the standard modeling approach is shown in the present research to predict forward-vs-backward-facing symmetry in perceived roll tilt, contradicting experimental data, and to predict perceived sideways motion, rather than forward or backward motion, around a curve. The present work develops a different whole-motion-based model taking into account the three-dimensional form of perceived motion and orientation. This model predicts perceived forward or backward motion around a curve, and predicts additional asymmetries such as the forward-backward difference in roll tilt. This model is based upon many of the same principles as the standard model, but includes an additional concept of familiarity of motions as a whole. C1 [Holly, Jan E.; Vrublevskis, Arturs; Carlson, Lindsay E.] Colby Coll, Dept Math, Waterville, ME 04901 USA. [Vrublevskis, Arturs] MIT, Dept Phys, Cambridge, MA 02139 USA. [Carlson, Lindsay E.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. RP Holly, JE (reprint author), Colby Coll, Dept Math, 5845 Mayflower Hill, Waterville, ME 04901 USA. EM jeholly@colby.edu FU National Institutes of Health [R15-DC008311] FX Thanks are extended to Ian Curthoys and Fred Guedry for discussions about subjects' perceptions in centrifuge runs. This work was supported by National Institutes of Health Grant R15-DC008311. NR 50 TC 7 Z9 7 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2008 VL 18 IS 4 BP 171 EP 186 PG 16 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 414ZN UT WOS:000263904200001 PM 19208962 ER PT J AU Sienko, KH Balkwill, MD Oddsson, LIE Wall, C AF Sienko, K. H. Balkwill, M. D. Oddsson, L. I. E. Wall, C. TI Effects of multi-directional vibrotactile feedback on vestibular-deficient postural performance during continuous multi-directional support surface perturbations SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE Vibrotactile; balance prosthesis; biofeedback; balance; intuitive display ID BALANCE PROSTHESIS; SENSORY SUBSTITUTION; HEAD STABILIZATION; BIOFEEDBACK; SWAY; SPACE; TILT AB Single-axis vibrotactile feedback of trunk tilt provided in real-time has previously been shown to significantly reduce the root-mean-square (RMS) trunk sway in subjects with vestibular loss during single-axis perturbation. This research examines the effect of multi-directional vibrotactile feedback on postural sway during continuous multi-directional surface perturbations when the subjects' eyes are closed. Eight subjects with vestibular loss donned a multi-axis feedback device that mapped body tilt estimates onto their torsos with a 3-row by 16-column array of tactile actuators (tactors). Tactor row indicated tilt magnitude and tactor column indicated tilt direction. Root-mean-square trunk tilt, elliptical fits to trunk sway trajectory areas, percentage of time spent outside a no vibrotactile feedback zone, RMS center of pressure, and anchoring index parameters indicating intersegmental coordination were used to assess the efficacy of the multi-directional vibrotactile balance aid. Four tactor display configurations in addition to the tactors off configuration were evaluated. Subjects had significantly reduced RMS trunk sway, significantly smaller elliptical fits of the trajectory area, and spent significantly less time outside of the no feedback zone in the tactors on versus the tactors off configuration. Among the displays evaluated in this study, there was not an optimal tactor column configuration for standing tasks involving continuous surface perturbations. Furthermore, subjects performed worse when erroneous information was displayed. Therefore, a spatial resolution of 90 degrees ( 4 columns) seems to be as effective as a spatial resolution of 22.5 degrees ( 16 columns) for control of standing. C1 [Sienko, K. H.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA. [Sienko, K. H.; Balkwill, M. D.; Wall, C.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Diagnost Lab, Boston, MA 02114 USA. [Wall, C.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Oddsson, L. I. E.] Boston Univ, Neuromuscular Res Ctr, Boston, MA 02215 USA. [Sienko, K. H.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA. [Oddsson, L. I. E.] Sister Kenny Rehabil Inst, Sister Kenny Res Ctr, Minneapolis, MN USA. RP Sienko, KH (reprint author), 2350 Hayward St,3116 GG Brown, Ann Arbor, MI 48109 USA. EM sienko@umich.edu FU National Institutes of Health [R01 DC6201] FX We greatly acknowledge Jimmy Robertsson, Heather Kubert, Dr. Ken Statler, and Matthew Christensen for their help in data collection. This researchwas supported by the National Institutes of Health (NIH NIDCD R01 DC6201). NR 26 TC 29 Z9 29 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2008 VL 18 IS 5-6 BP 273 EP 285 PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 465UV UT WOS:000267614800004 PM 19542601 ER PT J AU DeGottardi, MQ Lew, SK Piatak, M Jia, B Feng, Y Lee, SJ Brenchley, JM Douek, DC Kodama, T Lifson, JD Evans, DT AF DeGottardi, M. Quinn Lew, Sharon K. Piatak, Michael, Jr. Jia, Bin Feng, Yang Lee, Sandra J. Brenchley, Jason M. Douek, Daniel C. Kodama, Toshiaki Lifson, Jeffrey D. Evans, David T. TI Comparison of plasma viremia and antibody responses in Macaques inoculated with envelope variants of single-cycle simian immunodeficiency virus differing in infectivity and cellular tropism SO JOURNAL OF VIROLOGY LA English DT Article ID CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; MACROPHAGE TROPISM; LATENT RESERVOIR; RHESUS MACAQUES; CHEMOKINE RECEPTORS; TYPE-1 INFECTION; IN-VITRO; HIV-1; REPLICATION AB Molecular differences in the envelope glycoproteins of human immunodeficiency virus type I and simian immunodeficiency virus (SIV) determine virus infectivity and cellular tropism. To examine how these properties contribute to productive infection in vivo, rhesus macaques were inoculated with strains of single-cycle SIN (scSfV) engineered to express three different envelope glycoproteins with full-length (TMopen.) or truncated (TMstop) cytoplasmic tails. The 239 envelope uses CCR5 for infection of memory CD4(+) T cells, the 316 envelope also uses CCR5 but has enhanced infectivity for primary macrophages, and the 155T3 envelope uses CXCR4 for infection of both naive and memory CD4(+) T cells. Separate groups of six rhesus macaques were inoculated intravenously with mixtures of TMopen and TMstop scSIV(mac) 239, scSIV(mac) 316, and scSIV(mac) 155T3. A multiplex real-time PCR assay specific for unique sequence tags engineered into each virus was then used to measure viral loads for each strain independently. Viral loads in plasma peaked on day 4 for each strain and were resolved below the threshold. of detection within 4 to 10 weeks. Truncation of the envelope cytoplasmic tail significantly increased the peak of viremia for all three envelope variants and the titer of SIV-specific antibody responses. Although peak viremias were similar for both R5- and X4-tropic viruses, clearance of scSIV(mac) 155T3 TMstop was significantly delayed relative to the other strains, possibly reflecting the infection of a CXCR4(+) cell population that is less susceptible to the cytopathic effects of virus infection. These studies reveal differences in the peaks and durations of a single round of productive infection that reflect envelope-specific differences in infectivity, chemokine receptor specificity, and cellular tropism. C1 [DeGottardi, M. Quinn; Lew, Sharon K.; Jia, Bin; Evans, David T.] Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA. [Piatak, Michael, Jr.; Lifson, Jeffrey D.] Natl Canc Inst, SAIC Frederick, AIDS Vaccine Program, Ft Detrick, MD 21702 USA. [Feng, Yang; Lee, Sandra J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Brenchley, Jason M.; Douek, Daniel C.] NIH, NIAID, Vaccine Res Ctr, Human Immunol Sect, Bethesda, MD 20892 USA. [Kodama, Toshiaki] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15238 USA. RP Evans, DT (reprint author), Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, 1 Pine Hill Dr, Southborough, MA 01772 USA. EM devans@hms.harvard.edu FU NIAID NIH HHS [AI63993, AI52751, K22 AI052751, R01 AI063993] NR 56 TC 6 Z9 6 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2008 VL 82 IS 1 BP 321 EP 334 DI 10.1128/JVI.01094-07 PG 14 WC Virology SC Virology GA 244AO UT WOS:000251838600030 PM 17942538 ER PT J AU Pacheco, B Basmaciogullari, S LaBonte, JA Xiang, SH Sodroski, J AF Pacheco, Beatriz Basmaciogullari, Stephane LaBonte, Jason A. Xiang, Shi-Hua Sodroski, Joseph TI Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to New World monkey receptors SO JOURNAL OF VIROLOGY LA English DT Article ID T-LYMPHOTROPIC RETROVIRUS; AIDS-LIKE DISEASE; NEUTRALIZATION SENSITIVITY; PRIMARY PATIENT; RHESUS-MONKEYS; CD4 RECEPTOR; CELL-LINE; HTLV-III; INFECTION; REPLICATION AB Human immunodeficiency virus type 1 (HIV-1) infection encounters an early block in the cells of New World monkeys because the CD4 receptor does not efficiently support HIV-1 entry. We adapted HIV-1(NL4-3) and HIV-1(KB9), two HIV-1 variants with different envelope glycoproteins, to replicate efficiently in cells expressing the CD4 and CXCR4 proteins of the common marmoset, a New World monkey. The HIV-1 (NLA-3) adaptation involves three gp120 changes that result in a specific increase in affinity for the marmoset CD4 glycoprotein. The already high affinity of the HIV-1(KB9) envelope glycoproteins for marmoset CD4 did not significantly change as a result of the adaptation. Instead, changes in the gp120 variable loops and gp4l ectodomain resulted in improved replication in cells expressing the marmoset receptors. HIV-1(KB9) became relatively sensitive to neutralization by soluble CD4 and antibodies as a result of the adaptation. These results demonstrate the distinct mechanistic pathways by which the HIV-1 envelope glycoproteins can adapt to less-than-optimal CD4 molecules and provide HIV-1 variants that can overcome some of the early blocks in New World monkey cells. C1 [Sodroski, Joseph] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pacheco, Beatriz; Basmaciogullari, Stephane; LaBonte, Jason A.; Xiang, Shi-Hua; Sodroski, Joseph] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Dept Pathol,Div AIDS, Boston, MA 02115 USA. [Sodroski, Joseph] Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Sodroski, J (reprint author), Dana Farber Canc Inst, 44 Binney St,JFB 824, Boston, MA 02115 USA. EM joseph_sodroski@dfci.harvard.edu FU NIAID NIH HHS [R01 AI031783, AI 24755, R37 AI024755, AI 31783] NR 52 TC 10 Z9 10 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2008 VL 82 IS 1 BP 346 EP 357 DI 10.1128/JVI.01299-07 PG 12 WC Virology SC Virology GA 244AO UT WOS:000251838600032 PM 17959679 ER PT J AU Ruiz-Arguello, MB Smith, VP Campanella, GSV Baleux, F Arenzana-Seisdedos, F Luster, AD Alcami, A AF Ruiz-Argueello, M. Begona Smith, Vincent P. Campanella, Gabriele S. V. Baleux, Francoise Arenzana-Seisdedos, Fernando Luster, Andrew D. Alcami, Antonio TI An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain SO JOURNAL OF VIROLOGY LA English DT Article ID VACCINIA VIRUS; MYXOMA VIRUS; IN-VIVO; CAUSATIVE AGENT; DECOY RECEPTOR; HOST-DEFENSE; CELLS; INHIBITOR; EVASION; INTERLEUKIN-18 AB Poxviruses encode a number of secreted virulence factors that modulate the host immune response. The vaccinia virus A41 protein is an immunomodulatory protein with amino acid sequence similarity to the 35-kDa chemokine binding protein, but the host immune molecules targeted by A41 have not been identified. We report here that the vaccinia virus A41 ortholog encoded by ectromelia virus, a poxvirus pathogen of mice, named E163 in the ectromelia virus Naval strain, is a secreted 31-kDa glycoprotein that selectively binds a limited number of CC and CXC chemokines with high affinity. A detailed characterization of the interaction of ectromelia virus E163 with mutant forms of the chemokines CXCL10 and CXCL12 alpha indicated that E163 binds to the glycosaminoglycan binding site of the chemokines. This suggests that E163 inhibits the interaction of chemokines with glycosaminoglycans and provides a mechanism by which E163 prevents chemokine-induced leukocyte migration to the sites of infection. In addition to interacting with chemokines, E163 can interact with high affinity with glycosaminoglycan molecules, enabling E163 to attach to cell surfaces and to remain in the vicinity of the sites of viral infection. These findings identify E163 as a new chemokine binding protein in poxviruses and provide a molecular mechanism for the immunomodulatory activity previously reported for the vaccinia virus A41 ortholog. The results. reported here also suggest that the cell surface and extracellular matrix are important targeting sites for secreted poxvirus immune modulators. C1 [Ruiz-Argueello, M. Begona; Smith, Vincent P.; Alcami, Antonio] Univ Cambridge, Dept Med, Addenbrookes Hosp, Cambridge, England. [Ruiz-Argueello, M. Begona] Ctr Invest Sanidad Anim, Madrid, Spain. [Campanella, Gabriele S. V.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Baleux, Francoise; Arenzana-Seisdedos, Fernando] Inst Pasteur, Paris, France. [Alcami, Antonio] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain. RP Alcami, A (reprint author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Nicolas Cabrera 1,Campus Cantoblanco, E-28049 Madrid, Spain. EM aalcami@cbm.uam.es RI Alcami, Antonio/F-8512-2015; Arenzana-Seisdedos, Fernando/E-5835-2016 OI Alcami, Antonio/0000-0002-3333-6016; FU Medical Research Council [G9800943]; NCI NIH HHS [R01 CA069212, R01-CA69212]; Wellcome Trust [051087/Z/97/Z] NR 53 TC 33 Z9 33 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2008 VL 82 IS 2 BP 917 EP 926 DI 10.1128/JVI.02111-07 PG 10 WC Virology SC Virology GA 249LF UT WOS:000252229100032 PM 18003726 ER PT J AU Kim, KH Puoris'haag, M Maguluri, GN Umino, Y Cusato, K Barlow, RB de Boer, JF AF Kim, Ki Hean Puoris'haag, Mehron Maguluri, Gopi N. Umino, Yumiko Cusato, Karen Barlow, Robert B. de Boer, Johannes F. TI Monitoring mouse retinal degeneration with high-resolution spectral-domain optical coherence tomography SO JOURNAL OF VISION LA English DT Article DE spectral-domain optical coherence tomography; imaging; mouse model; retinal degeneration ID ULTRAHIGH-RESOLUTION; HIGH-SPEED; GENE-THERAPY; RODENT RETINA; RESTORATION; MICE; EYE AB Progression of retinal degeneration in a mouse model was studied in vivo with high-resolution spectral-domain optical coherence tomography (SD-OCT). Imaging in 3D with high depth resolution (<3 mu m), SD-OCT resolved all the major layers of the retina of control C57BL/6J mice. Images of transgenic mice having a null mutation of the rhodopsin gene revealed the anatomical consequences of retinal degeneration: thinning of the outer retina, including the outer plexiform layer (OPL), outer nuclear layer (ONL), and inner and outer segments (IS/OS). We monitored the progression of retinal degeneration in rd1 mice (C3H/HeJ) by periodically imaging the same mice from the time the pups opened their eyes on P13 to P34. SD-OCT images showed that the outer retina (OPL, ONL, IS/OS) had already thinned by 73% (100 to 27 mu m) at eye opening. The retina continued to degenerate, and by P20 the outer retina was not resolvable. The thickness of entire retina decreased from 228 mu m (control) to 152 mu m on P13 and to 98 mu m by P34, a 57% reduction with the complete loss in the outer retina. In summary, we show that SD-OCT can monitor the progression of retinal degeneration in transgenic mice. C1 [Kim, Ki Hean; Puoris'haag, Mehron; Maguluri, Gopi N.; de Boer, Johannes F.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Umino, Yumiko; Cusato, Karen; Barlow, Robert B.] SUNY Upstate Med Univ, Ctr Vis Res, Syracuse, NY USA. RP de Boer, JF (reprint author), 50 Blossom St, Boston, MA 02114 USA. EM deboer@helix.mgh.harvard.edu RI de Boer, Johannes/B-7590-2012 OI de Boer, Johannes/0000-0003-1253-4950 NR 29 TC 27 Z9 27 U1 0 U2 4 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 1534-7362 J9 J VISION JI J. Vision PY 2008 VL 8 IS 1 AR 17 DI 10.1167/8.1.17 PG 11 WC Ophthalmology SC Ophthalmology GA 302NP UT WOS:000255975400017 ER PT J AU Arboleda, BMW Frederick, AL AF Arboleda, Barbara M. Wilson Frederick, Arlette L. TI Considerations for maintenance of postural alignment for voice production SO JOURNAL OF VOICE LA English DT Article; Proceedings Paper CT Singers Seminar 2006 CY 2006 CL Massachusetts Eye & Ear Infirmary, Boston, MA HO Massachusetts Eye & Ear Infirmary DE voice and posture; postural alignment; exercise and voice ID FUNCTIONAL DYSPHONIA; WARM-UP; PERFORMANCE; FLEXIBILITY; PREVENTION; STRETCH; MUSCLES; BALANCE; TIME AB There is general agreement that postural alignment is important in optimizing voice function. A number of articles have illuminated the way in which posture, particularly. of the cervical spine, is directly related to vocal resonance and pitch control. Despite frequent involvement in muscle training, few speech pathologists have the background in,exercise physiology necessary to appreciate the contribution of muscular length-tension relationships to postural alignment. The purpose of this article is to provide voice therapists with information to help them formulate, appropriate recommendations for improving postural alignment. This article synthesizes information from the literature regarding the role of muscular length-tension balance in the attainment and maintenance of postural alignment. Important considerations in the assessment of muscle tension and weakness are presented along with advice regarding application to the treatment of voice-disordered patients. Concepts detailed include agonist/antagonist relationships, the biomechanics of stretching, postural assessment, and the relationship between muscle tension and muscle weakness. The role of both stretching and strength-based training is discussed. Specific exercises with emphasis on altering the alignment of the cervical and thoracic spine are presented with suggestions for their use in the, clinic. There is growing understanding of the physiology behind re. commendations of voice teachers and therapists to maintain optimal alignment. To effectively mediate postural misalignment, clinicians must have knowledge of the length-tension relationships between muscles. This understanding will lead to better interventions for postural alignment. C1 [Arboleda, Barbara M. Wilson; Frederick, Arlette L.] Beth Israel Deaconess Med Ctr, Dept Voice Speech & Swallowing, Boston, MA 02215 USA. [Arboleda, Barbara M. Wilson] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Arboleda, BMW (reprint author), Beth Israel Deaconess Med Ctr, Dept Voice Speech & Swallowing, SPAN 106,330 Brookline Ave, Boston, MA 02215 USA. EM bwilson@bidmc.harvard.edu NR 42 TC 14 Z9 19 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 J9 J VOICE JI J. Voice PD JAN PY 2008 VL 22 IS 1 BP 90 EP 99 DI 10.1016/j.jvoice.2006.08.001 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 250HK UT WOS:000252290400009 ER PT J AU Ritchie, CS Locher, JL Roth, DL Mcvie, T Sawyer, P Allman, R AF Ritchie, Christine S. Locher, Julie L. Roth, David L. McVie, Theresa Sawyer, Patricia Allman, Richard TI Unintentional weight loss predicts decline in activities of daily living function and life-space mobility over 4 years among community-dwelling older adults SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE weight loss; body composition; function; mobility ID BODY-MASS INDEX; PHYSICAL FUNCTION; RISK-FACTORS; WOMEN; INTENTION; QUALITY; OBESITY; PEOPLE; HEALTH; NHANES AB Background. The relationship between body mass index (BMI), weight loss, and changes in activities of daily living (ADL) function and mobility in older adults is not clear. We sought to study the relationship between BMI and weight loss on the rate of decline in ADL function and life-space mobility over a 4-year period among older African Americans and whites. Methods. The participants were 983 enrollees in the University of Alabama at Birmingham (UAB) Study of Aging, a longitudinal study of mobility among community-dwelling older adults stratified to achieve a balanced sample in terms of sex, race, and residence. Primary outcome measures were changes in ADL function and mobility assessed by the UAB Study of Aging Life-Space Assessment (LSA) which were measured every 6 months. Results. Relative to normal weight participants, those with BMI levels in the obese range did not show more rapid ADL functional decline, but a history of unintentional weight loss predicted more rapid decline. Relative to normal-weight participants, other BMI categories were not associated with more rapid decline in LSA scores. However, unintentional weight loss predicted more rapid declines in LSA. Intentional weight loss had no relation to ADL function or LSA decline. Conclusions. In this population of community-dwelling older African Americans and whites, neither BMI nor intentional weight loss had an association with rate of functional decline. Unintentional weight loss had a negative relation with rate of functional decline, regardless of baseline BMI. Whether this is causal remains to be determined. C1 [Ritchie, Christine S.; Locher, Julie L.; Sawyer, Patricia; Allman, Richard] UAB, Sch Med, Dept Med, Div Gerontol, Birmingham, AL 35924 USA. [Ritchie, Christine S.; Locher, Julie L.; Sawyer, Patricia; Allman, Richard] UAB, Dept Geriatr, Birmingham, AL 35924 USA. [Ritchie, Christine S.; Locher, Julie L.; Sawyer, Patricia; Allman, Richard] UAB, Dept Palliat Care, Birmingham, AL 35924 USA. [Locher, Julie L.] UAB, Dept Hlth Care Org & Policy, Birmingham, AL 35924 USA. [Locher, Julie L.] UAB, Dept Sociol, Birmingham, AL 35924 USA. [Locher, Julie L.; Sawyer, Patricia; Allman, Richard] UAB, Ctr Aging, Birmingham, AL USA. [Roth, David L.; McVie, Theresa] UAB, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Ritchie, Christine S.; Allman, Richard] Birmingham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. RP Ritchie, CS (reprint author), UAB, Sch Med, Dept Med, Div Gerontol, 1530 3rd Ave S,Ch-19,Rm 219, Birmingham, AL 35924 USA. EM critchie@uab.edu RI Allman, Richard/D-5964-2011 FU NIA NIH HHS [R01-AG-15062] NR 28 TC 36 Z9 38 U1 1 U2 6 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2008 VL 63 IS 1 BP 67 EP 75 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 301FU UT WOS:000255882600009 PM 18245763 ER PT J AU Zanjani, F Mavandadi, S TenHave, T Katz, I Durai, NB Krahn, D Llorente, M Kirchner, J Olsen, E Van Stone, W Cooley, S Oslin, DW AF Zanjani, Faika Mavandadi, Shahrzad TenHave, Tom Katz, Ira Durai, Nalla B. Krahn, Dean Llorente, Maria Kirchner, JoAnn Olsen, Edwin Van Stone, William Cooley, Susan Oslin, David W. TI Longitudinal course of substance treatment benefits in older male veteran at-risk drinkers SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE alcohol; at-risk drinking; problem drinkers ID MODERATE ALCOHOL-CONSUMPTION; RANDOMIZED CONTROLLED-TRIAL; BRIEF PHYSICIAN ADVICE; PRIMARY MEDICAL-CARE; BRIEF INTERVENTIONS; PRISM-E; DEPENDENCE; ADULTS; NALTREXONE; DRINKING AB Background. This investigation aims to determine the 12-month drinking trajectory of older at-risk drinkers in treatment. Furthermore, the drinking trajectory between at-risk drinkers who had met the threshold suggestive of alcohol dependence (problem at-risk drinkers) and those who did not meet this threshold (nonproblematic at-risk drinkers) were compared. Methods. This investigation is a component of the PRISM-E (Primary Care Research in Substance Abuse and Mental Health for the Elderly) Study, a multisite randomized trial comparing service use, outcomes, and cost between Integrated (IC) versus Enhanced Specialty Referral (ESR) care models for older (65-1 years) adults with depression, anxiety, and/or at-risk alcohol consumption. This investigation focuses only on at-risk drinkers, generally defined as exceeding recommended drinking limits, which in the case of older adults has been classified as consuming more than one drink per day. Two hundred fifty-eight randomized older at-risk drinkers were examined, of whom 56% were problem drinkers identified through the Short Michigan Alcohol Screening Test-Geriatric version. Results. Over time, all at-risk drinkers showed a significant reduction in drinking. Problem drinkers showed reductions in average weekly consumption and number of occurrences of binge drinking at 3, 6, and 12 months, whereas nonproblematic drinkers showed significant reductions in average weekly consumption at 3, 6, and 12 months and number of occurrences of binge drinking at only 6 months. IC treatment assignment led to higher engagement in treatment, which led to better binge drinking outcomes for problem drinkers. Despite significant reductions in drinking, approximately 29% of participants displayed at-risk drinking at the end of the study. Conclusions. Results suggest that older at-risk drinkers, both problem and nonproblematic, show a considerable decrease in drinking, with slightly greater improvement evidenced in problem drinkers and higher engagement in treatment seen in those assigned to IC. C1 Univ Kentucky, Grad Ctr Gerontol, Lexington, KY 40506 USA. [Mavandadi, Shahrzad; Katz, Ira] Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. [TenHave, Tom] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA. [Katz, Ira] Philadelphia Vet Affairs Med Ctr, VISN Mental Illness 4, Res Educ & Clin Ctr, Philadelphia, PA USA. [Durai, Nalla B.] Univ Illinois, Coll Med Psychiat, Chicago, IL 60680 USA. [Durai, Nalla B.] Chicago VA Med Ctr, Chicago, IL USA. [Krahn, Dean] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Krahn, Dean] Univ Wisconsin, Sch Med, Dept Psychiat, Madison, WI 53792 USA. [Llorente, Maria] Univ Miami, Dept Psychiat, Coral Gables, FL 33124 USA. [Kirchner, JoAnn] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Olsen, Edwin] Miami VAMC, Miami, FL USA. [Van Stone, William] US Dept Vet Affairs, Off Mental Hlth Serv, Washington, DC USA. [Cooley, Susan] US Dept Vet Affairs, Off Geriatr & Extended Care, W Palm Beach, FL USA. [Oslin, David W.] Philadelphia Ctr Excellence Subst Abuse Treatment, Philadelphia, PA USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA. RP Zanjani, F (reprint author), Univ Kentucky Gerontol, 306 B Wethington Hlth Sci Bldg,900 S Limestone, Lexington, KY 41094 USA. EM f.zanjani@uky.edu FU NIMH NIH HHS [5 T32 MH19931-08A1] NR 46 TC 8 Z9 8 U1 3 U2 4 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2008 VL 63 IS 1 BP 98 EP 106 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 301FU UT WOS:000255882600013 PM 18245767 ER PT J AU Vu, HLN Li, YW Casali, M Irimia, D Megeed, Z Yarmush, ML AF Vu, Halong N. Li, Yawen Casali, Monica Irimia, Daniel Megeed, Zaki Yarmush, Martin L. TI A microfluidic bioreactor for increased active retrovirus output SO LAB ON A CHIP LA English DT Article ID GENE-THERAPY; CELL-ADHESION; HIGH-TITER; VECTORS; TRANSDUCTION; INFECTION; SURFACES; DISEASE; SYSTEMS; SCALE AB Retroviruses are one of the most commonly used vectors in ongoing gene therapy clinical trials. To evaluate and advance virus production on the microscale platform, we have created a novel microfluidic bioreactor for continuous retrovirus production. We investigated the growth kinetics of a retroviral packaging cell line in microfluidic bioreactors for several compartment sizes, and packaging cells perfused in the microdevices showed similar growth kinetics to those cultured in conventional static conditions. To evaluate the efficiency of retrovirus production, virus titers from the microdevices were compared to those obtained from static tissue culture. When retrovirus production and collection were maintained at 37 degrees C, virus production levels were comparable for the microdevices and static tissue culture conditions. However, immediate cold storage downstream of the packaging cells in the microdevices resulted in 1.4- to 3.7-fold greater active virus production levels with the microdevices compared to the conventional static conditions over a 5 day period. Lastly, the use of microfluidics for virus production provides a continuous supply of virus supernatant for immediate infection of target cells or for preservation and storage. Such devices will be valuable for the optimization of production and evaluation of retroviruses and other viral vectors for gene therapy applications. C1 [Vu, Halong N.; Li, Yawen; Casali, Monica; Irimia, Daniel; Megeed, Zaki; Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Dept Surg, BioMEMS REsource Ctr, Boston, MA 02114 USA. [Vu, Halong N.; Li, Yawen; Casali, Monica; Irimia, Daniel; Megeed, Zaki; Yarmush, Martin L.] Massachusetts Gen Hosp, Shriners Hosp Children, Harvard Med Sch, Boston, MA 02114 USA. RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Ctr Engn Med, Dept Surg, BioMEMS REsource Ctr, 51 Blossom St,Rm 406, Boston, MA 02114 USA. EM ireis@sbi.org OI Irimia, Daniel/0000-0001-7347-2082 FU NIBIB NIH HHS [P41 EB002503] NR 27 TC 12 Z9 12 U1 0 U2 6 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2008 VL 8 IS 1 BP 75 EP 80 DI 10.1039/b711577f PG 6 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 243BX UT WOS:000251771000018 PM 18094764 ER PT J AU King, KR Wang, S Jayaraman, A Yarmush, ML Toner, M AF King, Kevin R. Wang, Sihong Jayaraman, Arul Yarmush, Martin L. Toner, Mehmet TI Microfluidic flow-encoded switching for parallel control of dynamic cellular microenvironments SO LAB ON A CHIP LA English DT Article ID NF-KAPPA-B; GENE-EXPRESSION; TEMPORAL CONTROL; SPECIFICITY; TIME; PROPAGATION; ACTIVATION; CROSSTALK; RECEPTORS; RESPONSES AB The temporal pattern of a biological stimulus is an important determinant of the resulting cellular response. We present a microfluidic parallel perfusion culture system for controlling the dynamics of soluble cell microenvironments while simultaneously performing live-cell imaging of cellular responses. A "Flow-encoded Switching'' (FES) design strategy is developed to simultaneously deliver many different temporal profiles of stimuli, including pulse train widths, lengths, and frequencies, to downstream adherent cells using a single input control. The design strategy uses principles of laminar flow and diffusion-limited mixing to encode the state of the network (the instantaneous stimulus concentrations in each channel) into the ratio of two flow rates, which is controlled by a single differential pressure. To demonstrate the utility of this experimental system, we investigated the effect of dynamic stimuli on NFkB transcriptional activation and cell fate determination. Our results illustrate that transcriptional responses and cell fate decisions depend both quantitatively and qualitatively on the timing of the stimulus. In summary, by encoding dynamic stimuli in a single input pressure, microfluidic flow-encoded switching offers a scalable experimental method for systematically probing the functional significance of temporally patterned cellular environments. C1 [King, Kevin R.; Yarmush, Martin L.; Toner, Mehmet] Harvard Univ, MIT, Div Hlth Sci & Technol, Boston, MA 02114 USA. [King, Kevin R.; Wang, Sihong; Yarmush, Martin L.; Toner, Mehmet] Massachusetts Gen Hosp, Surg Serv, Ctr Engn Med, Harvard Med Sch,Shriners Hosp Children, Boston, MA 02114 USA. [Jayaraman, Arul] Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA. RP Toner, M (reprint author), Harvard Univ, MIT, Div Hlth Sci & Technol, 51 Blosson St,Rm 408, Boston, MA 02114 USA. EM mtoner@hms.harvard.edu FU NIAID NIH HHS [AI063795]; NIBIB NIH HHS [P41 EB002503]; NIGMS NIH HHS [GM065474] NR 26 TC 56 Z9 57 U1 3 U2 15 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2008 VL 8 IS 1 BP 107 EP 116 DI 10.1039/b716962k PG 10 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 243BX UT WOS:000251771000022 PM 18094768 ER PT J AU Park, K Jang, J Irimia, D Sturgis, J Lee, J Robinson, JP Toner, M Bashir, R AF Park, Kidong Jang, Jaesung Irimia, Daniel Sturgis, Jennifer Lee, James Robinson, J. Paul Toner, Mehmet Bashir, Rashid TI 'Living cantilever arrays' for characterization of mass of single live cells in fluids SO LAB ON A CHIP LA English DT Article ID FORCE MICROSCOPE CANTILEVERS; HELA-CELLS; GROWTH; INTERROGATION; SENSITIVITY; BIOSENSOR; SENSORS; SPORES; CYCLE; MTOR AB The size of a cell is a fundamental physiological property and is closely regulated by various environmental and genetic factors. Optical or confocal microscopy can be used to measure the dimensions of adherent cells, and Coulter counter or flow cytometry ( forward scattering light intensity) can be used to estimate the volume of single cells in a flow. Although these methods could be used to obtain the mass of single live cells, no method suitable for directly measuring the mass of single adherent cells without detaching them from the surface is currently available. We report the design, fabrication, and testing of 'living cantilever arrays', an approach to measure the mass of single adherent live cells in fluid using silicon cantilever mass sensor. HeLa cells were injected into microfluidic channels with a linear array of functionalized silicon cantilevers and the cells were subsequently captured on the cantilevers with positive dielectrophoresis. The captured cells were then cultured on the cantilevers in a microfluidic environment and the resonant frequencies of the cantilevers were measured. The mass of a single HeLa cell was extracted from the resonance frequency shift of the cantilever and was found to be close to the mass value calculated from the cell density from the literature and the cell volume obtained from confocal microscopy. This approach can provide a new method for mass measurement of a single adherent cell in its physiological condition in a non-invasive manner, as well as optical observations of the same cell. We believe this technology would be very valuable for single cell time-course studies of adherent live cells. C1 [Bashir, Rashid] Univ Illinois, Dept Elect & Comp Engn & Bioengn, Micro & Nanotechnol Lab, Urbana, IL 61801 USA. [Park, Kidong] Purdue Univ, Birck Nanotechnol Ctr, W Lafayette, IN 47907 USA. [Park, Kidong] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA. [Irimia, Daniel; Toner, Mehmet] Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. [Sturgis, Jennifer; Robinson, J. Paul] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [Sturgis, Jennifer; Robinson, J. Paul] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA. [Lee, James] Ohio State Univ, Dept Chem Engn, Columbus, OH 43210 USA. [Robinson, J. Paul] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA. RP Bashir, R (reprint author), Univ Illinois, Dept Elect & Comp Engn & Bioengn, Micro & Nanotechnol Lab, Urbana, IL 61801 USA. EM rbashir@uiuc.edu RI Jang, Jaesung/E-9209-2010; Robinson, Joseph/K-8492-2012; OI Irimia, Daniel/0000-0001-7347-2082; Robinson, Joseph/0000-0001-8383-3240 FU NIBIB NIH HHS [P41 EB002503] NR 35 TC 61 Z9 65 U1 1 U2 25 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2008 VL 8 IS 7 BP 1034 EP 1041 DI 10.1039/b803601b PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 320LT UT WOS:000257236900007 PM 18584076 ER PT J AU Agrawal, N Toner, M Irimia, D AF Agrawal, Nitin Toner, Mehmet Irimia, Daniel TI Neutrophil migration assay from a drop of blood SO LAB ON A CHIP LA English DT Article ID POLYMORPHONUCLEAR LEUKOCYTES; MICROFLUIDIC DEVICE; P-SELECTIN; CHEMOTAXIS; GRADIENTS; ADHESION; INTERLEUKIN-8; INFLAMMATION; SEPARATION; SYSTEMS AB Neutrophil directional migration in response to chemical gradients, also known as chemotaxis, is one of the key phenomena in the immune responses against bacterial infection. To better study neutrophils chemotaxis, several in vitro assays have been developed that replicate chemotactic gradients around neutrophils isolated from whole blood. One drawback for most of these assays is the lengthy processing of blood required for neutrophils isolation, which can alter the responsiveness of neutrophils compared to the in vivo conditions. To address this limitation, we have designed a microfluidic chip for chemotaxis studies which can use neutrophils isolated on the chip, directly from whole blood. We have tested three different cell adhesion molecules as substrates for neutrophil isolation (P-selectin, E-selectin and fibronectin) and found average capture efficiencies of 20-40 neutrophils/mm(2) at optimized concentrations. Subsequent analysis of neutrophil migration in chemoattractant gradients of N-formyl-methyl-leucyl-phenylalanine ( fMLP) or Interleukin-8 (IL-8) shows higher average velocities over E-selectin as compared to the P-selectin. Our microfluidic assay uses just a drop of whole blood (< 10 mu L) for neutrophil isolation and provides a robust platform to perform chemotaxis assays in the competing environment of different chemokines. C1 [Irimia, Daniel] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Irimia, D (reprint author), Massachusetts Gen Hosp, BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02129 USA. EM dirimia@hms.harvard.edu OI Irimia, Daniel/0000-0001-7347-2082 FU Shriners Hospitals for Children; National Institute of Biomedical Imaging and Bioengineering BioMEMS Resource Center [P41 EB002503] FX Funding from Shriners Hospitals for Children and National Institute of Biomedical Imaging and Bioengineering BioMEMS Resource Center Grant (P41 EB002503). NR 33 TC 32 Z9 32 U1 0 U2 14 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2008 VL 8 IS 12 BP 2054 EP 2061 DI 10.1039/b813588f PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 383PT UT WOS:000261686200010 PM 19023468 ER PT J AU Hsu, CH Di Carlo, D Chen, CC Irimia, D Toner, M AF Hsu, Chia-Hsien Di Carlo, Dino Chen, Chihchen Irimia, Daniel Toner, Mehmet TI Microvortex for focusing, guiding and sorting of particles SO LAB ON A CHIP LA English DT Article ID ON-A-CHIP; MICROFLUIDIC SYSTEM; DENSITY-GRADIENT; FLOW-CYTOMETRY; SEPARATION; CELLS; LAB; MICROCHANNELS; BLOOD; MICROPARTICLES AB We report a microvortex manipulator (MVM) that is a passive, scalable system with great potential for the manipulation and separation of particulate samples in microfluidic environments. The movement of particles is determined by a unique combination of helical flow, buoyant, and gravitational forces. Helical flows are induced by topographically patterned microchannel surfaces, which have previously been used for molecular mixing in microfluidic devices. We illustrate the mechanism of MVM and its applications in passive focusing of beads and cells into parallel streams and guiding of particles and cells. We also explore the application of the unique density-selectivity of microvortex focusing and successfully sort a mixture of two bead populations whose density difference is as small as 0.1 g cm(-3). C1 [Hsu, Chia-Hsien; Di Carlo, Dino; Chen, Chihchen; Irimia, Daniel; Toner, Mehmet] Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Shriners Hosp Children, Boston, MA 02114 USA. [Hsu, Chia-Hsien; Di Carlo, Dino; Chen, Chihchen; Irimia, Daniel; Toner, Mehmet] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Toner, Mehmet] Massachusetts Gen Hosp, Boston, MA 02129 USA. RP Toner, M (reprint author), Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Shriners Hosp Children, Boston, MA 02114 USA. EM mtoner@hms.harvard.edu RI Hsu, Chia-Hsien/E-4957-2010; Hsu, Chia-Hsien /E-3946-2010; OI Chen, Chihchen/0000-0002-2195-4802; Irimia, Daniel/0000-0001-7347-2082 FU National Institute of Biomedical Imaging and Bioengineering [P41 EB002503]; American Cancer Society Postdoctoral Fellowship [PF-07-23701-CCE] FX We thank Octavio Hurtado for valuable assistance with microfabrication. This work was supported in part by the National Institute of Biomedical Imaging and Bioengineering (BioMEMS Resource Center, P41 EB002503). D. D. was supported by an American Cancer Society Postdoctoral Fellowship (PF-07-23701-CCE). NR 36 TC 55 Z9 56 U1 3 U2 40 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2008 VL 8 IS 12 BP 2128 EP 2134 DI 10.1039/b813434k PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 383PT UT WOS:000261686200018 PM 19023476 ER PT J AU Byrd, RH Mino-Kenudson, M Post, MD Roberts, DJ Ornvold, KT Lauwers, GY Srivastava, A AF Byrd, R. H. Mino-Kenudson, M. Post, M. D. Roberts, D. J. Ornvold, K. T. Lauwers, G. Y. Srivastava, A. TI Multilayered epithelium is present in the developing fetal esophagus: An autopsy study of 39 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 4 BP 4A EP 4A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100004 ER PT J AU Cao, D Polyak, K Iacobuzio-Donahue, C Goggins, M Wu, X Sukumar, S Hicks, J De Marzo, A Argani, P AF Cao, D. Polyak, K. Iacobuzio-Donahue, C. Goggins, M. Wu, X. Sukumar, S. Hicks, J. De Marzo, A. Argani, P. TI Serial analysis of gene expression of lobular carcinoma in situ identifies upregulation of metal loproteinase MMP-9 and downregulation of tight junction protein claudin 4 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Johns Hopkins Inst, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 106 BP 26A EP 26A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100106 ER PT J AU Hamed, O Acs, G Al-Khatib, SM Hattab, EM Lewis, JS Nassar, H Rajan, E Rajan, P Sgroi, DC Sharafaldeen, B Tawfik, O AF Hamed, O. Acs, G. Al-Khatib, S. M. Hattab, E. M. Lewis, J. S. Nassar, H. Rajan, E. Rajan, P. Sgroi, D. C. Sharafaldeen, B. Tawfik, O. TI A multinstitutional study comparing the Oncotype-DX recurrence rates with standard clinical and pathological features of breast cancer, the Nottingham Prognostic Index (NPI) and ADJUVANT! Online SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Alabama, Sch Med, Birmingham, AL USA. Indiana Univ, H Lee Moffitt Canc Ctr, Bloomington, IN 47405 USA. Washington Univ, Sch Med, St Louis, MO 63130 USA. Wayne State Univ, Loyola Univ, Chicago Med Ctr, Detroit, MI 48202 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Kansas, Ctr Med, Lawrence, KS 66045 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 152 BP 36A EP 36A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100152 ER PT J AU Rabhan, JT Lim, S Lerwill, MF Chen, YY Jordan, RC AF Rabhan, J. T. Lim, S. Lerwill, M. F. Chen, Y. Y. Jordan, R. C. TI Comparative genomic hybridization identifies high frequency chromosomal alterations in adenoid cystic carcinoma of the breast SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 222 BP 51A EP 51A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100222 ER PT J AU Wang, Y Collins, L Schmitt, S Garber, J Tung, N AF Wang, Y. Collins, L. Schmitt, S. Garber, J. Tung, N. TI Characterization of estrogen receptor positive breast cancers in BRCA1 mutation carriers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 264 BP 59A EP 60A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100264 ER PT J AU Balassanian, R Sauder, KJ Vrbin, CM Raab, SS AF Balassanian, R. Sauder, K. J. Vrbin, C. M. Raab, S. S. TI Review of false negative UroVysion (TM) test on cytologically atypical urine samples SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 307 BP 69A EP 69A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100307 ER PT J AU Ono, JC Wilbur, DC Krane, JF Bongiovanni, A Faquin, WC AF Ono, J. C. Wilbur, D. C. Krane, J. F. Bongiovanni, Al Faquin, W. C. TI Papillary thyroid carcinoma arising within follicular adenoma: A masked cytomorphologic analysis of 17 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Geneva Hop, CH-1211 Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 365 BP 81A EP 82A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100365 ER PT J AU Rao, RA Wilbur, DC Tambouret, RH Shen, J Balassanian, R Staats, PN Sauder, K Belsley, NA Faquin, WC Deshpande, V AF Rao, R. A. Wilbur, D. C. Tambouret, R. H. Shen, J. Balassanian, R. Staats, P. N. Sauder, K. Belsley, N. A. Faquin, W. C. Deshpande, V. TI Significance of the atypical category in urine cytology: An interobserver study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Rao, R. A.; Wilbur, D. C.; Tambouret, R. H.; Shen, J.; Balassanian, R.; Staats, P. N.; Sauder, K.; Belsley, N. A.; Faquin, W. C.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 372 BP 83A EP 83A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100372 ER PT J AU Houng, MP Mahalingam, M Bhawan, J Kapur, P High, WA AF Houng, M. P. Mahalingam, M. Bhawan, J. Kapur, P. High, W. A. TI Acute generalized exanthematous pustulosis: A clinical and histologic study of forty-five cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA USA. Boston Univ, Sch Med, Boston, MA 02215 USA. Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA. Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 424 BP 94A EP 94A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100424 ER PT J AU Johnson, MM Belsley, NA Jinushi, M Carrasco, DR Dranoff, G Mihm, MC AF Johnson, M. M. Belsley, N. A. Jinushi, M. Carrasco, D. R. Dranoff, G. Mihm, M. C. TI MFG-E8 expression in malignant melanoma and benign melanocytic nevi SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 428 BP 95A EP 95A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100428 ER PT J AU Nazarian, RM Mandal, RV Kagan, A Kay, J Duncan, LM AF Nazarian, R. M. Mandal, R. V. Kagan, A. Kay, J. Duncan, L. M. TI Quantitative assessment of dermal fibroblasts in nephrogenic systemic fibrosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Nazarian, R. M.; Mandal, R. V.; Kagan, A.; Kay, J.; Duncan, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 445 BP 99A EP 99A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100445 ER PT J AU Dotto, J Faquin, W Sadow, P Kozakewich, H Nose, V AF Dotto, J. Faquin, W. Sadow, P. Kozakewich, H. Nose, V. TI Familial non-medullary thyroid carcinoma: Morphologic patterns indicating an inherited trait SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 482 BP 106A EP 106A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100482 ER PT J AU Coco, D Huang, Q Odze, RD AF Coco, D. Huang, Q. Odze, R. D. TI Predictive value of mitosin and CDC2 expression in the development of adenocarcinoma in Barrett's esophagus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Boston VA Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 527 BP 116A EP 116A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100527 ER PT J AU Farris, AB Wang, WL Ganguly, A Lauwers, GY Deshpande, V AF Farris, A. B. Wang, W-L Ganguly, A. Lauwers, G. Y. Deshpande, V. TI Gall bladder involvement in AIP is a primary manifestation of the disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 535 BP 118A EP 118A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100535 ER PT J AU Gupta, M Mino-Kenudson, M Lauvers, GY Srivaslava, A AF Gupta, M. Mino-Kenudson, M. Lauvers, G. Y. Srivaslava, A. TI Expression of MUC-6, gastric (Sox-2) and intestinal (Cdx-2) transcription factors in long segment Barrett's esophagus: A complex interplay at the neo-squamocolumnar junction SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 552 BP 121A EP 121A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100552 ER PT J AU Lindberg, MR Havens, JM Lauwers, GY Scott, MA Lamps, LW AF Lindberg, M. R. Havens, J. M. Lauwers, G. Y. Scott, M. A. Lamps, L. W. TI Aeromonas: An emerging food-borne cause of infectious colitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Arkansas Vet Hlthcare Syst, Little Rock, AR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 575 BP 127A EP 127A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100575 ER PT J AU Maguire, A Sheahan, K Donoghue, DO Greenson, JK Lauwers, GY Ginsburg, RE Williams, GT Brown, IS AF Maguire, A. Sheahan, K. Donoghue, D. O. Greenson, J. K. Lauwers, G. Y. Ginsburg, R. E. Williams, G. T. Brown, I. S. TI Collagenous sprue - A Clinico-Pathological study of 9 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 St Vincent Univ Hosp, Dublin, Ireland. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Wales Coll Cardiff, Cardiff CF1 3NS, S Glam, Wales. San Nicolaides Pathol, Brisbane, Qld, Australia. RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 581 BP 128A EP 128A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100581 ER PT J AU Mandal, RV Mino-Kenudson, M Lauwers, GY AF Mandal, R. V. Mino-Kenudson, M. Lauwers, G. Y. TI The effect of tumor characteristics and duplication of the muscularis mucosae on endoscopic staging in Barrett esophagus related neoplasia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Mandal, R. V.; Mino-Kenudson, M.; Lauwers, G. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 582 BP 128A EP 129A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100582 ER PT J AU Sabo, E Meitner, T Moss, SF Gao, J Tavares, R Corless, CL Lauwers, GY Resnick, MB AF Sabo, E. Meitner, T. Moss, S. F. Gao, J. Tavares, R. Corless, C. L. Lauwers, G. Y. Resnick, M. B. TI Microarray gene expression analysis of high grade dysplasia in Barrett esophagus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Warren Alpert Brown Univ, Sch Med, Providence, RI USA. Oregon Hlth & Sci Univ, Portland, OR USA. Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 611 BP 135A EP 135A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100611 ER PT J AU R, KY Shia, J Hahn, H Klimstra, DS Odze, RD Misdraji, J AF R, K. Yantiss Shia, J. Hahn, H. Klimstra, D. S. Odze, R. D. Misdraji, J. TI Ruptured appendiceal mucinous neoplasms: Prognostic significance of localized extra-appendiceal mucin deposition SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY USA. Brigham & Womens Hosp, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 644 BP 142A EP 142A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100644 ER PT J AU Di Napoli, A Crisanzio, C Ghebremichael, M Seeley, A Amato, A Atkins, M Signoretti, S AF Di Napoli, A. Crisanzio, C. Ghebremichael, M. Seeley, A. Amato, A. Atkins, M. Signoretti, S. TI CAIX expression correlates with VHL mutational status in sporadic clear cell carcinoma of the kidney SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA USA. Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 700 BP 154A EP 154A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100700 ER PT J AU Mertz, KD Setlur, SR Hoshida, Y Demichelis, F Lupien, M Perner, S Sboner, A Pawidan, Y Andren, O Johnson, LA Tang, J Adami, HO Calza, S Chinnaiyan, AM Rhodes, D Tomlins, S Fall, K Mucci, LA Kantoff, PW Stampfer, MJ Anderson, SO Varenhorst, E Johansson, JE Brown, M Golub, TR Rubin, MA AF Mertz, K. D. Setlur, S. R. Hoshida, Y. Demichelis, F. Lupien, M. Perner, S. Sboner, A. Pawidan, Y. Andren, O. Johnson, L. A. Tang, J. Adami, H. O. Calza, S. Chinnaiyan, A. M. Rhodes, D. Tomlins, S. Fall, K. Mucci, L. A. Kantoff, P. W. Stampfer, M. J. Anderson, S. O. Varenhorst, E. Johansson, J. E. Brown, M. Golub, T. R. Rubin, M. A. TI TMPRSS2-ERG fusion prostate cancer is a molecularly distinct estrogen-sensitive subclass of aggressive prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Harvard Univ, MIT, Broad Inst, Cambridge, MA USA. Dana Farber Canc Inst, Boston, MA USA. Yale Univ, New Haven, CT 06520 USA. Karolinska Inst, S-10401 Stockholm, Sweden. Oerebro Univ Hosp, Oerebro, Sweden. Harvard Univ, Sch Publ Hlth, Boston, MA USA. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. Soeder Hosp, Stockholm, Sweden. RI Myles, Brown/B-6906-2008; Calza, Stefano/B-1915-2010 OI Calza, Stefano/0000-0003-4996-7995 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 779 BP 171A EP 171A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100779 ER PT J AU Mosquera, JM Mehra, R Regan, M Genega, EM Gaston, S Perner, S Connor, M Bueti, G Tomlins, DA Shah, RB Wei, J Kearney, M Johnson, LA Tang, JM Chinaaiyan, AM Sanda, MG Rubin, MA AF Mosquera, J. M. Mehra, R. Regan, M. Genega, E. M. Gaston, S. Perner, S. Connor, M. Bueti, G. Tomlins, D. A. Shah, R. B. Wei, J. Kearney, M. Johnson, L. A. Tang, J. M. Chinaaiyan, A. M. Sanda, M. G. Rubin, M. A. TI Prevalence of TMPRSS2-ERG fusion prostate cancer in men undergoing prostate biopsy in the United States SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Beth Israel Deaconess Med Ctr, Boston, MA USA. Michigan Urol Ctr, Ann Arbor, MI USA. Ctr Comprehens Canc, Ann Arbor, MI USA. Harvard Univ, Sch Med, MIT, Broad Inst, Cambridge, MA USA. Dana Farber Canc Inst, Boston, MA USA. RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 786 BP 172A EP 172A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100786 ER PT J AU Nielsen, GP Oliva, E AF Nielsen, G. P. Oliva, E. TI Papillary renal cell carcinoma of the kidney: A clinicopathologic study of 76 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Nielsen, G. P.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 795 BP 174A EP 174A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100795 ER PT J AU Rubin, MA Mucci, LA Pawitan, Y Demichelis, F Fall, K Stark, JR Adami, HO Anderson, SO Andren, O Holmberg, L Huang, W Kantoff, PW Kim, R Perner, S Stampfer, MJ Johansson, JE AF Rubin, M. A. Mucci, L. A. Pawitan, Y. Demichelis, F. Fall, K. Stark, J. R. Adami, H-O Anderson, S-O Andren, O. Holmberg, L. Huang, W. Kantoff, P. W. Kim, R. Perner, S. Stampfer, M. J. Johansson, J-E TI Testing a multigene model to predict lethal prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Karolinska Inst, Stockholm, Sweden. Orebro Univ Hosp, Orebro, Sweden. Uppsala Univ, Uppsala, Sweden. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Rider, Jennifer/A-5371-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 816 BP 178A EP 179A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100816 ER PT J AU Lilbright, TM Young, RH AF Lilbright, T. M. Young, R. H. TI Metastatic carcinoma to the testis: A study of 26 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Indiana Univ, Sch Med, Bloomington, IN 47405 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 851 BP 186A EP 186A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100851 ER PT J AU Wu, CL Ma, XJ McDougal, WS Erlanger, M AF Wu, C-L Ma, X-J McDougal, W. S. Erlanger, M. TI Gene expression signature predicting prostate cancer progression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. AviaraDx Inc, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 870 BP 190A EP 190A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100870 ER PT J AU Wu, CL Jordan, K McDougal, WS Cheng, LL AF Wu, C-L Jordan, K. McDougal, W. S. Cheng, L. L. TI Metabolomic imaging of prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Wu, C-L; Jordan, K.; McDougal, W. S.; Cheng, L. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 871 BP 190A EP 190A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181100871 ER PT J AU Carrick, J Soslow, R Oliva, E Ewanowich, C Gilks, CB Kobel, M AF Carrick, J. Soslow, R. Oliva, E. Ewanowich, C. Gilks, C. B. Koebel, M. TI Ovarian clear cell carcinomas reliably express an immunophenotype that is different from high-grade serous carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Vancouver Gen Hosp, British Columbia Canc Agcy, Vancouver, BC, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Alberta, Edmonton, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 910 BP 199A EP 199A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101039 ER PT J AU Chang, MC Drapkin, R McKeon, FD Mei, H Agoston, EA Crum, CP AF Chang, M. C. Drapkin, R. McKeon, F. D. Mei, H. Agoston, E. A. Crum, C. P. TI An immunophenotypic study of fimbrial mucosa SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 914 BP 200A EP 200A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101043 ER PT J AU Fallon, MA Wilbur, DC Prasad, ML AF Fallon, M. A. Wilbur, D. C. Prasad, M. L. TI Ovarian frozen section diagnosis: Use of whole slide digital imaging shows excellent correlation between virtual slide and original interpretations in a large series of cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 UMASS Mem Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 929 BP 203A EP 203A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101058 ER PT J AU Hofer, MD Liu, J Rubin, MA Matulonis, UA Hirsch, MS AF Hofer, M. D. Liu, J. Rubin, M. A. Matulonis, U. A. Hirsch, M. S. TI The metastasis-associated protein 1 (MTA1) is a prognostic biomarker for papillary serous ovarian carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 943 BP 206A EP 206A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101072 ER PT J AU Irving, JA Young, RH AF Irving, J. A. Young, R. H. TI Microcystic stromal tumor of the ovary: Report of 12 cases of a hitherto uncharacterized distinctive ovarian neoplasm SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Royal Jubilee Hosp, Victoria, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 946 BP 207A EP 207A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101075 ER PT J AU Jarboe, EA Pizer, E Miron, A Crum, CP AF Jarboe, E. A. Pizer, E. Miron, A. Crum, C. P. TI Evidence of a latent precursor (p53 signature) to uterine serous carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. CellNetrix Pathol, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 950 BP 208A EP 208A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101079 ER PT J AU Oliva, E Toledo, G AF Oliva, E. Toledo, G. TI Frequent lymphovascular invasion but not aggressive Behavior is characteristic of Endometrioid endometrial carcinomas with "MELF" features: A clinicopathologic study of 22 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Oliva, E.; Toledo, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Toledo, Gemma/H-9842-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 988 BP 216A EP 216A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101117 ER PT J AU Park, KJ Lamb, C Oliva, E Soslow, RA Kiyokawa, T AF Park, K. J. Lamb, C. Oliva, E. Soslow, R. A. Kiyokawa, T. TI Unusual endocervical adenocarcinomas: An immunohistochemical analysis with molecular detection of human papillomavirus SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Jikei Univ, Sch Med, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 993 BP 217A EP 217A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101122 ER PT J AU Rabban, JT Lerwill, MF McCluggage, WG Grenert, JP Zaloudek, CJ AF Rabban, J. T. Lerwill, M. F. McCluggage, W. G. Grenert, J. P. Zaloudek, C. J. TI Ovarian carcinoid tumors of primary versus metastatic origin: Pitfalls in diagnostic use of the intestinal marker CDX-2 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1004 BP 220A EP 220A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101133 ER PT J AU Roh, MH Liu, J Aster, JC Matuloins, UA Hirsch, MS AF Roh, M. H. Liu, J. Aster, J. C. Matuloins, U. A. Hirsch, M. S. TI Notch1 and Notch3 overexpression in young women with papillary serous ovarian carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1010 BP 221A EP 221A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101139 ER PT J AU Staats, PN Kuhlmann, G Garcia, JJ McCluggage, WG De Nictolis, M Soslow, RA Iafrate, AJ Oliva, E AF Staats, P. N. Kuhlmann, G. Garcia, J. J. McCluggage, W. G. De Nictolis, M. Soslow, R. A. Iafrate, A. J. Oliva, E. TI Uterine tumors resembling ovarian sex cord tumors (UTROSCT) lack the JAZF1-JJAZ1 gene fusion commonly seen in endometrial stromal tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. Univ Ancona, Ancona, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1030 BP 225A EP 225A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101159 ER PT J AU Toledo, G Growdon, WB Dias-Santagata, D Ganguly, A Auba, M Iafrate, AJ Oliva, E AF Toledo, G. Growdon, W. B. Dias-Santagata, D. Ganguly, A. Auba, M. Iafrate, A. J. Oliva, E. TI Microsatellite instability status and clinicopathologic profile of endometrial cancer (EC) in young women (<= 50 years) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp, Pamplona, Spain. RI Toledo, Gemma/H-9842-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1036 BP 226A EP 226A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101165 ER PT J AU Toledo, G Growdon, WB Palmeri, MLD Rueda, BR Oliva, E AF Toledo, G. Growdon, W. B. Palmeri, M. L. D. Rueda, B. R. Oliva, E. TI Utility of the mitosis marker anti-phosphohistone H3 (PHH3) in precise and rapid evaluation of mitotic index in leiomyomas with bizarre nuclei SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Toledo, G.; Growdon, W. B.; Palmeri, M. L. D.; Rueda, B. R.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1037 BP 226A EP 227A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101166 ER PT J AU Jacobson-Dunlop, E Le, C Patterson, J Warrick, A Harlow, A Azar, S Cruz, F Town, A Rubin, BP Hodi, FS Muller, S Heinrich, MC Corless, CL AF Jacobson-Dunlop, E. Le, C. Patterson, J. Warrick, A. Harlow, A. Azar, S. Cruz, F. Town, A. Rubin, B. P. Hodi, F. S. Muller, S. Heinrich, M. C. Corless, C. L. TI KIT mutations in mucosal melanoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Cleveland Clin, Cleveland, OH 44106 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1082 BP 236A EP 236A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101211 ER PT J AU Nero, CJ Wu, CL Powers, CN Krane, JF Faquin, WC AF Nero, C. J. Wu, C. L. Powers, C. N. Krane, J. F. Faquin, W. C. TI Minor salivary gland tumors of the larynx, a clinicopathologic study of 33 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1097 BP 239A EP 240A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101226 ER PT J AU O'Sullivan, ED Jain, R Faquin, WC Power, CN AF O'Sullivan, E. D. Jain, R. Faquin, W. C. Power, C. N. TI Eosinophilic angiocentric fibrosis: Clinicopathologic characteristics and potential pitfalls SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Virginia Commonwealth Univ, Richmond, VA 23284 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1098 BP 240A EP 240A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101227 ER PT J AU Ferry, JA Fung, CY Hasserjian, RP Lucarelli, MJ Harris, NL AF Ferry, J. A. Fung, C. Y. Hasserjian, R. P. Lucarelli, M. J. Harris, N. L. TI Ocular adnexal lymphomas: Outcome in 181 patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1160 BP 253A EP 253A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101289 ER PT J AU Hasserjian, RP Seliem, R Turbiner, J Wang, SA Pinkus, GS Harris, NL Iofrate, AJ AF Hasserjian, R. P. Seliem, R. Turbiner, J. Wang, S. A. Pinkus, G. S. Harris, N. L. Iofrate, A. J. TI BCL2, BCL6, and MYC rearrangements in follicular lymphoma: Comparison of FISH and immunohistochemistry results on a tissue microarray and correlation with patient outcome SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1172 BP 256A EP 256A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101301 ER PT J AU Kolman, OK Snuderl, M Ferry, JA Hochberg, EP Chen, YB Hasserjian, RP Rahemtullah, A AF Kolman, O. K. Snuderl, M. Ferry, J. A. Hochberg, E. P. Chen, Y. B. Hasserjian, R. P. Rahemtullah, A. TI Clinicopathologic features of B-cell lymphomas with concurrent BCL2 and C-MYC gene rearrangements SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Kolman, O. K.; Snuderl, M.; Ferry, J. A.; Hochberg, E. P.; Chen, Y. B.; Hasserjian, R. P.; Rahemtullah, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1191 BP 260A EP 260A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101319 ER PT J AU Louissaint, A Soupir, C Ganguly, A Hasserjian, RP Ferry, JA Harris, NL Zukerberg, LR AF Louissaint, A., Jr. Soupir, C. Ganguly, A. Hasserjian, R. P. Ferry, J. A. Harris, N. L. Zukerberg, L. R. TI Infectious mononucleosis; Morphology and immunophenotype in cervical lymph nodes and Waldeyer's ring SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Louissaint, A., Jr.; Soupir, C.; Ganguly, A.; Hasserjian, R. P.; Ferry, J. A.; Harris, N. L.; Zukerberg, L. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1202 BP 263A EP 263A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101330 ER PT J AU Rahemtullah, A Jaffe, ES Harris, NL Hasserjian, RP AF Rahemtullah, A. Jaffe, E. S. Harris, N. L. Hasserjian, R. P. TI Nodular lymphocyte predominant Hodgkin lymphoma with an interfollicular growth pattern and atypical T cells: A distinct disease variant? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1235 BP 270A EP 270A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101363 ER PT J AU Saenz, AJ Van Cott, E AF Saenz, A. J. Van Cott, E. TI Clinical significance of acquired activated protein C resistance caused by lupus anticoagulants SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Saenz, A. J.; Van Cott, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1246 BP 273A EP 273A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101374 ER PT J AU Slack, GW Ferry, JA Harris, NL Ganguly, A Zukerberg, LR AF Slack, G. W. Ferry, J. A. Harris, N. L. Ganguly, A. Zukerberg, L. R. TI Lymphocyte depleted classical Hodgkin lymphoma: A clinical, morphologic and immunohistologic study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Slack, G. W.; Ferry, J. A.; Harris, N. L.; Ganguly, A.; Zukerberg, L. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1254 BP 274A EP 275A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101382 ER PT J AU Soupir, CP Vergilio, J Dal Cin, P Hasserjiam, RP AF Soupir, C. P. Vergilio, J. Dal Cin, P. Hasserjiam, R. P. TI Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura (ITP) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1257 BP 275A EP 275A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101385 ER PT J AU Soupir, CP Vergilio, J Wang, SA Freeman, J Fend, F Hasserjian, RP AF Soupir, C. P. Vergilio, J. Wang, S. A. Freeman, J. Fend, F. Hasserjian, R. P. TI JAK2 V617F mutation defines two subsets of refractory anemia with ringed sideroblasts and marked thrombocytosis (RARS-T) with distinctive clinical and morphologic features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Massachusetts, Med Ctr, Worcester, MA 01605 USA. Baystate Med Ctr, Springfield, MA USA. Tech Univ Munich, D-8000 Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1256 BP 275A EP 275A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101384 ER PT J AU Tang, GL Hasserjian, RP Truong, F Woda, BA Wang, SA AF Tang, G. L. Hasserjian, R. P. Truong, F. Woda, B. A. Wang, S. A. TI Myelodysplastic syndrome with Erythroblasts >= 50%: Clinicopathologic features and prognostic grouping by blast enumeration SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA 01605 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1270 BP 278A EP 278A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101398 ER PT J AU Truong, F Hasserjian, RP Tang, G Woda, BA Wang, SA AF Truong, F. Hasserjian, R. P. Tang, G. Woda, B. A. Wang, S. A. TI Acute erythroleukemia (AML M6a) with myeloblasts < 20% of total marrow nucleated cells: A heterogeneous group of diseases? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Massachusetts, Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1273 BP 279A EP 279A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101401 ER PT J AU Truong, LD Zhai, QJ Shen, SS Hamilton, C Krishnan, H AF Truong, L. D. Zhai, Q. J. Shen, S. S. Hamilton, C. Krishnan, H. TI Renal injury associated with urinary obstruction. Participation of an immune mechanism? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Methodist Hosp, Houston, TX 77030 USA. Cornell Univ, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. DeBakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1350 BP 296A EP 296A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101478 ER PT J AU Truong, LD Zhai, QJ Shen, SS Krishnan, B Ro, J AF Truong, L. D. Zhai, Q. J. Shen, S. S. Krishnan, B. Ro, J. TI Lymphangiogenesis in chronic obstructive uropathy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Methodist Hosp, Houston, TX 77030 USA. Cornell Univ, New York, NY USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1349 BP 296A EP 296A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101477 ER PT J AU Deshpande, V Rubbia-Brandt, L Lauwers, G AF Deshpande, V. Rubbia-Brandt, L. Lauwers, G. TI Autoimmune pancreatitis related sclerosing cholangitis, primary sclerosing cholangitis and steroid responsive PSC: A comparative study of 27 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1383 BP 303A EP 303A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101511 ER PT J AU Hsu, M Srivastava, A Mino-Kenudson, M Deshpande, V Lauwers, GY AF Hsu, M. Srivastava, A. Mino-Kenudson, M. Deshpande, V. Lauwers, G. Y. TI Mismatch repair proteins in pancreatic endocrine neoplasms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1393 BP 305A EP 306A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101521 ER PT J AU Hsu, M Fukuoka, J Lauwers, GY Mino-Kenudson, M AF Hsu, M. Fukuoka, J. Lauwers, G. Y. Mino-Kenudson, M. TI Expression of inflammatory mediators in pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Toyama Med Univ, Toyama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1392 BP 305A EP 305A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101520 ER PT J AU Hsu, M Srivastava, A Hornick, JL Fukuoka, J Iafrate, AJ Lauwers, GY Mino-Kenudson, M AF Hsu, M. Srivastava, A. Hornick, J. L. Fukuoka, J. Iafrate, A. J. Lauwers, G. Y. Mino-Kenudson, M. TI Molecular alterations in morphologic subtypes of pancreatic intraductal papillary mucinous neoplasm (IPMN) are distinct from those seen in pancreatic ductal adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Toyama Med Univ, Toyama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1391 BP 305A EP 305A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101519 ER PT J AU Koreishi, AF Ferrone, CR Lauwers, GY Deshpande, V AF Koreishi, A. F. Ferrone, C. R. Lauwers, G. Y. Deshpande, V. TI Lessons learned from 5 year survivors of pancreatic adenocarcinoma: A critical look at the AJCC staging system SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Koreishi, A. F.; Ferrone, C. R.; Lauwers, G. Y.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1402 BP 307A EP 307A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101530 ER PT J AU Lennerz, JK Brunt, EM Dehner, LP Geller, SA Hart, J Lauwers, GY Washington, K Yerian, LM Wang, HL AF Lennerz, J. K. Brunt, E. M. Dehner, L. P. Geller, S. A. Hart, J. Lauwers, G. Y. Washington, K. Yerian, L. M. Wang, H. L. TI Immunoprofiling of hepatocellular nodules SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Washington Univ, St Louis, MO 63130 USA. St Louis Univ, St Louis, MO 63103 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Univ Chicago, Chicago, IL 60637 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Vanderbilt Univ, Nashville, TN USA. Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1407 BP 308A EP 309A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101535 ER PT J AU Lennerz, JL Brunt, EM Dehner, LP Geller, SA Hart, J Lauwers, GY Washington, K Yerian, LM Wang, HL AF Lennerz, J. L. Brunt, E. M. Dehner, L. P. Geller, S. A. Hart, J. Lauwers, G. Y. Washington, K. Yerian, L. M. Wang, H. L. TI Observer variability in the histopathologic diagnosis of hepatocellular nodules SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Washington Univ, St Louis, MO 63130 USA. St Louis Univ, St Louis, MO 63103 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Univ Chicago, Chicago, IL 60637 USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Vanderbilt Univ, Nashville, TN USA. Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1406 BP 308A EP 308A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101534 ER PT J AU Mino-Kenudson, M Smyrk, TC Deshpande, V Fujisawa, M Shimizu, M Uehara, T Nakazawa, T Kobashi, Y Lauwers, GY Notohara, K AF Mino-Kenudson, M. Smyrk, T. C. Deshpande, V. Fujisawa, M. Shimizu, M. Uehara, T. Nakazawa, T. Kobashi, Y. Lauwers, G. Y. Notohara, K. TI Autoimmune pancreatitis: West vs. east SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. Himeji Red Cross Hosp, Himeji, Hyogo, Japan. Saitama Med Univ, Saitama City, Saitama, Japan. Shinshu Univ, Sch Med, Matsumoto, Nagano 390, Japan. Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan. Tenri Hosp, Tenri, Nara 632, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1422 BP 312A EP 312A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101550 ER PT J AU Notohara, K Smyrk, TC Nakazawa, T Mino-Kenudson, M AF Notohara, K. Smyrk, T. C. Nakazawa, T. Mino-Kenudson, M. TI Regressing lymphoplasmacytic sclerosing pancreatitis (LPSP) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. Mayo Clin, Rochester, MN USA. Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1423 BP 312A EP 312A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101551 ER PT J AU Fedele, G Finn, SP Mueller, E Xie, W Shin, E Loda, MF AF Fedele, G. Finn, S. P. Mueller, E. Xie, W. Shin, E. Loda, M. F. TI Gene expression profiling and immunohistochemistry define roles for pFOXO1a and FASN in PI3K signature in prostate cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1490 BP 326A EP 326A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101618 ER PT J AU Roehrl, MH Rho, JH Wang, JY AF Roehrl, M. H. Rho, J. H. Wang, J. Y. TI Cancer tissue proteomics by heparin affinity fractionation enrichment (HAFE): Up-regulation of PSB7 and PRDX1 in colorectal adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1505 BP 330A EP 330A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101633 ER PT J AU Barletta, JA Weir, BA Perner, S Johnson, L Rubin, MA Johnson, BE Meyerson, M Chirieac, LR AF Barletta, J. A. Weir, B. A. Perner, S. Johnson, L. Rubin, M. A. Johnson, B. E. Meyerson, M. Chirieac, L. R. TI Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1532 BP 335A EP 335A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101660 ER PT J AU Behesti, J Sabo, E Janne, PA Joshi, V Wang, LJ Lindeman, NI AF Behesti, J. Sabo, E. Janne, P. A. Joshi, V. Wang, L. J. Lindeman, N. I. TI TTF-1 Positivity is a sensitive predictor of EGFR mutation and treatment response in pulmonary adenocarcinomas, by pathologist interpretation and by image analysis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Brown Univ, Sch Med, Providence, RI 02912 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1535 BP 336A EP 336A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101663 ER PT J AU Kulich, SM Cagle, PT Cozza, EM Land, SR Lenzner, D Brcic, L Dacic, S AF Kulich, S. M. Cagle, P. T. Cozza, E. M. Land, S. R. Lenzner, D. Brcic, L. Dacic, S. TI Immunohistochemical expression of signaling molecules Erb-b3, MKP-3, and Stat1 in non-small cell lung carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Methodist Hosp, Houston, TX 77030 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. Univ Zagreb, Sch Med, Zagreb 41000, Croatia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1571 BP 345A EP 345A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101699 ER PT J AU Matsubara, O Imazeki, N Tsuda, H Nakatani, Y Mark, EJ AF Matsubara, O. Imazeki, N. Tsuda, H. Nakatani, Y. Mark, E. J. TI Differences of fibroblastic foci of usual interstitial pneumonia (UIP) and intraalveolar buds of chronic organizing pneumonia (COP)/bronchiolitis obliterans organizing pneumonia (BOOP): Comparison of the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama 359, Japan. Chiba Univ, Chiba, Japan. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1581 BP 347A EP 347A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101709 ER PT J AU Meng, F Mark, EJ Matsubara, O AF Meng, F. Mark, E. J. Matsubara, O. TI Idiopathic tracheal stenosis: A clinicopathological study of 63 cases and comparison of the pathology to chondromalacia SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Meng, F.; Mark, E. J.; Matsubara, O.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1582 BP 347A EP 347A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101710 ER PT J AU Sholl, LM Iafrate, AJ Yeap, B Holmes, A Chou, Y Wu, M Goan, Y Su, L Janne, PA Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Yeap, B. Holmes, A. Chou, Y. Wu, M. Goan, Y. Su, L. Janne, P. A. Christiani, D. C. Chirieac, L. R. TI Genotype-phenotype correlation in non-small cell lung carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Gen Hosp, Boston, MA USA. Vet Gen Hosp, Kaohsiung, Taiwan. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1599 BP 351A EP 351A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101727 ER PT J AU Sholl, LM Iafrate, AJ Yeap, B Holmes, A Chou, YP Wu, MT Goan, YG Su, L Janne, PA Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Yeap, B. Holmes, A. Chou, Y. P. Wu, M. T. Goan, Y. G. Su, L. Jaenne, P. A. Christiani, D. C. Chirieac, L. R. TI EGER gene amplification is invariably associated with exon 19 deletion in non-small cell lung carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Gen Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Vet Gen Hosp, Kaohsiung, Taiwan. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1600 BP 351A EP 351A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101728 ER PT J AU Post, MD Listro, L MacMillan, D Misiano, D Rosenberg, AE AF Post, M. D. Listro, L. MacMillan, D. Misiano, D. Rosenberg, A. E. TI The benefits of hospital-wide electronic safety reporting systems in developing pathology-based quality improvement projects SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Post, M. D.; Listro, L.; MacMillan, D.; Misiano, D.; Rosenberg, A. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1631 BP 358A EP 358A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101759 ER PT J AU Belsley, NA Johnson, MM Selig, MK Nielsen, GP AF Belsley, N. A. Johnson, M. M. Selig, M. K. Nielsen, G. P. TI Use of electron microscopy in core biopsy diagnosis of oncocytic renal tumors SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1702 BP 374A EP 374A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101830 ER PT J AU Wilbur, DC Madi, K Colvin, RB Duncan, LM Faquin, WC Ferry, JA Frosch, MP Houser, SL Kradin, RL Lauwers, GY Louis, DN Mark, EJ Mino-Kenudson, M Misdraji, J Nielsen, GP Pitman, MB Raheintullah, A Rosenberg, AE Smith, RN Stone, JR Tambouret, RH Wu, CL Young, RH Zenbowicz, A Klietmann, W AF Wilbur, D. C. Madi, K. Colvin, R. B. Duncan, L. M. Faquin, W. C. Ferry, J. A. Frosch, M. P. Houser, S. L. Kradin, R. L. Lauwers, G. Y. Louis, D. N. Mark, E. J. Mino-Kenudson, M. Misdraji, J. Nielsen, G. P. Pitman, M. B. Raheintullah, A. Rosenberg, A. E. Smith, R. N. Stone, J. R. Tambouret, R. H. Wu, C-L Young, R. H. Zenbowicz, A. Klietmann, W. TI Whole slide imaging digital pathology: A pilot study using paired subspecialist correlations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. Harvard Med Sch, Boston, MA USA. Corista LLC, Concord, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1701 BP 374A EP 374A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101829 ER PT J AU Gupta, M Selig, MK Oliva, E Nielsen, GP AF Gupta, M. Selig, M. K. Oliva, E. Nielsen, G. P. TI Uterine tumors resembling ovarian sex cord stromal tumors (UTROSCTs): An ultrastructural analysis of 13 cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 DHMC, Lebanon, NH USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1704 BP 375A EP 375A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101832 ER PT J AU Saenz, AJ Selig, MK Deshpande, F AF Saenz, A. J. Selig, M. K. Deshpande, F. TI Acinar cell cystaclenoma of the pancreas: Role of electron microscopy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Saenz, A. J.; Selig, M. K.; Deshpande, F.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2008 VL 88 SU 1 MA 1708 BP 376A EP 376A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 248UG UT WOS:000252181101836 ER PT J AU Go, AS Singer, DE AF Go, Alan S. Singer, Daniel E. TI Stroke prevention in atrial fibrillation: another step sideways SO LANCET LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; XIMELAGATRAN; WARFARIN C1 [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Med, Clin Epidemiol Unit, Boston, MA 02114 USA. [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA. RP Go, AS (reprint author), Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. EM alan.s.go@kp.org NR 12 TC 2 Z9 2 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JAN-FEB PY 2008 VL 371 IS 9609 BP 278 EP 280 DI 10.1016/S0140-6736(08)60143-9 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 254VQ UT WOS:000252616500005 PM 18294981 ER PT J AU Modlin, IM Oberg, K Chung, DC Jensen, RT de Herder, WW Thakker, RV Caplin, M Delle Fave, G Kaltsas, GA Krenning, EP Moss, SF Nilsson, O Rindi, G Salazar, R Ruszniewski, P Sundin, A AF Modlin, Irvin M. Oberg, Kjell Chung, Daniel C. Jensen, Robert T. de Herder, Wouter W. Thakker, Rajesh V. Caplin, Martyn Delle Fave, Gianfranco Kaltsas, Greg A. Krenning, Eric P. Moss, Steven F. Nilsson, Ola Rindi, Guido Salazar, Ramon Ruszniewski, Philippe Sundin, Anders TI Gastroenteropancreatic neuroendocrine tumours SO LANCET ONCOLOGY LA English DT Review ID SOMATOSTATIN RECEPTOR SCINTIGRAPHY; MULTIPLE ENDOCRINE NEOPLASIA; ZOLLINGER-ELLISON-SYNDROME; POSITRON-EMISSION-TOMOGRAPHY; MIDGUT CARCINOID-TUMORS; LIVER METASTASES; SURGICAL-TREATMENT; CELL TUMORS; SURVIVAL; CHEMOEMBOLIZATION AB Gastroenteropancreatic (GEP) neuroendocrine tumours (NETS) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. Investigation and management should be highly individualised for a patient, taking into consideration the likely natural history of the tumour and general health of the patient. Management strategies include surgery for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoembolisation and radiofrequency ablation), chemotherapy, and somatostatin analogues to control symptoms that result from release of peptides and neuroamines. New biological agents and somatostatin-tagged radionuclides are under investigation. The complexity, heterogeneity, and rarity of GEP NETS have contributed to a paucity of relevant randomised trials and little or no survival increase over the past 30 years. To improve outcome from GEP NETS, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling. More-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed. Comparison between treatments is currently very difficult. Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics. C1 [Modlin, Irvin M.] Yale Univ, Dept Surg Gastroenterol, New Haven, CT 06520 USA. [Oberg, Kjell] Univ Uppsala Hosp, Dept Internal Med, Endocrine Oncol Unit, S-75185 Uppsala, Sweden. [Chung, Daniel C.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Jensen, Robert T.] NIDDK, Natl Inst Hlth, Dis Branch, Bethesda, MD USA. [de Herder, Wouter W.] Univ Rotterdam Hosp, Erasmus Med Ctr, Dept Internal Med 3, Rotterdam, Netherlands. [de Herder, Wouter W.] Univ Oxford, Nuffield Dept Clin Med, Acad Endocrine Unit, Oxford, England. [Caplin, Martyn] Royal Free Hosp, Ctr Gastroenterol, Neuroendocrine Tumour Unit, London NW3 2QG, England. [Delle Fave, Gianfranco] Univ Roma La Sapienza, Dept Digest & Liver Dis, Rome, Italy. [Kaltsas, Greg A.] George Genimatas Hosp, Dept Endocrinol, Athens, Greece. [Krenning, Eric P.] Erasmus MC, Dept Nucl Med, Rotterdam, Netherlands. [Moss, Steven F.] Brown Univ, Rhode Isl Hosp, Dept Med, Div Gastroenterol, Providence, RI 02903 USA. [Nilsson, Ola] Sahlgrens Univ Hosp, Lundberg Lab Cancer Res, Dept Pathol, S-41345 Gothenburg, Sweden. [Rindi, Guido] Univ Parma, Dept Pathol, I-43100 Parma, Italy. [Rindi, Guido] Univ Parma, Lab Med, I-43100 Parma, Italy. [Salazar, Ramon] Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain. [Ruszniewski, Philippe] Beaujon Hosp, Dept Gastroenterol, Clichy, France. [Sundin, Anders] Uppsala Univ, Dept Radiol, Ctr Med Imaging, Uppsala, Sweden. RP Modlin, IM (reprint author), Yale Univ, Dept Surg Gastroenterol, New Haven, CT 06520 USA. EM imodlin@optonline.net OI RINDI, Guido/0000-0003-2996-4404; Thakker, Rajesh/0000-0002-1438-3220 FU Medical Research Council [G9825289] NR 78 TC 641 Z9 674 U1 4 U2 45 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD JAN PY 2008 VL 9 IS 1 BP 61 EP 72 DI 10.1016/S1470-2045(07)70410-2 PG 12 WC Oncology SC Oncology GA 252RN UT WOS:000252464400027 PM 18177818 ER PT J AU Mirza, N Machtay, M Devine, PA Troxel, A Abboud, SK Doty, RL AF Mirza, Natasha Machtay, Mitchell Devine, Pamela A. Troxel, Andrea Abboud, Soo K. Doty, Richard L. TI Gustatory Impairment in Patients Undergoing Head and Neck Irradiation SO LARYNGOSCOPE LA English DT Article DE Radiation; taste; dysgeusia; videomicroscopy; taste pores ID TASTE-BUDS; FUNGIFORM PAPILLAE; SALIVARY FUNCTION; NERVE-FIBERS; HUMAN TONGUE; RADIOTHERAPY; PERFORMANCE; CANCER; RADIATION; RECOVERY AB Objectives: To determine whether radiation alters taste function and structure. Research Design: Prospective, longitudinal study. Methodology: Testing prior to starting radiation, and 2 weeks, 2 months, and 6 months after completing radiation. Results: Relative to controls, patients had lower taste identification test scores for bitter, salty, and sour tastes. Sour taste also showed a significant group-by-time interaction (P = .03). Taste pores were decreased in the irradiated group, with a significant group-by-time interaction (P = .03). Conclusion: Head and neck cancer patients have decreased taste function, and radiation adversely affected sour taste and taste pores. C1 [Mirza, Natasha; Abboud, Soo K.] Univ Penn, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Devine, Pamela A.] Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA USA. [Machtay, Mitchell] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA. [Troxel, Andrea] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Doty, Richard L.] Univ Penn, Ctr Smell & Taste, Philadelphia, PA 19104 USA. RP Mirza, N (reprint author), Univ Penn, Dept Otolaryngol Head & Neck Surg, 5 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA. EM Natasha.mirza@uphs.upenn.edu RI Doty, Richard/B-7623-2012; Doty, Richard/G-1602-2013; OI Troxel, Andrea/0000-0002-1393-3075 FU Department of Veterans Affairs; Philadelphia VA Medical Center; Competitive Pilot Project Fund FX This research was supported by a grant from the Department of Veterans Affairs, Philadelphia VA Medical Center, Competitive Pilot Project Fund. NR 43 TC 15 Z9 15 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2008 VL 118 IS 1 BP 24 EP 31 DI 10.1097/MLG.0b013e318155a276 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 386CR UT WOS:000261860400006 PM 17975512 ER PT J AU Leuin, S Cunningham, M Volk, MS Hartnick, C AF Leuin, Shelby Cunningham, Michael Volk, Mark S. Hartnick, Christopher TI Transhyoid Approach to Excision of Recurrent Vallecular Pseudocysts SO LARYNGOSCOPE LA English DT Article DE Vallecular cyst; pseudocyst; transhyoid approach ID AIRWAY-OBSTRUCTION; CELL-CARCINOMA; CYST; TONGUE; INFANTS; BASE; LARYNGOMALACIA C1 [Leuin, Shelby; Cunningham, Michael; Hartnick, Christopher] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Volk, Mark S.] Childrens Hosp Boston, Dept Otolaryngol, Boston, MA USA. [Leuin, Shelby; Cunningham, Michael; Volk, Mark S.; Hartnick, Christopher] Harvard Univ, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Hartnick, C (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM Christopher_Hartnick@meei.harvard.edu OI Volk, Mark/0000-0001-5708-5808 NR 14 TC 3 Z9 3 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2008 VL 118 IS 1 BP 124 EP 127 DI 10.1097/MLG.0b013e31814b8db7 PG 4 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 386CR UT WOS:000261860400023 PM 17975514 ER PT J AU Phung, TL Oble, DA Jia, W Benjamin, LE Mihm, MC Nelson, JS AF Phung, Thuy L. Oble, Darryl A. Jia, Wangeun Benjamin, Laura E. Mihm, Martin C., Jr. Nelson, J. Stuart TI Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks SO LASERS IN SURGERY AND MEDICINE LA English DT Article ID MTOR C1 [Oble, Darryl A.; Mihm, Martin C., Jr.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Phung, Thuy L.; Benjamin, Laura E.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Jia, Wangeun; Nelson, J. Stuart] Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA. RP Mihm, MC (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Warren Bldg 827,279 Charles St, Boston, MA 02114 USA. EM mmihm@partners.org RI Jia, Wangcun/A-9935-2011 FU NCI NIH HHS [R01 CA109086, R01 CA109086-02]; NCRR NIH HHS [P41 RR001192]; NHLBI NIH HHS [R01 HL071049-04, R01 HL071049]; NIAMS NIH HHS [AR47551, AR48458, K24 AR047551, R01 AR048458]; NIBIB NIH HHS [P41 EB015890]; NIGMS NIH HHS [GM62177, R01 GM062177] NR 13 TC 34 Z9 35 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2008 VL 40 IS 1 BP 1 EP 5 DI 10.1002/lsm.20599 PG 5 WC Dermatology; Surgery SC Dermatology; Surgery GA 259NC UT WOS:000252945000001 PM 18220264 ER PT J AU Smith, NA Wanner, M Sakamoto, FH Doukas, AG Farinelli, WA Anderson, RR AF Smith, Nicholas A. Wanner, Molly Sakamoto, Fernanda H. Doukas, Apostolos G. Farinelli, William A. Anderson, R. Rox TI Iontophoretically delivered ALA photodynamic therapy. A histological study SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Smith, Nicholas A.; Wanner, Molly; Sakamoto, Fernanda H.; Doukas, Apostolos G.; Farinelli, William A.; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 25 BP 9 EP 9 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600028 ER PT J AU Sakamoto, FH Doukas, A Farinelli, W Tannous, Z Smith, N Redmond, H Anderson, RR AF Sakamoto, Fernanda H. Doukas, Apostolos Farinelli, William Tannous, Zeina Smith, Nicholas Redmond, Holly Anderson, R. Rox TI Is there an optevial incubation time for ALA-photodynamic therapy? SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Sakamoto, Fernanda H.; Doukas, Apostolos; Farinelli, William; Tannous, Zeina; Smith, Nicholas; Redmond, Holly; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 26 BP 10 EP 10 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600029 ER PT J AU Al-Arashi, MY Salomatina, E Yaroslavsky, AN AF Al-Arashi, Munir Y. Salomatina, Elena Yaroslavsky, Anna N. TI In vivo noninvasive subsurface imaging of human skin SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 131 BP 18 EP 18 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600052 ER PT J AU Tannous, Z Mukherjee, S Al-Arashi, MY Yaroslavsky, AN AF Tannous, Zeina Mukherjee, Sonali Al-Arashi, Munir Y. Yaroslavsky, Anna N. TI Delineating melanoma using multispectral polarized light imaging SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Tannous, Zeina; Mukherjee, Sonali; Al-Arashi, Munir Y.; Yaroslavsky, Anna N.] Harvard Univ, Sch Med, Boston, MA USA. [Tannous, Zeina; Mukherjee, Sonali; Al-Arashi, Munir Y.; Yaroslavsky, Anna N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tannous, Zeina] Vet Adm Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 130 BP 18 EP 18 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600051 ER PT J AU Rubin, IK Farinelli, W Anderson, RR AF Rubin, Iris K. Farinelli, William Anderson, R. Rox TI Optimal wavelengths for vein-selective photothermolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Rubin, Iris K.; Farinelli, William; Anderson, R. Rox] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 50 BP 22 EP 22 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600063 ER PT J AU Izikson, L Anderson, RR AF Izikson, Leonid Anderson, R. Rox TI Treatment endpoints for port wine stains and hemangiomas with the 595 nm and 755 nm lasers SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 Harvard Univ, Sch Med, Laser & Cosmet Dermatol Ctr, Massachusetts Gen Hosp, Boston, MA USA. Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 57 BP 24 EP 24 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600070 ER PT J AU Thongsima, S Zurakowski, D Manstein, D AF Thongsima, Siremon Zurakowski, David Manstein, Dieter TI Histological comparison of two different fractional photothermolysis devices emitting at 1550 nm SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Thongsima, Siremon; Manstein, Dieter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Zurakowski, David] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 64 BP 26 EP 26 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600077 ER PT J AU Tannous, Z Altshuler, G Yaroslavsky, I Childs, J Cohen, R Tabatadze, D AF Tannous, Zeina Altshuler, Gregory Yaroslavsky, Ilya Childs, James Cohen, Richard Tabatadze, David TI Ablative micro-fractional resurfacing: Time-course histology and clinical correlations SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Tannous, Zeina] Harvard Univ, Massachusetts Gen Hosp, Sch Med, VAMC, Boston, MA USA. [Altshuler, Gregory; Yaroslavsky, Ilya; Childs, James; Cohen, Richard; Tabatadze, David] Palomar Med Technol Inc, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 71 BP 28 EP 28 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600084 ER PT J AU Sakamoto, FH Doukas, A Farinelli, W Tannous, Z Shinn, M Benson, S Williams, G Dylla, F Anderson, RR AF Sakamoto, Fernanda Hidemi Doukas, Apostolos Farinelli, William Tannous, Zeina Shinn, Michelle Benson, Steve Williams, Gwyn Dylla, Fred Anderson, R. Rox TI Selective photothermolysis to target sebaceous glands SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Sakamoto, Fernanda Hidemi; Doukas, Apostolos; Farinelli, William; Tannous, Zeina; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Shinn, Michelle; Benson, Steve; Williams, Gwyn; Dylla, Fred] Free Elect Laser Facil, Thomas Jefferson Labs, Newport News, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 83 BP 32 EP 32 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600094 ER PT J AU Kositratna, G Watanabe, K Chan, HH Anderson, RR Manstein, D AF Kositratna, G. Watanabe, K. Chan, H. H. Anderson, R. R. Manstein, D. TI Differences in threshold of various histological markers to detect thermal tissue damage SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Kositratna, G.; Watanabe, K.; Anderson, R. R.; Manstein, D.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Chan, H. H.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Chan, H. H.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 251 BP 77 EP 77 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600229 ER PT J AU Tsao, S Yao, M Henry, F Farinelli, W Redmond, R Kochevar, I AF Tsao, Sandy Yao, Min Henry, Frank Farinelli, William Redmond, Robert Kochevar, Irene TI A pilot study of photochemical tissue bonding for excisional wound repair SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Tsao, Sandy; Yao, Min; Henry, Frank; Farinelli, William; Redmond, Robert; Kochevar, Irene] Massachusetts Gen Hosp, Wellman Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 256 BP 78 EP 78 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600232 ER PT J AU Yao, M Bujold, KE Redmond, RW Kochevar, IE AF Yao, Min Bujold, Kenneth E. Redmond, Robert W. Kochevar, Irene E. TI Laser activated method for sealing surgical wounds: Possible phototoxicity SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Yao, Min; Bujold, Kenneth E.; Redmond, Robert W.; Kochevar, Irene E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 259 BP 79 EP 79 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600235 ER PT J AU Neel, VA Al-Arashi, M Salornatina, E Nelson, A Yaroslavsky, AN AF Neel, V. A. Al-Arashi, M. Salornatina, E. Nelson, A. Yaroslavsky, A. N. TI Intraoperative delineation of nonmelanoma skin cancers: An in vivo pilot trial SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 262 BP 80 EP 80 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600238 ER PT J AU Zhang, R Salomaitna, E Al-Arashi, M Yaroslavsky, AN AF Zhang, R. Salomaitna, E. Al-Arashi, M. Yaroslavsky, A. N. TI Optical imager for in vivo macro- and micro-scale evaluation of tissue SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med & Surg C1 [Zhang, R.; Salomaitna, E.; Al-Arashi, M.; Yaroslavsky, A. N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 261 BP 80 EP 80 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600237 ER PT J AU Izikson, L Avram, M AF Izikson, Leonid Avram, Mathew TI Transient immunoreactivity after laser tattoo removal: Report of 2 cases SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Laser & Cosmet Dermatol Ctr, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 312 BP 91 EP 91 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600270 ER PT J AU Kosaka, S Yasumoto, M Akilov, OE Hasan, T Kawana, S AF Kosaka, Sachiko Yasumoto, Minako Akilov, Oleg E. Hasan, Tayyaba Kawana, Seiji TI Comparative split face study of 5-aminolevulinic acid photodynamic therapy with intense pulsed light for photorejuvenation of Asian skin SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 [Kosaka, Sachiko; Yasumoto, Minako; Kawana, Seiji] Nippon Med Sch, Dept Dermatol, Tokyo 113, Japan. [Akilov, Oleg E.; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 327 BP 94 EP 94 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600280 ER PT J AU Manstein, D Laubach, H Watanabe, K Anderson, RR AF Manstein, Dieter Laubach, Hans Watanabe, Kanna Anderson, R. Rox TI A novel cryotherapy method of non-invasive, selective lipolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 28th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 02-06, 2008 CL Kissimmee, FL SP Amer Soc Laser Med Surg C1 Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2008 SU 20 MA 111 BP 104 EP 104 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 323EA UT WOS:000257425600309 ER PT J AU Bredy, TW Barad, M AF Bredy, Timothy W. Barad, Mark TI The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear SO LEARNING & MEMORY LA English DT Article ID MEMORY RECONSOLIDATION; PROTEIN-SYNTHESIS; FACILITATES EXTINCTION; MOUSE MODEL; LONG-TERM; REACTIVATION; HIPPOCAMPUS; MECHANISMS; RETRIEVAL; RAT AB Histone modifications contribute to the epigenetic regulation of gene expression, a process now recognized to be important for the consolidation of long-term memory. Valproic acid (VPA), used for many years as an anticonvulsant and a mood stabilizer, has effects on learning and memory and enhances the extinction of conditioned fear through its function as a histone deacetylase inhibitor (HDAC). Here we report that VPA enhances long-term memory for both acquisition and extinction of cued-fear. Interestingly, VPA enhances extinction, but also enhances renewal of the original conditioned fear when tested in a within-subjects design. This effect appears to be related to a reconsolidation-like process since a single CS reminder in the presence of VPA can enhance long-term memory for the original fear in the context in which fear conditioning takes place. We also show that by modifying the intertrial interval during extinction training, VPA can strengthen reconsolidation of the original fear memory or enhance long-term memory for extinction such that it becomes independent of context. These findings have important implications for the use of HDAC inhibitors as adjuncts to behavior therapy in the treatment of phobia and related anxiety disorders. C1 [Bredy, Timothy W.; Barad, Mark] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Bredy, Timothy W.; Barad, Mark] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Barad, Mark] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Barad, M (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. EM mbarad@mednet.ucla.edu NR 38 TC 148 Z9 157 U1 0 U2 21 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1072-0502 J9 LEARN MEMORY JI Learn. Mem. PD JAN PY 2008 VL 15 IS 1 BP 39 EP 45 DI 10.1101/lm.801108 PG 7 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 248WU UT WOS:000252188700006 PM 18174372 ER PT S AU Stoodley, CJ Ray, NJ Jack, A Stein, JF AF Stoodley, Catherine J. Ray, Nicola J. Jack, Anthea Stein, John F. BE Eden, GF Flower, DL TI Implicit Learning in Control, Dyslexic, and Garden-Variety Poor Readers SO LEARNING, SKILL ACQUISITION, READING, AND DYSLEXIA SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 25th Rodin Remediation Conference 2006 CY OCT 11-13, 2006 CL Georgetown Univ, Washington, DC HO Georgetown Univ DE developmental dyslexia; implicit learning; serial reaction time task; cerebellum ID REACTION-TIME-TASK; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; COGNITIVE-AFFECTIVE SYNDROME; FOCAL CEREBELLAR LESIONS; DEVELOPMENTAL DYSLEXIA; TUMOR RESECTION; CHILDREN; DEFICIT; AUTOMATICITY; MOVEMENT AB Developmental dyslexia is diagnosed when children fail to acquire literacy skills despite adequate education and intellectual ability. There is evidence of impaired implicit learning in dyslexia, and it is possible that poor implicit learning in dyslexic children affects their acquisition of complex skills such as reading. To assess whether children with dyslexia show evidence of poor implicit motor learning, 45 dyslexic children completed a serial reaction time task (SRTT). Age-matched controls (n = 44) and nondyslexic poor readers ("garden-variety" poor readers, n = 20) were used as comparison groups. The inclusion of the garden-variety poor-reader group allows us to address the specificity of implicit learning deficits to dyslexics, as opposed to poor readers who do not have a discrepancy between their intellectual and literacy skills. There were no significant differences between the three groups in performance accuracy. However, whereas the controls and garden-variety poor readers showed good implicit learning (measured by a significant reduction in response times from a block of random to a block of sequenced trials), the dyslexic group did not. These data suggest that implicit motor learning deficits may underlie the laborious learning seen in developmental dyslexia. Because garden-variety poor readers were as able as control children to use the sequence cues to achieve better task performance, there may be differences in how garden-variety poor readers and dyslexic children acquire knowledge. This has important implications for remediation programs that are specific to children with dyslexia and for distinguishing among varieties of poor readers. C1 [Stoodley, Catherine J.; Ray, Nicola J.; Jack, Anthea; Stein, John F.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England. RP Stoodley, CJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cognit Behav Neurol Grp, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM cstoodley@partners.org RI Stoodley, Catherine/P-2081-2016; OI Stoodley, Catherine/0000-0003-2629-0213; Ray, Nicola/0000-0001-9645-0812 FU University of Oxford; Garfield Weston and Dyslexia Research Trusts FX We would like to thank the schools and children who participated in this stud; and members of the Dyslexia Research Trust clinic for aiding in data acquisition. C.J. Stoodley was funded by a Goodger/Schorstein Research Fellowship from the University of Oxford and by the Garfield Weston and Dyslexia Research Trusts. NR 52 TC 22 Z9 23 U1 1 U2 15 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-702-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1145 BP 173 EP 183 DI 10.1196/annals.1416.003 PG 11 WC Education, Special; Linguistics; Multidisciplinary Sciences; Neurosciences SC Education & Educational Research; Linguistics; Science & Technology - Other Topics; Neurosciences & Neurology GA BIQ96 UT WOS:000262097100012 PM 19076396 ER PT J AU Chen, YB Spitzer, TR AF Chen, Y-B Spitzer, T. R. TI Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors SO LEUKEMIA LA English DT Review DE reduced-intensity transplantation; nonmyeloablative transplantation; alternative donors; matched unrelated donors; haploidentical donors; umbilical cord blood ID UMBILICAL-CORD BLOOD; BONE-MARROW-TRANSPLANTATION; KIR LIGAND INCOMPATIBILITY; ACUTE MYELOGENOUS LEUKEMIA; MATCHED UNRELATED DONOR; REFRACTORY HEMATOLOGIC MALIGNANCIES; HLA-IDENTICAL SIBLINGS; HEMATOPOIETIC TRANSPLANTS; CONDITIONING REGIMEN; PREPARATIVE REGIMEN AB The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options as well. The most experience thus far has been with MUD donors, mostly attributed to the development of allele-specific DNA-based HLA-typing methods. The biggest drawback remains the significant delay needed to locate a donor. Haploidentical donors exist for almost all patients, and offer the convenience of a living related donor. However, significant rates of graft-versus-host disease (GVHD) and other toxicities continue to complicate such HLA mismatching. UCB is the most recent option for source of stem cells. Frozen cord blood units can be acquired almost immediately and are able to safely traverse 1 or 2-HLA antigen mismatch barriers. The experience with UCB has been limited by the low cell dose, although recent innovations are attempting to overcome this. In this review, we summarize the current experience and knowledge with alternative donors as stem cell sources for reduced-intensity transplantation. C1 [Chen, Y-B; Spitzer, T. R.] Massachusetts Gen Hosp, Hematol Oncol Unit, Bone Marrow Transplant Program, Div Bone Marrow Transplantat, Boston, MA 02114 USA. RP Spitzer, TR (reprint author), Massachusetts Gen Hosp, Hematol Oncol Unit, Bone Marrow Transplant Program, Div Bone Marrow Transplantat, 55 Fruit St,O Emerson Pl, Boston, MA 02114 USA. EM tspitzer@partners.org NR 95 TC 13 Z9 13 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD JAN PY 2008 VL 22 IS 1 BP 31 EP 41 DI 10.1038/sj.leu.2404932 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA 251QL UT WOS:000252388400006 PM 17805330 ER PT J AU Stubbs, MC Kim, YM Krivtsov, AV Wright, RD Feng, Z Agarwal, J Kung, AL Armstrong, SA AF Stubbs, M. C. Kim, Y. M. Krivtsov, A. V. Wright, R. D. Feng, Z. Agarwal, J. Kung, A. L. Armstrong, S. A. TI MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment SO LEUKEMIA LA English DT Article DE MLL; FLT3; imaging; murine models ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; MLL REARRANGEMENTS; TYROSINE KINASE; BCR-ABL; HEMATOLOGICAL MALIGNANCIES; MYELOPROLIFERATIVE DISEASE; CHROMOSOME TRANSLOCATIONS; GENE AB Human leukemias harboring chromosomal translocations involving the mixed lineage leukemia ( MLL, HRX, ALL-1) gene possess high-level expression, and frequent activating mutations of the receptor tyrosine kinase FLT3. We used a murine bone marrow transplant model to assess cooperation between MLL translocation and FLT3 activation. We demonstrate that MLL-AF9 expression induces acute myelogenous leukemia (AML) in approximately 70 days, whereas the combination of MLL-AF9 and FLT3-ITD does so in less than 30 days. Secondary transplantation of splenic cells from diseased mice established that leukemia stem cells are present at a very high frequency of approximately 1: 100 in both diseases. Importantly, prospectively isolated granulocyte macrophage progenitors (GMPs) coinfected with MLL-AF9 and FLT3-ITD give rise to a similar AML, with shorter latency than from GMP transduced with MLL-AF9 alone. Cooperation between MLL-AF9 and FLT3-ITD was further verified by real-time assessment of leukemogenesis using noninvasive bioluminescence imaging. We used this model to demonstrate that MLL-AF9/FLT3-ITD-induced leukemias are sensitive to FLT3 inhibition in a 2-3 week in vivo assay. These data show that activated FLT3 cooperates with MLL-AF9 to accelerate onset of an AML from whole bone marrow as well as a committed hematopoietic progenitor, and provide a new genetically defined model system that should prove useful for rapid assessment of potential therapeutics in vivo. C1 [Stubbs, M. C.; Kim, Y. M.; Krivtsov, A. V.; Feng, Z.; Agarwal, J.; Kung, A. L.; Armstrong, S. A.] Childrens Hosp, Karp Family Res Labs, Div Hematol Oncol, Boston, MA 02215 USA. [Wright, R. D.; Kung, A. L.; Armstrong, S. A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kung, A. L.; Armstrong, S. A.] Harvard Univ, Sch Med, Boston, MA USA. RP Armstrong, SA (reprint author), Childrens Hosp, Karp Family Res Labs, Div Hematol Oncol, 1 Blackfan Circle, Boston, MA 02215 USA. EM Scott.Armstrong@childrens.harvard.edu OI Kung, Andrew/0000-0002-9091-488X FU NCI NIH HHS [CA92551, K08 CA092551, K08 CA092551-04, K08 CA092551-05] NR 42 TC 58 Z9 61 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2008 VL 22 IS 1 BP 66 EP 77 DI 10.1038/sj.leu.2404951 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA 251QL UT WOS:000252388400010 PM 17851551 ER PT J AU Buske, C Gisselbrecht, C Gribben, J Letai, T McLaughlin, P Wilson, W AF Buske, Christian Gisselbrecht, Christian Gribben, John Letai, Tony McLaughlin, Peter Wilson, Wyndham TI Refining the treatment of follicular lymphoma SO LEUKEMIA & LYMPHOMA LA English DT Article; Proceedings Paper CT 6th International Workshop on Non-Hodgkin Lymphoma CY NOV 16-17, 2007 CL Boston, MA DE follicular lymphoma; rituximab; FLIPI; biological factors; novel treatments ID LARGE-CELL LYMPHOMA; INTERNATIONAL PROGNOSTIC INDEX; NON-HODGKINS-LYMPHOMA; TERM-FOLLOW-UP; STUDY-GROUP EXPERIENCE; REGULATORY T-CELLS; STAGE-I; LOW-GRADE; PROLONGS SURVIVAL; FRONT-LINE AB Many effective treatments are currently available for patients with follicular lymphoma (FL). However, given the heterogeneity of this disease, identifying the most beneficial treatment for an individual patient remains a challenge, although clinical, genetic and biological features can all potentially be used to refine therapies in individual cases. The Follicular Lymphoma international prognostic index (FLIPI) algorithm is a valuable prognostic tool for risk categorisation. Despite its current limitations, further investigation will help to develop the role of FLIPI in treatment decision-making, and will increase its value in identifying the optimal therapy for individuals. Biological factors such as bulky disease, over-expression of Bcl-2, or histological grade can help to identify patients at high risk of relapse, and distinguish between the benefits of early intervention vs. a watch-and-wait policy in early-stage FL. The tumor microenvironment plays an important role in the development of FL, and identification of biological and genetic markers could help clinicians determine the prognosis of individual patients. Although much work remains to be done, a greater understanding of the biology of FL will lead to the development of novel therapeutic targets and therapies, bringing individualised treatment a step closer. C1 [Buske, Christian] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany. [Gisselbrecht, Christian] Hop St Louis, Inst Hematol, Paris, France. [Gribben, John] Barts & Royal London Sch Med, Inst Canc, London, England. [Letai, Tony] Dana Farber Canc Inst, Boston, MA 02115 USA. [McLaughlin, Peter] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA. [Wilson, Wyndham] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. RP Buske, C (reprint author), Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany. EM christian.buske@med.uni-muenchen.de NR 58 TC 7 Z9 8 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 SU 1 BP 18 EP 26 DI 10.1080/10428190802311409 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 354NI UT WOS:000259645900004 PM 18821429 ER PT J AU Hammond, SP Baden, LR AF Hammond, Sarah P. Baden, Lindsey R. TI Antibiotic prophylaxis for patients with acute leukemia SO LEUKEMIA & LYMPHOMA LA English DT Review DE clinical results; marrow and stem cell transplantation; myeloid leukemias and dysplasias; lymphoid leukemia ID RESISTANT ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE INFECTIONS; EMPIRICAL ANTIMICROBIAL THERAPY; NEUTROPENIC CANCER-PATIENTS; VIRIDANS GROUP STREPTOCOCCI; BLOOD-STREAM INFECTIONS; FLUOROQUINOLONE RESISTANCE; ANTIBACTERIAL PROPHYLAXIS; BACTERIAL-INFECTIONS; DOUBLE-BLIND AB Chemotherapy directed at acute leukemia (AL) causes predictable periods of neutropenia during which patients are at significant risk for bacterial infection and subsequent infection-related death. In an effort to diminish this risk, several studies have assessed the utility of prophylactic antibiotics during the neutropenic period. While prophylactic antibiotics have been associated with a decrease in the incidence of fever and bacterial infection, no placebo-controlled randomized trial has found a decrease in mortality. In addition, delayed adverse consequences associated with prophylaxis have emerged including increases in both colonization and infection with antimicrobial-resistant and unusual pathogens like quinolone-resistant Escherichia coli. To determine who would benefit most from prophylaxis, the immediate benefits including reduction in fever and infection must be balanced with the potential for emergence of resistant pathogens in this population. C1 [Hammond, Sarah P.; Baden, Lindsey R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Div Infect Dis, Boston, MA 02115 USA. RP Hammond, SP (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Div Infect Dis, 75 Francis St,PBBA 4, Boston, MA 02115 USA. EM shammond2@partners.org NR 59 TC 11 Z9 12 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 2 BP 183 EP 193 DI 10.1080/10428190701769673 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA 256WN UT WOS:000252760700005 PM 18231904 ER PT J AU Richardson, P Mitsiades, C Colson, K Reilly, E Mcbride, L Chiao, J Sun, L Ricker, J Rizvi, S Oerth, C Atkins, B Fearen, I Anderson, K Siegel, D AF Richardson, Paul Mitsiades, Constantine Colson, Kathleen Reilly, Eileen Mcbride, Laura Chiao, Judy Sun, Linda Ricker, Justin Rizvi, Syed Oerth, Carol Atkins, Barbara Fearen, Ivy Anderson, Kenneth Siegel, David TI Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma SO LEUKEMIA & LYMPHOMA LA English DT Article DE histone deacetylase inhibitor; multiple myeloma; SAHA; suberoylanilide hydroxamic acid; vorinostat; zolinza ID HISTONE DEACETYLASE INHIBITION; T-CELL LYMPHOMA; ADVANCED CANCER; BORTEZOMIB; APOPTOSIS AB A Phase I trial (NCT00109109) of oral vorinostat 200, 250 or 300mg twice daily for 5 days/week/4-week cycle or 200, 300, or 400mg twice daily for 14 days/3-week cycle until progressive disease or intolerable toxicity was conducted. Patients with measurable, relapsed/refractory multiple myeloma were eligible. The objectives were to determine maximum tolerated doses (MTDs) and assess activity and safety. Thirteen patients (median age, 63 years; median prior therapies, 3) were enrolled. MTDs were not determined due to early study termination by sponsor decision. One patient (250mg twice daily 5 days/week) developed dose-limiting toxicity (DLT; grade 3 fatigue). There were no other DLTs and the maximum administered doses were 250mg twice daily for 5 days/week/4-week cycle and 200mg twice daily for 14 days/3-week cycle. Drug-related adverse experiences included fatigue, anorexia, dehydration, diarrhea, and nausea and were mostly grade <= 2. Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease, demonstrating modest single-agent activity in relapsed/refractory multiple myeloma. C1 [Richardson, Paul; Mitsiades, Constantine; Colson, Kathleen; Anderson, Kenneth] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Reilly, Eileen; Mcbride, Laura; Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Chiao, Judy; Sun, Linda; Ricker, Justin; Rizvi, Syed; Oerth, Carol; Fearen, Ivy] Merck Res Labs, Gwynedd, PA USA. RP Richardson, P (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St Dana 1B02, Boston, MA 02115 USA. EM paul_richardson@dfci.harvard.edu NR 16 TC 124 Z9 128 U1 1 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 3 BP 502 EP 507 DI 10.1080/10428190701817258 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 267MO UT WOS:000253513300018 PM 18297527 ER PT J AU Friedberg, J Jacobsen, E Neuberg, D Kutok, J Munoz, O Boussiotis, V Reynolds, H Fisher, D Szot, A Van den Abbeele, A Freedman, A AF Friedberg, Jonathan Jacobsen, Eric Neuberg, Donna Kutok, Jeffrey Munoz, Olivier Boussiotis, Vassiliki Reynolds, Hazel Fisher, David Szot, Agnieszka Van den Abbeele, Annick Freedman, Arnold TI Targeting the follicular lymphoma microenvironment through blockade of TNF alpha with etanercept SO LEUKEMIA & LYMPHOMA LA English DT Article DE lymphoma and Hodgkin disease; chemotherapeutic; approaches; dendritic cell biology; immunobiology ID NECROSIS FACTOR THERAPY; NON-HODGKINS-LYMPHOMAS; RHEUMATOID-ARTHRITIS; GERMINAL-CENTERS; DENDRITIC CELLS; B-CELLS; BEVACIZUMAB; SURVIVAL; CANCER; LYMPHOCYTES AB Follicular dendritic cells (FDCs) support the survival of follicular lymphoma (FL). Tumor necrosis factor alpha (TNF alpha) is overexpressed by FL cells and is critical in the development and maintenance of FDCs. We hypothesised that TNF alpha might be an ideal therapeutic target. We treated seven patients with relapsed/refractory FL with 8 weeks of etanercept, 25mg SC on day 1 and 4 of each week. Patients without progression received 16 additional weeks of etanercept. All patients completed at least 8 weeks of etanercept and two patients completed 24 weeks. At the 8 week evaluation five patients had SD. Of the five with SD, two progressed at 9 and 12 weeks on therapy and the remaining three progressed between 12 and 24 weeks after initiating therapy. Minimal toxicity was observed. FDG-PET imaging demonstrated decreases in standardized uptake value (SUV) following treatment with etanercept in five patients. Further studies in FL targeting the microenvironment in conjunction with standard cytotoxic therapy are warranted. C1 [Jacobsen, Eric; Neuberg, Donna; Munoz, Olivier; Boussiotis, Vassiliki; Reynolds, Hazel; Fisher, David; Szot, Agnieszka; Van den Abbeele, Annick; Freedman, Arnold] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02114 USA. [Friedberg, Jonathan] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Kutok, Jeffrey] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Freedman, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02114 USA. EM arnold_freedman@dfci.harvard.edu FU NCI NIH HHS [CA-102216, R21CA099324] NR 30 TC 8 Z9 8 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 5 BP 902 EP 909 DI 10.1080/10428190801950033 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 298LI UT WOS:000255688800016 PM 18464109 ER PT J AU Leleu, X Moreau, AS Weller, E Roccaro, AM Coiteux, V Manning, R Nelson, M Leduc, R Robu, D Dupire, S Hatjiharissi, E Burwick, N Darre, S Hennache, B Treon, SP Facon, T Gertz, MA Ghobrial, IM AF Leleu, Xavier Moreau, Anne-Sophie Weller, Edie Roccaro, Aldo M. Coiteux, Valerie Manning, Robert Nelson, Marybeth Leduc, Renee Robu, Daniela Dupire, Sophie Hatjiharissi, Evdoxia Burwick, Nicholas Darre, Stephane Hennache, Bernadette Treon, Steven P. Facon, Thierry Gertz, Morie A. Ghobrial, Irene M. TI Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia SO LEUKEMIA & LYMPHOMA LA English DT Article DE Waldenstrom macroglobulinemia; serum-free light chain; tumor burden marker ID MULTIPLE-MYELOMA; INTERNATIONAL WORKSHOP; DIAGNOSIS; RECOMMENDATIONS; AMYLOIDOSIS; MANAGEMENT AB The serum IgM level has been utilised as a marker of tumor progression and to assess response to therapy in patients with Waldenstrom macroglobulinemia (WM). However, there are many limitations to the IgM protein level. The objective of this study was to evaluate the association of known tumor burden markers and prognostic factors with serum free light chain (sFLC) in 98 patients with WM. We demonstrated that sFLC measurement accurately differentiated IgM-MGUS compared with WM reflecting a measurement of tumor burden. In univariate and multivariate analysis, median sFLC at the cut-off at 60 mg/L was higher for WM patients with low hemoglobin and high beta 2M, when we applied the WM-IPSS cut-offs, but showed no association with IgM level. This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients. C1 [Leleu, Xavier; Moreau, Anne-Sophie; Roccaro, Aldo M.; Manning, Robert; Nelson, Marybeth; Leduc, Renee; Hatjiharissi, Evdoxia; Burwick, Nicholas; Treon, Steven P.; Ghobrial, Irene M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Leleu, Xavier; Moreau, Anne-Sophie; Roccaro, Aldo M.; Manning, Robert; Nelson, Marybeth; Leduc, Renee; Hatjiharissi, Evdoxia; Burwick, Nicholas; Treon, Steven P.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA. [Leleu, Xavier; Moreau, Anne-Sophie; Coiteux, Valerie; Robu, Daniela; Dupire, Sophie; Darre, Stephane; Facon, Thierry] CHRU, Serv Malad Sang, Lille, France. [Weller, Edie] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Weller, Edie] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hennache, Bernadette] CHRU, Biochim Lab, Lille, France. [Gertz, Morie A.] Mayo Clin, Div Hematol, Mayo Clin Coll Med, Rochester, MN USA. RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 1B127, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu RI FACON, THIERRY/M-9736-2014; OI FACON, THIERRY/0000-0001-7705-8460; Roccaro, Aldo/0000-0002-1872-5128 NR 15 TC 27 Z9 28 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 6 BP 1104 EP 1107 DI 10.1080/10428190802074619 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 313PS UT WOS:000256753100014 PM 18452095 ER PT J AU Vallet, S Palumbo, A Raje, N Boccadoro, M Anderson, KC AF Vallet, Sonia Palumbo, Antonio Raje, Noopur Boccadoro, Mario Anderson, Kenneth C. TI Thalidomide and lenalidomide: Mechanism-based potential drug combinations SO LEUKEMIA & LYMPHOMA LA English DT Review DE lenalidomide; thalidomide; multiple myeloma; bone marrow microenvironment; combination therapies ID MULTIPLE-MYELOMA CELLS; NEWLY-DIAGNOSED MYELOMA; NECROSIS-FACTOR-ALPHA; RESISTANCE CAM-DR; CD8(+) T-CELLS; BONE-MARROW; TNF-ALPHA; IN-VIVO; CYTOKINE PRODUCTION; OSTEOLYTIC LESIONS AB Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects. C1 [Vallet, Sonia; Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA USA. [Vallet, Sonia; Raje, Noopur; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Palumbo, Antonio; Boccadoro, Mario] Univ Turin, Dipartimento Med & Oncol Sperimentale, Cattedra Ematol, Turin, Italy. RP Vallet, S (reprint author), Massachusetts Gen Hosp, Dept Hematol Oncol, 55 Fruit St, Boston, MA 02114 USA. EM svallet@partners.org FU NCI NIH HHS [R0-1 CA 50947, IP50 CA10070-01]; PHS HHS [P0-1 78378] NR 78 TC 54 Z9 58 U1 1 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 7 BP 1238 EP 1245 DI 10.1080/10428190802005191 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 322AS UT WOS:000257348200007 PM 18452080 ER PT J AU Wetzler, M Donohue, KA Odenike, OM Feldman, EJ Hurd, DD Stone, RM Westerfelt, P Bloomfield, CD Larson, RA AF Wetzler, Meir Donohue, Kathleen A. Odenike, Olatoyosi M. Feldman, Eric J. Hurd, David D. Stone, Richard M. Westerfelt, Peter Bloomfield, Clara D. Larson, Richard A. TI Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cancer and leukemia group B study 10107 SO LEUKEMIA & LYMPHOMA LA English DT Article DE chronic myeloid leukemia; imatinib mesylate; resistance; oblimersen; bcl-2 ID CHRONIC MYELOGENOUS LEUKEMIA; BCL-2 ANTISENSE; CYTOGENETIC RESPONSES; SODIUM; SENSITIVITY; EXPRESSION; DASATINIB; FAILURE; TRIAL; CELLS AB The CALGB studied the feasibility and effectiveness of adding oblimersen (G3139; Genasense) to imatinib mesylate (IM) in imatinib-resistant chronic phase chronic myeloid leukemia (CML) patients. We hypothesised that IM resistant CML cells are no longer being driven to proliferate by Bcr/Abl activity alone. Instead, the anti-apoptotic protein Bcl-2 would regulate one of the pathways controlling growth and/or viability. Thus, blocking both Bcr/Abl and Bcl-2 simultaneously would result in hematologic and cytogenetic improvement. Oblimersen was administered via continuous intravenous infusion over 10 days every 21 days, along with daily IM. Doses of both drugs were escalated in 3 cohorts; the initial dose of IM was 600 mg/day. Response was defined as a decrease by >30% in the percentage of t(9;22) metaphase cells. Twelve patients had primary and nine had secondary imatinib resistance. Ten patients received 4 mg/kg/day oblimersen/600 mg IM, six patients received 7 mg/kg/day oblimersen/600 mg IM and five patients received 7 mg/kg/day oblimersen/800 mg IM. Only two (9.5%) patients achieved a decrease by >30% in the percentage of t(9;22) metaphase cells. Although the combination of oblimersen and IM is safe and feasible, we did not observe clinical benefit in these patients with imatinib-resistant CML using these doses and schedule. C1 [Wetzler, Meir] Roswell Pk Canc Inst, Dept Med, Leukemia Sect, Buffalo, NY 14263 USA. [Donohue, Kathleen A.] Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC USA. [Odenike, Olatoyosi M.; Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Feldman, Eric J.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Hurd, David D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Westerfelt, Peter] Univ Massachusetts, Sch Med, Boston, MA 02125 USA. [Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. RP Wetzler, M (reprint author), Roswell Pk Canc Inst, Dept Med, Leukemia Sect, Elm & Carlton St, Buffalo, NY 14263 USA. EM meir.wetzler@roswellpark.org OI Larson, Richard/0000-0001-9168-3203 FU NCI NIH HHS [CA32291, CA31946, U10 CA032291, U10 CA031946, CA03927, CA101140, CA77658, U10 CA003927, U10 CA077658, CA07968, CA02599, CA37135, CA41287, U10 CA033601, U10 CA041287, U10 CA101140, CA33601] NR 18 TC 10 Z9 10 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 7 BP 1274 EP 1278 DI 10.1080/10428190802043887 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 322AS UT WOS:000257348200011 PM 18452072 ER PT J AU Abel, GA Friese, CR Magazu, LS Richardson, LC Fernandez, ME De Zengotita, JJ Earle, CC AF Abel, Gregory A. Friese, Christopher R. Magazu, Lysa S. Richardson, Lisa C. Fernandez, Maria E. De Zengotita, Juan Jaime Earle, Craig C. TI Delays in referral and diagnosis for chronic hematologic malignancies: A literature review SO LEUKEMIA & LYMPHOMA LA English DT Article DE hematologic malignancy; delays; diagnosis; referral; primary care provider; lymphoma and Hodgkin disease; neoplasia; myeloid leukemias and dysplasias ID FAMILY PHYSICIANS KNOWLEDGE; CHRONIC MYELOID-LEUKEMIA; PRIMARY-CARE PHYSICIANS; BREAST-CANCER; COLORECTAL-CANCER; MULTIPLE-MYELOMA; NATIONAL-SURVEY; NHS-PATIENTS; STAGE; LYMPHOMA AB To better understand the extent of diagnostic and referral delays from primary care providers (PCPs) for chronic hematologic malignancies, causes of these delays, and their possible effects on cancer outcomes, an extensive review of the literature was performed. Over 50 studies were reviewed, including many that concern delays in referral and diagnosis for solid tumors, as there was only sparse literature on delays specific to the liquid tumors. Delays for some chronic hematologic malignancies have been documented, mainly in centralized health care systems. Possible reasons for delays include PCPs' lack of exposure to hematologic malignancies, limited knowledge of associated signs and symptoms, and a reliance on patient symptoms to prompt referral (as opposed to signs and screening). Patient characteristics such as age, gender and race-ethnicity are also likely to play a role, although it is unclear if these exert their effect primarily via patient or provider mechanisms. Unfortunately, the outcomes associated with such delays are largely unreported, possibly because delay is complex to define and difficult to measure. C1 [Abel, Gregory A.; Friese, Christopher R.; Magazu, Lysa S.; Earle, Craig C.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Med Oncol, Boston, MA 02115 USA. [Richardson, Lisa C.] Ctr Dis Control, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Fernandez, Maria E.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [De Zengotita, Juan Jaime] Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA. RP Abel, GA (reprint author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Med Oncol, 44 Binney St,Smith 271, Boston, MA 02115 USA. EM gregory_abel@dfci.harvard.edu RI Friese, Christopher/D-2097-2013 OI Friese, Christopher/0000-0002-2281-2056 NR 59 TC 9 Z9 9 U1 1 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 7 BP 1352 EP 1359 DI 10.1080/10428190802124281 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 322AS UT WOS:000257348200021 PM 18604724 ER PT J AU Oton, AB Wang, H Leleu, X Melhem, MF George, D Lacasce, A Foon, K Ghobrial, IM AF Oton, Ana B. Wang, Hong Leleu, Xavier Melhem, Mona F. George, Diane Lacasce, Ann Foon, Kenneth Ghobrial, Irene M. TI Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant SO LEUKEMIA & LYMPHOMA LA English DT Article DE post-transplant proliferative disorders; prognostic factors; organ-solid transplantation; Bcl-2 ID B-CELL LYMPHOMA; SINGLE-CENTER EXPERIENCE; EPSTEIN-BARR-VIRUS; RITUXIMAB; IDENTIFICATION; CHEMOTHERAPY; RECIPIENTS; DISEASE AB We sought to determine the clinical and immunohistopathological prognostic factors for overall survival (OS) in adult patients with post-transplant lymphoproliferative disorders (PTLDs). Eighty-four patients diagnosed with PTLDs between 1980 and 2004 at the University of Pittsburgh Medical Center were identified. Immunohistochemical staining was performed on tumor tissue at the time of diagnosis for the following proteins: Bcl-2, Bcl-6, c-myc and p53. The median survival for all patients was 20.8 months, 95% CI: (7.4-77.6). On univariate analysis for OS, the following poor prognostic factors were identified: age at transplant 60 years (p=0.024), multiorgan transplant (p=0.019), ECOG > 2 (p < 0.0001), grafted organ involvement (p < 0.0001), extranodal disease (p = 0.011), early ( < 1 year) PTLDs (p < 0.0001), stage IV (p = 0.0017), EBV positive (p = 0.012) and elevated white blood count (p = 0.010). Good prognostic factors included ECOG < 2 (p < 0.0001), late ( > 1 year) PTLDs (p = 0.002), early stage at diagnosis (stages I and II, p = 0.005), nodal disease (p = 0.0053), monomorphic disease (0.0034), initial immunosuppression reduction (p = 0.0015) and use of rituximab (p = 0.045). Bcl-2 but not Bcl-6, c-myc, or p53 correlated with poor survival, p = 0.0036. This study identifies new clinical and pathological markers for poor survival in PTLDs. C1 [Leleu, Xavier; Lacasce, Ann; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Oton, Ana B.; Foon, Kenneth] Univ Pittsburgh, Inst Canc, Dept Internal Med, Div Hematol Oncol, Pittsburgh, PA USA. [Wang, Hong] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Melhem, Mona F.; George, Diane] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA USA. [Melhem, Mona F.; George, Diane] VAPHS, Pittsburgh, PA USA. RP Ghobrial, IM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 548A, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu OI Wang, Hong/0000-0003-0477-2908 NR 25 TC 13 Z9 14 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 9 BP 1738 EP 1744 DI 10.1080/10428190802239162 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 348WJ UT WOS:000259240500016 PM 18798108 ER PT J AU Rahemtullah, A Harris, NL Dorn, ME Preffer, FI Hasserjian, RP AF Rahemtullah, Aliyah Harris, Nancy Lee Dorn, Michelle E. Preffer, Frederic I. Hasserjian, Robert P. TI Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma SO LEUKEMIA & LYMPHOMA LA English DT Article; Proceedings Paper CT 10th International Conference on Malignant Lymphoma CY JUN 04-07, 2008 CL Lugano, SWITZERLAND DE Lymphoma and Hodgkin disease; cytokine and chemokine biology; the thymus and the development of t lymphocytes; lymphocytes ID FINE-NEEDLE-ASPIRATION; FLOW-CYTOMETRY; PROGRESSIVE TRANSFORMATION; GERMINAL-CENTERS; LYMPHOPROLIFERATIVE DISORDERS; PERIPHERAL-BLOOD; CYNOMOLGUS MONKEYS; DISTINCT SUBSET; POTENTIAL ROLE; MEMORY CELLS AB Hodgkin lymphomas are characterised by the presence of rare malignant cells in a background of non-neoplastic inflammatory cells. Flow cytometric analysis of involved tissues is generally not thought to be useful in establishing the diagnosis, because of the small number of neoplastic cells present. However, two recent studies describing a CD4+CD8+ (double-positive) T-cell population in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) suggest that flow cytometry could play a role in the diagnosis of this Hodgkin lymphoma subtype. In addition, awareness of this unusual T-cell population is important in avoiding a misdiagnosis of a T-cell neoplasm. Although the function of CD4+CD8+ T-cells in NLPHL is not known, studies of phenotypically similar cells in other settings point to a reactive or regulatory role. CD4+CD8+ T-cells have also been identified in the benign entity progressive transformation of germinal centres (PTGC), suggesting a possible relationship between NLPHL and PTGC. C1 [Rahemtullah, Aliyah] Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Rahemtullah, A (reprint author), Massachusetts Gen Hosp, Dept Pathol, James Homer Wright Pathol Labs, 55 Fruit St,Warren 219, Boston, MA 02114 USA. EM arahemtullah@partners.org NR 48 TC 13 Z9 13 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PY 2008 VL 49 IS 10 BP 1870 EP 1878 DI 10.1080/10428190802308728 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 364HJ UT WOS:000260326500008 PM 18949610 ER PT J AU Martins, PNA Theruvath, TP Neuhaus, P AF Martins, Paulo N. A. Theruvath, Tom P. Neuhaus, Peter TI Rodent models of partial hepatectomies SO LIVER INTERNATIONAL LA English DT Review DE hepatectomy; microsurgery; rat; segmentectomy; technique ID DONOR LIVER-TRANSPLANTATION; REGENERATING RAT LIVER; HEPATIC-FAILURE; DEOXYRIBONUCLEIC ACID; CELL PROLIFERATION; MOUSE; MICE; METASTASES; RESECTION; VOLUME AB Small rodents are the most used experimental models in liver surgical research. Hepatic resections in rodents are commonly performed to study liver regeneration, acute liver failure, hepatic metastasis, hepatic function, 'small-for-size' transplantation and metabolic response to injury. Most resections require only basic skills, are fast, reliable and highly reproducible. The partial hepatectomy technique in rodents can be improved by microsurgical techniques, which permit individualized dissection and ligature of the vascular and biliary branches with minimal operative morbidity and mortality. This is particularly relevant for murine models of liver resection. However, it requires advanced microsurgical skills. Here, we review the models, surgical techniques, results and limitations of partial liver resections in rodent models. We also reported for the first time segmentectomies of the median lobe in rodent models. C1 [Martins, Paulo N. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr,Dept Surg, Boston, MA 02129 USA. [Theruvath, Tom P.] Med Univ S Carolina, Ctr Cel Deth Injury & Regenerat, Charleston, SC 29425 USA. [Neuhaus, Peter] Charite Univ Med Berlin, Virchow Clin, Dept Gen Visceral & Transplantat Surg, Berlin, Germany. RP Martins, PNA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr,Dept Surg, MGH East,Bldg 149-9019,13th St, Boston, MA 02129 USA. EM paulo.martins@tbrc.mgh.harvard.edu NR 51 TC 65 Z9 76 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1478-3223 J9 LIVER INT JI Liver Int. PD JAN PY 2008 VL 28 IS 1 BP 3 EP 11 DI 10.1111/j.1478-3231.2007.01628.x PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 242QH UT WOS:000251740000001 PM 18028319 ER PT J AU Jeffries, M Bruner, G Glenn, S Sadanandan, P Carson, CW Harley, JB Sawalha, AH AF Jeffries, M. Bruner, G. Glenn, S. Sadanandan, P. Carson, C. W. Harley, J. B. Sawalha, A. H. TI Sulpha allergy in lupus patients: a clinical perspective SO LUPUS LA English DT Article DE lupus; sulpha allergy; lymphopenia; pericarditis; serology ID SULFASALAZINE-INDUCED LUPUS; INDUCED AUTOIMMUNE ABNORMALITIES; RHEUMATIC DISEASE; REVISED CRITERIA; ERYTHEMATOSUS; ARTHRITIS; CLASSIFICATION AB Systemic lupus erythematosus is a chronic, relapsing autoimmune disease that can affect multiple organ systems. An increased prevalence of drug allergy has been reported in lupus patients compared with the general population. Using a cohort of 417 lupus patients, we found a history of sulpha allergy in 27.3% of patients. European-American lupus patients with sulpha allergy are about two times more likely to suffer from lymphopenia, two times more likely to have anti-Ro autoantibody, and four times less likely to have anti-nRNP antibodies compared with lupus patients without a reported sulpha allergy (P = 0.0075, 0.025, and 0.032, respectively). In African-American lupus patients, a history of sulpha allergy was associated with over three times increased odds of developing pericarditis (P = 0.005). C1 [Jeffries, M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA. [Jeffries, M.; Bruner, G.; Glenn, S.; Harley, J. B.; Sawalha, A. H.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. [Sadanandan, P.] Marion Gen Hosp, Marion, IN USA. [Carson, C. W.] Oklahoma Arthritis Ctr, Edmond, OK USA. [Harley, J. B.; Sawalha, A. H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Harley, J. B.; Sawalha, A. H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhse.edu FU NCRR NIH HHS [P20-RR015577, RR020143, P20-RR023477]; NIAID NIH HHS [AI31584, AI024717]; NIAMS NIH HHS [AR048940, AR42460, AR62277, P30 AR053483, AR0490084] NR 27 TC 6 Z9 6 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2008 VL 17 IS 3 BP 202 EP 205 DI 10.1177/0961203307086640 PG 4 WC Rheumatology SC Rheumatology GA 295KH UT WOS:000255472900007 PM 18372360 ER PT J AU Jeffries, M Hamadeh, F Aberle, T Glenn, S Kamen, DL Kelly, JA Reichlin, M Harley, JB Sawalha, AH AF Jeffries, M. Hamadeh, F. Aberle, T. Glenn, S. Kamen, D. L. Kelly, J. A. Reichlin, M. Harley, J. B. Sawalha, A. H. TI Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective SO LUPUS LA English DT Article DE anaemia; haemolysis; haemolytic; lupus ID REVISED CRITERIA; DISEASE-ACTIVITY; ERYTHEMATOSUS; CLASSIFICATION AB Systemic lupus erythematosus is a chronic autoimmune disease that can be associated with a variety of haematological manifestations. We identified 76 patients with haemolytic anaemia in a cohort of 1251 unrelated female lupus patients enrolled in our studies. The presence of the various American College of Rheumatology clinical criteria for lupus and serological specificities were determined in lupus patients with haemolytic anaemia and compared with a group of race-matched control lupus patients without haemolytic anaemia. Clinical data were obtained from medical records, and serological specificities were determined in our clinical immunology laboratory at OMRF. The presence of haemolytic anaemia in lupus patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR=2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015). These findings were independent of the presence of thrombocytopenia, which was approximately five times more common in lupus patients with haemolytic anaemia. Lupus patients with haemolytic anaemia were about 8 years younger than lupus patients without haemolytic anaemia at the time of disease onset (P = 0.000001). In the absence of thrombocytopenia, lupus patients with haemolytic anaemia were approximately two times more likely to have anti-dsDNA antibodies (P = 0.024). The presence of haemolytic anaemia is associated with a subset of lupus characterized by a younger age of disease onset, and a more severe disease with a higher likelihood of renal involvement, seizures, serositis and other cytopenias. C1 [Jeffries, M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA. [Jeffries, M.; Aberle, T.; Glenn, S.; Kelly, J. A.; Reichlin, M.; Harley, J. B.; Sawalha, A. H.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. [Hamadeh, F.; Reichlin, M.; Harley, J. B.; Sawalha, A. H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Kamen, D. L.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Reichlin, M.; Harley, J. B.; Sawalha, A. H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU National Center for Research Resources [P20-RR015577]; University of Oklahoma College of Medicine; Arthritis National Research Foundation (AHS); NIH [AR42460, AI024717, AI31584, AR62277, AR048940, AR0490084, RR020143]; Kirkland Scholar award; Alliance for Lupus Research; US Department of Veterans Affairs (JBH) FX This publication was made possible by NIH Grant Number P20-RR015577 from the National Center for Research Resources and by funding from the University of Oklahoma College of Medicine and the Arthritis National Research Foundation (AHS) and NIH Grants Number AR42460, AI024717, AI31584, AR62277, AR048940, AR0490084, RR020143, Kirkland Scholar award, Alliance for Lupus Research, and US Department of Veterans Affairs (JBH). NR 14 TC 17 Z9 21 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2008 VL 17 IS 8 BP 739 EP 743 DI 10.1177/0961203308090990 PG 5 WC Rheumatology SC Rheumatology GA 337MT UT WOS:000258440900007 PM 18625652 ER PT J AU Sestak, AL Nath, SK Kelly, JA Bruner, GR James, JA Harley, JB AF Sestak, A. L. Nath, S. K. Kelly, J. A. Bruner, G. R. James, J. A. Harley, J. B. TI Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race SO LUPUS LA English DT Article DE SLE; familial; sporadic; genders; race; clinical profile ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; 3 ETHNIC-GROUPS; IMMUNOLOGICAL FEATURES; GENOME SCAN; LINKAGE; COHORT; MANIFESTATIONS; SEX; AGE AB Few large, multi-ethnic studies have examined the clinical and serologic differences between familial and sporadic SLE patients. Understanding these similarities and differences is critical for interpreting genetic studies and developing therapeutic strategies. We compiled information on 1915 patients with SLE in a large multi-racial cohort, including general demographics, pedigree structure and the specific American College of Rheumatology (ACR) criteria met. One patient was randomly selected from each multiplex family for analysis, yielding 554 European-Americans (EA), 373 African-Americans (AA), 193 Hispanics (HI) and 237 patients of other of mixed races. When comparing familial and sporadic patients stratified by race, lupus erythematosus (LE) cells and arthritis were increased in white familial cases (P = 5.5 x 10(-6) and P = 0.028, respectively), but no other significant differences between familial and sporadic patients were found. We found that there were profound differences in clinical profiles between races. For example, photosensitivity and malar rash were decreased in AA (P = 1.3 x 10(-13) and 1.4 x 10(-7), respectively), whereas discoid rash was increased in AA (P = 5.5x10(-6)). EA had significantly less renal disease (P = 5.4x10(-13)), proteinuria (P = 4 x 10(-12)) and anti-Sm (P = 1.7 x 10(-12)) than AA or HI. We therefore, conclude that familial and sporadic onset patients may be treated similarly with respect to clinical and genetic studies. Lupus (2008) 17, 1004-1009. C1 [Sestak, A. L.; Nath, S. K.; Kelly, J. A.; Bruner, G. R.; James, J. A.; Harley, J. B.] Oklahoma Med Res Fdn, Dept Arthritis & Immunol, Oklahoma City, OK 73104 USA. [James, J. A.; Harley, J. B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Nath, S. K.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA. [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sestak, AL (reprint author), Oklahoma Med Res Fdn, Dept Arthritis & Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Andrea-Sestak@omrf.ouhsc.edu FU National Institute of Health [AR012253, AR012753, RR020143, AI024717, AR042460, AR048940, AR049084, AR049272, AI063622, AR053483]; The Alliance for Lupus Research; The Kirkland Foundation; US Department of Veterans Affairs FX We would like to thank the staff of the LFRR, as well as contributing physicians Dr Maria Ballesteros, Dr Craig Carson, Dr Luis R Espinoza, Dr Gary S Gilkeson, Dr Diane L Kamen, Dr David Karp, Dr Joan Merrill, Dr Michelle Petri, Dr Marilyn Punaro, Dr Ana Quintero, Dr Roberto Rivera and Dr Daniel Wallace. This study is supported by National Institute of Health (grants AR012253, AR012753, RR020143, AI024717, AR042460, AR048940, AR049084, AR049272, AI063622, AR053483), The Alliance for Lupus Research, The Kirkland Foundation and the US Department of Veterans Affairs. NR 25 TC 11 Z9 11 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PY 2008 VL 17 IS 11 BP 1004 EP 1009 DI 10.1177/0961203308091969 PG 6 WC Rheumatology SC Rheumatology GA 369UW UT WOS:000260720400007 PM 18852224 ER PT S AU Cho, H Ryu, S Ackerman, JL Song, YQ AF Cho, HyungJoon Ryu, Seungoh Ackerman, Jerome L. Song, Yi-Qiao BE Hurlimann, MD Song, YQ Fantazzini, P Bortolotti, V TI Characterization of Internal Magnetic Fields in Porous Media SO MAGNETIC RESONANCE IN POROUS MEDIA SE AIP Conference Proceedings LA English DT Proceedings Paper CT 9th International Bologna Conference on Magnetic Resonance in Porous Media CY JUL 13-17, 2008 CL Cambridge, MA SP Schlumberger, Chevron, Bruker, Magritek, Tecmag, T2 Biosystems, ABQMR, Westview Press, Springer, Alma Mater Studiorum, Univ Bologna, Varian, ACT NMR Solut, Spinlock, Nova Med, JS Res, Spectra Phys, Oxford Univ Press, Wiley VCH, Newport DE Internal gradients; susceptibility; diffusion; DDIF; porous media AB When a porous material is inserted in a uniform magnetic field, Spatially varying fields typically arise inside the pore space due to susceptibility contrasts between the solid matrix and the surrounding fluid. Susceptibility contrast is present in many porous media of interest, such as fluid filled rocks, cements, granular media, colloids and trabecular bones. The presence of non-uniform internal fields often interferes with NMR relaxation and diffusion measurements. Recently, die idea of utilizing internal gradients as a finger-print of pore geometry, for detailed pore structure information has been implemented and gave a new insight upon quantifying die Structure related properties of internal gradients in porous media.[1,2] In this contribution, we further investigate and develop new NMR methods utilizing susceptibility induced internal gradient. First, die strength and orientation of internal gradients are visualized using diffusion based MR sequence for a 2D phantom of packed cylindrical capillaries. Second, it is shown that the structure factor of die granular and porous media can be approximated by the pair correlation function of inhomogeneous internal magnetic field, followed by experimental and numerical demonstrations using a randomly packed glass beads phantom [3]. C1 [Cho, HyungJoon; Song, Yi-Qiao] Mem Sloan Kettering Canc Ctr, 1275 1st Ave, New York, NY 10065 USA. [Cho, HyungJoon; Ryu, Seungoh] Schlumberger Doll Res Ctr, Cambridge, MA 02139 USA. [Ackerman, Jerome L.; Song, Yi-Qiao] Massachusetts Gen Hosp, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Cho, H (reprint author), Mem Sloan Kettering Canc Ctr, 1275 1st Ave, New York, NY 10065 USA. EM choh@mskcc.org; sryu@slb.com; jerry@nmr.mgh.harvard.edu; ysong@nmr.mgh.harvard.edu OI Ackerman, Jerome/0000-0001-5176-7496 FU NIH [EB003869] FX The authors thank E. E. Sigmund, P. N. Sen, S. Ryu, P. Singer, M.D. Hurlimann, L. Zielinski, and D. L. Johnson for stimulating discussions. This work is supported in part by NIH (Grant No. EB003869). NR 6 TC 0 Z9 0 U1 0 U2 3 PU AMER INST PHYSICS PI MELVILLE PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA SN 0094-243X BN 978-0-7354-0612-4 J9 AIP CONF PROC PY 2008 VL 1081 BP 75 EP + PG 2 WC Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Physics; Radiology, Nuclear Medicine & Medical Imaging GA BIS75 UT WOS:000262472000019 ER PT S AU Hamblin, MR AF Hamblin, Michael R. BE Hamblin, MR Waynant, RW Anders, J TI The role of nitric oxide in low level light therapy - art. no. 684602 SO MECHANISMS FOR LOW-LIGHT THERAPY III SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy III CY JAN 20, 2008 CL San Jose, CA SP SPIE DE biostimulation; low level laser therapy; mitochondria; cytochrome C oxidase; nitric oxide ID CYTOCHROME-C-OXIDASE; HELIUM-NEON LASER; RAT-LIVER MITOCHONDRIA; EMITTING DIODE IRRADIATION; OXYGEN-CONSUMPTION; PROTEIN-KINASE; IN-VITRO; SMOOTH MUSCLES; ATP SYNTHESIS; RESPIRATION AB The use of low levels of visible or near infrared light for reducing pain, inflammation and edema, promoting healing of wounds, deeper tissues and nerves, and preventing tissue damage by reducing cellular apoptosis has been known for almost forty years since the invention of lasers. Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, LLLT remains controversial. Firstly the biochemical mechanisms underlying the positive effects are incompletely understood, and secondly the complexity of choosing amongst a large number of illumination parameters has led to the publication of a number of negative studies as well as many positive ones. This review will focus on the role of nitric oxide in the cellular and tissue effects of LLLT. Red and near-IR light is primarily absorbed by cytochrome c oxidase (unit four in the mitochondrial respiratory chain). Nitric oxide produced in the mitochondria can inhibit respiration by binding to cytochrome c oxidase and competitively displacing oxygen, especially in stressed or hypoxic cells. If light absorption displaced the nitric oxide and thus allowed the cytochrome c oxidase to recover and cellular respiration to resume, this would explain many of the observations made in LLLT. Why the effect is only seen in hypoxic, stressed or damaged cells or tissues? How the effects can keep working for some time (hours or days) post-illumination? Why increased NO concentrations are sometimes measured in cell culture or in animals? How blood flow can be increased? Why angiogenesis is sometimes increased after LLLT in vivo?. C1 [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 NR 78 TC 2 Z9 2 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7021-8 J9 P SOC PHOTO-OPT INS PY 2008 VL 6846 BP 84602 EP 84602 DI 10.1117/12.764918 PG 14 WC Medicine, General & Internal; Optics SC General & Internal Medicine; Optics GA BHQ15 UT WOS:000255357000001 ER PT J AU Ellinor, PT Yi, BA MacRae, CA AF Ellinor, Patrick T. Yi, B. Alexander MacRae, Calum A. TI Genetics of atrial fibrillation SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID OF-FUNCTION MUTATION; FAMILIAL AGGREGATION; KCNQ1 MUTATION; RISK; POLYMORPHISM; ASSOCIATION; LOCUS; SUSCEPTIBILITY; IDENTIFICATION; DETERMINANTS AB Recent studies of atrial fibrillation (AF) have identified mutations in a series of ion mutations; however, these channels appear to be relatively rare causes of AF Recent genome-wide association studies for AF have identified novel variants associated with the disease, although the mechanism of action for these variants remains unknown. Ultimately, a greater understanding of the genetics of AF should yield insights into novel pathways, therapeutic targets, and diagnostic testing for this common arrhythmia. C1 [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Ellinor, Patrick T.; MacRae, Calum A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Yi, B. Alexander; MacRae, Calum A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Ellinor, Patrick T.; Yi, B. Alexander; MacRae, Calum A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Ellinor, PT (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St, Boston, MA 02114 USA. EM pellinor@partners.org FU NHLBI NIH HHS [HL71632, R01 HL075431-03, HL75431, R01 HL075431, K23 HL071632, K23 HL071632-05] NR 40 TC 11 Z9 11 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JAN PY 2008 VL 92 IS 1 BP 41 EP + DI 10.1016/j.mcna.2007.09.005 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 246YU UT WOS:000252045100004 PM 18060996 ER PT J AU Reddy, VY AF Reddy, Vivek Y. TI Atrial fibrillation: Unanswered questions and future directions SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID PULMONARY VEIN ISOLATION; CIRCUMFERENTIAL ULTRASOUND ABLATION; RADIOFREQUENCY CATHETER ABLATION; ESOPHAGEAL FISTULA; BALLOON CATHETER; APPENDAGE SYSTEM; EXPERIENCE; STENOSIS; EFFICACY; IMAGE AB Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF. C1 [Reddy, Vivek Y.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Reddy, Vivek Y.] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA. [Reddy, Vivek Y.] Harvard Univ, Sch Med, Boston, MA USA. RP Reddy, VY (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB-109, Boston, MA 02114 USA. EM vreddy@partners.org NR 48 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JAN PY 2008 VL 92 IS 1 BP 237 EP + DI 10.1016/j.mena.2007.09.008 PG 23 WC Medicine, General & Internal SC General & Internal Medicine GA 246YU UT WOS:000252045100015 PM 18061007 ER PT J AU Finegold, SM AF Finegold, Sydney M. TI Therapy and epidemiology of autism-clostridial spores as key elements SO MEDICAL HYPOTHESES LA English DT Article ID SPECTRUM DISORDERS; ONSET AUTISM; CHILDREN; MICROFLORA; DIFFICILE; HANDS AB This manuscript reviews evidence indicating that intestinal, bacteria, specifically clostridia, may play a role in certain cases of autism and hypothesizes that the clostridial spores (which are notably resistant to antimicrobial agents and commonly used germicides) are involved in: (1) relapse in the autistic subject after a response to an agent such as oral vancomycin, after the drug is discontinued, (2) the unexplained increased incidence of autism in recent years, and (3) the unexplained increase in numbers of multiple cases in the same family. Hypothesis (1), if established as valid, would spur research to find well-tolerated and safe agents that could be given together with vancomycin (or other appropriate antimicrobial agent) to eliminate spores; this would revolutionize the therapeutic approach. Hypotheses (2) and (3) relate to widespread use of antimicrobial agents, poor hygiene in young autistic children, and difficulty in removing spores from the home environment. These tatter two hypotheses have major implications with regard to the epidemiology of this important and distressing disease and would encourage research into methods to eliminate clostridial spores from the home and other environments. (c) 2007 Elsevier Ltd. All rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111F, Los Angeles, CA 90073 USA. [Finegold, Sydney M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Finegold, Sydney M.] Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90073 USA. RP Finegold, SM (reprint author), W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sidfinegol@aol.com NR 13 TC 39 Z9 44 U1 0 U2 15 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2008 VL 70 IS 3 BP 508 EP 511 DI 10.1016/j.mehy.2007.07.019 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 268WI UT WOS:000253610300009 PM 17904761 ER PT J AU Bianchi, MT AF Bianchi, Matt T. TI Non-serotonin anti-depressant actions: Direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy SO MEDICAL HYPOTHESES LA English DT Article ID ANTIDEPRESSANT DRUGS; METABOLITE NORFLUOXETINE; REUPTAKE INHIBITORS; POTASSIUM CURRENTS; CALCIUM-CHANNELS; FLUOXETINE; DISORDERS; RECEPTORS; MECHANISMS; DISCOVERY AB Medical therapies targeting infections and neoplasms often involve a multi-pronged strategy sometimes called "rational poly-pharmacy", while other disorders such as Parkinson's disease emphasize targeting a single neurotransmitter system (dopamine). Although the clinical literature favors a "serotonin hypothesis" for depression, a growing basic science literature suggests that selective serotonin reuptake inhibitors (SSRIs) directly modulate neurotransmitter-and voltage-gated neuronal ion channels. In addition, biosynthesis of neurosteroids (themselves promiscuous ion channel modulators), is activated by SSRIs. These non-canonical effects are entirely independent of serotonin signaling, and they occur in the range of SSRI concentrations reported in the brains of treated patients (1-10 mu M). The protean impact of these diverse channel targets on neuronal excitability raises interesting and potentially testable hypotheses about depression pathophysiology and treatment. Specifically, emerging network theories are embracing the non-linearity and complexity of brain circuitry and its oscillatory behavior, with clinical correlations in psychiatry and neurology. Is it possible that certain brain dysfunction (such as depression) may be more amenable to a poly-pharmacy approach? The promiscuity of SSRIs suggests that such poly-pharmacy can emerge from a single agent. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bianchi, Matt T.] Brigham & Womens Hosp, Neurol Clin, Boston, MA 02114 USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Fruit St,Wang Ambulatory Ctr 8th Floor, Boston, MA 02114 USA. EM mtbianchi@partners.org NR 40 TC 24 Z9 25 U1 2 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PY 2008 VL 70 IS 5 BP 951 EP 956 DI 10.1016/j.mehy.2007.09.012 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 295BU UT WOS:000255450800011 PM 18031942 ER PT S AU Van Leemput, K Bakkour, A Benner, T Wiggins, G Wald, LL Augustinack, J Dickerson, BC Golland, P Fischl, B AF Van Leemput, Koen Bakkour, Akram Benner, Thomas Wiggins, Graham Wald, Lawrence L. Augustinack, Jean Dickerson, Bradford C. Golland, Polina Fischl, Bruce BE Metaxas, D Axel, L Fichtinger, G Szekely, G TI Model-Based Segmentation of Hippocampal Subfields in Ultra-High Resolution In Vivo MRI SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2008, PT I, PROCEEDINGS SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 11th International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI2008) CY SEP 06-10, 2008 CL New York, NY SP Rutgers Univ, New York Univ, Robarts Res Inst, NE Digital Inc, Medtron Inc, Siemens Corp Res, Philips, GE ID IMAGE REGISTRATION; BRAIN; ATLAS; FRAMEWORK AB Recent developments in MR data acquisition technology are starting to yield images that show anatomical features of the hippocampal formation at all unprecedented level of detail, providing the basis for hippocampal subfield measurement. Because of the role of the hippocampus in human memory and it's implication in a variety of disorders and conditions, the ability to reliably and efficiently quantify its subfields through in vivo neuroimaging is of great interest to both basic neuroscience and clinical research. In this paper, we propose a fully-automated method for segmenting the hippocampal subfields in ultra-high resolution MRI data. Using a Bayesian approach, we build a computational model of how images around the hippocampal area are generated, and use this model to obtain automated segmentations. We validate the proposed technique by comparing our segmentation results with corresponding manual delineations in ultra-high resolution MRI scans of five individuals. C1 [Van Leemput, Koen; Bakkour, Akram; Benner, Thomas; Wiggins, Graham; Wald, Lawrence L.; Augustinack, Jean; Dickerson, Bradford C.; Fischl, Bruce] Harvard Univ, Sch Med, MGH, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Cambridge, MA 02138 USA. [Van Leemput, Koen; Golland, Polina; Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Bakkour, Akram; Dickerson, Bradford C.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Boston, MA USA. [Wald, Lawrence L.; Fischl, Bruce] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Van Leemput, K (reprint author), Harvard Univ, Sch Med, MGH, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Cambridge, MA 02138 USA. RI Van Leemput, Koen/A-9197-2009; anzhi, yue/A-8609-2012; Wald, Lawrence/D-4151-2009 OI Van Leemput, Koen/0000-0001-6466-5309; FU NIH NCRR [P41-RR14075, R01 RR16594-01A1, NAC P41-RR13218]; BIRN Morphometric Project [BIRN002, U24 RR021382]; NIBIB [R01 EB001550, R01EB006758, NAMIC U54-EB005149]; NINDS [R01 NS052585-01, R01 NS051826]; MIND Institute; The Autism & Dyslexia Project - Ellison Medical Foundation FX Support for this research was provided in part by the NIH NCRR (P41-RR14075, R01 RR16594-01A1, NAC P41-RR13218, and the BIRN Morphometric Project BIRN002, U24 RR021382), the NIBIB (R01 EB001550, R01EB006758, NAMIC U54-EB005149), the NINDS (R01 NS052585-01, R01 NS051826) as well as the MIND Institute. Additional support was provided by The Autism & Dyslexia Project funded by the Ellison Medical Foundation. NR 19 TC 5 Z9 5 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-540-85987-1 J9 LECT NOTES COMPUT SC PY 2008 VL 5241 BP 235 EP + PG 3 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods; Imaging Science & Photographic Technology SC Computer Science; Imaging Science & Photographic Technology GA BIO76 UT WOS:000261373700029 ER PT S AU Meyer, C Manzke, R Peters, J Ecabert, O Kneser, R Reddy, VY Chan, RC Weese, J AF Meyer, Carsten Manzke, Robert Peters, Jochen Ecabert, Olivier Kneser, Reinhard Reddy, Vivek Y. Chan, Raymond C. Weese, Juergen BE Metaxas, D Axel, L Fichtinger, G Szekely, G TI Automatic Intra-operative Generation of Geometric Left Atrium/Pulmonary Vein Models from Rotational X-Ray Angiography SO MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2008, PT II, PROCEEDINGS SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 11th International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI2008) CY SEP 06-10, 2008 CL New York, NY SP Rutgers Univ, New York Univ, Robarts Res Inst, NE Digital Inc, Medtron Inc, Siemens Corp Res, Philips, GE ID LEFT ATRIUM SEGMENTATION; PULMONARY VEINS; FIBRILLATION; ABLATION AB Pre-procedural imaging with cardiac CT or MR has become popular for guiding complex electrophysiology procedures such as those used for atrial fibrillation ablation therapy. Electroanatomical mapping and ablation within the left atrium and pulmonary veins (LAPV) is facilitated using such data, however the pre-procedural anatomy can be quite different from that at the time of intervention. Recently, a method for intra-procedural LAPV imaging has been developed based on contrast-enhanced 3-D rotational X-ray angiography (3D RA). These intraprocedural data now create a compelling need for rapid and automated extraction of the LAPV geometry for catheter guidance. We present a new approach to automatic intra-procedural generation of LAPV surfaces from 3-D RA volumes. Using model-based segmentation, our technique is robust to imaging noise and artifacts typical of 3-D BA imaging, strongly minimizes the user interaction time required for segmentation, and eliminates intel-subject variability. Our findings in 33 patients indicate that intra-procedural LAPV surface models accurately represent the anatomy at the time of intervention and are comparable to pre-procedural models derived from CTA or MRA. C1 [Meyer, Carsten; Peters, Jochen; Ecabert, Olivier; Kneser, Reinhard; Weese, Juergen] Philips Res Labs, X Ray Imaging Syst, Weisshausstr 2, D-52066 Aachen, Germany. [Manzke, Robert; Chan, Raymond C.] Philips Res North Amer, Clin Sites Res, Briarcliff Manor, NY USA. [Reddy, Vivek Y.] Massachusetts General Hosp, Cardiac Arrhythmia Serv, Expt Electphysiol Lab, Boston, MA USA. RP Meyer, C (reprint author), Philips Res Labs, X Ray Imaging Syst, Weisshausstr 2, D-52066 Aachen, Germany. EM carsten.meyer@philips.com; robert.manzke@philips.com; juergen.weese@philips.com NR 17 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-540-85989-5 J9 LECT NOTES COMPUT SC PY 2008 VL 5242 BP 61 EP 69 PG 9 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods; Imaging Science & Photographic Technology SC Computer Science; Imaging Science & Photographic Technology GA BIO77 UT WOS:000261373800008 ER PT S AU Cai, WL Zalis, M Yoshida, H AF Cai, Wenli Zalis, Michael Yoshida, Hiroyuki BE Giger, ML Karssemeijer, N TI Mosaic decomposition method for detection and removal of inhomogeneously tagged regions in electronic cleansing for CT colonography - art. no. 69150D SO MEDICAL IMAGING 2008: COMPUTER-AIDED DIAGNOSIS, PTS 1 AND 2 SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Medical Imaging 2008 Conference CY FEB 17-19, 2008 CL San Diego, CA SP SPIE, Amer Assoc Phys Med, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mole Imaging, DICOM Standards Comm DE computer-aided diagnosis; X-ray and CT; abdominal ID COLORECTAL-CANCER; COLONOSCOPY; PREFERENCES AB Electronic cleansing (EC) is a method that segments fecal material tagged by an X-ray-opaque oral contrast agent in CT colonography (CTC) images, and effectively removes the material for digitally cleansing the colon. In this study, we developed a novel EC method, called mosaic decomposition, for reduction of the artifacts due to incomplete cleansing of heterogeneously tagged fecal material in reduced- or non-cathartic fecal-tagging CTC examinations. In our approach, a segmented colonic lumen, including the tagged regions, was first partitioned into a set of local homogeneous regions by application of a watershed transform to the gradient of the CTC images. Then, each of the local homogeneous regions was classified into five different material classes, including air, soft tissue, tagged feces, air bubbles, and foodstuff, based on texture features of the tile. A single index, called a soft-tissue index, is formulated for differentiation of these materials from the submerged solid soft-tissue structures such as polyps and folds. Here, a larger value of the index indicates a higher likelihood of soft tissue. Then, EC is performed by first initializing the level-set front with the classified tagged regions, and the front is evolved by use of a speed function that was designed, based on the soft-tissue index, to reserve the submerged soft-tissue structures while suppressing the air bubbles and foodstuff. Visual assessment and application of our computer-aided detection (CAD) of polyps showed that the use of our new EC method substantially improved the detection performance of CAD, indicating the effectiveness of our EC method in reducing incomplete cleansing artifacts. C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 19 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7099-7 J9 P SOC PHOTO-OPT INS PY 2008 VL 6915 BP D9150 EP D9150 DI 10.1117/12.771206 PG 8 WC Biophysics; Engineering, Biomedical; Mathematical & Computational Biology; Radiology, Nuclear Medicine & Medical Imaging SC Biophysics; Engineering; Mathematical & Computational Biology; Radiology, Nuclear Medicine & Medical Imaging GA BHU04 UT WOS:000256380300012 ER PT S AU Do, S Liang, ZL Karl, WC Brady, T Pien, H AF Do, Synho Liang, Zhuangli Karl, William Clem Brady, Thomas Pien, Homer BE Hsieh, J Samei, E TI A projection-driven pre-correction technique for iterative reconstruction of helical cone-beam cardiac CT images SO MEDICAL IMAGING 2008: PHYSICS OF MEDICAL IMAGING, PTS 1-3 SE Proceedings of SPIE LA English DT Proceedings Paper CT Medical Imaging 2008 Conference CY FEB 17-19, 2008 CL San Diego, CA SP SPIE, Amer Assoc Phys Med, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mol Imaging, DICOM Standards Comm DE iterative reconstruction; tomography; cardiac CT; ROI reconstruction ID IN-VITRO EVALUATION; TOMOGRAPHY; ARTIFACTS; SCANNER; STENTS AB Modem CT systems have advanced at a dramatic rate. Algebraic iterative reconstruction techniques have shown promising and desirable image characteristics, but are seldom used due to their high computational cost for complete reconstruction of large volumetric datasets. In many cases, however, interest in high resolution reconstructions is restricted to smaller regions of interest within the complete volume. In this paper we present an implementation of a simple and practical method to produce iterative reconstructions of reduced-sized ROI from 3D helical tomographic data. We use the observation that the conventional filtered back-projection reconstruction is generally of high quality throughout the entire volume to predict the contributions to ROI-related projections arising from volumes outside the ROI. These predictions are then used to pre-correct the data to produce a tomographic inversion problem of substantially reduced size and memory demands. Our work expands on those of other researchers who have observed similar potential computational gains by exploiting FBP results. We demonstrate our approach using cardiac CT cone-beam imaging, illustrating our results with both ex vivo and in vivo multi-cycle EKG-gated examples. C1 [Do, Synho; Brady, Thomas; Pien, Homer] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Do, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM sdo@partners.org NR 14 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-7097-3 J9 PROC SPIE PY 2008 VL 6913 AR 69132U DI 10.1117/12.770187 PN 1-3 PG 9 WC Engineering, Biomedical; Physics, Applied; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Physics; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BHV05 UT WOS:000256660300097 ER PT J AU Seco, J Sharp, GC Wu, Z Gierga, D Buettner, F Paganetti, H AF Seco, Joao Sharp, Greg C. Wu, Ziji Gierga, David Buettner, Florian Paganetti, Harald TI Dosimetric impact of motion in free-breathing and gated lung radiotherapy: A 4D Monte Carlo study of intrafraction and interfraction effects SO MEDICAL PHYSICS LA English DT Article DE organ motion; IGRT; Monte Carlo; 4DCT; motion average dose ID DOSE CALCULATION; RESPIRATORY MOTION; TISSUE PARAMETERS; IMRT TREATMENTS; ORGAN MOTION; CT NUMBERS; PHOTON; CANCER; DISTRIBUTIONS; REGISTRATION AB The purpose of this study was to investigate if interfraction and intrafraction motion in free-breathing and gated lung IMRT can lead to systematic dose differences between 3DCT and 4DCT. Dosimetric effects were studied considering the breathing pattern of three patients monitored during the course of their treatment and an in-house developed 4D Monte Carlo framework. Imaging data were taken in free-breathing and in cine mode for both 3D and 4D acquisition. Treatment planning for IMRT delivery was done based on the free-breathing data with the CORVUS (North American Scientific, Chatsworth, CA) planning system. The dose distributions as a function of phase in the breathing cycle were combined using deformable image registration. The study focused on (a) assessing the accuracy of the CORVUS pencil beam algorithm with Monte Carlo dose calculation in the lung, (b) evaluating the dosimetric effect of motion on the individual breathing phases of the respiratory cycle, and (c) assessing intrafraction and interfraction motion effects during free-breathing or gated radiotherapy. The comparison between (a) the planning system and the Monte Carlo system shows that the pencil beam algorithm underestimates the dose in low-density regions, such as lung tissue, and overestimates the dose in high-density regions, such as bone, by 5% or more of the prescribed dose (corresponding to approximately 3-5 Gy for the cases considered). For the patients studied this could have a significant impact on the dose volume histograms for the target structures depending on the margin added to the clinical target volume (CTV) to produce either the planning target (PTV) or internal target volume (ITV). The dose differences between (b) phases in the breathing cycle and the free-breathing case were shown to be negligible for all phases except for the inhale phase, where an underdosage of the tumor by as much as 9.3 Gy relative to the free-breathing was observed. The large difference was due to breathing-induced motion/deformation affecting the soft/lung tissue density and motion of the bone structures (such as the rib cage) in and out of the beam. Intrafraction and interfraction dosimetric differences between (c) free-breathing and gated delivery were found to be small. However, more significant dosimetric differences, of the order of 3%-5%, were observed between the dose calculations based on static CT (3DCT) and the ones based on time-resolved CT (4DCT). These differences are a consequence of the larger contribution of the inhale phase in the 3DCT data than in the 4DCT. (c) 2008 American Association of Physicists in Medicine. C1 [Seco, Joao; Sharp, Greg C.; Wu, Ziji; Gierga, David; Buettner, Florian; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Seco, Joao; Sharp, Greg C.; Wu, Ziji; Gierga, David; Buettner, Florian; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Seco, J (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RI Seco, Joao/J-4451-2012; OI Buettner, Florian/0000-0001-5587-6761 FU NCI NIH HHS [R01 CA111590, R01 CA111590-03, R01-CA 111590] NR 31 TC 41 Z9 42 U1 1 U2 7 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 2008 VL 35 IS 1 BP 356 EP 366 DI 10.1118/1.2821704 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 245BU UT WOS:000251910300037 PM 18293590 ER PT J AU Ho, MJ Yao, G Lee, KL Beach, MC Green, AR AF Ho, Ming-Jung Yao, Grace Lee, Keng-Lin Beach, Mary Catherine Green, Alexander R. TI Cross-cultural medical education: Can patient-centered cultural competency training be effective in non-Western countries? SO MEDICAL TEACHER LA English DT Article AB Background: No evidence addresses the effectiveness of patient-centered cultural competence training in non-Western settings. Aims: To examine whether a patient-centered cultural competency curriculum improves medical students' skills in eliciting the patients' perspective and exploring illness-related social factors. Method: Fifty-seven medical students in Taiwan were randomly assigned to either the control (n = 27) or one of two intervention groups: basic (n = 15) and extensive (n = 15). Both intervention groups received two 2-hour patient-centered cultural competency workshops. In addition, the extensive intervention group received a 2-hour practice session. The control group received no training. Results: At the end of the clerkship, all students were evaluated with an objective structured clinical examination (OSCE). Students in the extensive intervention group scored significantly higher than the basic intervention and control groups in eliciting the patient's perspective (F = 18.38, p < 0.001, eta(2) = 0.40). Scores of both intervention groups were significantly higher than the control group in the exploring social factors (F = 6.66, p = 0.003, eta(2) = 0.20). Conclusion: Patient-centered cultural competency training can produce improvement in medical students' cross-cultural communication skills in non-Western settings, especially when adequate practice is provided. C1 [Ho, Ming-Jung; Yao, Grace; Lee, Keng-Lin] Natl Taiwan Univ, Taipei 10764, Taiwan. [Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Green, Alexander R.] Harvard Univ, Sch Med, Boston, MA USA. [Green, Alexander R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Green, AR (reprint author), Dispar Solut Ctr, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM argreen@partners.org OI HO, MING-JUNG/0000-0003-1415-8282; YAO, KAI-PING GRACE/0000-0003-0841-3507 FU National Science Council of Taiwan, R.O.C; National Taiwan University FX This research project was supported by National Science Council of Taiwan, R.O.C. M Ho was sponsored by the National Taiwan University to attend the Harvard Macy Institute Program for Educators in Health Professions, which shaped the design of this research. The authors would like to thank Dean Ding-Shinn Chen, Drs. Tien-Shang Huang, Kwan-Dun Wu, Fen-Yu Tseng, Yen-Ling Chiu and Yao-Juan Hsiao in the Department of Internal Medicine who made the workshops and the OSCE possible. The authors also thank all of the students and standardized patients who participated in this study. NR 1 TC 12 Z9 12 U1 2 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2008 VL 30 IS 7 BP 719 EP 721 DI 10.1080/01421590802232842 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 345EM UT WOS:000258978900020 PM 18777429 ER PT B AU Mroz, P Tegos, GP Gali, H Wharton, T Sarna, T Hamblin, MR AF Mroz, Pawel Tegos, George P. Gali, Hariprasad Wharton, Timothy Sarna, Tadeusz Hamblin, Michael R. BE Cataldo, F DaRos, T TI Fullerenes as Photosensitizers in Photodynamic Therapy SO MEDICINAL CHEMISTRY AND PHARMACOLOGICAL POTENTIAL OF FULLERENES AND CARBON NANOTUBES SE Carbon Materials-Chemistry and Physics LA English DT Article; Book Chapter DE Photodynamic therapy; Photosensitizer; Photochemistry; Reactive oxygen species; Cancer; Microorganism; Infection ID MESOSUBSTITUTED CATIONIC PORPHYRINS; GRAM-NEGATIVE BACTERIA; SINGLET OXYGEN O-1(2); LIPID-PEROXIDATION; PHOTOINDUCED CYTOTOXICITY; FUNCTIONALIZED FULLERENES; BIOLOGICAL APPLICATIONS; DNA-CLEAVAGE; JURKAT CELLS; MALONIC-ACID AB Fullerenes are a class of closed-cage nanomaterials made exclusively from carbon atoms. A great deal of attention has been focused on developing medical uses of these unique molecules especially when they are derivatized with functional groups to make them soluble and therefore able to interact with biological systems. Due to their extended pi-conjugation they absorb visible light, have a high triplet yield and can generate reactive oxygen species (ROS) upon illumination, suggesting a possible role of fullerenes in photodynamic therapy (PDT). Depending on the functional groups introduced into the molecule, fullerenes can effectively photoinactivate either or both pathogenic microbial cells and malignant cancer cells. The mechanism appears to involve superoxide anion as well as singlet oxygen, and under the right conditions fullerenes may have advantages over clinically applied photosensitizers (PSs) for mediating photodynamic therapy of certain diseases. C1 [Mroz, Pawel; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Mroz, Pawel; Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Gali, Hariprasad; Wharton, Timothy] Lynntech Inc, College Stn, TX USA. [Sarna, Tadeusz] Jagiellonian Univ, Dept Biophys, Krakow, Poland. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR 414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu NR 108 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-1-4020-6844-7 J9 CARBON MATER-CHEM PH PY 2008 VL 1 BP 79 EP + D2 10.1007/978-1-4020-6845-4 PG 30 WC Biochemistry & Molecular Biology; Chemistry, Organic; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA BKE68 UT WOS:000267899700004 ER PT J AU Tolle, J Waxman, A Systrom, D AF Tolle, James Waxman, Aaron Systrom, David TI Impaired systemic oxygen extraction at maximum exercise in pulmonary hypertension SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article; Proceedings Paper CT 55th Annual Meeting of the ACSM CY MAY 25-31, 2008 CL Indianapolis, IN SP Amer Coll Sports Med DE vasoconstrictors; vasodilators; mitochondria; oxygen use; pulmonary circulation ID CHRONIC HEART-FAILURE; MUSCLE BLOOD-FLOW; SKELETAL-MUSCLE; NITRIC-OXIDE; LIMITATION; CAPACITY; DISSOCIATION; EXPRESSION; KINETICS; DISEASE AB Purpose: To determine the relative contributions of the Fick principle variables to impaired exercise tolerance in pulmonary arterial hypertension compared with pulmonary venous hypertension. Methods: One hundred forty-seven consecutive, complete, clinically indicated card iopu I monary exercise tests done with radial and pulmonary arterial catheters and radionuclide ventriculographic scanning were screened for an exercise limit attributable to 1) pulmonary arterial hypertension (N = 34), 2) left ventricular systolic (N = 23), or 3) diastolic dysfunction (N = 36), defined by mean pulmonary artery pressure, pulmonary capillary wedge pressure, and left ventricular ejection fraction. Systolic and diastolic dysfunction are together referred to as pulmonary venous hypertension. Patients with other limits were excluded, including those with a pulmonary mechanical limit. For the resulting 93 exercise tests, the Fick principle variables' contributions to a depressed maximum oxygen consumption were compared by ANOVA and ANCOVA. Results: Maximum oxygen consumption (54.5 +/- 15.5 vs 73.2 +/- 20.1 vs 66.0 +/- 15.7% predicted) and oxygen delivery (1457 456 vs 2161 824 vs 2007 665 mL.min(-1)) were reduced in systolic dysfunction versus both diastolic dysfunction and pulmonary arterial hypertension, respectively (P < 0.05 by ANOVA). Maximum systemic oxygen extraction ratio was highest in systolic dysfunction, intermediate in diastolic dysfunction, and lowest in pulmonary arterial hypertension (0.744 +/- 0.091 vs 0.680 +/- 0.091 vs 0.619 +/- 0.113, respectively, P < 0.05 among all groups). Systemic oxygen extraction at peak exercise was inversely related to maximum cardiac output in pulmonary arterial hypertension, but it was blunted versus systolic dysfunction throughout the range of peak cardiac outputs (P < 0.05 by ANCOVA). Conclusions: Maximum systemic oxygen extraction is impaired in pulmonary arterial versus pulmonary venous hypertension and contributes to the exercise limit. C1 [Tolle, James; Waxman, Aaron; Systrom, David] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. RP Tolle, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM jtolle@partners.org OI Systrom, David/0000-0002-9610-6330 FU NHLBI NIH HHS [HL04022-05, HL074859] NR 30 TC 24 Z9 24 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD JAN PY 2008 VL 40 IS 1 BP 3 EP 8 DI 10.1249/mss.0b013e318159d1b8 PG 6 WC Sport Sciences SC Sport Sciences GA 244MV UT WOS:000251870900002 PM 18091026 ER PT J AU Schwid, HA AF Schwid, Howard A. BE Westwood, JD Haluck, RS Hoffman, HM Mogel, GT Phillips, R Robb, RA Vosburgh, KG TI Open-Source Shared Case Library SO MEDICINE MEETS VIRTUAL REALITY 16 SE Studies in Health Technology and Informatics LA English DT Proceedings Paper CT 16th Conference on Medicine Meets Virtual Reality CY JAN 30-FEB 01, 2008 CL Long Beach, CA DE Simulation; case library AB Sharing simulator case scenarios among educators will greatly reduce the cost and effort involved in bringing simulation to our students. A library of 72 cases was posted to the internet to freely share. The cases in the library consist of text files utilizing a simple open-source format. In the first four months after posting, cases were downloaded over 18,000 times. In addition, the library encouraged the development of 23 new cases by 16 new contributors. This experience indicates a strong interest in obtaining free cases, but only modest willingness to share new scenarios among authors and institutions. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Schwid, HA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM hschwid@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU I O S PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 J9 ST HEAL T PY 2008 VL 132 BP 442 EP 445 PG 4 WC Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA BMK36 UT WOS:000272668400095 PM 18391339 ER PT S AU Toner, M Irimia, D AF Toner, Mehmet Irimia, Daniel GP IEEE TI Cell manipulation in microsystems for clinical and biological applications SO MEMS 2008: 21ST IEEE INTERNATIONAL CONFERENCE ON MICRO ELECTRO MECHANICAL SYSTEMS, TECHNICAL DIGEST SE PROCEEDINGS: IEEE MICRO ELECTRO MECHANICAL SYSTEMS LA English DT Proceedings Paper CT 21st IEEE International Conference on Micro Electro Mechanical Systems (MEMS 2008) CY JAN 13-17, 2008 CL Tucson, AZ SP IEEE Robot & Automat Soc ID LEUKOCYTES; ARRAY AB The mission of the center is to develop and promote living-cell-based microdevices as key technologies in medicine and biological sciences. By integrating engineering methods and biological research into novel microsystem technologies, we aim to provide unique capabilities to biomedical investigators to probe, manipulate.. engineer, and analyze biological cells for diagnostic, prognostic and therapeutic advances and basic biology discovery. This brief review describes our recent work in microchips for blood analysis, microfabricated living cell arrays, and microfluidic gradient generators for studies of cellular chemotaxis. C1 [Toner, Mehmet; Irimia, Daniel] Harvard Univ, Sch Med,Div Hlth Sci Technol, BioMEMS Resource Ctr,Harvard MIT, Massachusetts Gen Hosp,Shriners Burns Hosp, Boston, MA 02115 USA. RP Toner, M (reprint author), Harvard Univ, Sch Med,Div Hlth Sci Technol, BioMEMS Resource Ctr,Harvard MIT, Massachusetts Gen Hosp,Shriners Burns Hosp, Boston, MA 02115 USA. OI Irimia, Daniel/0000-0001-7347-2082 NR 10 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1084-6999 BN 978-1-4244-1792-6 J9 PROC IEEE MICR ELECT PY 2008 BP 54 EP 57 PG 4 WC Engineering, Electrical & Electronic; Engineering, Mechanical SC Engineering GA BHH75 UT WOS:000253356900014 ER PT J AU Pulliam, SJ AF Pulliam, Samantha J. TI Fracture and prolapse: is there a connection? SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID PELVIC ORGAN PROLAPSE; URINARY-INCONTINENCE; RISK; WOMEN; SYMPTOMS; SUPPORT; FALLS C1 Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Pulliam, SJ (reprint author), Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv, Boston, MA 02114 USA. NR 16 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2008 VL 15 IS 1 BP 14 EP 15 DI 10.1097/gme.0b013e31815b7eld PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 249YJ UT WOS:000252266400006 PM 18000473 ER PT S AU Welt, CK AF Welt, Corrine K. BE Gordon, CM Welt, C Rebar, RW Hillard, PJA Matzuk, MM Nelson, LM TI Autoimmune oophoritis in the adolescent SO MENSTRUAL CYCLE AND ADOLESCENT HEALTH SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Meeting on the Menstrual Cycle and Adolescent Health CY OCT 17-19, 2007 CL Potomac, MD DE premature ovarian failure; premature menopause; autoimmune polyendocrine syndromes; adrenal insufficiency ID PREMATURE OVARIAN FAILURE; ADRENAL-CORTEX AUTOANTIBODIES; STEROID-PRODUCING CELLS; ADDISONS-DISEASE; 21-HYDROXYLASE AUTOANTIBODIES; POLYENDOCRINE SYNDROMES; INSUFFICIENCY; RISK; IMMUNOFLUORESCENCE; DYSFUNCTION AB Autoimmune oophoritis presents in adolescents as a component of autoimmune polyendocrine syndrome type I or type II. Autoimmune oophoritis can be diagnosed in women with primary ovarian insufficiency in the presence of adrenal cortical or steroid cell antibodies, and/or antibodies to adrenal and ovarian steroidogenic enzymes. The ovaries are cystic macroscopically, with a lymphocytic infiltrate in the steroidogenic theca cells. The immune infiltrate results in low estradiol levels and a compensatory increase in FSH levels. Granulosa cells are spared, and inhibin A and B levels are normal to high. Treatment is aimed at symptom relief with further investigation needed to assess treatment options such as immunosuppression. C1 Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA. RP Welt, CK (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, BHX 511,55 Fruit St, Boston, MA 02114 USA. EM cwelt@partners.org OI Welt, Corrine/0000-0002-8219-5504 NR 37 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-715-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1135 BP 118 EP 122 DI 10.1196/annals.1429.006 PG 5 WC Multidisciplinary Sciences; Obstetrics & Gynecology SC Science & Technology - Other Topics; Obstetrics & Gynecology GA BHY42 UT WOS:000257452900015 PM 18574216 ER PT S AU Cohen, LE AF Cohen, Laurie E. BE Gordon, CM Welt, C Rebar, RW Hillard, PJA Matzuk, MM Nelson, LM TI Cancer treatment and the ovary - The effects of chemotherapy and radiation SO MENSTRUAL CYCLE AND ADOLESCENT HEALTH SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Meeting on the Menstrual Cycle and Adolescent Health CY OCT 17-19, 2007 CL Potomac, MD DE chemotherapy; radiation; bone marrow transplant; premature ovarian failure ID BONE-MARROW TRANSPLANTATION; LONG-TERM SURVIVORS; CHILDHOOD-CANCER; GONADAL-FUNCTION; MENOPAUSE; DISEASES; CHILDREN; DAMAGE AB Certain chemotherapeutic drugs ("alkylators") and radiation therapy are toxic to the ovaries, leading to both loss of sex steroid hormone production and infertility. Higher doses and older age at treatment are both associated with greater damage. Even patients with spontaneous menstrual cycles have evidence of decreased ovarian potential. Adolescents who are treated for cancer with these agents should be counseled about future fertility risks. C1 [Cohen, Laurie E.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Cohen, Laurie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cohen, Laurie E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Cohen, LE (reprint author), Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. EM laurie.cohen@childrens.harvard.edu NR 19 TC 13 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-715-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1135 BP 123 EP 125 DI 10.1196/annals.1429.023 PG 3 WC Multidisciplinary Sciences; Obstetrics & Gynecology SC Science & Technology - Other Topics; Obstetrics & Gynecology GA BHY42 UT WOS:000257452900016 PM 18574217 ER PT S AU Misra, M AF Misra, Madhusmita BE Gordon, CM Welt, C Rebar, RW Hillard, PJA Matzuk, MM Nelson, LM TI Long-term skeletal effects of eating disorders with onset in adolescence SO MENSTRUAL CYCLE AND ADOLESCENT HEALTH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Meeting on the Menstrual Cycle and Adolescent Health CY OCT 17-19, 2007 CL Potomac, MD DE anorexia nervosa; bone density; bone turnover markers; adolescents ID BONE-MINERAL DENSITY; COGNITIVE DIETARY RESTRAINT; ANOREXIA-NERVOSA PATIENTS; BULIMIA-NERVOSA; YOUNG-WOMEN; HYPOTHALAMIC AMENORRHEA; PUBERTAL DEVELOPMENT; HEALTHY ADOLESCENTS; PREMENOPAUSAL WOMEN; SECRETORY DYNAMICS AB Anorexia nervosa (AN), an eating disorder characterized by severe undernutrition and associated with hypogonadotropic hypogonadism, causes marked deficits in bone mass accrual when the disorder begins in the teenage years. Although bone mass accrual improves with weight gain and menstrual recovery, residual deficits persist. Women with a history of teenage onset of AN are more likely to be osteopenic than age-matched women without this history, even after many years of weight and menstrual recovery. Non-recovered women with persistent low weight and amenorrhea have continued decreases in bone density, with a high prevalence of both osteopenia and osteoporosis. Unlike anorexia nervosa, normal-weight bulimia is not associated with low bone density, unless there is a past history of low weight or amenorrhea. A second possible skeletal effect of teenage-onset anorexia nervosa is short stature. Duration of illness and time of onset of anorexia nervosa in relation to the pubertal growth spurt are likely important determinants of statural growth. Adolescent boys with anorexia nervosa are more likely than adolescent girls to have short stature, possibly because growth potential persists for two years longer in boys than in girls. Thus, many adolescent girls may have completed growth or be close to growth completion at the time that they develop anorexia nervosa, whereas adolescent boys may still have significant growth potential remaining. This remaining growth potential may be impaired as a consequence of low levels of insulin-like growth factor-I (IGF-I) levels from persistent undernutrition. C1 [Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA USA. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org NR 67 TC 23 Z9 23 U1 2 U2 11 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-715-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1135 BP 212 EP 218 DI 10.1196/annals.1429.002 PG 7 WC Multidisciplinary Sciences; Obstetrics & Gynecology SC Science & Technology - Other Topics; Obstetrics & Gynecology GA BHY42 UT WOS:000257452900026 PM 18574227 ER PT S AU Joffe, H Hayes, FJ AF Joffe, Hadine Hayes, Frances J. BE Gordon, CM Welt, C Rebar, RW Hillard, PJA Matzuk, MM Nelson, LM TI Menstrual cycle dysfunction associated with neurologic and psychiatric disorders - Their treatment in adolescents SO MENSTRUAL CYCLE AND ADOLESCENT HEALTH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Meeting on the Menstrual Cycle and Adolescent Health CY OCT 17-19, 2007 CL Potomac, MD DE bipolar disorder; epilepsy; hypothalamic-pituitary-gonadal (HPG) axis; menstrual cycle dysfunction; migraines; polycystic ovarian syndrome (PCOS); valproate ID REPRODUCTIVE ENDOCRINE DISORDERS; POLYCYSTIC-OVARIAN-SYNDROME; BIPOLAR DISORDER; PROLACTIN LEVELS; INDUCED HYPERPROLACTINEMIA; VALPROIC ACID; SCHIZOPHRENIC-PATIENTS; SEXUAL DYSFUNCTION; SERUM PROLACTIN; PSYCHOTROPIC MEDICATIONS AB Epilepsy, bipolar disorder, and migraines are common disorders that are often associated with disturbances in menstrual function in adolescent girls. Women with untreated epilepsy are more likely to have irregular menstrual cycles than are nonepileptic controls, indicating that the disease itself plays a role in the etiology of these reproductive abnormalities. In addition, many girls with these disorders require chronic maintenance treatment with agents that may perturb the hypothalamic-pituitary-ovarian axis. Valproate is a highly effective antiepileptic drug used widely to treat epilepsy, bipolar disorder, and migraines. Valproate induces features of the polycystic ovary syndrome (PCOS) in approximately 7% of women. Girls with epilepsy, and possibly bipolar disorder, appear particularly susceptible to developing PCOS features on valproate, perhaps on account of the relative immaturity of their hypothalamic-pituitary-ovarian axes. Antipsychotics are highly effective drugs used widely to treat adolescents with bipolar disorder, psychotic disorders, and behavioral disturbances. Some, but not all of the antipsychotic, induce hyperprolactinemia, which may result in oligo- or amenorrhea. Prolonged amenorrhea in association with hyperprolactinemia incurs significant risks for bone health in adolescent girls. Because of the potential reproductive health risks associated with use of specific antiepileptic drugs and selective antipsychotics, these agents are vital treatments for adolescents with severe illnesses. Use of these agents should be considered and weighed against the risk of using alternative agents, which have their own side effects, or not treating these serious neurologic and psychiatric disorders. C1 [Joffe, Hadine; Hayes, Frances J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit,Dept Med, Boston, MA 02114 USA. [Joffe, Hadine] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA. RP Joffe, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit,Dept Med, Room 2296,185 Cambridge St, Boston, MA 02114 USA. EM hjoffe@partners.org FU NIMH NIH HHS [N01 MH080001] NR 93 TC 13 Z9 14 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-715-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1135 BP 219 EP 229 DI 10.1196/annals.1429.030 PG 11 WC Multidisciplinary Sciences; Obstetrics & Gynecology SC Science & Technology - Other Topics; Obstetrics & Gynecology GA BHY42 UT WOS:000257452900027 PM 18574228 ER PT B AU Meigs, JB AF Meigs, James B. BE Hansen, BC Bray, GA TI The Role of Obesity in Insulin Resistance Epidemiological and Metabolic Aspects SO METABOLIC SYNDROME: EPIDEMIOLOGY, CLINICAL TREATMENT, AND UNDERLYING MECHANISMS SE Contemporary Endocrinology LA English DT Article; Book Chapter ID NECROSIS-FACTOR-ALPHA; TYPE-2 DIABETES-MELLITUS; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; ENDOTHELIUM-DEPENDENT VASODILATION; NITRIC-OXIDE SYNTHASE; BODY-MASS INDEX; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CANNABINOID-1 RECEPTOR BLOCKER; CARDIOVASCULAR RISK-FACTORS C1 Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 193 TC 5 Z9 5 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-738-9 J9 CONTEMP ENDOCRINOL S PY 2008 BP 37 EP 55 DI 10.1007/978-1-60327-116-5_3 D2 10.1007/978-1-60327-116-5 PG 19 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO56 UT WOS:000266907200004 ER PT J AU Wildman, WJ McNamara, P AF Wildman, Wesley J. McNamara, Patrick TI Challenges Facing the Neurological Study of Religious Behavior, Belief, and Experience SO METHOD & THEORY IN THE STUDY OF RELIGION LA English DT Article DE evolution; neuroscience; religious belief; religious behavior; religious experience ID TEMPORAL-LOBE EPILEPSY; PSYCHOLOGY; MIND AB The neurological study of religious behavior, belief, and experience faces many challenges related to research conception, experimental design, and interpretation of results. Some of these problems are common to other types of neurological study of behavioral and cognitive phenomena. Others are distinctive to the specifically religious domain of behavior, belief, and experience. This paper discusses eight of these problems and three key strategic principles for mitigating them. It then proposes an eight-step framework for research into the neurology of religious behavior, belief, and experience that implements the three strategic principles and addresses all eight of the problems. C1 [Wildman, Wesley J.] Boston Univ, Sch Theol, Boston, MA 02215 USA. [McNamara, Patrick] Boston Univ, Sch Med, Dept Neurol 127, Boston, MA 02118 USA. [McNamara, Patrick] VA Boston Healthcare Syst, Boston, MA USA. RP Wildman, WJ (reprint author), Boston Univ, Sch Theol, 745 Commonwealth Ave, Boston, MA 02215 USA. EM wwildman@bu.edu; mcnamar@bu.edu NR 71 TC 3 Z9 3 U1 0 U2 3 PU BRILL ACADEMIC PUBLISHERS PI LEIDEN PA PLANTIJNSTRAAT 2, P O BOX 9000, 2300 PA LEIDEN, NETHERLANDS SN 0943-3058 J9 METH THEORY STUD REL JI Meth. Theory Study Relig. PY 2008 VL 20 IS 3 BP 212 EP 242 DI 10.1163/157006808X317455 PG 31 WC Religion SC Religion GA 432ZO UT WOS:000265173200002 ER PT J AU Erban, JK Lau, J AF Erban, John K. Lau, Joseph BE Hayat, MA TI Systemic Therapy for Breast Cancer: Using Toxicity Data to Inform Decisions SO METHODS OF CANCER DIAGNOSIS, THERAPY AND PROGNOSIS, VOL 1: BREAST CARCINOMA SE Methods of Cancer Diagnosis Therapy and Prognosis LA English DT Article; Book Chapter ID SURGICAL ADJUVANT BREAST; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; COGNITIVE FUNCTION; COLORECTAL-CANCER; CHEMOTHERAPY; DOXORUBICIN; CYCLOPHOSPHAMIDE; TAMOXIFEN; PLUS C1 [Erban, John K.] Massachusetts Gen Hosp, Gillete Ctr Breast Canc, Boston, MA 02116 USA. [Lau, Joseph] Tufts Univ New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA. RP Erban, JK (reprint author), Massachusetts Gen Hosp, Gillete Ctr Breast Canc, 55 Fruit St, Boston, MA 02116 USA. EM JLaul@tufts-nemc.org NR 42 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4020-8369-3 J9 METHODS CANCER DIAGN PY 2008 VL 1 BP 373 EP 394 DI 10.1007/978-1-4020-8369-3_28 D2 10.1007/978-1-4020-8369-3 PG 22 WC Oncology; Medicine, General & Internal SC Oncology; General & Internal Medicine GA BNO99 UT WOS:000275163000029 ER PT J AU Bafford, AC Garber, JE Chittenden, A Golshan, M AF Bafford, Andrea Chao Garber, Judy E. Chittenden, Anu Golshan, Mehra BE Hayat, MA TI Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2 SO METHODS OF CANCER DIAGNOSIS, THERAPY AND PROGNOSIS, VOL 1: BREAST CARCINOMA SE Methods of Cancer Diagnosis Therapy and Prognosis LA English DT Article; Book Chapter ID OVARIAN-CANCER; SUSCEPTIBILITY GENE; MUTATION CARRIERS; CONSERVATIVE TREATMENT; CLINICAL-EXPERIENCE; FOLLOW-UP; STAGE-I; MASTECTOMY; CARCINOMA; FLAP C1 [Bafford, Andrea Chao] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Garber, Judy E.; Chittenden, Anu; Golshan, Mehra] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Oncol, Boston, MA 02115 USA. RP Bafford, AC (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA. EM mgolshan@partners.org NR 43 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4020-8369-3 J9 METHODS CANCER DIAGN PY 2008 VL 1 BP 483 EP 491 DI 10.1007/978-1-4020-8369-3_33 D2 10.1007/978-1-4020-8369-3 PG 9 WC Oncology; Medicine, General & Internal SC Oncology; General & Internal Medicine GA BNO99 UT WOS:000275163000034 ER PT J AU Martins, PNA Neuhaus, P AF Martins, Paulo Ney Aguiar Neuhaus, Peter TI Hepatic lobectomy and segmentectomy models using microsurgical techniques SO MICROSURGERY LA English DT Article ID PARTIAL-HEPATECTOMY; RAT; LIVER; TRANSPLANTATION; ANATOMY; MOUSE; MICE AB The mouse and rat models are the most commonly utilized experimental models of partial liver resection. Microscope-assisted partial hepatectomy is associated with better outcomes by reducing the risk of vena cava stenosis after ligature and injury to other liver pedicles. In addition, microsurgery allows lobectornies and segmentectornies after individual ligation of intrahepatic vascular branches, including the left and right segments of the median lobe, which has not been reported before. Here, we describe a new technique (catheter-assisted suture technique) and report our experience with partial hepatectornies in rodents using a microsurgical approach. (c) 2008 Wiley-Liss, Inc. C1 [Martins, Paulo Ney Aguiar] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplant Biol Res Ctr,Dept Surg, Boston, MA 02129 USA. [Neuhaus, Peter] Charite Univ Med Berlin, Virchow Clin, Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany. RP Martins, PNA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplant Biol Res Ctr,Dept Surg, MGH E,Bldg 149-9019,13th St, Boston, MA 02129 USA. EM paulo.martins@tbrc.mgh.harvard.edu NR 14 TC 8 Z9 11 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0738-1085 J9 MICROSURG JI Microsurgery PY 2008 VL 28 IS 3 BP 187 EP 191 DI 10.1002/micr.20478 PG 5 WC Surgery SC Surgery GA 280NJ UT WOS:000254433200011 PM 18286652 ER PT J AU Martins, PNA AF Martins, Paulo Ney Aguiar TI ASSESSMENT OF GRAFT FUNCTION IN RODENT MODELS OF HEART TRANSPLANTATION SO MICROSURGERY LA English DT Review ID CARDIAC ALLOGRAFT-REJECTION; 1990 WORKING FORMULATION; CORONARY-ARTERY-DISEASE; MOUSE HEART; HISTOCOMPATIBILITY ANTIGEN; H-Y; MICE; RATS; ECHOCARDIOGRAPHY; DONOR AB Heterotopic heart transplantation in rats and mice is the most commonly used model to study allograft immune response and to test immunosuppressive drugs and tolerance induction protocols. Standardization of both the surgical procedure and the evaluation of graft function is essential for data interpretation. The most popular way to monitor graft function has been the palpation method. However, there are some proposal for more objective assessment methods like electrocardiogram and echocardiogram. Although, complementary tests might add some relevant information when assessing minor effects of immunosuppressive therapy, palpation by an experienced investigator is very predictive and so far the simplest method to determine heart allograft function. Minor complications during the surgical procedure and unreliable assessment can have a major impact on the interpretation of experiment results. Here, the author reviews the literature and presents some suggestions that help eliminating biases on the assessment of heart allograft function. (C)2008 Wiley-Liss, Inc. Microsurgery 28:565-570, 2008. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplant Biol Res Ctr,Dept Surg, Boston, MA 02129 USA. RP Martins, PNA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplant Biol Res Ctr,Dept Surg, MGH E,Bldg 149-9019,13th St, Boston, MA 02129 USA. EM paulo.martins@tbrc.mgh.harvard.edu NR 53 TC 10 Z9 11 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0738-1085 EI 1098-2752 J9 MICROSURG JI Microsurgery PY 2008 VL 28 IS 7 BP 565 EP 570 DI 10.1002/micr.20544 PG 6 WC Surgery SC Surgery GA 360MA UT WOS:000260060400015 PM 18767132 ER PT J AU Stone, AM AF Stone, Andrew M. TI Dual agency for VA clinicians: Defining an evolving ethical question SO MILITARY PSYCHOLOGY LA English DT Article ID MENTAL-HEALTH PROBLEMS; AFGHANISTAN; IRAQ AB Changing patterns of military service have altered the circumstances of patients being treated in the facilities of the Department of Veterans Affairs (VA). Formerly, all patients seen by the VA were veterans who had completed their service; now, many are eligible to return to duty. Potential redeployment of patients raises new questions for VA mental health practitioners. This article describes the current situation, presenting representative cases and discussing questions of assessment and diagnosis. The topic of dual agency, the obligations of the provider both to the individual and to the system, inherent in the military context, is explored as a model. Ethical mandates and issues of the various mental health disciplines involved are reviewed. Differences in the roles of military and VA mental health providers are discussed, and approaches to decision-making with application of relevant principles are presented. C1 [Stone, Andrew M.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Stone, Andrew M.] Univ Penn, Philadelphia, PA 19104 USA. RP Stone, AM (reprint author), VA Med Ctr Philadelphia 116MHC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Andrew.Stone2@med.va.gov NR 16 TC 2 Z9 2 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0899-5605 J9 MIL PSYCHOL JI Milit. Psychol. PY 2008 VL 20 IS 1 BP 37 EP 48 DI 10.1080/08995600701753177 PG 12 WC Psychology, Multidisciplinary SC Psychology GA 256GG UT WOS:000252715100004 ER PT S AU Rosas, HD Salat, DH Lee, SY Zaleta, AK Hevelone, N Hersch, SM AF Rosas, H. Diana Salat, David H. Lee, Stephanie Y. Zaleta, Alexandra K. Hevelone, Nathanael Hersch, Steven M. BE Gibson, GE Ratan, RR Beal, MF TI Complexity and Heterogeneity: What Drives the Ever-changing Brain in Huntington's Disease? SO MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Mitochondria and Oxisative Stress in Neurodegenerative Disorders CY SEP 26-29, 2007 CL New York Acad Sci, New York, NY SP Weill Med Coll, Cornell Univ, Grad Sch Med Sci, Ellison Med Fdn, Burke Med Res Inst HO New York Acad Sci DE Huntington's disease; cortex; neurodegeneration; premanifest HD; subcortical atrophy; white matter degeneration; oxidative stress; circuitry ID CAG REPEAT LENGTH; AGE-OF-ONSET; CEREBRAL-CORTEX; OXIDATIVE DAMAGE; WHITE-MATTER; NEURODEGENERATIVE DISEASES; MITOCHONDRIAL DYSFUNCTION; POLYGLUTAMINE TRACT; CELLULAR TOXICITY; STRIATAL NEURONS AB Significant advances are being made in our understanding of basic pathophyiological and biochemical mechanisms that cause Huntington's disease (HD). There is increasing reason to believe that pathologic alterations occur in the brain for years before symptoms manifest. The "classic" hallmark of neuropathology in HD is selective neurodegeneration in which vulnerable populations of neurons degenerate while less vulnerable populations are spared. While the earliest and most striking neuropathologic changes have been found in the neostriatum, neuronal loss has been identified in many other regions of the brain. We report topologically selective, early, and progressive changes in the cortex, striatum, extrastriatal brain structures, and white matter throughout the spectrum of disease. Our growing understanding of HD underscores the reality that points to the complexity of HD. A single, well-defined, genetic mutation causes a cascade of events whose final result is an aggregate insult of the homeostatic process. We explore possible explanations for the selective vulnerability of the brain in HD. The ultimate goal in HD is to develop disease-modifying therapies that will prevent the onset of clinical symptoms in those individuals who are at risk and. slow the progression of symptoms in those individuals already affected with symptoms. Understanding changes in brain morphometry and their relationship to clinical symptoms may provide important and new insights into basic pathophysiological mechanisms at play in the disease. C1 [Rosas, H. Diana] Massachusetts Gen Hosp, Dept Neurol, Ctr Neuroimaging Aging & Neurodegenerat Dis, Charlestown, MA 02129 USA. [Rosas, H. Diana; Lee, Stephanie Y.; Zaleta, Alexandra K.; Hersch, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Rosas, H. Diana; Salat, David H.; Lee, Stephanie Y.; Zaleta, Alexandra K.; Hersch, Steven M.] Harvard Univ, Sch Med, Boston, MA USA. [Rosas, H. Diana; Salat, David H.; Lee, Stephanie Y.; Zaleta, Alexandra K.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Hevelone, Nathanael] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Rosas, HD (reprint author), Massachusetts Gen Hosp, Dept Neurol, Ctr Neuroimaging Aging & Neurodegenerat Dis, 149 13th St,Room 2275, Charlestown, MA 02129 USA. EM rosas@helix.mgh.harvard.edu OI Hevelone, Nathanael/0000-0003-4740-2085 FU National Institutes of Health; National Institute for Neurological Disorders and Stroke [NS042861, NTS045242, P01NS058793]; National Center for Complementary and Alternative Medicine [AT000613]; National Institute on Aging [NIAAG024898]; High Q Foundation FX Funding for this work was provided by the National Institutes of Health. National Institute for Neurological Disorders and Stroke (NS042861, NTS045242, P01NS058793), National Center for Complementary and Alternative Medicine (AT000613), the National Institute on Aging (NIAAG024898), and the High Q Foundation. NR 84 TC 21 Z9 22 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-713-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1147 BP 196 EP 205 DI 10.1196/annals.1427.034 PG 10 WC Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology SC Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology GA BIR99 UT WOS:000262397800018 PM 19076442 ER PT S AU Henchcliffe, C Shungu, DC Mao, XL Huang, CR Nirenberg, MJ Jenkins, BG Beal, MF AF Henchcliffe, Claire Shungu, Dikoma C. Mao, Xiangling Huang, Chaorui Nirenberg, Melissa J. Jenkins, Bruce G. Beal, M. Flint BE Gibson, GE Ratan, RR Beal, MF TI Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease SO MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Mitochondria and Oxisative Stress in Neurodegenerative Disorders CY SEP 26-29, 2007 CL New York Acad Sci, New York, NY SP Weill Med Coll, Cornell Univ, Grad Sch Med Sci, Ellison Med Fdn, Burke Med Res Inst HO New York Acad Sci DE Parkinson's disease; magnetic resonance spectroscopy; mitochondria; neurodegenerative disease; lactate; high-energy phosphates ID PROTON MR SPECTROSCOPY; PROGRESSIVE SUPRANUCLEAR PALSY; N-ACETYLASPARTATE; LACTIC-ACIDOSIS; SKELETAL-MUSCLE; NEUROLOGICAL IMPAIRMENT; CORTICAL DYSFUNCTION; EXCITOTOXIC LESIONS; CEREBROSPINAL-FLUID; ANXIETY DISORDER AB Parkinson's disease (PD) is a common and often devastating neurodegenerative disease affecting up to one million individuals in the United. States alone. Multiple lines of evidence support mitochondrial dysfunction as a primary or secondary event in PD pathogenesis; a better understanding, therefore, of how mitochondrial function is altered in vivo in brain tissue in PD is a critical step toward developing potential PD biomarkers. In vivo study of mitochondrial metabolism in human subjects has previously been technically challenging. However, proton and phosphorus magnetic resonance spectroscopy ((1)H and (31)P MRS) are powerful noninvasive techniques that allow evaluation in vivo of lactate, a marker of anaerobic glycolysis, and high energy phosphates, such as adenosine triphosphate and phosphocreatine, directly reflecting mitochondrial function. This article reviews previous (1)H and (31)P MRS studies in PD, which demonstrate metabolic abnormalities consistent with mitochondrial dysfunction, and then presents recent (1)H MRS data revealing abnormally elevated lactate levels in PD subjects. C1 [Henchcliffe, Claire; Huang, Chaorui; Nirenberg, Melissa J.; Beal, M. Flint] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA. [Shungu, Dikoma C.; Mao, Xiangling] Cornell Univ, Weill Med Coll, Dept Radiol, New York, NY 10021 USA. [Jenkins, Bruce G.] Massachusetts Gen Hosp, Dept Radiol, NMR Ctr, Charlestown, MA USA. [Jenkins, Bruce G.] Harvard Univ, Sch Med, Charlestown, MA USA. RP Henchcliffe, C (reprint author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 428 E 72nd St,Suite 400, New York, NY 10021 USA. EM clh2007@med.cornell.edu OI Shungu, Dikoma/0000-0001-9452-2245 NR 82 TC 20 Z9 22 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-713-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1147 BP 206 EP 220 DI 10.1196/annals.1427.037 PG 15 WC Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology SC Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology GA BIR99 UT WOS:000262397800019 PM 19076443 ER PT S AU Qin, WP Zhao, W Ho, L Wang, J Walsh, K Gandy, S Pasinetti, GM AF Qin, Weiping Zhao, Wei Ho, Lap Wang, Jun Walsh, Kenneth Gandy, Sam Pasinetti, Giulio Maria BE Gibson, GE Ratan, RR Beal, MF TI Regulation of Forkhead Transcription Factor FoxO3a Contributes to Calorie Restriction-induced Prevention of Alzheimer's Disease-type Amyloid Neuropathology and Spatial Memory Deterioration SO MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Mitochondria and Oxisative Stress in Neurodegenerative Disorders CY SEP 26-29, 2007 CL New York Acad Sci, New York, NY SP Weill Med Coll, Cornell Univ, Grad Sch Med Sci, Ellison Med Fdn, Burke Med Res Inst HO New York Acad Sci DE Alzheimer's disease; amyloid-beta peptide; calorie restriction; Forkhead transcription factor FoxO3a ID TRANSGENIC MOUSE MODEL; INSULIN-RESISTANCE; SIGNALING PATHWAY; CELL-SURVIVAL; SIRT1; LONGEVITY; MICE; BIM; DEACETYLASE; MODULATION AB Forkhead transcription factor FoxO3a, also known as DAF-16 in Caenorhabditis elegans, is a key regulator of the insulin receptor (IR)/insulin-like growth factor-I signaling pathway mediated extension of life span in worms and yeast. In this study, we report that calorie restriction (CR)-mediated activation of the IR signaling pathway leads to hyperphosphorylation of FoxO3a transcription factor and, consequently, its exclusion front the nucleus. This inactivation of FoxO3a activity is correlated with attenuation of Alzheimer's disease (AD)-type amyloid neuropathology and with preservation of spatial reference memory in the Tg2576 mouse model of AD. Further, in vitro studies reveal that exogenous expression of viral, triple-mutant, constitutively active FoxO3a resulting in increased nuclear FoxO3a activity in primary neuron cultures derived from Tg2576 mouse embryos, causally promotes AD amyloid-beta peptide (AP) levels by inhibiting non-amyloidogenic a-secretase activity, indicating the existence of an inverse correlation between FoxO3a activity and cerebral As amyloidosis. Moreover, we report for the first time that the exclusion of the FoxO3a transcription factor from the nucleus in combination with inhibition of nuclear FoxO3a activity by SIRT1-mediated deacetylation in response to CR is a mechanism resulting in the repression of Rho-associated protein kinase-1 gene expression, thereby activating nonamyloidogenic alpha-secretase processing of the amyloid precursor protein and lowering AS generation. This study provides a novel metabolic pathway for prevention and/or treatment of AD. C1 [Qin, Weiping; Zhao, Wei; Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio Maria] James J Peters VA Med Ctr, Geriatr Res Clin Ctr, Bronx, NY USA. [Walsh, Kenneth] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010 FU Atkins Foundation; National Institute of Health (NIH) [AG14766, AG10491]; Danal Foundation FX These studies were supported by the Dr. Robert C. Atkins Foundation, National Institute of Health (NIH) AG14766, the Danal Foundation for Brain Research Initiative, and Merit Review to G.P.; S.M. was supported by NIH Program Project AG10491. We thank Drs. W. Todd Penberthy and Soumya Chari for their editorial comments. NR 28 TC 55 Z9 56 U1 3 U2 9 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-713-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1147 BP 335 EP 347 DI 10.1196/annals.1427.024 PG 13 WC Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology SC Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology GA BIR99 UT WOS:000262397800031 PM 19076455 ER PT J AU Cao, D Polyak, K Iacobuzio-Donahue, C Goggins, M Wu, X Sukumar, S Hicks, J De Marzo, A Argani, P AF Cao, D. Polyak, K. Iacobuzio-Donahue, C. Goggins, M. Wu, X. Sukumar, S. Hicks, J. De Marzo, A. Argani, P. TI Serial analysis of gene expression of lobular carcinoma in situ identifies Upregulation of metalloproteinase MMP-9 and downregulation of tight junction protein claudin 4 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Johns Hopkins Med Inst, Baltimore, MD 21205 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 106 BP 26A EP 26A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200106 ER PT J AU Hameed, O Acs, G Al-Khatib, SM Hattab, EM Lewis, JS Nassar, H Rajan, E Rajan, P Sgroi, DC Sharafaldeen, B Tawfik, O AF Hameed, O. Acs, G. Al-Khatib, S. M. Hattab, E. M. Lewis, J. S. Nassar, H. Rajan, E. Rajan, P. Sgroi, D. C. Sharafaldeen, B. Tawfik, O. TI A multinstitutional study comparing the Oncotype-DX recurrence rates with standard clinical and pathological features of breast cancer, the Nottingham prognostic index (NPI) and ADJUVANT! Online SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Alabama, Sch Med, Birmingham, AL 47405 USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 63130 USA. Indiana Univ, Bloomington, IN 48202 USA. Washington Univ, St Louis, MO 60153 USA. Wayne State Univ, Detroit, MI 02114 USA. Loyola Univ Med Ctr, Maywood, IL 66045 USA. Massachusetts Gen Hosp, Boston, MA USA. Univ Kansas, Med Ctr, Lawrence, KS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 152 BP 36A EP 36A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200152 ER PT J AU Rabban, JT Lim, S Lerwill, MF Chen, YY Jordan, RC AF Rabban, J. T. Lim, S. Lerwill, M. F. Chen, Y. Y. Jordan, R. C. TI Comparative genomic hybridization identifies high frequency chromosomal alterations in adenoid cystic carcinoma of the breast SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 222 BP 51A EP 51A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200222 ER PT J AU Wang, Y Collins, G Schnitt, S Garber, J Tung, N AF Wang, Y. Collins, G. Schnitt, S. Garber, J. Tung, N. TI Characterization of estrogen receptor positive breast cancers in BRCA1 mutation carriers SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 264 BP 59A EP 60A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180200264 ER PT J AU Balassanian, R Sander, KJ Vrbin, CM Raab, SS AF Balassanian, R. Sander, K. J. Vrbin, C. M. Raab, S. S. TI Review of false negative UroVysion (TM) test on cytologically atypical urine samples SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 307 BP 69A EP 69A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200307 ER PT J AU Ono, JC Wilbur, DC Krane, JF Bongiovanni, M Faquin, WC AF Ono, J. C. Wilbur, D. C. Krane, J. F. Bongiovanni, M. Faquin, W. C. TI Papillary thyroid carcinoma arising within follicular adenoma: A masked cytomorphologic analysis of 17 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Hop Univ Geneve, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 365 BP 81A EP 82A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180200365 ER PT J AU Rao, RA Wilbur, DC Tambouret, RH Shen, J Balassanian, R Staats, PN Sauder, K Belsley, NA Faquin, WC Deshpande, V AF Rao, R. A. Wilbur, D. C. Tambouret, R. H. Shen, J. Balassanian, R. Staats, P. N. Sauder, K. Belsley, N. A. Faquin, W. C. Deshpande, V. TI Significance of the atypical category in urine cytology: An interobserver study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Rao, R. A.; Wilbur, D. C.; Tambouret, R. H.; Shen, J.; Balassanian, R.; Staats, P. N.; Sauder, K.; Belsley, N. A.; Faquin, W. C.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 372 BP 83A EP 83A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200372 ER PT J AU Hoang, MP Mahalingam, M Bhawan, J Kapur, P High, WA AF Hoang, M. P. Mahalingam, M. Bhawan, J. Kapur, P. High, W. A. TI Acute generalized exanthematous pustulosis: A clinical and histologic study of forty-five cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 424 BP 94A EP 94A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200424 ER PT J AU Johnson, MM Belsley, NA Jinushi, M Carrasco, DR Dranoff, G Mihm, MC AF Johnson, M. M. Belsley, N. A. Jinushi, M. Carrasco, D. R. Dranoff, G. Mihm, M. C. TI MFG-E8 expression in malignant melanoma and benign melanocytic nevi SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Jinushi, Masahisa/A-4311-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 428 BP 95A EP 95A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200428 ER PT J AU Nazarian, RM Mandal, RV Kagan, A Kay, J Duncan, LM AF Nazarian, R. M. Mandal, R. V. Kagan, A. Kay, J. Duncan, L. M. TI Quantitative assessment of dermal fibroblasts in nephrogenic systemic fibrosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Nazarian, R. M.; Mandal, R. V.; Kagan, A.; Kay, J.; Duncan, L. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 445 BP 99A EP 99A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200445 ER PT J AU Dotto, J Faquin, W Sadow, P Kozakewich, H Nose, V AF Dotto, J. Faquin, W. Sadow, P. Kozakewich, H. Nose, V. TI Familial non-medullary thyroid carcinoma: Morphologic patterns indicating an inherited trait SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 BP 106A EP 106A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200482 ER PT J AU Farris, AB Yang, WL Ganguly, A Lauwers, GY Deshpande, V AF Farris, A. B. Yang, W-L Ganguly, A. Lauwers, G. Y. Deshpande, V. TI Gall bladder involvement in AIP is a primary manifestation of the disease SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 535 BP 118A EP 118A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200535 ER PT J AU Gupta, M Mino-Kenudson, M Lauwers, GY Srivastava, S AF Gupta, M. Mino-Kenudson, M. Lauwers, G. Y. Srivastava, S. TI Expression of MUC-6, gastric (Sox-2) and intestinal (Cdx-2) transcription factors in long segment Barrett's esophagus: A complex interplay at the neo-squamocolumnar junction SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 552 BP 121A EP 121A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200551 ER PT J AU Lindberg, MR Havens, JM Lauwers, GY Scott, MA Lamps, LW AF Lindberg, M. R. Havens, J. M. Lauwers, G. Y. Scott, M. A. Lamps, L. W. TI Aeromonas: An emerging food-borne cause of infectious colitis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 575 BP 127A EP 127A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200574 ER PT J AU Maguire, A Shehan, K O'Donoghue, D Greenson, JK Lauwers, GY Ginsburg, RE Williams, GT Brown, IS AF Maguire, A. Shehan, K. O'Donoghue, D. Greenson, J. K. Lauwers, G. Y. Ginsburg, R. E. Williams, G. T. Brown, I. S. TI Collagenous sprue - A clinico-pathological study of 9 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 St Vincents Univ Hosp, Dublin, Ireland. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Jackson Hosp & Clin Inc, Montgomery, AL USA. Univ Wales Coll Cardiff, Cardiff, Wales. San Nicolaides Pathol, Brisbane, Qld, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 581 BP 128A EP 128A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200580 ER PT J AU Mondal, RV Mino-Kenudson, M Lauwers, GY AF Mondal, R. V. Mino-Kenudson, M. Lauwers, G. Y. TI The effect of tumor characteristics and duplication of the muscularis mucosae on endoscopic staging in barrett esophagus related neoplasia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Mondal, R. V.; Mino-Kenudson, M.; Lauwers, G. Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 582 BP 128A EP 129A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180200581 ER PT J AU Sabo, E Meilner, T Moss, SF Gao, J Tavares, R Corless, CL Lauwers, GY Resnick, MB AF Sabo, E. Meilner, T. Moss, S. F. Gao, J. Tavares, R. Corless, C. L. Lauwers, G. Y. Resnick, M. B. TI Microarray gene expression analysis of high grade dysplasia in Barrett esophagus SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Warren Alpert Brown Univ, Sch Med, Providence, RI USA. Oregon Hlth & Sci Univ, Portland, OR USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 611 BP 135A EP 135A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200610 ER PT J AU Yantiss, RK Shia, J Hahn, H Klimstra, DS Odze, RD Misdraji, J AF Yantiss, R. K. Shia, J. Hahn, H. Klimstra, D. S. Odze, R. D. Misdraji, J. TI Ruptured appendiceal mucinous neoplasms: Prognostic significance of localized extra-appendiceal mucin deposition SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 644 BP 142A EP 142A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200643 ER PT J AU Di Napoli, A Grisanzio, C Ghebremichael, M Seeley, A Amato, A Atkins, M Signoretti, S AF Di Napoli, A. Grisanzio, C. Ghebremichael, M. Seeley, A. Amato, A. Atkins, M. Signoretti, S. TI CAIX expression correlates with VHL mutational status in sporadic clear cell carcinoma of the kidney SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Harvard Med Sch, Boston, MA 02115 USA. Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 700 BP 154A EP 154A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200699 ER PT J AU Mertz, KD Setlur, SR Hoshida, Y Demichelis, F Lupien, M Perner, S Sboner, A Pawidan, Y Andren, O Johnson, LA Tang, J Adami, HO Calza, S Chinnaiyan, AM Rhodes, D Tomlins, S Fall, K Mucci, LA Kantoff, PW Stampfer, MJ Anderson, SO Varenhorst, E Johansson, JE Brown, M Golub, TR Rubin, MA AF Mertz, K. D. Setlur, S. R. Hoshida, Y. Demichelis, F. Lupien, M. Perner, S. Sboner, A. Pawidan, Y. Andren, O. Johnson, L. A. Tang, J. Adami, H. O. Calza, S. Chinnaiyan, A. M. Rhodes, D. Tomlins, S. Fall, K. Mucci, L. A. Kantoff, P. W. Stampfer, M. J. Anderson, S. O. Varenhorst, E. Johansson, J. E. Brown, M. Golub, T. R. Rubin, M. A. TI TMPRSS2-ERG fusion prostate cancer is a molecularly distinct estrogen-sensitive subclass of aggressive prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. MIT, Broad Inst, Cambridge, MA 02139 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Univ, New Haven, CT USA. Karolinska Inst, Stockholm, Sweden. Orebro Univ Hosp, Orebro, Sweden. Harvard Sch Publ Hlth, Boston, MA USA. Univ Michigan, Sch Med, Ann Arbor, MI USA. Soeder Hosp, Stockholm, Sweden. RI Myles, Brown/B-6906-2008 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 779 BP 171A EP 171A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200778 ER PT J AU Mosquera, JM Mehra, R Regan, M Genega, EM Gaslon, S Perner, S Connor, M Bueli, G Tomlins, SA Shah, RB Kearney, M Johnson, LA Tang, JM Chinnaiyan, AM Sanda, MG Rubin, MA AF Mosquera, J. M. Mehra, R. Regan, M. Genega, E. M. Gaslon, S. Perner, S. Connor, M. Bueli, G. Tomlins, S. A. Shah, R. B. Kearney, M. Johnson, L. A. Tang, J. M. Chinnaiyan, A. M. Sanda, M. G. Rubin, M. A. TI Prevalence of TMPRSS2-ERG fusion prostate cancer in men undergoing prostate biopsy in the United States SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Beth Israel Deaconess Med Ctr, Boston, MA USA. Michigan Urol Ctr, Ann Arbor, MI USA. Ctr Comprehens Canc, Ann Arbor, MI USA. MIT, Harvard Med Sch, Broad Inst, Cambridge, England. Dana Farber Harvard Comprehens Canc Ctr, Boston, MA USA. RI Sanda, Martin/A-6202-2013; Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 786 BP 172A EP 172A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200785 ER PT J AU Nielsen, GP Oliva, E AF Nielsen, G. P. Oliva, E. TI Papillary renal cell carcinoma of the kidney: A clinicopathologic study of 76 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Nielsen, G. P.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 795 BP 174A EP 174A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200794 ER PT J AU Rubin, MA Mucci, LA Pawilan, Y Demichelis, F Fall, K Stark, JR Adami, HO Andersson, SO Andren, O Holmberg, L Huang, W Kanloff, PW Kim, R Pernet, S Stampfer, MJ Johansson, JF AF Rubin, M. A. Mucci, L. A. Pawilan, Y. Demichelis, F. Fall, K. Stark, J. R. Adami, H-O Andersson, S-O Andren, O. Holmberg, L. Huang, W. Kanloff, P. W. Kim, R. Pernet, S. Stampfer, M. J. Johansson, J-F TI Testing a multigene model to predict lethal prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Sch Publ Hlth, Boston, MA USA. Karolinska Inst, S-10401 Stockholm, Sweden. Univ Orebro, Orebro, Sweden. Uppsala Univ, S-75105 Uppsala, Sweden. Dana Farber Canc Inst, Boston, MA USA. RI Rider, Jennifer/A-5371-2011 NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 816 BP 178A EP 179A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180200815 ER PT J AU Ulbright, TM Young, RH AF Ulbright, T. M. Young, R. H. TI Metastatic carcinoma to the testis: A study of 26 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Indiana Univ, Sch Med, Indianapolis, IN USA. Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 851 BP 186A EP 186A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200850 ER PT J AU Wu, CL Mu, XJ McDougal, WS Erlander, M AF Wu, C-L Mu, X-J McDougal, W. S. Erlander, M. TI Gene expression signature predicting prostate cancer progression SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. AviaraDx Inc, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 870 BP 190A EP 190A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200869 ER PT J AU Wu, CL Jordan, K McDougal, WS Cheng, LL AF Wu, C-L Jordan, K. McDougal, W. S. Cheng, L. L. TI Metabolomic imaging of prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Wu, C-L; Jordan, K.; McDougal, W. S.; Cheng, L. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 871 BP 190A EP 190A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180200870 ER PT J AU Carrick, J Soslow, R Oliva, E Ewanowich, C Gilks, CB Kobel, A AF Carrick, J. Soslow, R. Oliva, E. Ewanowich, C. Gilks, C. B. Kobel, A. TI Ovarian clear cell carcinomas reliably express an immunophenotype that is different from high-grade serous carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Vancouver Gen Hosp, British Columbia Canc Agcy, Vancouver, BC, Canada. Mem Sloan Kettering Canc Ctr, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Alberta, Edmonton, AB T6G 2M7, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 910 BP 199A EP 199A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201039 ER PT J AU Chang, MC Drapkin, R McKeon, FD Mei, H Agoston, EA Crum, CP AF Chang, M. C. Drapkin, R. McKeon, F. D. Mei, H. Agoston, E. A. Crum, C. P. TI An immunophenotypic study of fimbrial mucosa SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 914 BP 200A EP 200A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201043 ER PT J AU Fallon, MA Wilbin, DC Prasad, ML AF Fallon, M. A. Wilbin, D. C. Prasad, M. L. TI Ovarian frozen section diagnosis: Use of whole slide digital imaging shows excellent correlation between virtual slide and original interpretations in a large series of cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 UMASS Mem Med Ctr, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 929 BP 203A EP 203A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201058 ER PT J AU Hofer, MD Liu, J Rubin, MA Matulonis, UA Hirsch, MS AF Hofer, M. D. Liu, J. Rubin, M. A. Matulonis, U. A. Hirsch, M. S. TI The metastasis-associated protein 1 (MTA1) is a prognostic biomarker for papillary serous ovarian carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 943 BP 206A EP 206A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201072 ER PT J AU Irving, JA Young, RH AF Irving, J. A. Young, R. H. TI Microcystic stromal tumor of the ovary: Report of 12 cases of a hitherto uncharacterized distinctive ovarian neoplasm SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Royal Jubilee Hosp, Victoria, BC, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 946 BP 207A EP 207A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201075 ER PT J AU Jarboe, EA Pizer, E Miron, A Crum, CP AF Jarboe, E. A. Pizer, E. Miron, A. Crum, C. P. TI Evidence of a latent precursor (p53 signature) to uterine serous carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Cell Netix Pathol, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 950 BP 208A EP 208A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201079 ER PT J AU Oliva, E Toledo, G AF Oliva, E. Toledo, G. TI Frequent lymphovascular invasion but not aggressive behavior is characteristic of endometrioid endometrial carcinomas with "MELF" features: A clinicopathologic study of 22 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Oliva, E.; Toledo, G.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 988 BP 216A EP 216A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201117 ER PT J AU Park, KJ Lamb, C Oliva, E Soslow, RA Kiyokawa, T AF Park, K. J. Lamb, C. Oliva, E. Soslow, R. A. Kiyokawa, T. TI Unusual endocervical adenocarcinomas: An immunohistochemical analysis with molecular detection of human papillomavirus SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY USA. Massachusetts Gen Hosp, Boston, MA USA. Jikei Univ, Sch Med, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 993 BP 217A EP 217A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201122 ER PT J AU Rabban, JT Leriwill, MF McCluggage, WG Grenert, JP Zaloudek, CJ AF Rabban, J. T. Leriwill, M. F. McCluggage, W. G. Grenert, J. P. Zaloudek, C. J. TI Ovarian carcinoid tumors of primary versus metastatic origin: Pitfalls in diagnostic use of the intestinal marker CDX-2 SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Grp Hosp Trust, Belfast, Antrim, North Ireland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1004 BP 220A EP 220A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201133 ER PT J AU Staats, PN Kuhlmann, G Garcia, JJ McCluggage, WG De Nictolis, M Soslow, RA Iafrate, AJ Oliva, E AF Staats, P. N. Kuhlmann, G. Garcia, J. J. McCluggage, W. G. De Nictolis, M. Soslow, R. A. Iafrate, A. J. Oliva, E. TI Uterine tumors resembling ovarian sex cord tumors (UTROSCT) lack the JAZF1-JJAZ1 gene fusion commonly seen in endometrial stromal tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY USA. Royal Grp Hosp, Belfast, Antrim, North Ireland. Univ Ancona, Ancona, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1030 BP 225A EP 225A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201159 ER PT J AU Todedo, G Growdon, WB Dias-Santagarata, D Ganguly, A Aubi, M Iafrate, AJ Oliva, E AF Todedo, G. Growdon, W. B. Dias-Santagarata, D. Ganguly, A. Aubi, M. Iafrate, A. J. Oliva, E. TI Microsatellite instability status and clinicopathologic profile of endometrial cancer (EC) in young women (< 50 years) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp, Pamplona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1036 BP 226A EP 226A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201165 ER PT J AU Toledo, G Growdon, WB Palmeri, MLD Rueda, BR Oliva, E AF Toledo, G. Growdon, W. B. Palmeri, M. L. D. Rueda, B. R. Oliva, E. TI Utility of the mitosis marker anti-phosphohistone H3 (PHH3) in precise and rapid evaluation of mitotic index in leiomyomas with bizarre nuclei SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Toledo, G.; Growdon, W. B.; Palmeri, M. L. D.; Rueda, B. R.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Toledo, Gemma/H-9842-2012 NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1037 BP 226A EP 227A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180201166 ER PT J AU Jacobson-Dunlop, E Le, C Patterson, J Warrick, A Harlow, A Azar, S Cruz, F Town, A Rubin, BP Hodi, FS Muller, S Heinrich, MC Corless, CL AF Jacobson-Dunlop, E. Le, C. Patterson, J. Warrick, A. Harlow, A. Azar, S. Cruz, F. Town, A. Rubin, B. P. Hodi, F. S. Muller, S. Heinrich, M. C. Corless, C. L. TI KIT mutations in mucosal melanoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Cleveland Clin, Cleveland, OH USA. Dana Farber Canc Inst, Boston, MA USA. Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1082 BP 236A EP 236A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201211 ER PT J AU Nero, CJ Wu, CL Powers, CN Krane, JF Faquin, WC AF Nero, C. J. Wu, C. L. Powers, C. N. Krane, J. F. Faquin, W. C. TI Minor salivary gland tumors of the larynx, a clinicopathologic study of 33 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1097 BP 239A EP 240A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180201226 ER PT J AU O'Sullivan, ED Jain, R Faquin, WC Powers, CN AF O'Sullivan, E. D. Jain, R. Faquin, W. C. Powers, C. N. TI Eosinophilic angiocentric fibrosis: Clinicopathologic characteristics and potential pitfalls SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Virginia Commonwealth Univ, Richmond, VA 23284 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1098 BP 240A EP 240A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201227 ER PT J AU Ferry, JA Fung, CY Hasserjian, RP Lucarelli, MJ Harris, NL AF Ferry, J. A. Fung, C. Y. Hasserjian, R. P. Lucarelli, M. J. Harris, N. L. TI Ocular adnexal lymphomas: Outcome in 181 patients SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Wisconsin, Madison, WI 53706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1160 BP 253A EP 253A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201289 ER PT J AU Hasserjian, RP Seliem, R Turbiner, J Wang, SA Pinkus, GS Harris, NL Iafrute, AJ AF Hasserjian, R. P. Seliem, R. Turbiner, J. Wang, S. A. Pinkus, G. S. Harris, N. L. Iafrute, A. J. TI BCL2, BCL6, and MYC rearrangements in follicular lymphoma: comparison of FISH and immunohistochemistry results on a tissue microarray and correlation with patient outcome SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1172 BP 256A EP 256A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201301 ER PT J AU Kolman, OK Snuderl, M Ferry, JA Hochberg, EP Chen, YB Hasserjion, RP Rahemtullah, A AF Kolman, O. K. Snuderl, M. Ferry, J. A. Hochberg, E. P. Chen, Y. B. Hasserjion, R. P. Rahemtullah, A. TI Clinicopathologic features of B-Cell lymphomas with concurrent BCL2 and C-MYC gene rearrangements SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Kolman, O. K.; Snuderl, M.; Ferry, J. A.; Hochberg, E. P.; Chen, Y. B.; Hasserjion, R. P.; Rahemtullah, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1191 BP 260A EP 260A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201320 ER PT J AU Louissaint, A Soupir, C Ganguly, A Hasserjian, RP Ferry, JA Harris, NL Zukerherg, LR AF Louissaint, A., Jr. Soupir, C. Ganguly, A. Hasserjian, R. P. Ferry, J. A. Harris, N. L. Zukerherg, L. R. TI Infectious mononucleosis; Morphology and immunophenotype in cervical lymph nodes and Walcleyer's ring SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Louissaint, A., Jr.; Soupir, C.; Ganguly, A.; Hasserjian, R. P.; Ferry, J. A.; Harris, N. L.; Zukerherg, L. R.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1202 BP 263A EP 263A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201331 ER PT J AU Rahemtullah, A Jaffe, ES Harris, NL Hassejian, RP AF Rahemtullah, A. Jaffe, E. S. Harris, N. L. Hassejian, R. P. TI Nodular lymphocyte predominant Hodgkin lymphoma with an interfollicular growth pattern and atypical T cells: A distinct disease variant? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA USA. Natl Canc Inst, Bethesda, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1235 BP 270A EP 270A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201364 ER PT J AU Saenz, AJ Van Cott, E AF Saenz, A. J. Van Cott, E. TI Clinical significance of acquired activated protein C resistance caused by lupus anticoagulants SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Saenz, A. J.; Van Cott, E.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1246 BP 273A EP 273A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201375 ER PT J AU Slack, GW Ferry, JA Harris, NL Gonguly, A Zukerberg, LR AF Slack, G. W. Ferry, J. A. Harris, N. L. Gonguly, A. Zukerberg, L. R. TI Lymphocyte depleted classical Hodgkin lymphoma: A clinical, morphologic and immunohistologic study SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Slack, G. W.; Ferry, J. A.; Harris, N. L.; Gonguly, A.; Zukerberg, L. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1254 BP 274A EP 275A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180201383 ER PT J AU Soupir, CP Vergilio, J Dal Cin, P Hasserjian, RP AF Soupir, C. P. Vergilio, J. Dal Cin, P. Hasserjian, R. P. TI Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura (ITP) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1257 BP 275A EP 275A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201386 ER PT J AU Soupir, CP Vergilio, J Wang, SA Freeman, J Fend, F Hasserjian, RP AF Soupir, C. P. Vergilio, J. Wang, S. A. Freeman, J. Fend, F. Hasserjian, R. P. TI JAK2 V617F mutation defines two subsets of refractory anemia with ringed sideroblasts and marked thrombocytosis (RARS-T) with distinctive clinical and morphologic SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Massachusetts, Med Ctr, Worcester, MA USA. Baystate Med Ctr, Springfield, MA USA. Tech Univ Munich, D-8000 Munich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1256 BP 275A EP 275A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201385 ER PT J AU Truong, F Hasseijian, RP Tang, G Woda, BA Wang, SA AF Truong, F. Hasseijian, R. P. Tang, G. Woda, B. A. Wang, S. A. TI Acute erythroleukemia (AML M6a) with myeloblasts < 20% of total marrow nucleated cells: A heterogeneous group of diseases? SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Univ Massachusetts, Ctr Med, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1273 BP 279A EP 279A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201402 ER PT J AU Deshpande, V Rubbia-Brandt, L Lauwers, G AF Deshpande, V. Rubbia-Brandt, L. Lauwers, G. TI Autoimmune pancreatitis related sclerosing cholangitis, primary sclerosing cholangitis and steroid responsive PSC: A comparative study of 27 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1383 BP 303A EP 303A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201512 ER PT J AU Hsu, A Srivastava, A Hornick, JL Fukuoka, J Lafrate, AJ Louwers, GY Mino-Kenudson, M AF Hsu, A. Srivastava, A. Hornick, J. L. Fukuoka, J. Lafrate, A. J. Louwers, G. Y. Mino-Kenudson, M. TI Molecular alterations in morphologic subtypes of pancreatic intraductal papillary mucinous neoplasm (IPMN) are distinct from those seen in pancreatic ductal adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Toyama Med Univ, Toyama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1391 BP 305A EP 305A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201520 ER PT J AU Hsu, M Fukuoda, J Lauwers, GY Mino-Kenudson, M AF Hsu, M. Fukuoda, J. Lauwers, G. Y. Mino-Kenudson, M. TI Expression of inflammatory mediators in pancreatic intraductal papillary mucinous neoplasm (IPMN) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Toyama Med Univ, Toyama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1392 BP 305A EP 305A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201521 ER PT J AU Hsu, M Srivastava, A Mino-Kenudson, M Deshpande, V Lauwers, GY AF Hsu, M. Srivastava, A. Mino-Kenudson, M. Deshpande, V. Lauwers, G. Y. TI Mismatch repair proteins in pancreatic endocrine neoplasms SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1393 BP 305A EP 306A PG 2 WC Pathology SC Pathology GA 248UA UT WOS:000252180201522 ER PT J AU Koreishi, AF Ferrone, CR Lauwers, GY Deshpande, V AF Koreishi, A. F. Ferrone, C. R. Lauwers, G. Y. Deshpande, V. TI Lessons learned from 5 year survivors of pancreatic adenocarcinoma: A critical look at the AJCC staging system SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Koreishi, A. F.; Ferrone, C. R.; Lauwers, G. Y.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1402 BP 307A EP 307A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201531 ER PT J AU Leanerz, JK Brunt, EM Dehner, LP Geller, SA Hart, J Lauwers, GY Washington, K Yerian, LM Wang, HL AF Leanerz, J. K. Brunt, E. M. Dehner, L. P. Geller, S. A. Hart, J. Lauwers, G. Y. Washington, K. Yerian, L. M. Wang, H. L. TI Observer variability in the histopathologic diagnosis of hepatocellular nodules SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Washington Univ, St Louis, MO USA. St Louis Univ, St Louis, MO USA. Cedars Sinai Med Ctr, Los Angeles, CA USA. Univ Chicago, Chicago, IL USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. Vanderbilt Univ, Nashville, TN USA. Cleveland Clin, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1406 BP 308A EP 308A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201535 ER PT J AU Mino-Kenudson, M Smyrk, TC Deshpande, V Fujisawa, M Shimizu, M Uehara, T Nakazawa, T Kobashi, Y Lauwers, GY Notohara, K AF Mino-Kenudson, M. Smyrk, T. C. Deshpande, V. Fujisawa, M. Shimizu, M. Uehara, T. Nakazawa, T. Kobashi, Y. Lauwers, G. Y. Notohara, K. TI Autoimmune pancreatitis: West vs. East SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. Himeji Red Cross Hosp, Himeji, Hyogo, Japan. Saitama Med Univ, Kawagoe, Saitama, Japan. Shinshu Univ, Sch Med, Matsumoto, Nagano, Japan. Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan. Tenri Hosp, Tenri, Nara, Japan. Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. NR 0 TC 3 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1422 BP 312A EP 312A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201551 ER PT J AU Notohara, K Smyrk, TC Nakazawa, T Mino-Kemudson, M AF Notohara, K. Smyrk, T. C. Nakazawa, T. Mino-Kemudson, M. TI Regressing lymphoplasmacytic sclerosing pancreatitis (LPSP) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. Mayo Clin, Rochester, MN USA. Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1423 BP 312A EP 312A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201552 ER PT J AU Fedele, G Finn, SP Mueller, E Xie, W Shin, E Loda, MF AF Fedele, G. Finn, S. P. Mueller, E. Xie, W. Shin, E. Loda, M. F. TI Gene expression profiling and immunohistochemistry define roles for pFOXO1a and FASN in PI3K signature in prostate cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 MA 1490 BP 326A EP 326A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201618 ER PT J AU Roehrl, MH Rho, JH Wang, JY AF Roehrl, M. H. Rho, J. H. Wang, J. Y. TI Cancer tissue proteomics by heparin affinity fractionation enrichment (HAFE): Up-regulation of PSB7 and PRDX1 in colorectal adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Roehrl, M. H.; Rho, J. H.; Wang, J. Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1505 BP 330A EP 330A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201633 ER PT J AU Barletta, JA Weir, BA Perner, S Johnson, L Rubin, MA Johnson, BE Meyerson, M Chirieac, LR AF Barletta, J. A. Weir, B. A. Perner, S. Johnson, L. Rubin, M. A. Johnson, B. E. Meyerson, M. Chirieac, L. R. TI Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1532 BP 335A EP 335A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201660 ER PT J AU Beheshti, J Sabo, E Janne, PA Joshi, V Wang, LJ Lindeman, NI AF Beheshti, J. Sabo, E. Janne, P. A. Joshi, V. Wang, L. J. Lindeman, N. I. TI TTF-1 positivity is a sensitive predictor of EGFR mutation and treatment response in pulmonary adenocarcinomas, by pathologist interpretation and by image analysis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA USA. Brown Univ, Rhode Isl Hosp, Sch Med, Providence, RI USA. Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1535 BP 336A EP 336A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201663 ER PT J AU Matsubara, O Linazeki, N Tsuda, H Nakalani, Y Mark, EJ AF Matsubara, O. Linazeki, N. Tsuda, H. Nakalani, Y. Mark, E. J. TI Differences of fibroblastic foci of usual interstitial pneumonia (UIP) and intraalveolar buds of chronic organizing pneumonia (COPY bronchiolitis obliterans organizing pneumonia (BOOP): Comparison of the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Natl Def Med Coll, Tokorozawa, Saitama, Japan. Chiba Univ, Chiba, Japan. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1581 BP 347A EP 347A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201709 ER PT J AU Meng, F Mark, EJ Malsubara, O AF Meng, F. Mark, E. J. Malsubara, O. TI Idiopathic tracheal stenosis: A clinicopathological study of 63 cases and comparison of the pathology to chondromalacia SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Meng, F.; Mark, E. J.; Malsubara, O.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1582 BP 347A EP 347A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201710 ER PT J AU Sholl, LM Iafrate, AJ Yeap, B Holmes, A Chou, YP Wu, MT Goan, YG Su, L Jaenne, PA Christiani, DC Chirieac, LR AF Sholl, L. M. Iafrate, A. J. Yeap, B. Holmes, A. Chou, Y. P. Wu, M. T. Goan, Y. G. Su, L. Jaenne, P. A. Christiani, D. C. Chirieac, L. R. TI EGFR gene amplification is invariably associated with exon 19 deletion in non-small cell lung carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan. Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1600 BP 351A EP 351A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201728 ER PT J AU Sholl, LM Lafrate, AJ Yeap, B Holmes, A Chou, Y Wu, A Goan, Y Su, L Jaenne, PA Christiani, DC Chirieac, LR AF Sholl, L. M. Lafrate, A. J. Yeap, B. Holmes, A. Chou, Y. Wu, A. Goan, Y. Su, L. Jaenne, P. A. Christiani, D. C. Chirieac, L. R. TI Genotype-phenotype correlation in non-small cell lung carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 BP 351A EP 351A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201727 ER PT J AU Post, MD Listro, L MacMillan, D Misiano, D Rosenberg, AE AF Post, M. D. Listro, L. MacMillan, D. Misiano, D. Rosenberg, A. E. TI The benefits of hospital-wide electronic safety reporting systems in developing pathology-based quality improvement projects SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Post, M. D.; Listro, L.; MacMillan, D.; Misiano, D.; Rosenberg, A. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1631 BP 358A EP 358A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201759 ER PT J AU Belsley, NA Johnson, MM Selig, MK Nielsen, GP AF Belsley, N. A. Johnson, M. M. Selig, M. K. Nielsen, G. P. TI Use of electron microscopy in core biopsy diagnosis of oncocytic renal tumors SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1702 BP 374A EP 374A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201830 ER PT J AU Wilbur, DC Madi, K Colvin, RB Duncan, LM Faquin, WC Ferry, JA Frosch, MP Houser, SL Krodin, RL Lauwers, GY Louis, DN Mark, EJ Mino-Knudson, M Misdraji, J Nielsen, GP Pitman, MB Rahemtullah, A Rosenberg, AE Smith, RN Stone, JR Tambouret, RH Wu, CL Young, RH Zembowicz, A Klietmann, W AF Wilbur, D. C. Madi, K. Colvin, R. B. Duncan, L. M. Faquin, W. C. Ferry, J. A. Frosch, M. P. Houser, S. L. Krodin, R. L. Lauwers, G. Y. Louis, D. N. Mark, E. J. Mino-Knudson, M. Misdraji, J. Nielsen, G. P. Pitman, M. B. Rahemtullah, A. Rosenberg, A. E. Smith, R. N. Stone, J. R. Tambouret, R. H. Wu, C-L Young, R. H. Zembowicz, A. Klietmann, W. TI Whole slide imaging digital pathology: A pilot study using paired subspecialist correlations SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. Harvard Univ, Sch Med, Boston, MA USA. Corista LLC, Concord, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1701 BP 374A EP 374A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201829 ER PT J AU Gupta, M Selig, MK Oliva, E Nielsen, GP AF Gupta, M. Selig, M. K. Oliva, E. Nielsen, G. P. TI Uterine tumors resembling ovarian sex cord stromal tumors (UTROSCTs): An ultrastructural analysis of 13 cases SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 DHMC, Lebanon, NH USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1704 BP 375A EP 375A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201832 ER PT J AU Saenz, AJ Selig, MK Nielsen, GP Deshpande, V AF Saenz, A. J. Selig, M. K. Nielsen, G. P. Deshpande, V. TI Acinar cell cystadenoma of the pancreas: Role of electron microscopy SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 01-07, 2008 CL Denver, CO SP US & Canadian Acad Pathol C1 [Saenz, A. J.; Selig, M. K.; Nielsen, G. P.; Deshpande, V.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2008 VL 21 SU 1 MA 1708 BP 376A EP 376A PG 1 WC Pathology SC Pathology GA 248UA UT WOS:000252180201836 ER PT S AU Szymusiak, R McGinty, D AF Szymusiak, Ronald McGinty, Dennis BE Pfaff, DW Kieffer, BL TI Hypothalamic regulation of sleep and arousal SO MOLECULAR AND BIOPHYSICAL MECHANISMS OF AROUSAL, ALERTNESS, AND ATTENTION SE Annals of the New York Academy of Sciences LA English DT Article DE median preoptic nucleus; ventrolateral preoptic area; sleep homeostasis; hypocretin; monoamines; GABA; adenosine ID EYE-MOVEMENT SLEEP; VENTROLATERAL PREOPTIC NUCLEUS; PERIFORNICAL LATERAL HYPOTHALAMUS; WAKING DISCHARGE PATTERNS; POSTTRAUMATIC-STRESS-DISORDER; BASAL FOREBRAIN NEURONS; FOS PROTEIN EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DORSAL RAPHE NEURONS; LOCUS-COERULEUS AB Normal waking is associated with neuronal activity in several chemically defined ascending arousal systems. These include monoaminergic neurons in the brainstem and posterior hypothalamus, cholinergic neurons in the brainstem and basal forebrain, and hypocretin (orexin) neurons in the lateral hypothalamus. Collectively, these systems impart tonic activation to their neuronal targets in the diencephalon and neocortex that is reflected in the low-voltage fast-frequency electroencephalogram patterns of wakefulness. Neuronal discharge in these arousal systems declines rapidly at sleep onset. Transitions from waking to sleep, therefore, involve coordinated inhibition of multiple arousal systems. An important source of sleep-related inhibition of arousal arises from neurons located in the preoptic hypothalamus. These preoptic neurons are strongly activated during sleep, exhibiting sleep/waking state-dependent discharge patterns that are the reciprocal of that observed in the arousal systems. The majority of preoptic sleep regulatory neurons synthesize the inhibitory neurotransmitter GABA. Anatomical and functional evidence supports the hypothesis that GABAergic neurons in the median preoptic nucleus (MnPN) and ventrolateral preoptic area (VLPO) exert inhibitory control over the monoaminergic systems and the hypocretin system during sleep. Recent findings indicate that MnPN and VLPO neurons integrate homeostatic aspects of sleep regulation and are important targets for endogenous sleep factors, such as adenosine and growth hormone releasing hormone. C1 [Szymusiak, Ronald; McGinty, Dennis] Greater Los Angeles Healthcare Syst, Vet Adm, Res Serv, Los Angeles, CA USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91434 USA. EM rszym@ucla.edu NR 110 TC 114 Z9 117 U1 5 U2 16 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-703-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1129 BP 275 EP 286 DI 10.1196/annals.1417.027 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BHU95 UT WOS:000256620900025 PM 18591488 ER PT J AU Smith, D Shimamura, T Barbera, S Bejcek, BE AF Smith, Denise Shimamura, Takeshi Barbera, Stephanie Bejcek, Bruce E. TI NF-kappa B controls growth of glioblastomas/astrocytomas SO MOLECULAR AND CELLULAR BIOCHEMISTRY LA English DT Article DE PDGF; NF-kappa B; glioblastoma ID PDGF BETA-RECEPTOR; FACTOR-ALPHA-RECEPTOR; PROTEASE-ACTIVATED LIGAND; PHOSPHOLIPASE-C-GAMMA; CANCER CELL-LINES; BREAST-CANCER; IN-VIVO; PHOSPHOTYROSINE PHOSPHATASE; AUTOPHOSPHORYLATION SITES; HUMAN-FIBROBLASTS AB NF-kappa B is a family of transcription factors that have been shown to be elevated in a variety of tumor types and in some cases central to their survival and growth. Here we present evidence that U-87 MG and U-118 MG growth is regulated by NF-kappa B and controlled by PDGF. NF-kappa B activity was suppressed by a dominant negative mutant of the human PDGF type beta receptor and PDGF-B chain neutralizing antibodies. Creation of cell lines that had inducible expression of shRNAs directed against either c-Rel or RelA inhibited growth almost 90% indicating that NF-kappa B plays a central role in glioblastoma growth. C1 Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Bejcek, BE (reprint author), Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA. EM bruce.bejcek@wmich.edu NR 59 TC 25 Z9 27 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0300-8177 J9 MOL CELL BIOCHEM JI Mol. Cell. Biochem. PD JAN PY 2008 VL 307 IS 1-2 BP 141 EP 147 DI 10.1007/s11010-007-9593-4 PG 7 WC Cell Biology SC Cell Biology GA 237KQ UT WOS:000251373000016 PM 17828582 ER PT J AU Cai, XM Lietha, D Ceccarelli, DF Karginov, AV Rajfur, Z Jacobson, K Hahn, KM Eck, MJ Schaller, MD AF Cai, Xinming Lietha, Daniel Ceccarelli, Derek F. Karginov, Andrei V. Rajfur, Zenon Jacobson, Ken Hahn, Klaus M. Eck, Michael J. Schaller, Michael D. TI Spatial and temporal regulation of focal adhesion kinase activity in living cells SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID PLECKSTRIN HOMOLOGY DOMAIN; RESONANCE ENERGY-TRANSFER; HIGH-AFFINITY BINDING; FERM DOMAIN; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; SPATIOTEMPORAL DYNAMICS; IN-VIVO; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CATALYTIC-ACTIVITY AB Focal adhesion kinase (FAK) is an essential kinase that regulates developmental processes and functions in the pathology of human disease. An intramolecular autoinhibitory interaction between the FERM and catalytic domains is a major mechanism of regulation. Based upon structural studies, a fluorescence resonance energy transfer (FRET)-based FAK biosensor that discriminates between autoinhibited and active conformations of the kinase was developed. This biosensor was used to probe FAK conformational change in live cells and the mechanism of regulation. The biosensor demonstrates directly that FAK undergoes conformational change in vivo in response to activating stimuli. A conserved FERM domain basic patch is required for this conformational change and for interaction with a novel ligand for FAK, acidic phospholipids. Binding to phosphatidylinositol 4,5-bisphosphate (PIP2) -containing phospholipid vesicles activated and induced conformational change in FAK in vitro, and alteration of PIP2 levels in vivo changed the level of activation of the conformational biosensor. These findings provide direct evidence of conformational regulation of FAK in living cells and novel insight into the mechanism regulating FAK conformation. C1 [Cai, Xinming; Rajfur, Zenon; Jacobson, Ken; Schaller, Michael D.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA. [Karginov, Andrei V.; Hahn, Klaus M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA. [Jacobson, Ken; Hahn, Klaus M.; Schaller, Michael D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Schaller, Michael D.] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA. [Lietha, Daniel; Ceccarelli, Derek F.; Eck, Michael J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Schaller, MD (reprint author), Univ N Carolina, Dept Cell & Dev Biol, 534 Taylor Hall,CB 7090, Chapel Hill, NC 27599 USA. EM crispy@med.unc.edu RI Rajfur, Zenon/H-2506-2013; Lietha, Daniel/L-8041-2014; OI Lietha, Daniel/0000-0002-6133-6486; Rajfur, Zenon/0000-0003-1265-6480 FU NHLBI NIH HHS [HL45100, P01 HL045100]; NIGMS NIH HHS [GM0064346, U54 GM064346] NR 60 TC 95 Z9 98 U1 1 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2008 VL 28 IS 1 BP 201 EP 214 DI 10.1128/MCB.01324-07 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 245HI UT WOS:000251925300017 PM 17967873 ER PT J AU Provot, S Nachtrab, G Paruch, J Chen, AP Silva, A Kronenberg, HM AF Provot, Sylvain Nachtrab, Gregory Paruch, Jennifer Chen, Adele Pin Silva, Alcino Kronenberg, Henry M. TI A-Raf and B-Raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID FACIO-CUTANEOUS SYNDROME; GROWTH-PLATE CARTILAGE; PROTEIN-KINASE; INDIAN-HEDGEHOG; TARGETED DISRUPTION; PTH/PTHRP RECEPTOR; CELL-PROLIFERATION; OSTEOBLASTIC CELLS; IN-VIVO; DIFFERENTIATION AB Parathyroid hormone-related peptide (PTHrP) and the parathyroid hormone-PTHrP receptor increase chondrocyte proliferation and delay chondrocyte maturation in endochondral bone development at least partly through cyclic AMP (cAMP)-dependent signaling pathways. Because data suggest that the ability of cAMP to stimulate cell proliferation involves the mitogen-activated protein kinase kinase kinase B-Raf, we hypothesized that B-Raf might mediate the proliferative action of PTHrP in chondrocytes. Though B-Raf is expressed in proliferative chondrocytes, its conditional removal from cartilage did not affect chondrocyte proliferation and maturation or PTHrP-induced chondrocyte proliferation and PTHrP-delayed maturation. Similar results were obtained by conditionally removing B-Raf from osteoblasts. Because A-raf and B-raf are expressed similarly in cartilage, we speculated that they may fulfill redundant functions in this tissue. Surprisingly, mice with chondrocytes deficient in both A-Raf and B-Raf exhibited normal endochondral bone development. Activated extracellular signal-regulated kinase (ERK) was detected primarily in hypertrophic chondrocytes, where C-raf is expressed, and the suppression of ERK activation in these cells by PTHrP or a MEK inhibitor coincided with a delay in chondrocyte maturation. Taken together, these results demonstrate that B-Raf and A-Raf are dispensable for endochondral bone development and they indicate that the main role of ERK in cartilage is to stimulate not cell proliferation, but rather chondrocyte maturation. C1 [Provot, Sylvain; Nachtrab, Gregory; Paruch, Jennifer; Kronenberg, Henry M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA. [Provot, Sylvain] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA. [Chen, Adele Pin; Silva, Alcino] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA USA. [Chen, Adele Pin; Silva, Alcino] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Chen, Adele Pin; Silva, Alcino] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Chen, Adele Pin; Silva, Alcino] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Kronenberg, HM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, 50 Blossom St,Thier 1101, Boston, MA 02114 USA. EM hkronenberg@partners.org.t FU NIAMS NIH HHS [AR046238, R01 AR046238]; NIDDK NIH HHS [DK56246, P01 DK056246] NR 51 TC 26 Z9 28 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2008 VL 28 IS 1 BP 344 EP 357 DI 10.1128/MCB.00617-07 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 245HI UT WOS:000251925300030 PM 17967876 ER PT J AU Karagianni, P Amazit, L Qin, J Wong, JM AF Karagianni, Panagiota Amazit, Larbi Qin, Jun Wong, Jiemin TI ICBP90, a novel methyl K9H3 binding protein linking protein ubliquitination with heterochromatin formation SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID UBIQUITIN LIGASE ACTIVITY; II-ALPHA EXPRESSION; HISTONE H3 TAIL; ANDROGEN-RECEPTOR; MAMMALIAN-CELLS; PERICENTRIC HETEROCHROMATIN; LYSINE-4 METHYLATION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PLANT HOMEODOMAIN AB Methylation of histone H3 on lysine 9 is critical for diverse biological processes including transcriptional repression, heterochromatin formation, and X inactivation. The biological effects of histone methylation are thought to be mediated by effector proteins that recognize and bind to specific patterns of methylation. Using an unbiased in vitro biochemical approach, we have identified ICBP90, a transcription and cell cycle regulator, as a novel methyl K9 H3-specific binding protein. ICBP90 and its murine homologue Np95 are enriched in pericentric heterochromatin of interphase nuclei, and this localization is dependent on H3K9 methylation. Specific binding of ICBP90 to methyl K9 H3 depends on two functional domains, a PHD (plant homeodomain) finger that defines the binding specificity and an SRA (SET- and RING-associated) domain that promotes binding activity. Furthermore, we present evidence that ICBP90 is required for proper heterochromatin formation in mammalian cells. C1 [Karagianni, Panagiota] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Amazit, Larbi] INSERM, U643, F-94276 Le Kremlin Bicetre, France. [Karagianni, Panagiota; Amazit, Larbi; Qin, Jun; Wong, Jiemin] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. RP Karagianni, P (reprint author), Harvard Univ, Sch Med, Dept Med, Bldg 149,Room 7-213,13th St, Charlestown, MA 02129 USA. EM pkaragianni@partners.org FU NIDDK NIH HHS [DK58679, R01 DK058679] NR 74 TC 126 Z9 135 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2008 VL 28 IS 2 BP 705 EP 717 DI 10.1128/MCB.01598-07 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 250ER UT WOS:000252283300016 PM 17967883 ER PT J AU Tsutsumi, T Kuwabara, H Arai, T Xiao, Y DeCaprio, JA AF Tsutsumi, Takeya Kuwabara, Hiroshi Arai, Takehiro Xiao, Yonghong DeCaprio, James A. TI Disruption of the Fbxw8 gene results in pre- and postnatal growth retardation in mice SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID FACTOR-II GENE; TARGETED DISRUPTION; CYCLIN-E; CARDIOVASCULAR DEVELOPMENT; CELLULAR-TRANSFORMATION; UBIQUITIN LIGASES; TRANSGENIC MICE; CUL7; SCF; MUTATIONS AB CUL7 binds to SKP1, RBX1, and FBXW8 to form a cullin-RING ligase, or an SKP1-cullin-F box protein complex. The targeted disruption of the Cul7 gene in mice results in significant reduction in embryo size and neonatal lethality. In humans, CUL7 was found to be mutated in the 3-M dwarfism syndrome characterized by severe pre- and postnatal growth retardation, indicating that CUL7 is closely associated with human and mouse growth. We generated mice lacking Fbxw8 by gene trapping. Similar to CUl7(-/-)animals, Fbxw8(-/-) embryos and placentas were smaller than wild-type and heterozygous littermates and placentas. Approximately 30% of the expected number of Fbxw8(-/-) mice survived birth, but these mice remained smaller than their wild-type and heterozygous littermates throughout postnatal development. FBXW8 expression was detected in most organs of wild-type mice examined, and the organs in Fbxw8(-/-) mice were smaller than those in wild-type mice. Fbxw8 expression levels were highest in skeletal muscle, cartilage, and lung tissue. Expression profiling revealed elevated levels of insulin-like growth factor binding protein 1 (IGFBP1) transcripts in Fbxw8(-/-) embryos. Furthermore, we observed increased levels of IGFBP2 in Cul7(-/-) as well as Fbxw8(-/-) fibroblasts. These results demonstrate that the FBXW8-CUL7 complex plays a significant role in growth control. C1 [Tsutsumi, Takeya; Kuwabara, Hiroshi; Arai, Takehiro; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Tsutsumi, Takeya; Kuwabara, Hiroshi; Arai, Takehiro; DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Xiao, Yonghong; DeCaprio, James A.] Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA. RP DeCaprio, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. EM james_decaprio@dfci.harvard.edu FU NCI NIH HHS [R01 CA093804] NR 34 TC 31 Z9 32 U1 4 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2008 VL 28 IS 2 BP 743 EP 751 DI 10.1128/MCB.01665-07 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 250ER UT WOS:000252283300019 PM 17998335 ER PT J AU Quinones, MP Kalkonde, Y Estrada, CA Jimenez, F Ramirez, R Mahimainathan, L Mummidi, S Choudhury, GG Martinez, H Adams, L Mack, M Reddick, RL Maffi, S Haralambous, S Probert, L Ahuja, SK Ahuja, SS AF Quinones, Marlon P. Kalkonde, Yogeshwar Estrada, Carlos A. Jimenez, Fabio Ramirez, Robert Mahimainathan, Lenin Mummidi, Srinivas Choudhury, Goutam G. Martinez, Hernan Adams, Lisa Mack, Matthias Reddick, Robert L. Maffi, Shivani Haralambous, Sylva Probert, Lesley Ahuja, Sunil K. Ahuja, Seema S. TI Role of astrocytes and chemokine systems in acute TNF alpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappa B and Akt SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Article DE multiple sclerosis; chemokines; TNF alpha; biomarker; inflammation; transgenic mice ID TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; NEURONAL SURVIVAL; MCP-1 CCL2; RECEPTOR 2; EXPRESSION; DISEASE AB Chemotactic factors known as chemokines play an important role in the pathogenesis of multiple sclerosis (MS). Transgenic expression of TNF alpha in the central nervous system (CNS) leads to the development of a demyelinating phenotype (TNF alpha-induced demyelination; TID) that is highly reminiscent of MS. Little is known about the role of chemokines in TID but insights derived from studying this model might extend our current understanding of MS pathogenesis and complement data derived from the classic autoimmune encephalomyelitis (EAE) model system. Here we show that in TID, chemokines and their receptors were significantly increased during the acute phases of disease. Notably, the CCL2 (MCP-1)-CCR2 axis and the closely related ligand-receptor pair CCR1-CCL3 (MIP-1 alpha) were among the most up-regulated during disease. On the other hand, receptors like CCR3 and CCR4 were not elevated. This significant increase in the levels of chemokines/receptors correlated with robust immune infiltration of the CNS by inflammatory cells, i.e., macrophages, and immune cells particularly T and B cells. Immurrostaining and confocal microscopy, along with in vitro studies revealed that astrocytes were a major source of locally produced chemokines and expressed functional chemokine receptors such as CCR2. Using an in vitro system we demonstrate that expression of CCR2 was functional in astrocytes and that signaling via this receptor lead to activation of NF-kappa B and Akt and was associated with increased astrocyte survival. Collectively, our data suggests that transgenic murine models of NIS are useful to dissect mechanisms of disease and that in these models, up-regulation of chemokines and their receptors may be key determinants in TID. (C) 2007 Elsevier Inc. All rights reserved. C1 [Quinones, Marlon P.; Kalkonde, Yogeshwar; Estrada, Carlos A.; Jimenez, Fabio; Ramirez, Robert; Mahimainathan, Lenin; Mummidi, Srinivas; Choudhury, Goutam G.; Martinez, Hernan; Adams, Lisa; Maffi, Shivani; Ahuja, Sunil K.; Ahuja, Seema S.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Estrada, Carlos A.; Jimenez, Fabio; Ramirez, Robert; Mahimainathan, Lenin; Mummidi, Srinivas; Choudhury, Goutam G.; Martinez, Hernan; Adams, Lisa; Maffi, Shivani; Ahuja, Sunil K.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.; Ahuja, Seema S.] Vet Adm Ctr Res AIDS & HIV 1 Infect, San Antonio, TX USA. [Mack, Matthias] Univ Munich, Munich, Germany. [Probert, Lesley] Hellenic Pasteur Inst, Mol Genet Lab, Athens, Greece. [Haralambous, Sylva] Mol Genet Lab, Transgen Technol Unit, Athens, Greece. RP Ahuja, SS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7870, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ahuja@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU NCI NIH HHS [P30 CA054174, P30 CA54174]; NIA NIH HHS [P01 AG019316, P01AG19316, P30 AG013319]; NIAID NIH HHS [AI48644, R01 AI048644, R01 AI048644-05]; NIAMS NIH HHS [AR 052755, R01 AR052755, R01 AR052755-02] NR 49 TC 36 Z9 38 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD JAN PY 2008 VL 37 IS 1 BP 96 EP 109 DI 10.1016/j.mcn.2007.08.017 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 255UM UT WOS:000252683100009 PM 17949991 ER PT J AU Rapoport, I Boll, W Yu, A Bocking, T Kirchhausen, T AF Rapoport, Iris Boll, Werner Yu, Anan Bocking, Till Kirchhausen, Tom TI A motif in the clathrin heavy chain required for the Hsc70/auxilin uncoating reaction SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID COATED VESICLES; ELECTRON CRYOMICROSCOPY; AP-2 ADAPTER; J-DOMAIN; IN-VIVO; AUXILIN; PROTEIN; ENDOCYTOSIS; DISSOCIATION; DYNAMIN AB The 70-kDa heat-shock cognate protein (Hsc70) chaperone is an ATP-dependent "disassembly enzyme" for many subcellular structures, including clathrin-coated vesicles where it functions as an uncoating ATPase. Hsc70, and its cochaperone auxilin together catalyze coat disassembly. Like other members of the Hsp70 chaperone family, it is thought that ATP-bound Hsc70 recognizes the clathrin triskelion through an unfolded exposed hydrophobic segment. The best candidate is the unstructured C terminus (residues 1631-1675) of the heavy chain at the foot of the tripod below the hub, containing the sequence motif QLMLT, closely related to the sequence bound preferentially by the substrate groove of Hsc70 (Fotin et al., 2004b). To test this hypothesis, we generated in insect cells recombinant mammalian triskelions that in vitro form clathrin cages and clathrin/AP-2 coats exactly like those assembled from native clathrin. We show that coats assembled from recombinant clathrin are good substrates for ATP- and auxilin-dependent, Hsc70-catalyzed uncoating. Finally, we show that this uncoating reaction proceeds normally when the coats contain recombinant heavy chains truncated C-terminal to the QLMLT motif, but very inefficiently when the motif is absent. Thus, the QLMLT motif is required for Hsc-70-facilitated uncoating, consistent with the proposal that this sequence is a specific target of the chaperone. C1 [Kirchhausen, Tom] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. EM kirchhausen@crystal.harvard.edu OI Bocking, Till/0000-0003-1165-3122 FU National Institutes of Health [GM-036548]; Human Frontier Science Program FX We are grateful to S. C. Harrison for helpful discussions throughout the project. This work has been supported by National Institutes of Health grant GM-036548 (to T. K.) T. B. is supported by a Human Frontier Science Program Fellowship. NR 45 TC 25 Z9 26 U1 2 U2 7 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD JAN PY 2008 VL 19 IS 1 BP 405 EP 413 DI 10.1091/mbc.E07-09-0870 PG 9 WC Cell Biology SC Cell Biology GA 343IT UT WOS:000258847500037 PM 17978091 ER PT J AU Qiao, LY Hamamichi, S Caldwell, KA Caldwell, GA Yacoubian, TA Wilson, S Xie, ZL Speake, LD Parks, R Crabtree, D Liang, QL Crimmins, S Schneider, L Uchiyama, Y Iwatsubo, T Zhou, Y Peng, LS Lu, YM Standaert, DG Walls, KC Shacka, JJ Roth, KA Zhang, JH AF Qiao, Liyan Hamamichi, Shusei Caldwell, Kim A. Caldwell, Guy A. Yacoubian, Talene A. Wilson, Scott Xie, Zuo-Lei Speake, Lisa D. Parks, Rachael Crabtree, Donna Liang, Qiuli Crimmins, Stephen Schneider, Lonnie Uchiyama, Yasuo Iwatsubo, Takeshi Zhou, Yi Peng, Lisheng Lu, YouMing Standaert, David G. Walls, Ken C. Shacka, John J. Roth, Kevin A. Zhang, Jianhua TI Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity SO MOLECULAR BRAIN LA English DT Article AB alpha-synuclein (alpha-syn) is a main component of Lewy bodies (LB) that occur in many neurodegenerative diseases, including Parkinson's disease (PD), dementia with LB (DLB) and multi-system atrophy. alpha-syn mutations or amplifications are responsible for a subset of autosomal dominant familial PD cases, and overexpression causes neurodegeneration and motor disturbances in animals. To investigate mechanisms for alpha-syn accumulation and toxicity, we studied a mouse model of lysosomal enzyme cathepsin D (CD) deficiency, and found extensive accumulation of endogenous alpha-syn in neurons without overabundance of alpha-syn mRNA. In addition to impaired macroautophagy, CD deficiency reduced proteasome activity, suggesting an essential role for lysosomal CD function in regulating multiple proteolytic pathways that are important for alpha-syn metabolism. Conversely, CD overexpression reduces alpha-syn aggregation and is neuroprotective against alpha-syn overexpression-induced cell death in vitro. In a C. elegans model, CD deficiency exacerbates alpha-syn accumulation while its overexpression is protective against alpha-syn-induced dopaminergic neurodegeneration. Mutated CD with diminished enzymatic activity or overexpression of cathepsins B (CB) or L (CL) is not protective in the worm model, indicating a unique requirement for enzymatically active CD. Our data identify a conserved CD function in alpha-syn degradation and identify CD as a novel target for LB disease therapeutics. C1 [Qiao, Liyan; Xie, Zuo-Lei; Speake, Lisa D.; Parks, Rachael; Crabtree, Donna; Liang, Qiuli; Crimmins, Stephen; Schneider, Lonnie; Walls, Ken C.; Shacka, John J.; Roth, Kevin A.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Hamamichi, Shusei; Caldwell, Kim A.; Caldwell, Guy A.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL USA. [Caldwell, Kim A.; Caldwell, Guy A.; Yacoubian, Talene A.; Wilson, Scott; Zhou, Yi; Standaert, David G.; Roth, Kevin A.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA. [Caldwell, Kim A.; Caldwell, Guy A.; Yacoubian, Talene A.; Standaert, David G.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Caldwell, Kim A.; Caldwell, Guy A.; Yacoubian, Talene A.; Shacka, John J.; Roth, Kevin A.; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL 35294 USA. [Uchiyama, Yasuo] Osaka Univ, Dept Cell Biol & Neurosci, Osaka, Japan. [Iwatsubo, Takeshi] Univ Tokyo, Dept Neuropathol, Dept Neuropathol & Neurosci, Grad Sch Med,Grad Sch Pharmaceut Sci, Tokyo, Japan. [Peng, Lisheng; Lu, YouMing] Burnett Coll Biomed Sci, Biomol Sci Ctr, Orlando, FL USA. [Shacka, John J.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM lqiao@uab.edu; hamam@bama.ua.edu; kcaldwell@ua.edu; gcaldwell@ua.edu; tyacoub@uab.edu; wilson@nrc.uab.edu; xie_zl1969@yahoo.com.cn; ldspeake@bsu.edu; rparks1@mvnu.edu; donna.crabtree@gmail.com; lianglql02@gmail.com; scrimmins@nrc.uab.edu; lonnie11@uab.edu; y-uchi@anat1.med.osaka-u.ac.jp; iwatsubo@mol.f.u-tokyo.ac.jp; yzhou@nrc.uab.edu; youming@mail.ucf.edu; youming@mail.ucf.edu; dstandaert@uab.edu; kcwalls@uab.edu; shacka@uab.edu; karoth@uab.edu; zhanja@uab.edu RI zhang, jianhua/D-3404-2009 FU American Parkinson's Disease Association; Michael J. Fox Foundation; Batten Disease Support and Research Association; VA career development award; UAB Alzheimer Disease Research Center; NIH [NS35107, NS41962]; UAB faculty development and start-up fund; UAB Neuroscience Core Facilities [NS47466, NS57098]; American Heart Association [05553413]; NIH/NINDS [R01NS5051383]; NIH/NIA [R01AG033282] FX We thank Songsong Cao for generating the alpha-syn::GFP transgenic worms, Dr. Pam McLean for plasmids used for alpha-syn aggregation assay in H4 cells, Drs. M Brenner and Y-F Chen for critically reading the manuscript, Drs. J Wu and J Tucholski, and members of our laboratories for technical assistance and discussions. Ctsd mutant mice were generously provided by Dr. P Saftig (University of Kiel). We thank Genta Ito for handling the shipping of the phospho-alpha-syn antibody. This work is funded by the American Parkinson's Disease Association and Michael J. Fox Foundation (GAC, KAC, DGS), Batten Disease Support and Research Association, VA career development award, and UAB Alzheimer Disease Research Center (JJS), NIH grants NS35107 and NS41962 (KAR), a UAB faculty development and start-up fund, UAB Alzheimer Disease Research Center, the American Parkinson's Disease Association, and Michael J. Fox Foundation (JZ). This work is also supported by UAB Neuroscience Core Facilities (NS47466 and NS57098). This work was also supported by the American Heart Association (05553413, YL), NIH/NINDS (R01NS5051383, YL) and NIH/NIA (R01AG033282, YL). NR 72 TC 98 Z9 98 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-6606 J9 MOL BRAIN JI Mol. Brain PY 2008 VL 1 DI 10.1186/1756-6606-1-17 PG 18 WC Neurosciences SC Neurosciences & Neurology GA V25CV UT WOS:000208457000017 PM 19021916 ER PT J AU El-Jawahri, A Patel, D Zhang, M Mladkova, N Chakravarti, A AF El-Jawahri, Areej Patel, Disha Zhang, Min Mladkova, Nikol Chakravarti, Arnab TI Biomarkers of clinical responsiveness in brain tumor patients - Progress and potential SO MOLECULAR DIAGNOSIS & THERAPY LA English DT Article ID GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; LOW-GRADE GLIOMAS; REPAIR GENE MGMT; PHASE-III TRIAL; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; ANAPLASTIC OLIGODENDROGLIOMAS; CHROMOSOME 1P; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE AB Gliomas are the most common primary brain tumors in adults. Anaplastic astrocytoma and glioblastoma multiforme represent malignant astrocytomas, which are the most common type of malignant gliomas. Despite research efforts in cancer therapy, the prognosis of patients with malignant gliomas remains poor. Research efforts in recent years have focused on investigating the cellular. molecular, and genetic pathways involved in the progression of malignant gliomas. As a result, biomarkers have emerged as diagnostic, predictive, and prognostic tools that have the potential to transform the field of brain tumor diagnostics. An increased understanding of the important molecular pathways that have been implicated in the progression of malignant gliomas has led to the identification of potential diagnostic, prognostic, and predictive biomarkers, some bearing clinical implications for targeted therapy. Some of the most promising biomarkers to date include loss of chromosomes 1p/19q in oligodendrogliomas and expression of O-6-methylguanine-DNA methyltransferase (MGMT) or epidermal growth factor receptor (EGFR) Status in glioblastomas. Other promising biomarkers in glioma research include glial fibrillary acidic protein, galectins, Kir potassium channel proteins, angiogenesis. and apoptosis pathway markers. Research into the clinical relevance and applicability of such biomarkers has the potential to revolutionize our approach to the diagnosis and treatment of patients with malignant gliomas. C1 [El-Jawahri, Areej; Patel, Disha; Zhang, Min; Mladkova, Nikol; Chakravarti, Arnab] Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Lab Mol & Cellular Radiat Neurooncol,Sch Med, Boston, MA 02114 USA. RP Chakravarti, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Lab Mol & Cellular Radiat Neurooncol,Sch Med, Cox 3,100 Blossom St, Boston, MA 02114 USA. EM achakravarti@partners.org FU NIH/NCI [ROICA108633]; Goldhirsh Foundation Award; Brain Tumor Funder's Collaborative Grant FX This work was supported by the following grants to Dr Chakravarti: NIH/NCI Grant ROICA108633, Goldhirsh Foundation Award, the Brain Tumor Funder's Collaborative Grant, and Brian D. Silber Fund.; The authors have no conflicts of interest that tire directly relevant to the content of this review. NR 71 TC 8 Z9 10 U1 1 U2 4 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1177-1062 EI 1179-2000 J9 MOL DIAGN THER JI Mol. Diagn. Ther. PY 2008 VL 12 IS 4 BP 199 EP 208 PG 10 WC Genetics & Heredity; Pharmacology & Pharmacy SC Genetics & Heredity; Pharmacology & Pharmacy GA 340JS UT WOS:000258642500001 PM 18652516 ER PT J AU Dean, T Vilardaga, JP Potts, JT Gardella, TJ AF Dean, Thomas Vilardaga, Jean-Pierre Potts, John T., Jr. Gardella, Thomas J. TI Altered selectivity of parathyroid hormone (PTH) and PTH-Related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID OSTEOBLAST-DERIVED PTHRP; LIGAND-BINDING; TYPE-1 RECEPTOR; ANABOLIC AGENT; BONE-FORMATION; PEPTIDE; AGONIST; NUCLEOTIDE; MECHANISM; REGION AB PTH and PTHrP use the same G protein-coupled receptor, the PTH/PTHrP receptor (PTHR), to mediate their distinct biological actions. The extent to which the mechanisms by which the two ligands bind to the PTHR differ is unclear. We examined this question using several pharmacological and biophysical approaches. Kinetic dissociation and equilibrium binding assays revealed that the binding of [I-125] PTHrP(1-36) to the PTHR was more sensitive to GTP gamma S (added to functionally uncouple PTHR-G protein complexes) than was the binding of [I-125] PTH(1-34) (similar to 75% maximal inhibition vs. similar to 20%). Fluorescence resonance energy transfer-based kinetic analyses revealed that PTHrP(1-36) bound to the PTHR more slowly and dissociated from it more rapidly than did PTH(1-34). The cAMP signaling response capacity of PTHrP(1-36) in cells decayed more rapidly than did that of PTH(1-34) (t(1/2) = similar to 1 vs. similar to 2 h). Divergent residue 5 in the ligand, IIe in PTH and His in PTHrP, was identified as a key determinant of the altered receptor-interaction responses exhibited by the two peptides. We conclude that whereas PTH and PTHrP bind similarly to the G protein-coupled PTHR conformation (RG), PTH has a greater capacity to bind to the G protein-uncoupled conformation (R-0) and, hence, can produce cumulatively greater signaling responses (via R(0 ->)RG isomerization) than can PTHrP. Such conformational selectivity may relate to the distinct modes by which PTH and PTHrP act biologically, endocrine vs. paracrine, and may help explain reported differences in the effects that the ligands have on calcium and bone metabolism when administered to humans. C1 [Dean, Thomas; Vilardaga, Jean-Pierre; Potts, John T., Jr.; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Vilardaga, Jean-Pierre] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Gardella, TJ (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. EM Gardella@helix.mgh.harvard.edu FU NIDDK NIH HHS [DK-11794, P01 DK011794] NR 42 TC 75 Z9 75 U1 2 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 2008 VL 22 IS 1 BP 156 EP 166 DI 10.1210/me.2007-0274 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 246FZ UT WOS:000251994200016 PM 17872377 ER PT J AU Nowling, TK Fulton, JD Chike-Harris, K Gilkeson, GS AF Nowling, Tamara K. Fulton, Jennifer Dziadyk Chike-Harris, Katherine Gilkeson, Gary S. TI Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes SO MOLECULAR IMMUNOLOGY LA English DT Article DE transcription; gene regulation; transcription factors; Ets; B cells; T cells; systemic lupus erythematosus ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DNA-BINDING SPECIFICITIES; MURINE LEUKEMIA-VIRUS; TRANSCRIPTION FACTOR; RENAL-DISEASE; GENE; FAMILY; EXPRESSION; PROTEIN; CELLS AB Fli1 is an Ets family member that is essential for embryonic development. Increasing evidence suggests modulating FIR gene expression impacts lymphocyte development/function and is an important mediator in the autoimmune disease lupus. Fli1 is over-expressed in splenic lymphocytes in lupus prone mouse strains and in PBMCs of lupus patients. Presently, it is unknown how Fli1 gene expression is controlled in lymphocytes or how it becomes over-expressed in lupus. Therefore, we examined Fli1 regulation in a murine B cell line and T cell line and identified several cis-regulatory elements within a 230 bp region that contribute to Fli1 promoter activity. Ets factors Elf 1, Tel and Fli1 bind in vitro to this region and increase endogenous Fli1 expression when over-expressed in a T cell line. In addition, we determined that a microsatellite located adjacent to the region containing these cis-regulatory elements is polymorphic in three lupus prone mouse strains and that the length of the microsatellite is inversely correlated with promoter activity in a T cell line. These results suggest that several Ets factors, including Fli1 itself, are involved in the transcriptional regulation of Fli1 in lymphocytes. Furthermore, the presence of a polymorphic microsatellite in the Fli1 promoter may contribute to increased Fli1 expression in T cells during lupus disease progression. (C) 2007 Elsevier Ltd. All rights reserved. C1 Med Univ S Carolina, Div Rheumatol, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Med Res Serv, Charleston, SC 29425 USA. RP Nowling, TK (reprint author), Med Univ S Carolina, Div Rheumatol, Dept Med, 96 Jonathan Lucas St,Ste 912 CSB, Charleston, SC 29425 USA. EM nowling@muse.edu FU NIAMS NIH HHS [R01 AR047451, AR47451]; NIDDK NIH HHS [K01 DK072306-01, DK072306, K01 DK072306-02, K01 DK072306] NR 37 TC 14 Z9 14 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2008 VL 45 IS 1 BP 1 EP 12 DI 10.1016/j.molimm.2007.05.018 PG 12 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 218KE UT WOS:000250013600001 PM 17606295 ER PT J AU Drouin, EE Glickstein, L Kwok, WW Nepom, GT Steere, AC AF Drouin, Elise E. Glickstein, Lisa Kwok, William W. Nepom, Gerald T. Steere, Allen C. TI Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis SO MOLECULAR IMMUNOLOGY LA English DT Article DE Borrelia burgdorferi; Lyme disease; T cells; molecular mimicry; MHC molecules ID SURFACE PROTEIN-A; HLA-DR MOLECULES; CLASS-II MOLECULES; TREATMENT-RESISTANT; PEPTIDE BINDING; ANTIBODY-RESPONSE; BURGDORFERI DNA; IDENTIFICATION; AUTOIMMUNITY; MIMICRY AB Antibiotic-refractory Lyme arthritis, which may result from infection-induced autoimmunity, is associated with HLA-DR molecules that bind an epitope of Borrelia burgdorferi (Bb) outer-surface protein A (OspA(165-173)) and with T cell reactivity with this epitope. One potential mechanism to explain these associations is molecular mimicry between OspA(165-173) and a self-peptide. Here, we searched the published human genome for peptides with sequence homology with OspA(165-173). The two peptides identified with the greatest sequence homology with the OspA epitope were MAWD-BP276-288, which had identity at eight of the nine core amino acid residues, and T-span7(58-70), which had identity at six residues. MAWD-BP mRNA was expressed by synoviocytes, while T-span7 mRNA was not. However, neither peptide bound all of the HLA-DR molecules associated with antibiotic-refractory Lyme arthritis. Among 11 patients, 9 had T cell reactivity with OspA(161-170), 6 had responses to MAWD-BP176-288, and 3 had reactivity with T-span7(58-70), but reactivity with the self-peptides was lower than that induced by the spirochetal epitope. Thus, there remains an association between OspA(165-173) and antibiotic-refractory Lyme arthritis, and infection-induced autoimmunity is an attractive hypothesis to explain this outcome. However, molecular mimicry due to sequence homology between OspA(165-173) and a human peptide seems unlikely to be the critical mechanism. (C) 2007 Elsevier Ltd. All rights reserved. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. Virginia Mason Med Ctr, Benaroya Res Inst, Seattle, WA 98101 USA. RP Drouin, EE (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammmatory Dis, 149 13th St,Room 8301, Charlestown, MA 02129 USA. EM edrouin@partners.org OI Nepom, Gerald/0000-0002-8063-1464 FU NIAMS NIH HHS [R01 AR020358, R01 AR020358-30, AR-20358, R01 AR020358-29] NR 44 TC 12 Z9 12 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 2008 VL 45 IS 1 BP 180 EP 189 DI 10.1016/j.molimm.2007.04.017 PG 10 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 218KE UT WOS:000250013600020 PM 17555819 ER PT S AU Ehsan, A Herrick, JL AF Ehsan, Aamir Herrick, Jennifer L. BE Zander, DS Popper, HH Jagirdar, J Haque, AK Cagle, PT Barrios, R TI Posttransplantation Lymphoproliferative Disorder SO MOLECULAR PATHOLOGY OF LUNG DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID EPSTEIN-BARR-VIRUS; ORGAN TRANSPLANT RECIPIENTS; LATENT MEMBRANE PROTEIN-1; CYTOTOXIC T-CELLS; MONOCLONAL-ANTIBODY RITUXIMAB; BURKITTS-LYMPHOMA CELLS; INFECTED B-CELLS; SOLID-ORGAN; PERIPHERAL-BLOOD; LIVER-TRANSPLANT C1 [Ehsan, Aamir] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ehsan, Aamir] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Ehsan, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. NR 90 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-0-387-72429-4 J9 MOL PATHOL LIB PY 2008 VL 1 BP 315 EP 333 DI 10.1007/978-0-387-72430-0_31 D2 10.1007/978-0-387-72430-0 PG 19 WC Biochemistry & Molecular Biology; Pathology SC Biochemistry & Molecular Biology; Pathology GA BKG48 UT WOS:000268026600031 ER PT J AU Cortes, ML Oehmig, A Saydam, O Sanford, JD Perry, KF Fraefel, C Breakefield, XO AF Cortes, Maria L. Oehmig, Angelika Saydam, Okay Sanford, Jocelyn D. Perry, Katherine F. Fraefel, Cornel Breakefield, Xandra O. TI Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector SO MOLECULAR THERAPY LA English DT Article ID SITE-SPECIFIC INTEGRATION; ADENOASSOCIATED VIRUS AAV; ATAXIA-TELANGIECTASIA; TRANSGENE INTEGRATION; DEFICIENT MICE; GENE-TRANSFER; DNA-DAMAGE; IN-VIVO; EXPRESSION; SYSTEM AB Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by neurodegeneration, immunodeficiency, cancer predisposition, genome instability, and sensitivity to ionizing radiation (IR). We have previously shown that a herpes simplex virus type 1 (HSV-1) amplicon vector carrying the human ataxia-telangiectasia mutated (ATM) complementary DNA (cDNA) is able to correct aspects of the cellular phenotype of human A-T cells in culture, and is also able to transfer the ATM cDNA to the Atm(-/-) mouse cerebellum. In order to achieve stable gene replacement, we have generated an HSV/adeno-associated virus (AAV) hybrid amplicon vector carrying the expression cassettes for the ATM cDNA [(9.2 kilobases (kb)] and enhanced green fluorescent protein (EGFP), flanked by AAV inverted terminal repeats (ITRs). This hybrid vector, in the presence of AAV Rep proteins, mediates site-specific integration into the AAVS1 site on chromosome 19 in human cells and in Atm(-/-) mice carrying that human locus. The functional activity of the vector-derived ATM was confirmed in vitro and in vivo by ATM autophosphorylation at Ser-1981 after IR. This proof-of-principle study establishes the ability of HSV/AAV hybrid amplicon vectors to mediate functional targeted integration of the ATM cDNA into A-T cells in culture and in Atm(-/-) mice in vivo, thus laying a foundation for possible gene therapy approaches in the treatment of A-T patients. C1 [Cortes, Maria L.; Oehmig, Angelika; Saydam, Okay; Sanford, Jocelyn D.; Perry, Katherine F.; Breakefield, Xandra O.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Cortes, Maria L.; Oehmig, Angelika; Saydam, Okay; Sanford, Jocelyn D.; Perry, Katherine F.; Breakefield, Xandra O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA USA. [Cortes, Maria L.; Oehmig, Angelika; Saydam, Okay; Sanford, Jocelyn D.; Perry, Katherine F.; Breakefield, Xandra O.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Cortes, Maria L.; Oehmig, Angelika; Saydam, Okay; Sanford, Jocelyn D.; Perry, Katherine F.; Breakefield, Xandra O.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. [Fraefel, Cornel] Univ Zurich, Inst Virol, Zurich, Switzerland. RP Cortes, ML (reprint author), Massachusetts Gen Hosp E, Dept Neurol, 13th St,Bldg 149,6th Floor, Charlestown, MA 02129 USA. EM cortes@helix.mgh.harvard.edu FU NINDS NIH HHS [R21 NS047503] NR 45 TC 17 Z9 19 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD JAN PY 2008 VL 16 IS 1 BP 81 EP 88 DI 10.1038/sj.mt.6300338 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 243TU UT WOS:000251821000016 PM 17998902 ER PT J AU Iezzoni, LI Ngo, LH Kinkel, RP AF Iezzoni, L. I. Ngo, L. H. Kinkel, R. P. TI Working-age persons with multiple sclerosis and access to disease-modifying medications SO MULTIPLE SCLEROSIS LA English DT Article DE access; disease-modifying medications; health insurance; multiple sclerosis ID DISPARITIES GEOCODING PROJECT; MEDICARE DRUG BENEFIT; UNITED-STATES; PART-D; HEALTH; DISABILITY; PREVALENCE; THERAPY; BETA; MS AB US residents can face serious financial barriers to obtaining prescription medications, including disease-modifying medications for multiple sclerosis ( MS). We conducted 30-min telephone surveys with 983 persons with MS nationwide, 21-64 years old, to explore how financial and health insurance concerns affect access to services including MS drugs. Almost everyone (96.3%) had some health insurance. Multivariable logistic regression analyses accounted for demographic, disease and insurance characteristics. Only 10.8% of those < 40 years old had never received disease-modifying medications, compared with 41.1% of persons aged 60-64. Among the uninsured, 36.8% reported having never taken these medications, compared with 21.2% of persons with health insurance. Adjusted odds ratio (95% CI) of using these drugs in prior 12 months among the uninsured ( compared with insured persons) was 0.28 (0.08, 0.95). Just over 16% of persons with public health plans reported that their insurer initially denied coverage for MS medication. When asked about MS medications in general, 22.3% reported having not filled prescriptions, skipping doses or splitting pills because of cost concerns; 22.4% worried 'a lot' about getting MS medications when they needed them. Substantial fractions of persons with MS confront financial and health plan-related barriers to obtaining MS drugs. C1 [Iezzoni, L. I.; Ngo, L. H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Dept Med,Sch Med,Charles A Dana Res Inst, Boston, MA 02115 USA. [Kinkel, R. P.] Harvard Thorndike Lab, Boston, MA 02115 USA. RP Iezzoni, LI (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, 50 Staniford St,Room 901, Boston, MA 02115 USA. EM liezzoni@partners.org NR 39 TC 7 Z9 7 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD JAN PY 2008 VL 14 IS 1 BP 112 EP 122 DI 10.1177/1352458507080466 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 277MJ UT WOS:000254216400014 PM 17893109 ER PT J AU Zhao, JB Zhang, YF Zhao, WD Wu, Y Pan, JP Bauman, WA Cardozo, C AF Zhao, Jingbo Zhang, Yuangfei Zhao, Weidong Wu, Yong Pan, Jiiangping Bauman, William A. Cardozo, Christopher TI Effects of nandrolone on denervation atrophy depend upon time after nerve transection SO MUSCLE & NERVE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Paraplegia-Society CY SEP 05-07, 2006 CL Las Vegas, NV SP Amer Paraplegia Soc ID SKELETAL-MUSCLE ATROPHY; GENE-EXPRESSION; UBIQUITIN LIGASES; MESSENGER-RNA; IGF-I; RAT; TESTOSTERONE; DECANOATE; MEN; OXANDROLONE AB Anabolic steroids prevent disuse atrophy and reverse atrophy caused by glucocorticoids. To determine whether these beneficial effects extend to denervation atrophy, we tested whether nandrolone blocked denervation atrophy acutely or reversed subacute denervation atrophy. We also tested the association of such anabolic effects with expression of MAFbx, MuRF1 (both of which accelerate denervation atrophy), and IGF-1 (which prevents such atrophy). When begun at the time of denervation, nandrolone did not alter atrophy or expression of MAFbx, MuRF1, or IGF-1 measured 3, 7, or 14 days thereafter. When nandrolone administration was begun 28 days after denervation, atrophy was significantly reduced 7 and 28 days later (16% and 30%, respectively), and this was associated with significant reductions in expression of MAFbx and MuRF1, without alterations in the expression of IGF-1. The findings indicate that the actions of nandrolone depend on time after nerve transection and that the timing of anabolic steroid administration is an important determinant of responses of atrophying muscle to these agents. C1 [Zhao, Jingbo; Zhang, Yuangfei; Zhao, Weidong; Wu, Yong; Pan, Jiiangping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Dept Vet Affairs, Bronx, NY 10468 USA. [Zhao, Jingbo; Bauman, William A.; Cardozo, Christopher] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Dept Vet Affairs, Room 1E-02, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu NR 38 TC 26 Z9 26 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD JAN PY 2008 VL 37 IS 1 BP 42 EP 49 DI 10.1002/mus.20888 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 247WV UT WOS:000252114200007 PM 17763458 ER PT S AU Giraud, M Vandiedonck, C Garchon, HJ AF Giraud, Matthieu Vandiedonck, Claire Garchon, Henri Jean BE Kaminski, HJ Barohn, RJ TI Genetic factors in autoimmune myasthenia gravis SO MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 11th International Conference on Myasthenia Gravis and Related Disorder CY MAY 13-15, 2007 CL Chicago, IL DE myasthenia gravis; genetics; autoimmunity; multifactorial; MHC; linkage disequilibrium; CHRNA1; self-antigen; immune tolerance; IRF8 ID MUSCLE ACETYLCHOLINE-RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISMS; EXTENDED HUMAN MHC; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-TITIN ANTIBODIES; COPY-NUMBER VARIATION; LINKAGE-DISEQUILIBRIUM; HLA ANTIGENS; HUMAN GENOME; RHEUMATOID-ARTHRITIS AB Autoimmune myasthenia gravis (MG) is a multifactorial disease, markedly influenced by genetic factors, even though it shows limited heritability. The clinically typical form of autoimmune MG with thymus hyperplasia shows the most reproducible genetic associations, especially with the Al-B8-DR3 (8.1) haplotype of the major histocompatibility complex (MHC). However, because of strong linkage disequilibrium, the causative polymorphism in this region is not known yet. Increasing the density of genetic markers has nevertheless recently revealed the complex, but highly significant contribution of this essential genetic region in controlling the disease phenotype and the quantitative expression of serum autoantibodies. The advances of the human genome program, the development of genotyping and sequencing tools with increasing throughput, and the availability of powerful statistical methods now make feasible the dissection of a complex genetic region, such as the MHC and beyond, the systematic search throughout the genome for variants influencing disease predisposition. The identification of such functional variants should provide new clues to the pathogenesis of MG, as recently illustrated by the study of a promoter polymorphism of the CHRNA1 locus, influencing its thymic expression and central tolerance, or of a coding variant of the PTPN22 intracellular phosphatase. C1 [Giraud, Matthieu] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA USA. [Vandiedonck, Claire] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England. [Garchon, Henri Jean] INSERM, Paris, France. [Garchon, Henri Jean] Univ Paris 05, Paris, France. RP Garchon, HJ (reprint author), Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France. EM henri-jean.garchon@inserm.fr RI Giraud, Matthieu/E-4972-2017 OI Giraud, Matthieu/0000-0002-1208-9677 NR 103 TC 48 Z9 49 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-687-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1132 BP 180 EP 192 DI 10.1196/annals.1405.027 PG 13 WC Multidisciplinary Sciences; Clinical Neurology; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BHX10 UT WOS:000257139900022 PM 18567868 ER PT J AU Mylonakis, E AF Mylonakis, Eleftherios TI Galleria mellonella and the study of fungal pathogenesis: Making the case for another genetically tractable model host SO MYCOPATHOLOGIA LA English DT Editorial Material ID INNATE IMMUNE-RESPONSE; DROSOPHILA-MELANOGASTER; CRYPTOCOCCUS-NEOFORMANS; PATHOGENICITY; VIRULENCE; LARVAE C1 Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Mylonakis, E (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Gray 5,GRJ-504, Boston, MA 02114 USA. EM emylonakis@partners.org NR 16 TC 58 Z9 62 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0301-486X J9 MYCOPATHOLOGIA JI Mycopathologia PD JAN PY 2008 VL 165 IS 1 BP 1 EP 3 DI 10.1007/s11046-007-9082-z PG 3 WC Mycology SC Mycology GA 255RR UT WOS:000252675600001 PM 18060516 ER PT B AU Raab, MS Anderson, KC AF Raab, Marc S. Anderson, Kenneth C. BE Lonial, S TI Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID MULTIPLE-MYELOMA CELLS; ENDOTHELIAL GROWTH-FACTOR; MEDIATED DRUG-RESISTANCE; MARROW STROMAL CELLS; NF-KAPPA-B; PROTEASOME INHIBITOR PS-341; CYCLIN-D DYSREGULATION; IN-SITU HYBRIDIZATION; BONE-DISEASE; OSTEOBLAST DIFFERENTIATION C1 [Raab, Marc S.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Raab, MS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA. NR 129 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 23 EP 39 PG 17 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600003 ER PT B AU Munshi, NC Tai, YT AF Munshi, Nikhil C. Tai, Yu-Tzu BE Lonial, S TI Antibody and Other Immune-Based Therapies for Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID HUMAN MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; BONE-MARROW ENVIRONMENT; CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; CYTOTOXIC T-LYMPHOCYTES; SUPER-ANTAGONIST SANT7; PHASE-II MULTICENTER C1 [Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Munshi, NC (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 177 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 167 EP 202 PG 36 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600012 ER PT B AU Richardson, PG Mitsiades, CS Schlossman, R Hideshima, T Ghobrial, I Munshi, NC Anderson, KC AF Richardson, Paul G. Mitsiades, Constantine S. Schlossman, Robert Hideshima, Teru Ghobrial, Irene Munshi, Nikhil C. Anderson, Kenneth C. BE Lonial, S TI The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID PROTEASOME INHIBITOR PS-341; PEGYLATED LIPOSOMAL DOXORUBICIN; INTERMITTENT THALIDOMIDE VMDT; OVERCOMES DRUG-RESISTANCE; IMPAIRED RENAL-FUNCTION; THERAPEUTIC APPLICATIONS; COMBINATION THERAPY; PHASE-1 TRIAL; RELAPSED/REFRACTORY MYELOMA; HEMATOLOGIC MALIGNANCIES C1 [Richardson, Paul G.; Hideshima, Teru] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Richardson, PG (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 70 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 239 EP 252 PG 14 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600015 ER PT B AU Mitsiades, CS Hideshima, T Munshi, NC Richardson, PG Anderson, KC AF Mitsiades, Constantine S. Hideshima, Teru Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. BE Lonial, S TI The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID PHASE-I TRIAL; SOLUBLE HSP90 INHIBITOR; HISTONE DEACETYLASE INHIBITION; REFRACTORY ADVANCED CANCERS; NF-KAPPA-B; SOLID TUMORS; ANTITUMOR-ACTIVITY; HEAT-SHOCK-PROTEIN-90 INHIBITORS; HEMATOLOGIC MALIGNANCIES; GLUCOCORTICOID-RECEPTOR C1 [Mitsiades, Constantine S.; Hideshima, Teru] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Mitsiades, CS (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 76 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 291 EP 308 PG 18 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600019 ER PT B AU Hideshima, T AF Hideshima, Teru BE Lonial, S TI Histone Deacetylase Inhibitors in Multiple Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID SUBEROYLANILIDE HYDROXAMIC ACID; CELL LUNG-CANCER; VIVO ANTITUMOR-ACTIVITY; CHRONIC LYMPHOCYTIC-LEUKEMIA; CASPASE-DEPENDENT APOPTOSIS; PROTEASOME INHIBITOR; IN-VITRO; PHASE-I; DEPSIPEPTIDE FR901228; FK228 DEPSIPEPTIDE C1 [Hideshima, Teru] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Hideshima, Teru] Harvard Univ, Sch Med, Boston, MA USA. RP Hideshima, T (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 78 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 379 EP 392 PG 14 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600024 ER PT B AU Chauhan, D Singh, A Anderson, K AF Chauhan, Dharminder Singh, Ajita Anderson, Kenneth BE Lonial, S TI Proteasome Inhibitors as Therapy in Multiple Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID NF-KAPPA-B; MULTICATALYTIC PROTEINASE COMPLEX; MOLECULAR-WEIGHT PROTEASES; ATP-DEPENDENT PROTEOLYSIS; PANCREATIC-CANCER CELLS; MARROW STROMAL CELLS; EXTENDED FOLLOW-UP; RABBIT RETICULOCYTES; ANTIMYELOMA ACTIVITY; ANTITUMOR-ACTIVITY C1 [Chauhan, Dharminder; Anderson, Kenneth] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Chauhan, Dharminder] Dana Farber Canc Inst, Jerome Lipper Ctr Myeloma Res, Boston, MA 02115 USA. RP Chauhan, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,LeBow Inst Myeloma Therapeut, 44 Binney St, Boston, MA 02115 USA. NR 109 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 421 EP 432 PG 12 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600026 ER PT B AU Sloan, MJ Raje, N AF Sloan, Mark J. Raje, Noopur BE Lonial, S TI Anemia and Erythropoeitic Growth Factors in Multiple Myeloma SO MYELOMA THERAPY: PURSUING THE PLASMA CELL SE Contemporary Hematology LA English DT Article; Book Chapter ID QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; CHEMOTHERAPY-INDUCED ANEMIA; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; EPOETIN-ALPHA; CANCER-PATIENTS; DARBEPOETIN-ALPHA; INTERFERON-GAMMA; DOUBLE-BLIND C1 [Raje, Noopur] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 87 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-82-4 J9 CONTEMP HEMATOL PY 2008 BP 455 EP 468 PG 14 WC Hematology SC Hematology GA BKF47 UT WOS:000267953600028 ER PT J AU Eggert, US Superti-Furga, G AF Eggert, Ulrike S. Superti-Furga, Giulio TI Drugs in action SO NATURE CHEMICAL BIOLOGY LA English DT Editorial Material ID INHIBITORS; ABL; KINASE; CYTOKINESIS; DASATINIB; REVEALS; TARGETS AB How do drugs work? What molecular changes do they cause in cells and in organisms? Is there a paradigm shift in the way we can predict and appreciate the impact of small molecules on biological systems in the 21st century? These were some of the questions addressed at a meeting in Vienna in August 2007. C1 [Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Superti-Furga, Giulio] Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria. RP Eggert, US (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Dana Farber Canc Inst, 250 Longwood Ave, Boston, MA 02115 USA. EM ulrike_eggert@dfci.harvard.edu; gsuperti@cemm.oeaw.ac.at RI Superti-Furga, Giulio/F-4755-2015 OI Superti-Furga, Giulio/0000-0002-0570-1768 NR 20 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1552-4450 J9 NAT CHEM BIOL JI Nat. Chem. Biol. PD JAN PY 2008 VL 4 IS 1 BP 7 EP 11 DI 10.1038/nchembio0108-7 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 246EJ UT WOS:000251990000003 PM 18084271 ER PT J AU Yui, PB Hong, CC Sachidanandan, C Babitt, JL Deng, DY Hoyng, SA Lin, HY Bloch, KD Peterson, RT AF Yui, Paul B. Hong, Charles C. Sachidanandan, Chetana Babitt, Jodie L. Deng, Donna Y. Hoyng, Stefan A. Lin, Herbert Y. Bloch, Kenneth D. Peterson, Randall T. TI Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism SO NATURE CHEMICAL BIOLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; DORSOVENTRAL PATTERN-FORMATION; HEPCIDIN EXPRESSION; ZEBRAFISH EMBRYO; SMAD PROTEINS; MUSCLE-CELLS; RECEPTOR; MOUSE; LIVER; OVERLOAD AB Bone morphogenetic protein (BMP) signals coordinate developmental patterning and have essential physiological roles in mature organisms. Here we describe the first known small-molecule inhibitor of BMP signaling-dorsomorphin, which we identified in a screen for compounds that perturb dorsoventral axis formation in zebrafish. We found that dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation. Using dorsomorphin, we examined the role of BMP signaling in iron homeostasis. in vitro, dorsomorphin inhibited BMP-, hemojuvelin- and interleukin 6-stimulated expression of the systemic iron regulator hepcidin, which suggests that BMP receptors regulate hepcidin induction by all of these stimuli. In vivo, systemic challenge with iron rapidly induced SMADI/5/8 phosphorylation and hepcidin expression in the liver, whereas treatment with dorsomorphin blocked SMAD1/5/8 phosphorylation, normalized hepcidin expression and increased serum iron levels. These findings suggest an essential physiological role for hepatic BMP signaling in iron-hepcidin homeostasis. C1 [Yui, Paul B.; Hong, Charles C.; Sachidanandan, Chetana; Deng, Donna Y.; Hoyng, Stefan A.; Bloch, Kenneth D.; Peterson, Randall T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Yui, Paul B.; Hong, Charles C.; Sachidanandan, Chetana; Deng, Donna Y.; Hoyng, Stefan A.; Bloch, Kenneth D.; Peterson, Randall T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Cardiol, Charlestown, MA 02129 USA. [Yui, Paul B.; Peterson, Randall T.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Babitt, Jodie L.; Lin, Herbert Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol, Boston, MA 02114 USA. [Babitt, Jodie L.; Lin, Herbert Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Nephrol, Boston, MA 02114 USA. [Bloch, Kenneth D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Bloch, KD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA. EM kdbloch@partners.org; peterson@cvrc.mgh.harvard.edu RI Hong, Charles/C-9989-2010; OI Hoyng, Stefan/0000-0001-8371-3871; Yu, Paul/0000-0003-2145-4944 FU NCI NIH HHS [CA118498, R01 CA118498]; NHLBI NIH HHS [K08 HL081535, HL074352, HL079267, HL079943, HL081535, K08 HL079943, K08 HL079943-02, K08 HL081535-04, R01 HL074352, R01 HL079267]; NIDDK NIH HHS [DK071837, DK075846, K08 DK075846, K08 DK075846-02, R01 DK071837] NR 50 TC 35 Z9 36 U1 5 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1552-4450 EI 1552-4469 J9 NAT CHEM BIOL JI Nat. Chem. Biol. PD JAN PY 2008 VL 4 IS 1 BP 33 EP 41 DI 10.1038/nchembio.2007.54 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 246EJ UT WOS:000251990000011 PM 18026094 ER PT J AU Huang, G Zhang, P Hirai, H Elf, S Yan, X Chen, Z Koschmieder, S Okuno, Y Dayaram, T Growney, JD Shivdasani, RA Gilliland, DG Speck, NA Nimer, SD Tenen, DG AF Huang, Gang Zhang, Pu Hirai, Hideyo Elf, Shannon Yan, Xiaomei Chen, Zhao Koschmieder, Steffen Okuno, Yutaka Dayaram, Tajhal Growney, Joseph D. Shivdasani, Ramesh A. Gilliland, D. Gary Speck, Nancy A. Nimer, Stephen D. Tenen, Daniel G. TI PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis SO NATURE GENETICS LA English DT Article ID ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR PU.1; STEM-CELLS; LINEAGE COMMITMENT; POINT MUTATIONS; GENE; EXPRESSION; MICE; DIFFERENTIATION; DOMAIN AB Both PU.1 (also called SFPI1), an Ets-family transcription factor, and AML1 (also called RUNX1), a DNA-binding subunit of the CBF transcription factor family, are crucial for the generation of all hematopoietic lineages, and both act as tumor suppressors in leukemia. An upstream regulatory element (URE) of PU.1 has both enhancer and repressor activity and tightly regulates PU.1 expression. Here we show that AML1 binds to functionally important sites within the PU.1 upstream regulatory element and regulates PU.1 expression at both embryonic and adult stages of development. Analysis of mice carrying conditional AML1 knockout alleles and knock-in mice carrying mutations in all three AML1 sites of the URE proximal region demonstrated that AML1 regulates PU.1 both positively and negatively in a lineage dependent manner. Dysregulation of PU.1 expression contributed to each of the phenotypes observed in these mice, and restoration of proper PU.1 expression rescued or partially rescued each phenotype. Thus, our data demonstrate that PU.1 is a major downstream target gene of AML1. C1 [Huang, Gang; Zhang, Pu; Hirai, Hideyo; Koschmieder, Steffen; Okuno, Yutaka; Dayaram, Tajhal; Tenen, Daniel G.] Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, Boston, MA 02115 USA. [Huang, Gang; Yan, Xiaomei] Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, New York, NY 10021 USA. [Hirai, Hideyo; Nimer, Stephen D.] Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto 6028566, Japan. [Chen, Zhao; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Growney, Joseph D.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Speck, Nancy A.] Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA. RP Tenen, DG (reprint author), Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM dtenen@bidmc.harvard.edu OI Tenen, Daniel/0000-0002-6423-3888 FU NCI NIH HHS [CA66996, CA41456]; NIDDK NIH HHS [DK52208] NR 49 TC 107 Z9 113 U1 2 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 2008 VL 40 IS 1 BP 51 EP 60 DI 10.1038/ng.2007.7 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 247YN UT WOS:000252118600018 PM 17994017 ER PT J AU Asaad, W Eskandar, E AF Asaad, Wael Eskandar, Emad TI The movers and shakers of deep brain stimulation SO NATURE MEDICINE LA English DT Editorial Material ID TREMOR AB Deep brain stimulation is increasingly used in the treatment of Parkinson's disease, essential tremor and other disorders, yet its mechanism of action remains unknown. New findings suggest that at least some of its action involves the release of adenosine, dampening tremors (pages 75-80). C1 [Asaad, Wael; Eskandar, Emad] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Asaad, W (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. EM eeskandar@partners.org RI Asaad, Wael/I-8485-2012 OI Asaad, Wael/0000-0003-4406-9096 NR 6 TC 3 Z9 3 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2008 VL 14 IS 1 BP 17 EP 19 DI 10.1038/nm0108-17 PG 4 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 249IV UT WOS:000252222400010 PM 18180713 ER PT J AU Tager, AM LaCamera, P Shea, BS Campanella, GS Selman, M Zhao, Z Polosukhin, V Wain, J Karimi-Shah, BA Kim, ND Hart, WK Pardo, A Blackwell, TS Xu, Y Chun, J Luster, AD AF Tager, Andrew M. LaCamera, Peter Shea, Barry S. Campanella, Gabriele S. Selman, Moises Zhao, Zhenwen Polosukhin, Vasiliy Wain, John Karimi-Shah, Banu A. Kim, Nancy D. Hart, William K. Pardo, Annie Blackwell, Timothy S. Xu, Yan Chun, Jerold Luster, Andrew D. TI The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak SO NATURE MEDICINE LA English DT Article ID BRONCHOALVEOLAR LAVAGE FLUID; EDG-FAMILY; RHO-KINASE; FIBROCYTES; EXPRESSION; MIGRATION; CELLS; IDENTIFICATION; INFLAMMATION; REQUIREMENT AB Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA(1), are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis. C1 [Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Luster, Andrew D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Div Rheumatol Allergy & Im, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA. [Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Karimi-Shah, Banu A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02129 USA. [Selman, Moises] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. [Zhao, Zhenwen; Xu, Yan] Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA. [Polosukhin, Vasiliy; Blackwell, Timothy S.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. [Wain, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA 02114 USA. [Pardo, Annie] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico. [Chun, Jerold] Scripps Res Inst, Helen L Dorris Inst Neurol & Psychiat Disorders, Dept Mol Biol, La Jolla, CA 92037 USA. RP Luster, AD (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Div Rheumatol Allergy & Im, Ctr Immunol & Inflammatory Dis, CNY149-8301,149 13th St, Boston, MA 02129 USA. EM aluster@mgh.harvard.edu RI Pardo, Annie/A-4746-2008 FU NCI NIH HHS [R01-CA095042, R01-CA69212, R01-CA89228]; NIMH NIH HHS [K02-MH01723, R01-MH51699]; NINDS NIH HHS [R01-NS048478] NR 50 TC 293 Z9 301 U1 4 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2008 VL 14 IS 1 BP 45 EP 54 DI 10.1038/nm1685 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 249IV UT WOS:000252222400021 PM 18066075 ER PT J AU Wei, C Moeller, CC Altintas, MM Li, J Schwarz, K Zacchigna, S Xie, L Henger, A Schmid, H Rastaldi, MP Cowan, P Kretzler, M Parrilla, R Bendayan, S Gupta, V Nikolic, B Kalluri, R Carmeliet, P Mundel, P Reiser, J AF Wei, Changli Moeller, Clemens C. Altintas, Mehmet M. Li, Jing Schwarz, Karin Zacchigna, Serena Xie, Liang Henger, Anna Schmid, Holger Rastaldi, Maria P. Cowan, Peter Kretzler, Matthias Parrilla, Roberto Bendayan, Se Gupta, Vineet Nikolic, Boris Kalluri, Raghu Carmeliet, Peter Mundel, Peter Reiser, Jochen TI Modification of kidney barrier function by the urokinase receptor SO NATURE MEDICINE LA English DT Article ID GLOMERULAR SLIT DIAPHRAGM; INTEGRIN ALPHA(V)BETA(3); NEPHROTIC-SYNDROME; GENE-EXPRESSION; CATHEPSIN-L; MICE; PODOCYTES; MIGRATION; VITRONECTIN; DISEASE AB Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease. Therapies aimed at the cellular level of the disease are currently not available. Here we show that induction of urokinase receptor ( uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of alpha v beta 3 integrin. Mice lacking uPAR (Plaur(-/-)) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active beta 3 integrin. Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria. Mechanistically, uPAR is required to activate alpha v beta 3 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1. Blockade of alpha v beta 3 integrin reduces podocyte motility in vitro and lowers proteinuria in mice. Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability. C1 [Wei, Changli; Moeller, Clemens C.; Altintas, Mehmet M.; Li, Jing; Gupta, Vineet; Nikolic, Boris; Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Nephrol Div, Boston, MA 02129 USA. [Wei, Changli; Moeller, Clemens C.; Altintas, Mehmet M.; Li, Jing; Gupta, Vineet; Nikolic, Boris; Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Program Glamerular Dis, Boston, MA 02129 USA. Univ Homburg, Inst Anat & Cell Biol, D-66421 Homburg, Germany. [Zacchigna, Serena; Carmeliet, Peter] Katholieke Univ Leuven, Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium. [Zacchigna, Serena; Carmeliet, Peter] Vlaans Interuniv Inst Biotechnol, Dept Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium. [Xie, Liang; Kalluri, Raghu] Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA. [Henger, Anna; Kretzler, Matthias] Univ Michigan Hosp, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA. [Schmid, Holger] Univ Munich, Med Poliklin, D-80336 Munich, Germany. [Rastaldi, Maria P.] San Carlo Borromeo Hosp, Assoc Nuova Nefrol & Fdn Damico Ricerca Malattie, Renal Immunopathol Lab, I-20153 Milan, Italy. [Cowan, Peter] St Vincents Hosp, Immunol Res Ctr, Fitzroy, Vic 3065, Australia. [Parrilla, Roberto] CSIC, Ctr Invest Biol, Dept Pathophysiol & Human Mol Genet, Madrid 28040, Spain. [Bendayan, Se] Univ Montreal, Dept Pathol, Montreal, PQ H3T 1J4, Canada. [Mundel, Peter] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Reiser, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Nephrol Div, Boston, MA 02129 USA. EM jreiser@partners.org RI Parrilla, Roberto/B-6307-2008; Kalluri, Raghu/E-2677-2015; OI Cowan, Peter/0000-0001-9016-4954; Kalluri, Raghu/0000-0002-2190-547X; Gupta, Vineet/0000-0001-6987-2550; Altintas, Mehmet/0000-0002-1871-6985 FU NIDDK NIH HHS [DK062472, DK064236, DK057683, DK073495, DK38452, K01 DK068253, K01 DK068253-05, T32DK007540] NR 51 TC 233 Z9 253 U1 2 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2008 VL 14 IS 1 BP 55 EP 63 DI 10.1038/nm1696 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 249IV UT WOS:000252222400022 PM 18084301 ER PT J AU Hu, WG Ferris, SP Tweten, RK Wu, GX Radaeva, S Gao, B Bronson, RT Halperin, JA Qin, XB AF Hu, Weiguo Ferris, Sean P. Tweten, Rodney K. Wu, Gongxiong Radaeva, Svetlana Gao, Bin Bronson, Roderick T. Halperin, Jose A. Qin, Xuebin TI Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin SO NATURE MEDICINE LA English DT Article ID STREPTOCOCCUS-INTERMEDIUS; PLATELET ACTIVATION; NITRIC-OXIDE; IN-VIVO; RECEPTOR; DISEASE; ENDOTHELIUM; HEMOGLOBIN; THROMBOSIS; HEMOLYSIS AB Conditional targeted cell ablation is a powerful approach for investigating the pathogenesis of human diseases and in vivo cellular functions. Intermedilysin (ILY) is a cytolytic poreforming toxin secreted by Streptococcus intermedius that lyses human cells exclusively, owing to its receptor specificity for human CD59. We generated two transgenic mouse strains that express human CD59 either on erythrocytes (strain ThCD59(RBC)) or on endothelia (strain ThCD59(END)). Intravenous injection of ILY in ThCD59(RBC) mice induced acute intravascular hemolysis, leading to reduced nitric oxide bioavailability, increased platelet activation and rapid death. In ThCD59(END) mice, ILY induced rapid endothelial damage, leading to acute death and disseminated intravascular coagulation. Additionally, we show that human serum contains ILY-specific neutralizing antibodies not found in any other animal species. Together, these results suggest that this new rapid conditional targeted ILY-mediated cell ablation technique can be used in combination with any available transgenic expression system to study the physiologic role of specific cell populations. C1 [Hu, Weiguo; Halperin, Jose A.; Qin, Xuebin] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Hu, Weiguo; Ferris, Sean P.; Wu, Gongxiong; Halperin, Jose A.; Qin, Xuebin] Harvard Univ, Sch Med, Lab Translat Res, Cambridge, MA 02139 USA. [Tweten, Rodney K.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA. [Radaeva, Svetlana] NIAAA, Natl Inst Hlth, Lab Physiol Studies, Div Metab & Hlth Effects, Bethesda, MD 20892 USA. [Gao, Bin] NIAAA, Natl Inst Hlth, Sect Liver Biol, Lab Physiol Studies, Bethesda, MD 20892 USA. [Bronson, Roderick T.] Harvard Univ, Ctr Canc, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA. RP Qin, XB (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. EM xuebin_qin@hms.harvard.edu FU NIAID NIH HHS [R01 AI061174, R01 AI063444]; NIDDK NIH HHS [R01 DK060979] NR 29 TC 20 Z9 21 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD JAN PY 2008 VL 14 IS 1 BP 98 EP 103 DI 10.1038/nm1674 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 249IV UT WOS:000252222400029 PM 18157141 ER PT J AU Vinegoni, C Pitsouli, C Razansky, D Perrimon, N Ntziachristos, V AF Vinegoni, Claudio Pitsouli, Chrysoula Razansky, Daniel Perrimon, Norbert Ntziachristos, Vasilis TI In vivo imaging of Drosophila melanogaster pupae with mesoscopic fluorescence tomography SO NATURE METHODS LA English DT Article ID MICROSCOPY; METAMORPHOSIS; VISUALIZATION AB We report a technique for fluorescence tomography that operates beyond the penetration limits of tissue-sectioning fluorescence microscopy. The method uses multi-projection illumination and photon transport description in opaque tissues. We demonstrate whole-body three-dimensional visualization of the morphogenesis of GFP-expressing salivary glands and wing imaginal discs in living Drosophila melanogaster pupae in vivo and over time. C1 [Vinegoni, Claudio; Razansky, Daniel; Ntziachristos, Vasilis] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. [Vinegoni, Claudio; Razansky, Daniel; Ntziachristos, Vasilis] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Vinegoni, Claudio] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Vinegoni, Claudio] Harvard Univ, Sch Med, Richard B Simches Res Ctr, Boston, MA 02129 USA. [Pitsouli, Chrysoula; Perrimon, Norbert] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Pitsouli, Chrysoula; Perrimon, Norbert] Howard Hughes Med Inst, Boston, MA 02129 USA. [Razansky, Daniel; Ntziachristos, Vasilis] Tech Univ Munich, Inst Biol & Med Imaging, D-85764 Neuherberg, Germany. [Razansky, Daniel; Ntziachristos, Vasilis] Helmholtz Ctr Munich, D-85764 Neuherberg, Germany. RP Vinegoni, C (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Bldg 149,13th St, Charlestown, MA 02129 USA. EM cvinegoni@mgh.harvard.edu OI Razansky, Daniel/0000-0001-8676-0964 FU NIBIB NIH HHS [R01 EB006432]; PHS HHS [R01000750] NR 13 TC 57 Z9 58 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 J9 NAT METHODS JI Nat. Methods PD JAN PY 2008 VL 5 IS 1 BP 45 EP 47 DI 10.1038/NMETH1149 PG 3 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 247ZH UT WOS:000252120600016 PM 18066071 ER PT J AU Ni, JQ Markstein, M Binari, R Pfeiffer, B Liu, LP Villalta, C Booker, M Perkins, L Perrimon, N AF Ni, Jian-Quan Markstein, Michele Binari, Richard Pfeiffer, Barret Liu, Lu-Ping Villalta, Christians Booker, Matthew Perkins, Lizabeth Perrimon, Norbert TI Vector and parameters for targeted transgenic RNA interference in Drosophila melanogaster SO NATURE METHODS LA English DT Article ID EXPRESSION; GENE; BEHAVIOR; PHI-C31; SYSTEM; GAL4; CELL AB The conditional expression of hairpin constructs in Drosophila melanogaster has emerged in recent years as a method of choice in functional genomic studies. To date, upstream activating site driven RNA interference constructs have been inserted into the genome randomly using P-element-mediated transformation, which can result in false negatives due to variable expression. To avoid this problem, we have developed a transgenic RNA interference vector based on the phiC31 site-specific integration method. C1 [Ni, Jian-Quan; Markstein, Michele; Binari, Richard; Liu, Lu-Ping; Villalta, Christians; Booker, Matthew; Perrimon, Norbert] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02175 USA. [Ni, Jian-Quan; Binari, Richard; Liu, Lu-Ping; Villalta, Christians; Perrimon, Norbert] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02175 USA. [Pfeiffer, Barret] Howard Hughes Med Inst, Ashburn, VA 20147 USA. [Perkins, Lizabeth] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA. RP Perrimon, N (reprint author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02175 USA. EM perrimon@receptor.med.harvard.edu OI Markstein, Michele/0000-0003-2635-8118; Booker, Matthew/0000-0002-6902-1032 FU Howard Hughes Medical Institute; NIGMS NIH HHS [R01 GM067761, R01 GM067761-05, R01 GM084947] NR 11 TC 126 Z9 128 U1 5 U2 21 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 J9 NAT METHODS JI Nat. Methods PD JAN PY 2008 VL 5 IS 1 BP 49 EP 51 DI 10.1038/NMETH1146 PG 3 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 247ZH UT WOS:000252120600017 PM 18084299 ER PT J AU Scarcelli, G Yun, SH AF Scarcelli, Giuliano Yun, Seok Hyun TI Confocal Brillouin microscopy for three-dimensional mechanical imaging SO NATURE PHOTONICS LA English DT Article ID HIGH-RESOLUTION; BIOLOGICAL TISSUES; ELASTIC PROPERTIES; LIGHT-SCATTERING; SPECTROSCOPY; COLLAGEN; LENS; EYE AB Acoustically induced inelastic light scattering, first reported in 1922 by Brillouin(1), allows non-contact, direct readout of the viscoelastic properties of a material and has widely been investigated for material characterization 2, structural monitoring 3 and environmental sensing'. Extending the Brillouin technique from point sampling spectroscopy to imaging modality(5) would open up new possibilities for mechanical imaging, but has been challenging because rapid spectrum acquisition is required. Here, we demonstrate a confocal Brillouin microscope based on a fully parallel spectrometer-a virtually imaged phased array-that improves the detection efficiency by nearly 100-fold over previous approaches. Using the system, we show the first cross-sectional Brillouin imaging based on elastic properties as the contrast mechanism and monitor fast dynamic changes in elastic modulus during polymer crosslinking. Furthermore, we report the first in situ biomechanical measurement of the crystalline lens in a mouse eye. These results suggest multiple applications of Brillouin microscopy in biomedical and biomaterial science. C1 [Scarcelli, Giuliano; Yun, Seok Hyun] Harvard Univ, Wellman Ctr Photomed, Boston, MA 02114 USA. [Scarcelli, Giuliano; Yun, Seok Hyun] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Scarcelli, Giuliano; Yun, Seok Hyun] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA. RP Yun, SH (reprint author), Harvard Univ, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA. EM syun@hms.harvard.edu OI scarcelli, giuliano/0000-0002-1736-077X FU NIBIB NIH HHS [R21 EB008472, R21 EB008472-01A1] NR 30 TC 97 Z9 98 U1 9 U2 37 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1749-4885 J9 NAT PHOTONICS JI Nat. Photonics PD JAN PY 2008 VL 2 IS 1 BP 39 EP 43 DI 10.1038/nphoton.2007.250 PG 5 WC Optics; Physics, Applied SC Optics; Physics GA 254OL UT WOS:000252595800018 PM 19812712 ER PT J AU Jones, RC Capen, DE Petersen, B Jain, RK Duda, DG AF Jones, Rosemary C. Capen, Diane E. Petersen, Bodil Jain, Rakesh K. Duda, Dan G. TI A protocol for a lung neovascularization model in rodents SO NATURE PROTOCOLS LA English DT Article ID HYPEROXIC PULMONARY-HYPERTENSION; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; OXYGEN; INJURY AB By providing insight into the cellular events of vascular injury and repair, experimental model systems seek to promote timely therapeutic strategies for human disease. The goal of many current studies of neovascularization is to identify cells critical to the process and their role in vascular channel assembly. We propose here a protocol to analyze, in an in vivo rodent model, vessel and capillary remodeling (reorganization and growth) in the injured lung. Sequential analyses of stages in the assembly of vascular structures, and of relevant cell types, provide further opportunities to study the molecular and cellular determinants of lung neovascularization. C1 [Jones, Rosemary C.; Capen, Diane E.; Petersen, Bodil] Massachusetts Gen Hosp, Dept Anesthesia Crit Care, Boston, MA 02114 USA. [Jain, Rakesh K.; Duda, Dan G.] Massachusetts Gen Hosp, Steele Lab Tumor Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Jones, RC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care, 55 Fruit St, Boston, MA 02114 USA. EM rcjones@partners.org FU NCI NIH HHS [R01CA115767, R01 CA115767, R01 CA115767-01A1]; NHLBI NIH HHS [R01 HL089252, R01 HL070866, R01 HL070866-01A1, R01HL 070866] NR 12 TC 9 Z9 9 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2008 VL 3 IS 3 BP 378 EP 387 DI 10.1038/nprot.2007.536 PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 276JM UT WOS:000254137100006 PM 18323809 ER PT J AU Jones, RC Capen, DE Cohen, KS Munn, LL Jain, RK Duda, DG AF Jones, Rosemary C. Capen, Diane E. Cohen, Kenneth S. Munn, Lance L. Jain, Rakesh K. Duda, Dan G. TI A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents SO NATURE PROTOCOLS LA English DT Article ID SMOOTH-MUSCLE-CELLS; HYPEROXIC PULMONARY-HYPERTENSION; ANGIOGENESIS; MOLECULES; PDGF AB The goal of many current studies of neovascularization is to define the phenotype of vascular cell populations of different origins and to determine how such cells promote assembly of vascular channel. Here, we describe a protocol to immunophenotype vascular cells by high-resolution imaging and by fluorescence-activated flow cytometry in an in vivo rodent model of pulmonary microvascular remodeling. Analysis of cells by this combined approach will characterize their phenotype, quantify their number and identify their role in the assembly of vascular channels. C1 [Jones, Rosemary C.; Capen, Diane E.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Jones, Rosemary C.; Capen, Diane E.; Cohen, Kenneth S.; Munn, Lance L.; Jain, Rakesh K.; Duda, Dan G.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Cohen, Kenneth S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Cohen, Kenneth S.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. [Munn, Lance L.; Jain, Rakesh K.; Duda, Dan G.] Massachusetts Gen Hosp, Steele Lab Tumor Biol, Boston, MA 02114 USA. RP Jones, RC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA. EM rcjones@partners.org RI Munn, Lance/L-3950-2016 OI Munn, Lance/0000-0003-0698-7232 FU NCI NIH HHS [R01CA115767, R01 CA115767-01A1, R01 CA115767]; NHLBI NIH HHS [R01 HL089252, R01 HL070866, R01 HL070866-01A1, R01HL 070866] NR 11 TC 9 Z9 10 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2008 VL 3 IS 3 BP 388 EP 397 DI 10.1038/nprot.2007.537 PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 276JM UT WOS:000254137100007 PM 18323810 ER PT J AU Tampakakis, E Okoli, I Mylonakis, E AF Tampakakis, Emmanouil Okoli, Ikechukwu Mylonakis, Eleftherios TI A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds SO NATURE PROTOCOLS LA English DT Article ID CANDIDA-ALBICANS; CAENORHABDITIS-ELEGANS; MICROBIAL VIRULENCE; INNATE IMMUNITY; INFECTION; MODEL; HOST; RESISTANCE; MECHANISMS; DISCOVERY AB Traditional antimicrobial screens focus on compounds that block the growth of microbial organisms. A new Caenorhabditis elegans-based bioassay can be used for the identification of antifungal compounds that are effective against Candida albicans. According to the protocol, adult nematodes are infected with C. albicans and moved to 96-well plates containing the tested compounds. In the presence of compounds with no antifungal activity, the fungus kills the worms and develops filaments that penetrate through the cuticle. In contrast to traditional screening methods and mammalian models, this facile, time-efficient and less costly assay allows the study of Candida cells in nonplanktonic form and may allow the concurrent evaluation of toxicity and antifungal activity and identify compounds that target virulence factors or modify host immune response. The screening assay takes about 5-6 d depending on the experimental design. C1 [Tampakakis, Emmanouil; Okoli, Ikechukwu; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Mylonakis, E (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Gray Jackson 504,55 Fruit St, Boston, MA 02114 USA. EM emylonakis@partners.org FU NIH [R01-AI075286] FX Support was provided by NIH R01 award AI075286 (E. M.). We are grateful to Melanie de Silva of Broad Institute of Massachusetts Institute of Technology, USA, for technical assistance. NR 27 TC 29 Z9 31 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2008 VL 3 IS 12 BP 1925 EP 1931 DI 10.1038/nprot.2008.193 PG 7 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 441PR UT WOS:000265781700011 PM 19180076 ER PT J AU Javitt, DC Spencer, KM Thaker, GK Winterer, G Hajos, M AF Javitt, Daniel C. Spencer, Kevin M. Thaker, Gunvant K. Winterer, Georg Hajos, Mihaly TI Neurophysiological biomarkers for drug development in schizophrenia SO NATURE REVIEWS DRUG DISCOVERY LA English DT Review ID EVENT-RELATED POTENTIALS; PURSUIT EYE-MOVEMENTS; MISMATCH NEGATIVITY GENERATION; SCHIZOTYPAL PERSONALITY-DISORDER; NICOTINIC ACETYLCHOLINE-RECEPTOR; SENSORIMOTOR GATING DEFICITS; PREPULSE INHIBITION DEFICITS; CONTEXT-PROCESSING DEFICITS; AUDITORY-EVOKED RESPONSES; DOPAMINE D3 RECEPTOR AB Schizophrenia represents a pervasive deficit in brain function, leading to hallucinations and delusions, social withdrawal and a decline in cognitive performance. As the underlying genetic and neuronal abnormalities in schizophrenia are largely unknown, it is challenging to measure the severity of its symptoms objectively, or to design and evaluate psychotherapeutic interventions. Recent advances in neurophysiological techniques provide new opportunities to measure abnormal brain functions in patients with schizophrenia and to compare these with drug-induced alterations. Moreover, many of these neurophysiological processes are phylogenetically conserved and can be modelled in preclinical studies, offering unique opportunities for use as translational biomarkers in schizophrenia drug discovery. C1 [Hajos, Mihaly] Pfizer Global Res & Dev, CNS Discovery, Dept Neurosci, Groton, CT 06340 USA. [Javitt, Daniel C.] NYU, Sch Med, Nathan Kline Inst Schizophrenia Res, Orangeburg, NY 10962 USA. [Spencer, Kevin M.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Brockton, MA 02301 USA. [Thaker, Gunvant K.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA. [Winterer, Georg] Univ Dusseldorf, Dept Psychiat, D-40629 Dusseldorf, Germany. RP Hajos, M (reprint author), Pfizer Global Res & Dev, CNS Discovery, Dept Neurosci, Groton, CT 06340 USA. EM mihaly.hajos@pfizer.com RI Hajos, Mihaly/A-8287-2008; OI Spencer, Kevin/0000-0002-5500-7627 FU NIMH NIH HHS [R01 MH067014, R01 MH-49826, K02 MH001439, K02 MH01439, R01 MH-67014, R01 MH049826, R01 MH49334, R03 MH76760, R01 MH067014-05] NR 245 TC 153 Z9 156 U1 6 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD JAN PY 2008 VL 7 IS 1 BP 68 EP 83 DI 10.1038/nrd2463 PG 16 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 247QO UT WOS:000252094600015 PM 18064038 ER PT J AU Jones, DL Wagers, AJ AF Jones, D. Leanne Wagers, Amy J. TI No place like home: anatomy and function of the stem cell niche SO NATURE REVIEWS MOLECULAR CELL BIOLOGY LA English DT Review ID HEMATOPOIETIC PROGENITOR CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; HUMAN EPIDERMAL-KERATINOCYTES; COLONY-STIMULATING FACTOR; PRIMORDIAL GERM-CELLS; SELF-RENEWAL; DROSOPHILA-OVARY; HAIR FOLLICLE; BONE-MARROW; SKELETAL-MUSCLE AB Stem cells are rare cells that are uniquely capable of both reproducing themselves (self-renewing) and generating the differentiated cell types that are needed to carry out specialized functions in the body. Stem cell behaviour, in particular the balance between self-renewal and differentiation, is ultimately controlled by the integration of intrinsic factors with extrinsic cues supplied by the surrounding microenvironment, known as the stem cell niche. The identification and characterization of niches within tissues has revealed an intriguing conservation of many components, although the mechanisms that regulate how niches are established, maintained and modified to support specific tissue stem cell functions are just beginning to be uncovered. C1 [Jones, D. Leanne] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA. [Wagers, Amy J.] Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. [Wagers, Amy J.] Harvard Stem Cell Inst, Boston, MA 02215 USA. RP Jones, DL (reprint author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM ljones@salk.edu; amy.wagers@joslin.harvard.edu FU NIA NIH HHS [R01 AG028092] NR 138 TC 328 Z9 342 U1 7 U2 55 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-0072 J9 NAT REV MOL CELL BIO JI Nat. Rev. Mol. Cell Biol. PD JAN PY 2008 VL 9 IS 1 BP 11 EP 21 DI 10.1038/nrm2319 PG 11 WC Cell Biology SC Cell Biology GA 249MA UT WOS:000252231300009 PM 18097443 ER PT J AU Ballard, RA Walsh, MC Zupancic, JA Palermo, L AF Ballard, R. A. Walsh, M. C. Zupancic, J. A. Palermo, L. CA NO CLD Study Grp TI Safety and cost effectiveness of inhaled nitric oxide in preterm infants at high risk of bronchopulmonary dysplasia SO NEONATOLOGY LA English DT Meeting Abstract C1 [Ballard, R. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Palermo, L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Walsh, M. C.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Zupancic, J. A.] Harvard Univ, Sch Med, Div Newborn Med, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-7800 J9 NEONATOLOGY JI Neonatology PY 2008 VL 93 IS 4 MA 16 BP 334 EP 335 PG 2 WC Pediatrics SC Pediatrics GA 311AS UT WOS:000256572900038 ER PT S AU Jankovic, M Martinez, P Chen, Z Cichocki, A AF Jankovic, Marko Martinez, Pablo Chen, Zhe Cichocki, Andrzej BE Ishikawa, M Doya, K Miyamoto, H Yamakawa, T TI Modified Modulated Hebb-Oja learning rule: A method for biologically plausible principal component analysis SO NEURAL INFORMATION PROCESSING, PART I SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 14th International Conference on Neural Information Processing (ICONIP 2007) CY NOV 13-16, 2007 CL Kitakyushu, JAPAN SP RIKEN Brain Sci Inst, Adv Telecommun Res Inst Int, Japan Soc Fuzzy Theory & Intelligent Informat, IEEE CIS Japan Chap, Fuzzy Log Syst Inst DE principal component analysis; time oriented hierarchy; stiefel submanifold; local learning rules ID NEURAL NETWORKS; ALGORITHMS; APPROXIMATION; ANALYZER; TRACKING; MODEL AB This paper presents Modified Modulated Hebb-Oja (MHO) method that performs principal component analysis. Method is based on implementation of Time-Oriented Hierarchical Method applied on recently proposed principal subspace analysis rule called Modulated Hebb-Oja learning rule. Comparing to some other well-known methods for principal component analysis, the proposed method has one feature that could be seen as desirable from the biological point of view - synaptic efficacy learning rule does not need the explicit information about the value of the other efficacies to make individual efficacy modification. Simplicity of the "neural circuits" that perform global computations and a fact that their number does not depend on the number of input and output neurons, could be seen as good features of the proposed method. The number of necessary global calculation circuit is one. Some similarity to a part of the frog retinal circuit will be suggested, too. C1 [Jankovic, Marko; Martinez, Pablo; Cichocki, Andrzej] RIKEN, Brain Sci Inst, Lab Adv Brain Signal Proc, 2-1 Hirosawa, Wako, Saitama 3510198, Japan. [Chen, Zhe] Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Neurosci Stat Res Lab, Boston, MA 02114 USA. RP Jankovic, M (reprint author), RIKEN, Brain Sci Inst, Lab Adv Brain Signal Proc, 2-1 Hirosawa, Wako, Saitama 3510198, Japan. EM elmarkoni@brain.riken.jp; zhechen@neurostat.mgh.harvard.edu; cia@brain.riken.jp RI Cichocki, Andrzej/A-1545-2015; OI Cichocki, Andrzej/0000-0002-8364-7226; Chen, Zhe/0000-0002-6483-6056; Jankovic, Marko/0000-0002-7651-7327 NR 28 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-540-69154-9 J9 LECT NOTES COMPUT SC PY 2008 VL 4984 BP 527 EP + PN I PG 3 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods SC Computer Science GA BHX61 UT WOS:000257246100055 ER PT S AU Tillisch, K Wang, Z Kilpatrick, L Hoischneider, DP Mayer, EA AF Tillisch, Kirsten Wang, Zhuo Kilpatrick, Lisa Hoischneider, Daniel P. Mayer, Emeran A. BE Goetzl, EJ TI Studying the Brain-Gut Axis with Pharmacological Imaging SO Neural Signaling: Opportunities for Novel Diagnostic Approaches and Therapies SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT International Conference on Neural Signaling - Opportunities for Novel Diagnostic Approaches and Therapies CY FEB 16-20, 2008 CL Pacific Grove, CA DE irritable bowel syndrome; brain-gut axis; neuroimaging; functional gastrointestinal disorder ID IRRITABLE-BOWEL-SYNDROME; C-FOS EXPRESSION; NOXIOUS COLORECTAL DISTENSION; RECEPTOR ANTAGONIST ALOSETRON; LUMBOSACRAL SPINAL-CORD; COLONIC DISTENSION; VISCERAL STIMULATION; ANTERIOR CINGULATE; MAJOR DEPRESSION; PAIN AB Pharmacological imaging provides great potential both for evaluating the efficacy of new candidate compounds in the treatment of gastrointestinal symptom-based disorders, and for furthering our understanding of the underlying pathophysiology of such disorders. By combining evaluation of symptoms, behavior, and brain responses to relevant stimuli, use of neuroimaging is able to move the study of brain-gut disorders away from more subjective outcomes and emphasize the underlying neural networks involved in symptom generation and treatment. This chapter reviews the state of the art in pharmacological imaging studies, both in human subjects and in animal models of brain-gut interactions. C1 [Mayer, Emeran A.] Univ Calif Los Angeles, Ctr Neurobiol Stress, Div Digest Dis, Dept Med,David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hoischneider, Daniel P.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Hoischneider, Daniel P.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Hoischneider, Daniel P.] Univ Calif Los Angeles, Dept Cell & Neurobiol, Los Angeles, CA 90095 USA. [Hoischneider, Daniel P.] Univ Calif Los Angeles, Dept Biomed Engn, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Wang, Zhuo; Hoischneider, Daniel P.; Mayer, Emeran A.] Greater Los Angeles Vet Adm Healthcare Syst, Res Serv, Los Angeles, CA USA. RP Mayer, EA (reprint author), Univ Calif Los Angeles, Ctr Neurobiol Stress, Div Digest Dis, Dept Med,David Geffen Sch Med, 10945 Le Conte Ave,Ste 2338,Room F, Los Angeles, CA 90095 USA. EM emayer@ucla.edu RI Kilpatrick, Lisa/E-6995-2015 FU NIDDK NIH HHS [R01 DK048351] NR 49 TC 6 Z9 6 U1 0 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-704-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2008 VL 1144 BP 256 EP 264 DI 10.1196/annals.1418.025 PG 9 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BIT17 UT WOS:000262481000028 PM 19076383 ER PT J AU Demidenko, A Vakili, R Eggenberger, ER Kaufman, DI AF Demidenko, Alexander Vakili, Roya Eggenberger, Eric R. Kaufman, David I. TI Late onset Leber's hereditary optic neuropathy SO NEURO-OPHTHALMOLOGY LA English DT Article DE mitochondrial disorder; genetics; LHON; optic neuropathy; neuroopthalmology AB Leber's Hereditary Optic Neuropathy is a mitochondrial genetic disorder that causes acute to subacute bilateral central loss of vision. It typically presents in young men in their second or third decade of life and onset later in life is rare. We describe a case of a 58-year-old man with late onset of LHON and discuss the importance of suspecting the diagnosis in appropriate cases. C1 [Demidenko, Alexander] Massachusetts Gen Hosp, Dept Ophthalmol, Boston, MA USA. [Vakili, Roya] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Eggenberger, Eric R.; Kaufman, David I.] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA. RP Vakili, R (reprint author), Univ Michigan, Dept Neurol, 2926 Mt Hope Ave, Okemos, MI 48864 USA. EM rvakilik@yahoo.com NR 9 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0165-8107 J9 NEURO-OPHTHALMOLOGY JI Neuro-Ophthalmol. PY 2008 VL 32 IS 1 BP 41 EP 42 DI 10.1080/01658100701619372 PG 2 WC Clinical Neurology; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA 261OO UT WOS:000253089500009 ER PT B AU Walker, RH Saiki, S Danek, A AF Walker, R. H. Saiki, S. Danek, A. BE Walker, RH Saiki, S Danek, A TI Neuroacanthocytosis syndromesA current overview SO NEUROACANTHOCYTOSIS SYNDROMES II LA English DT Proceedings Paper CT International Conference on Neuroacanthocytosis Syndromes CY 2006 CL Bethesda, MD ID HEREDITARY NEUROLOGICAL DISEASE; ERYTHROCYTE-MEMBRANE ABNORMALITIES; DOMINANT CHOREA-ACANTHOCYTOSIS; MCLEOD SYNDROME GENE; HUNTINGTONS-DISEASE; AMYOTROPHIC CHOREA; INVOLUNTARY MOVEMENTS; CHAC GENE; FAMILY; MUTATION AB Neuroacanthocytosis syndromes are characterized by the presence of "thorny" red blood cells and neurodegeneration of the basal ganglia, along with peripheral neuromuscular findings, seizures, and a variety of neuropsychiatric features. In recent years significant progress has been made in understanding the molecular pathophysiology of these disorders; cases are now identified as autosomal recessive chorea-acanthocytosis, X-linked McLeod syndrome, or more rarely, pantothenase kinase-associated neurodegeneration or Huntington's disease-like 2. Molecular analysis of classic reports of neuroacanthocytosis will clarify nomenclature and improve understanding of genotype-phenotype correlations. In addition, there are issues of atypical inheritance patterns which remain to be elucidated. A relatively high incidence of chorea-acanthocytosis in Japan may indicate a genetic founder effect, and has led to significant developments from Japanese researchers. C1 [Walker, R. H.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Saiki, S.] Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust, Cambridge CB2 2XY, England. [Danek, A.] Univ Munich, Neurol Klin, D-81366 Munich, Germany. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM ruth.walker@mssm.edu; ss644@cam.ac.uk; danek@lmu.de RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 153 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-71692-1 PY 2008 BP 3 EP + DI 10.1007/978-3-540-71693-8_1 PG 8 WC Neurosciences SC Neurosciences & Neurology GA BHG19 UT WOS:000252885800001 ER PT J AU Yaffe, K Kanaya, AM Lindquist, K Hsueh, WC Cummings, SR Beamer, B Newman, A Rosano, C Li, R Harrisi, T AF Yaffe, K. Kanaya, A. M. Lindquist, K. Hsueh, W. C. Cummings, S. R. Beamer, B. Newman, A. Rosano, C. Li, R. Harrisi, T. TI PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders SO NEUROBIOLOGY OF AGING LA English DT Article DE cognitive function; PPAR-gamma; cognitive impairment; dementia; metabolism ID BODY-MASS INDEX; ACTIVATED RECEPTOR-GAMMA-2 GENE; AFRICAN-AMERICANS; ALZHEIMER-DISEASE; OLDER WOMEN; PEROXISOME; PPAR-GAMMA-2; POLYMORPHISM; DEMENTIA; INSULIN AB Background: The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has been associated with decreased risk of diabetes and obesity, both disorders linked to cognitive impairment. We tested whether this polymorphism is associated with cognition. Methods: Two thousand nine hundred sixty-one participants (mean age, 74.1; 41% Black; 52% women) were administered the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) at baseline and 4 year follow-up. Test scores were adjusted for age, sex, education, cerebrovascular disease, depression and APOE genotype and additionally for race. We determined the association between Ala allele and development of cognitive decline (3MS decline of >= 5 points). Results: At baseline, unadjusted scores on both cognitive tests were higher for Ala carriers compared to non-carriers (3MS, 94.2 versus 92.5, p<0.001; DSST, 40.2 versus 34.5, p<0.001). Similarly, follow-up scores were higher for Ala carriers. Multivariable adjustment led to similar results; additional adjustment for race attenuated the baseline 3MS results. After 4 years, 17.5% of Ala carriers developed cognitive decline compared to 25% among non-carriers (unadjusted OR = 0.61; 95%CI, 0.46-0.82; adjusted OR = 0.75; 95%CI, 0.55-1.02). Further adjustment for metabolic variables including fasting blood glucose and lipid level did not change the results. Conclusions: The PPAR-gamma Ala12 allele carriers may have less risk of developing cognitive decline. (C) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Geriatr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Calif Pacific Med Ctr, San Francisco, CA USA. Johns Hopkins Univ, Dept Med, Baltimore, MD USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. Univ Tennessee, Ctr Hlth Sci, Ctr Genom & Bioinformat, Dept Prevent Med, Memphis, TN 38163 USA. NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat & Neurol, POB 181,4150 Clement St, San Francisco, CA 94121 USA. EM Kristine.yaffe@ucsf.edu RI Newman, Anne B./C-6408-2013; OI Newman, Anne B./0000-0002-0106-1150; Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU Intramural NIH HHS; NIA NIH HHS [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01 AG021918, R01 AG021918-03]; NIDDK NIH HHS [DK070713, R21 DK070713, R21 DK070713-01] NR 29 TC 20 Z9 21 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JAN PY 2008 VL 29 IS 1 BP 78 EP 83 DI 10.1016/j.neurobiolaging.2006.09.010 PG 6 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 239SD UT WOS:000251537100008 PM 17052804 ER PT J AU Huttunen, HJ Kovacs, DM AF Huttunen, Henri J. Kovacs, Dora M. TI ACAT as a drug target for Alzheimer's disease SO NEURODEGENERATIVE DISEASES LA English DT Article; Proceedings Paper CT 8th International Conference on Alzheimers and Parkinsons Diseases CY MAR 14-18, 2007 CL Salzburg, AUSTRIA DE Alzheimer's disease; amyloid; cholesterol; lipids; endoplasmic; reticulum ID A-CHOLESTEROL ACYLTRANSFERASE; ACYL-COENZYME; REDUCTASE INHIBITORS; GENETIC ASSOCIATION; STATINS; BRAIN; RISK; APP AB Accumulation of P-amyloid peptide (A beta) in the brain regions responsible for memory and cognitive functions is a neuropathological hallmark of Alzheimer's disease. Cholesterol may be involved in many aspects of A beta metabolism. It affects generation, aggregation and clearance of A beta in the brain. Not only the amount but also the distribution of cholesterol within cells appears to modulate A beta biogenesis. ACAT is an enzyme that regulates subcellular cholesterol distribution by converting membrane cholesterol to cholesteryl esters for storage and transport. We have used various cell- and animal based models to show that inhibition of ACAT strongly reduces A beta generation and protects from amyloid pathology. Here, we discuss data supporting ACAT inhibition as a strategy to treat Alzheimer's disease. Copyright (c) 2008 S. KargerAG, Basel. C1 [Huttunen, Henri J.; Kovacs, Dora M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit,Neurobiol Dis Lab,MIND, Boston, MA 02129 USA. RP Kovacs, DM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit,Neurobiol Dis Lab,MIND, 114 16th St, Boston, MA 02129 USA. EM Dora_Kovacs@hms.harvard.edu OI Huttunen, Henri/0000-0002-9867-4438 FU NINDS NIH HHS [R01 NS045860-08, R01 NS045860, R01 NS045860-07] NR 18 TC 26 Z9 31 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2854 J9 NEURODEGENER DIS JI Neurodegener. Dis. PY 2008 VL 5 IS 3-4 BP 212 EP 214 DI 10.1159/000113705 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 275ZA UT WOS:000254109700029 PM 18322393 ER PT J AU Sattin, A Pekary, AE Blood, J AF Sattin, Albert Pekary, Albert E. Blood, James TI Escitalopram regulates expression of TRH and TRH-like peptides in rat brain and peripheral tissues SO NEUROENDOCRINOLOGY LA English DT Article DE thyrotropin-releasing hormone; escitalopram; limbic system; epididymis ID THYROTROPIN-RELEASING-HORMONE; SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; HIPPOCAMPAL-LESIONS; RAPID MODULATION; PANIC DISORDER; CITALOPRAM; RECEPTORS; ANXIETY; NEURONS AB Background: Escitalopram (eCIT) is a highly selective serotonin reuptake inhibitor (SSRI) that can be an effective treatment for a number of neuropsychiatric disorders including major depression. We, and others, have previously reported that thyrotropin-releasing hormone (TRH, pGlu-His-ProNH 2) and TRH-like peptides with the general structure pGlu-X-Pro-NH2, where 'X' can be any amino acid residue, have neuroprotective, antidepressant, analeptic, arousal, and anti-epileptic effects that could mediate the neuropsychiatric and therapeutic effects of a variety of neurotropic agents. The present work explores the possible mediation of the therapeutic effects of eCIT by TRH and TRH-like peptides. Methods: In order to extend our understanding of the range of neurotransmitter systems that are modulated by and, in turn, influence the expression of TRH and TRH-like peptides, 16 male Sprague-Dawley rats were injected i.p. with eCIT (24 mg/kg BW) and the brain levels of TRH and TRH-like peptides in various brain regions involved in mood regulation and peripheral tissues with serotonergic innervation were measured 0, 2, 4, and 6 h later by combined HPLC and RIA. Results and Conclusion: Remarkable 3- to 25-fold increases in TRH and TRH-like peptide levels were observed 2 h after i.p. eCIT in the epididymis. This reproductive tissue has the highest level of serotonin found in most mammals. The acute ( 2 h) effect of eCIT in brain regions involved in mood regulation, particularly the nucleus accumbens and medulla oblongata, cerebellum, and striatum was to increase the levels of TRH-like peptides, most consistently Phe-TRH. An important exception was a decrease in the level of TRH in the nucleus accumbens. These responses, in general, were the opposite of those we have previously observed after acute restraint stress in this same rat strain. We conclude that some of the therapeutic effects of inhibition of serotonin reuptake are mediated by altered release of TRH and TRH-like peptides. Copyright (C) 2008 S. Karger AG, Basel. C1 [Pekary, Albert E.] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Pekary, Albert E.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Sattin, Albert; Pekary, Albert E.; Blood, James] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov NR 62 TC 13 Z9 13 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2008 VL 88 IS 2 BP 135 EP 146 DI 10.1159/000121595 PG 12 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 343TV UT WOS:000258879000008 PM 18354249 ER PT J AU Plockinger, U Couvelard, A Falconi, M Sundin, A Salazar, R Christ, E De Herder, WW Gross, D Knapp, WH Knigge, UP Kulke, MH Pape, UF AF Ploeckinger, Ursula Couvelard, Anne Falconi, Massimo Sundin, Anders Salazar, Ramon Christ, Emanuel De Herder, Wouter W. Gross, David Knapp, Wolfram H. Knigge, Ulrich P. Kulke, Matthew H. Pape, Ulrich F. CA Frascati Consensus Conference Part TI Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma SO NEUROENDOCRINOLOGY LA English DT Article; Proceedings Paper CT Conference on ENETS Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumor CY NOV 01-04, 2006 CL Frascati, ITALY ID SOMATOSTATIN RECEPTOR SCINTIGRAPHY; GASTROINTESTINAL-TRACT; COMPUTED-TOMOGRAPHY; SURGICAL-TREATMENT; ENDOCRINE TUMORS; GRADING SYSTEM; PROGNOSIS; METASTASES; EXPERIENCE; NEOPLASMS C1 [Ploeckinger, Ursula] Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, DE-13353 Berlin, Germany. [Couvelard, Anne] Hop Beaujon, Serv Gastroenterol, Clichy, France. [Falconi, Massimo] Univ Verona, Med & Surg Gen Surg Sect, I-37100 Verona, Italy. [Sundin, Anders] Univ Uppsala Hosp, Dept Radiol, Uppsala, Sweden. [Salazar, Ramon] Inst Catala Oncol, Barcelona, Spain. [Christ, Emanuel] Univ Bern, Inselspital, CH-3010 Bern, Switzerland. [De Herder, Wouter W.] Erasmus MC, Dept Internal Med, Endocrinol Sect, Rotterdam, Netherlands. [Gross, David] Hadassah Univ Hosp, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel. [Knapp, Wolfram H.] MHH, Klin Nukl Med, Hannover, Germany. [Knigge, Ulrich P.] Rigshosp Blegdamsvej, Dept Surg, Copenhagen, Denmark. [Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pape, Ulrich F.] Charite Univ Med Berlin, Dept Internal Med, Div Gastroenterol & Hepatol, Berlin, Germany. RP Plockinger, U (reprint author), Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, Augustenburger Pl 1, DE-13353 Berlin, Germany. EM ursula.ploeckinger@charite.de RI Lopes, Jose Manuel/J-7428-2013; scarpa, aldo/K-6832-2016; Christ, Emanuel/F-1196-2015; OI Lopes, Jose Manuel/0000-0001-8597-3474; scarpa, aldo/0000-0003-1678-739X; Christ, Emanuel/0000-0002-5604-4606; Falconi, Massimo/0000-0001-9654-7243; RINDI, Guido/0000-0003-2996-4404; OConnor, Juan Manuel/0000-0002-6975-5466; Perren, Aurel/0000-0002-6819-6092 NR 47 TC 50 Z9 53 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2008 VL 87 IS 1 BP 20 EP 30 DI 10.1159/000109876 PG 11 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 241MX UT WOS:000251661600003 PM 17934252 ER PT J AU Hughes, VA Boepple, PA Crowley, WF Seminara, SB AF Hughes, Virginia A. Boepple, Paul A. Crowley, William F., Jr. Seminara, Stephanie B. TI Interplay between dose and frequency of GnRH administration in determining pituitary gonadotropin responsiveness SO NEUROENDOCRINOLOGY LA English DT Article DE gonadotropins, pituitary; dose-response, pulsatility; luteinizing hormone ID POLYCYSTIC OVARIAN DISEASE; HORMONE-RELEASING HORMONE; LUTEINIZING-HORMONE; DEFICIENT MEN; RESPONSE RELATIONSHIP; MENSTRUAL-CYCLE; SECRETION; LH; TESTOSTERONE; METABOLISM AB Background/Aims: The dose, frequency and contour of GnRH stimulation of the pituitary gonadotrope have been shown to be independent variables influencing pituitary LH secretion. The dynamic interaction between these variables during physiological and pathophysiological states has yet to be examined. Methods: Twelve men with GnRH deficiency and idiopathic hypogonadotropic hypogonadism undergoing GnRH therapy participated in a series of studies in which 2 log orders of GnRH doses (2.5-250 ng/kg) were administered at frequencies varying from 0.5 to 8 hourly. Pituitary responses were characterized by pulse amplitudes and nadirs. The relative sensitivity of the gonadotrope to GnRH was defined as that dose of GnRH capable of eliciting an LH pulse amplitude equal to the mean LH amplitude in normal men. Results: As GnRH stimulation of the gonadotrope slowed from 0.5 to 8 hourly, pulse amplitudes of LH increased whereas mean nadirs decreased (p < 0.05). Unique, curvilinear dose-response curves were found for each frequency that demonstrated an increasing slope (p < 0.03) as the frequency of GnRH stimulation slowed. Thus, the relative sensitivity of the gonadotrope increased as the frequency of GnRH stimulation decreased over the range of physiological frequencies tested. Conclusions: We conclude that a delicate interplay exists between the dose and frequency of GnRH stimulation of the gonadotrope that determines pituitary LH gonadotropin responsiveness in the human. Slower frequencies favor increased LH release largely due to decreasing LH nadirs and improved sensitivity of the gonadotropes to GnRH stimulation. Copyright (c) 2007 S. Karger AG, Basel. C1 Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. RP Seminara, SB (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Bartlett Hall Extens 505,55 Fruit St, Boston, MA 02114 USA. EM seminara.stephanie@mgh.harvard.edu FU NCRR NIH HHS [RR1066]; NICHD NIH HHS [R01 HD043341, U54 HD028138, U54 HD029164, U01 HD044417]; PHS HHS [R01-15788-22] NR 22 TC 4 Z9 5 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2008 VL 87 IS 3 BP 142 EP 150 DI 10.1159/000112421 PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 289XR UT WOS:000255087700003 PM 18063854 ER PT J AU Llinas-Regla, J Lopez-Pousa, S Vilalta-Franch, J Garre-Olmo, J Roman, GC AF Llinas-Regla, Jordi Lopez-Pousa, Secundino Vilalta-Franch, Joan Garre-Olmo, Josep Roman, Gustavo C. TI Mortality after a diagnosis of dementia in a population aged 75 and over in Spain SO NEUROEPIDEMIOLOGY LA English DT Article DE dementia; mortality rates; dementia; comorbidity; elderly population; Spain ID ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; COGNITIVE IMPAIRMENT; FUNCTIONAL STATUS; CACHE COUNTY; SURVIVAL; COMMUNITY; DEATH; PREVALENCE; PREDICTORS AB Objectives: To examine the impact of incident dementia on the risk of death, taking into account other chronic illnesses potentially related to death. Design: Six-year, prospective, two-phase, observational cohort study. Setting: 8 municipalities from a rural area in Girona (Spain). Participants: A representative community-based cohort of 1,153 adults aged over 70 living at home at study enrolment. Measurements: Surviving participants underwent detailed clinical evaluation and were assessed by means of the Cambridge Examination for Mental Disorders of the Elderly. Relatives of deceased participants were interviewed using the Retrospective Collateral Dementia Interview. Mortality rates and relative risk of death for subjects with a diagnosis of dementia were calculated. The Cox proportional hazards regression model was used to assess the relationship between mortality and the diagnosis of dementia. Results: In this cohort, 40.0% (n = 49) of the subjects with a diagnosis of dementia died. The mortality rate specific to dementia was 1.0 per 100 person-years. Mortality risk ratios for dementia were 1.79 in men [95% confidence interval (CI) = 1.06-3.02], and 3.14 in women (95% CI = 2.04-4.85). The population death risk attributable to the diagnosis of dementia in our cohort was 11.8%. The most important mortality risks were severe dementia (hazard ratio = 5.7, 95% CI = 3.7-8.6), cancer (hazard ratio = 3.2, 95% CI = 2.2-4.5), heart disease, and an age over 85 (hazard ratio = 1.4, 95% CI = 1.1-1.9). Conclusion: Dementia is a major risk factor for death in advanced age, with the highest mortality rates in women. Moderate and severe dementia was associated with an increased mortality risk even after appropriate control of comorbid conditions. Copyright (C) 2008 S. Karger AG, Basel. C1 [Llinas-Regla, Jordi; Lopez-Pousa, Secundino; Vilalta-Franch, Joan; Garre-Olmo, Josep] Parc Hosp Marti & Julia, Memory & Dementia Unit, Salt, Spain. [Roman, Gustavo C.] Univ Texas Hlth Sci Ctr San Antonio, Div Neurol, San Antonio, TX 78229 USA. [Roman, Gustavo C.] Vet Adm Hosp, San Antonio, TX USA. RP Lopez-Pousa, S (reprint author), C Dr Castany S-N, ES-17190 Salt, Spain. EM uvamid@ias.scs.es OI Garre-Olmo, Josep /0000-0002-7817-0814 FU Spanish National Healthcare System [90-0797, 94-1799] FX We are thankful to the residents from the 8 municipalities participating in the Girona dementia study. This research was supported by Health Research Fund Grants 90-0797 and 94-1799 of the Spanish National Healthcare System. NR 59 TC 17 Z9 18 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2008 VL 31 IS 2 BP 80 EP 88 DI 10.1159/000144088 PG 9 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 348SU UT WOS:000259231200002 PM 18622143 ER PT J AU Chang, L Kahler, KH Sarawate, C Quimbo, R Kralstein, J AF Chang, L. Kahler, K. H. Sarawate, C. Quimbo, R. Kralstein, J. TI Assessment of potential risk factors associated with ischaemic colitis SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE constipation; irritable bowel syndrome; ischaemic colitis; risk factors ID IRRITABLE-BOWEL-SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GASTROESOPHAGEAL-REFLUX; AORTOILIAC SURGERY; COLONIC ISCHEMIA; CONSTIPATION; PREVALENCE; COMPLICATIONS; POPULATION; OPERATIONS AB Ischaemic colitis (IC) has been associated with a number of diverse disorders and risk factors, including irritable bowel syndrome (IBS) and constipation. We sought to assess, through a large-scale population study, the potential risk factors associated with IC. Patients with IC and matched controls without IC were identified using the medical and pharmacy claims data from the HealthCore Managed Care Database from 1st January 2000 to 31st May 2005. A multivariate conditional logistic regression model was developed to identify significant risk factors of IC. Interactions of age, sex, prior IBS diagnosis, and prior constipation diagnosis were further evaluated. We identified 1754 patients with IC and 6970 non-IC controls; 64% were women, and mean ages were 63 and 62 years respectively. The final parsimonious model comprised 19 independent variables associated with increased risk for IC including shock, dysentery, bloating, IBS, colon carcinoma, constipation, cardiovascular disease, dyspepsia, abdominal, aortic, or cardiovascular surgery, 12-month laxative, H(2) receptor blocker and oral contraceptive use. A significant interaction was observed between age and prior IBS on risk for IC. In conclusion, multiple risk factors for IC were identified and we confirmed that patients with IBS or constipation are at greater risk for IC. C1 [Chang, L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Div Digest Dis,Ctr Neurovisceral Sci & Womens Hlt, Los Angeles, CA 90073 USA. [Kahler, K. H.; Kralstein, J.] Novartis Pharmaceut, E Hanover, NJ USA. [Sarawate, C.; Quimbo, R.] HealthCore Inc, Wilmington, DE USA. RP Chang, L (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Div Digest Dis,Ctr Neurovisceral Sci & Womens Hlt, 11301 Wilshire Blvd,Bldg 115,Room 223, Los Angeles, CA 90073 USA. EM linchang@ucla.edu NR 32 TC 23 Z9 27 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD JAN PY 2008 VL 20 IS 1 BP 36 EP 42 DI 10.1111/j.1365-2982.2007.01015.x PG 7 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 242QO UT WOS:000251740700007 PM 17919313 ER PT J AU Alpert, NM Yuan, F AF Alpert, Nathaniel M. Yuan, F. TI A general method of Bayesian estimation for parametric imaging of the brain SO NEUROIMAGE LA English DT Meeting Abstract CT 7th International Symposium on Functional Neuroreceptor Mapping of the Living Brain CY JUL 17-19, 2008 CL Pittsburgh, PA SP Natl Inst Ment Hlth, Amgen, GE Healthcare, GlaxoSmithKline, Johnson & Johnson, MathworksMatlab, Merek & Co Inc, Pfizer, PMOD Technol, Raytest, GmBH, Siemens Med Syst C1 [Alpert, Nathaniel M.; Yuan, F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PY 2008 VL 41 SU 2 BP T58 EP T58 DI 10.1016/j.neuroimage.2008.04.029 PG 1 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 326QK UT WOS:000257673800045 ER PT J AU Dickerson, BC Fenstermacher, E Salat, DH Wolk, DA Maguire, RP Desikan, R Pacheco, J Quinn, BT Van der Kouwe, A Greve, DN Blacker, D Albert, MS Killiany, RJ Fischl, B AF Dickerson, B. C. Fenstermacher, E. Salat, D. H. Wolk, D. A. Maguire, R. P. Desikan, R. Pacheco, J. Quinn, B. T. Van der Kouwe, A. Greve, D. N. Blacker, D. Albert, M. S. Killiany, R. J. Fischl, B. TI Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths SO NEUROIMAGE LA English DT Article ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; ALZHEIMERS-DISEASE; ENTORHINAL CORTEX; MEMORY PERFORMANCE; BRAIN SEGMENTATION; COORDINATE SYSTEM; SURFACE; HIPPOCAMPAL; DEMENTIA AB In normal humans, relationships between cognitive test performance and cortical structure have received little study, in part, because of the paucity of tools for measuring cortical structure. Computational morphometric methods have recently been developed that enable the measurement of cortical thickness from MRI data, but little data exist on their reliability. We undertook this study to evaluate the reliability of an automated cortical thickness measurement method to detect correlates of interest between thickness and cognitive task performance. Fifteen healthy older participants were scanned four times at 2-week intervals on three different scanner platforms. The four MRI data sets were initially treated independently to investigate the reliability of the spatial localization of findings from exploratory whole-cortex analyses of cortical thickness-cognitive performance correlates. Next, the first data set was used to define cortical Rolls based on the exploratory results that were then applied to the remaining three data sets to determine whether the relationships between cognitive performance and regional cortical thickness were comparable across different scanner platforms and field strengths. Verbal memory performance was associated with medial temporal cortical thickness, while visuomotor speed/set shifting was associated with lateral parietal cortical thickness. These effects were highly reliable - in terms of both spatial localization and magnitude of absolute cortical thickness measurements - across the four scan sessions. Brain-behavior relationships between regional cortical thickness and cognitive task performance can be reliably identified using an automated data analysis system, suggesting that these measures may be useful as imaging biomarkers of disease or performance ability in multicenter studies in which MRI data are pooled. (C) 2007 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Harvard Med Sch, Dept Psychiat, Boston, MA USA. Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Boston, MA USA. Massachusetts Gen Hosp, Harvard Med Sch, Massachusetts Alzheimers Dis Res Ctr, Boston, MA USA. Massachusetts Gen Hosp, Harvard Med Sch, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. Brigham & Womens Hosp, Dept Neurol, Div Cognit & Behav Neurol, Boston, MA USA. Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA. Pfizer Pharmaceut Inc, Groton, CT USA. Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA. Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA USA. MIT, CSAIL, Cambridge, MA USA. RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Boston, MA 02114 USA. EM bradd@nmr.mgh.harvard.edu OI Maguire, Ralph/0000-0003-3937-6622 FU NCRR NIH HHS [P41-RR14075, R01 RR016594, R01 RR16594-01A1, U24 RR021382, U24-RR021382]; NIA NIH HHS [K23 AG022509, K23 AG022509-04, K23-AG22509]; NIBIB NIH HHS [R01 EB001550, U54 EB005149]; NINDS NIH HHS [R01 NS052585]; PHS HHS [BIRN002] NR 61 TC 131 Z9 132 U1 3 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JAN 1 PY 2008 VL 39 IS 1 BP 10 EP 18 DI 10.1016/j.neuroimage.2007.08.042 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 237WB UT WOS:000251406000002 PM 17942325 ER PT J AU Szekely, CA Breitner, JCS Fitzpatrick, AL Rea, TD Psaty, BM Kuller, LH Zandi, PP AF Szekely, C. A. Breitner, J. C. S. Fitzpatrick, A. L. Rea, T. D. Psaty, B. M. Kuller, L. H. Zandi, P. P. TI NSAID use and dementia risk in the cardiovascular health study - Role of APOE and NSAID type SO NEUROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; DOUBLE-BLIND; INDOMETHACIN; INFLAMMATION; POPULATION; ROFECOXIB; DIAGNOSIS; ASPIRIN AB Background: Epidemiologic and laboratory studies suggest that nonsteroidal antiinflammatory drugs (NSAIDs) reduce risk of Alzheimer disease ( AD). We therefore investigated the association between use of NSAIDs, aspirin, and the non-NSAID analgesic acetaminophen with incidence of dementia and AD. Methods: Participants in the Cardiovascular Health Cognition Study included 3,229 individuals aged 65 or older, free of dementia at baseline, with information on medication use. We used Cox proportional hazards regression to estimate the association of medication use with incident all-cause dementia, AD, and vascular dementia (VaD). Additional analyses considered the NSAID-AD relationship as a function of age, presence of at least one epsilon 4 allele at APOE, race, and individual NSAIDs' reported ability to reduce production of the amyloid-beta peptide variant A beta(42). Results: Use of NSAIDs was associated with a lower risk of dementia ( adjusted hazard ratio or aHR 0.76, 95% CI or CI 0.60 - 0.96) and, in particular, AD (aHR 0.63, CI 0.45-0.88), but not VaD (aHR 0.92, CI 0.65-1.28). No similar trends were observed with acetaminophen (aHR 0.99, CI 0.79-1.24). Closer examination suggested AD risk reduction with NSAIDs only in participants having an APOE epsilon 4 allele (aHR 0.34, CI 0.18-0.65; aHR for others 0.88, CI 0.59-1.32). There was no advantage in AD risk reduction with NSAIDs reported to selectively reduce A beta(42). Conclusions: Results were consistent with previous cohort studies showing reduced risk of AD in NSAID users, but this association was found only in those with an APOE epsilon 4 allele, and there was no advantage for A beta(42)-lowering NSAIDs. C1 [Rea, T. D.; Psaty, B. M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Fitzpatrick, A. L.; Psaty, B. M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Breitner, J. C. S.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Breitner, J. C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Kuller, L. H.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA. [Szekely, C. A.; Zandi, P. P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. RP Zandi, PP (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway, Baltimore, MD 21205 USA. EM pzandi@jhsph.edu RI Szekely, Christine/C-1342-2009 FU NHLBI NIH HHS [N01 HC015103, N01 HC035129, N01 HC045133, N01-HC-55222, N01-HC-75150, N01-HC-85079, N01-HC-85086, N01HC55222, N01HC75150, N01HC85079, N01HC85086, U01 HL080295, U01 HL080295-01, U01-HL080295]; NIA NIH HHS [R01 AG009556, R01 AG015928, R01-AG-09556, R01-AG-88930, R01-AG15928] NR 39 TC 98 Z9 104 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JAN 1 PY 2008 VL 70 IS 1 BP 17 EP 24 DI 10.1212/01.wnl.0000284596.95156.48 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 246ZL UT WOS:000252046800005 PM 18003940 ER PT J AU Winkelman, JW Shahar, E Sharief, I Gottlieb, DJ AF Winkelman, John W. Shahar, Eyal Sharief, Imran Gottlieb, Daniel J. TI Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study SO NEUROLOGY LA English DT Article ID GENERAL-POPULATION; AUTONOMIC ACTIVITY; MOVEMENTS; EPIDEMIOLOGY; PREVALENCE; SYMPTOMS; RISK; ACTIVATION; DIAGNOSIS; IMPACT AB Objective: We evaluated the cross-sectional association between restless legs syndrome (RLS) and prevalent cardiovascular disease (CVD) in a large community-based sample of middle- aged and elderly subjects. Methods: This is a cross-sectional observational study of 1,559 men and 1,874 women (mean age of 67.9 years) who were enrolled in the Sleep Heart Health Study, a community-based study of the cardiovascular consequences of sleep-disordered breathing. RLS was defined by positive responses on a self-administered questionnaire to the four diagnostic criteria, with symptoms occurring at least five times per month and associated with at least moderate distress. Coronary artery disease (CAD) was determined by self-report of doctor-diagnosed angina, myocardial infarction, or coronary revascularization procedure. Total CVD included CAD or history of physician-diagnosed stroke or heart failure. The relation of RLS to prevalent CAD and CVD was examined by multivariable logistic regression models Results: RLS was present in 6.8% of women (n = 128) and 3.3% of men (n = 51). After adjustment for age, sex, race, body mass index, diabetes mellitus, systolic blood pressure, antihypertensive medication use, total: high-density lipoprotein cholesterol ratio, and smoking history, the ORs for CAD were 2.05 (95% CI 1.38 to 3.04) and for CVD were 2.07 (1.43 to 3.00) for subjects with RLS compared to those without RLS. The associations of RLS with CAD and CVD were stronger in those with RLS symptoms at least 16 times per month and were stronger in those with severe than in those with moderately bothersome symptoms. Conclusions: Restless legs syndrome (RLS) is associated with prevalent coronary artery disease and cardiovascular disease. This association appears stronger in those with greater frequency or severity of RLS symptoms. C1 [Winkelman, John W.] Brigham & Womens Hosp, Harvard Med Sch, Div Sleep Med, Brighton, MA 02135 USA. [Shahar, Eyal] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Div Epidemiol & Biostat, Tucson, AZ USA. [Sharief, Imran] Univ Arizona, Arizona Resp & Sleep Disorders Ctr, Dept Med, Pulm & Crit Care Med Sect, Tucson, AZ USA. [Gottlieb, Daniel J.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02215 USA. RP Winkelman, JW (reprint author), Brigham & Womens Hosp, Harvard Med Sch, Div Sleep Med, 1505 Commonwealth Ave, Brighton, MA 02135 USA. EM JWinkelman@sleephealth.com FU NHLBI NIH HHS [HL53938-07S1, R01 HL71515, U01 HL53916, U01 HL53931, U01 HL53934, U01 HL53937, U01 HL53938, U01 HL53940, U01 HL53941, U01 HL63429, U01 HL63463, U01 HL64360] NR 20 TC 195 Z9 199 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD JAN 1 PY 2008 VL 70 IS 1 BP 35 EP 42 DI 10.1212/01.wnl.0000287072.93277.c9 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 246ZL UT WOS:000252046800007 PM 18166705 ER PT J AU de Gelder, B Van den Stock, J Balaguer, RDD Bachoud-Levi, AC AF de Gelder, Beatrice Van den Stock, Jan Diego Balaguer, Ruth de Bachoud-Levi, Anne-Catherine TI Huntington's disease impairs recognition of angry and instrumental body language SO NEUROPSYCHOLOGIA LA English DT Article DE emotion; striatum; action representation ID BASAL GANGLIA; DISGUST; EXPRESSIONS; PERCEPTION; SELECTION; STRIATUM; EMOTIONS; ATROPHY; GENDER; DAMAGE AB Patients with Huntington's disease (HD) exhibit motor impairments as well as cognitive and emotional deficits. So far impairments in the ability to recognize emotional stimuli have mostly been investigated by using facial expressions and emotional voices. Other important emotional signals are provided by the whole body. To investigate the impact of motor deficits on body recognition and the relation between motor disorders and emotion perception deficits, we tested recognition of emotional body language (instrumental, angry, fearful and sad) in 19 HD patients and their matched controls with a nonverbal whole body expression matching task. Results indicate that HD patients are impaired in recognizing both instrumental and angry whole body postures. Furthermore, the body language perception deficits are correlated with measures of motor deficit. Taken together the results suggest a close relationship between emotion recognition (specifically anger) and motor abilities. (c) 2007 Elsevier Ltd. All rights reserved. C1 [de Gelder, Beatrice] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [de Gelder, Beatrice; Van den Stock, Jan] Tilburg Univ, Lab Cognit & Affect Neurosci, Tilburg, Netherlands. [Diego Balaguer, Ruth de; Bachoud-Levi, Anne-Catherine] INSERM, Team Neuropsychol Intervent 1, U841, F-75654 Paris 13, France. [Diego Balaguer, Ruth de; Bachoud-Levi, Anne-Catherine] Ecole Normale Super, Dept Etud Cognit, Paris, France. [Diego Balaguer, Ruth de] Univ Barcelona, E-08007 Barcelona, Spain. [Diego Balaguer, Ruth de] ICREA, Barcelona, Spain. [Bachoud-Levi, Anne-Catherine] Hosp Henri Mondor, AP HP, Dept Neurol, Creteil, France. [Bachoud-Levi, Anne-Catherine] Univ Paris 07, Fac Med, F-75221 Paris 05, France. RP de Gelder, B (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Room 417,Bldg 36,1st St, Charlestown, MA 02129 USA. EM degelder@nmr.mgh.harvard.edu RI Van den Stock, Jan/F-1906-2014; OI Van den Stock, Jan/0000-0001-5756-3195; de Diego-Balaguer, Ruth/0000-0002-2357-5195 NR 32 TC 22 Z9 22 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PY 2008 VL 46 IS 1 BP 369 EP 373 DI 10.1016/j.neuropsychologia.2007.10.015 PG 5 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 265ME UT WOS:000253362300036 PM 18061217 ER PT J AU Tamietto, M de Gelder, B AF Tamietto, Marco de Gelder, Beatrice TI Affective blindsight in the intact brain: Neural interhemispheric summation for unseen fearful expressions SO NEUROPSYCHOLOGIA LA English DT Article DE emotion; affective blindsight; backward masking; non-conscious perception; redundant target effect; interhemispheric summation ID EMOTIONAL FACIAL EXPRESSIONS; EVENT-RELATED FMRI; SPLIT-BRAIN; CORPUS-CALLOSUM; SPATIAL SUMMATION; VISUAL MASKING; HUMAN AMYGDALA; ANGRY FACES; AWARENESS; RECOGNITION AB The emotional valence of facial expressions can be reliably discriminated even in the absence of conscious visual experience by patients with lesions to the primary visual cortex (affective blindsight). Prior studies in one such patient (GY) also showed that this non-conscious perception can influence conscious recognition of normally seen emotional faces. Here we report a similar online interaction across hemispheres between conscious and non-conscious perception of emotions in normal observers. Fearful and happy facial expressions were presented either unilaterally (to the left or right visual field) or simultaneously to both visual fields. In bilateral displays, conscious perception of one face in a pair was prevented by backward masking after 20 ms, while the opposite expression remained normally visible. The results showed a bidirectional influence of non-conscious fear processing over conscious recognition of happy as well as fearful expressions. Consciously perceived fearful faces were more readily recognized when they were paired with invisible emotionally congruent fearful expressions in the opposite field, as compared to the single presentation of the same unmasked faces. On the other hand, recognition of unmasked happy faces was delayed by the simultaneous presence of a masked fearful face. No such effect was reported for masked happy expressions. These findings show that non-conscious processing of fear may modulate ongoing conscious evaluation of facial expressions via neural interhemispheric summation even in the intact brain. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Tamietto, Marco] Univ Turin, Dept Psychol, I-10123 Turin, Italy. [Tamietto, Marco; de Gelder, Beatrice] Tilburg Univ, Cognit & Affect Neurosci Lab, NL-5000 LE Tilburg, Netherlands. [de Gelder, Beatrice] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. RP Tamietto, M (reprint author), Univ Turin, Dept Psychol, Via Po 14, I-10123 Turin, Italy. EM tamietto@psych.unito.it; degelder@nmr.mgh.harvard.edu RI Frank, David/E-8213-2012; OI Tamietto, Marco/0000-0002-8815-8499 NR 67 TC 27 Z9 29 U1 6 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PY 2008 VL 46 IS 3 BP 820 EP 828 DI 10.1016/j.neuropsychologia.2007.11.002 PG 9 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 284UL UT WOS:000254731700006 PM 18160081 ER PT J AU Dickerson, BC Sperling, RA AF Dickerson, Bradford C. Sperling, Reisa A. TI Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: Insights from functional MRI studies SO NEUROPSYCHOLOGIA LA English DT Article DE Alzheimer's disease; mild cognitive impairment; functional magnetic resonance imaging; hippocampus; entorhinal cortex; parahippocampal gyrus ID ENTORHINAL AREA 28; HIPPOCAMPAL-FORMATION; WORKING-MEMORY; RHESUS-MONKEY; BRAIN-REGIONS; 35 CORTICES; INDIVIDUAL-DIFFERENCES; MULTIPLE-SCLEROSIS; EPISODIC MEMORY; CORTEX NEURONS AB Functional MRI (fMRI) studies of mild cognitive impairment (MCI) and Alzheimer's disease (AD) have begun to reveal abnormalities in memory circuit function in humans suffering from memory disorders. Since the medial temporal lobe (MTL) memory system is a site of very early pathology in AD, a number of studies, reviewed here, have focused on this region of the brain. By the time individuals are diagnosed clinically with AD dementia, the substantial memory impairments appear to be associated with not only MTL atrophy but also hypoactivation during memory task performance. Prior to dementia, when individuals are beginning to manifest signs and symptoms of memory impairment, the hippocampal formation and other components of the MTL memory system exhibit substantial functional abnormalities during memory task performance. It appears that, early in the course of MCI when memory deficits and hippocampal atrophy are less prominent, there may be hyperactivation of MTL circuits, possibly representing inefficient compensatory activity. Later in the course of MCI, when considerable memory deficits are present, MTL regions are no longer able to activate during attempted learning, as is the case in AD dementia. Recent fMRI data in MCI and AD are beginning to reveal relationships between abnormalities of functional activity in the MTL memory system and in functionally connected brain regions, such as the precuneus. As this work continues to mature, it will likely contribute to our understanding of fundamental memory processes in the human brain and how these are perturbed in memory disorders. We hope these insights will translate into the incorporation of measures of task-related brain function into diagnostic assessment or therapeutic monitoring, such as for use in clinical trials. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Dickerson, Bradford C.; Sperling, Reisa A.] Harvard Univ, Sch Med, Boston, MA USA. [Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA. [Dickerson, Bradford C.; Sperling, Reisa A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Dickerson, Bradford C.; Sperling, Reisa A.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Dept Neurol, Boston, MA 02115 USA. RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Gerontol Res Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu FU NIA NIH HHS [K23 AG022509, K23 AG022509-05, K23-AG22509, R01 AG029411, R01 AG029411-02, R21 AG029840, R21 AG029840-02]; NINDS NIH HHS [K23 NS002189, K23-NS02189] NR 90 TC 173 Z9 177 U1 3 U2 35 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PY 2008 VL 46 IS 6 BP 1624 EP 1635 DI 10.1016/j.neuropsychologia.2007.11.030 PG 12 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 318YH UT WOS:000257128200004 PM 18206188 ER PT J AU Trivedi, MA Schmitz, TW Ries, ML Hess, TM Fitzgerald, ME Atwood, CS Rowley, HA Asthana, S Sager, MA Johnson, SC AF Trivedi, Mehul A. Schmitz, Taylor W. Ries, Michele L. Hess, Timothy M. Fitzgerald, Michele E. Atwood, Craig S. Rowley, Howard A. Asthana, Sanjay Sager, Mark A. Johnson, Sterling C. TI FMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease SO NEUROPSYCHOLOGIA LA English DT Article DE aging; Alzheimer disease; hippocampus; functional imaging; self; APOE genotype ID MILD COGNITIVE IMPAIRMENT; AGE-RELATED-CHANGES; SELF-APPRAISAL; BRAIN ACTIVITY; GENETIC RISK; OLDER-ADULTS; MEMORY; ANOSOGNOSIA; MECHANISMS; NETWORKS AB In the present study, we used fMRI to examine the influence of age on two other known risk factors for Alzheimer's disease (AD), APOE genotype and parental history of AD (FH status), during episodic encoding (ENC) and metacognitive self-appraisal (SA) paradigms. These paradigms have previously been shown to evoke activity from brain regions that are implicated in AD. First we examined the effect of age across the adult lifespan (age 18-84 years) on cerebral activity in a large sample (n = 23 1) of cognitively healthy individuals. Next we examined a subset (n = 155) on whom APOE status and FH status were known. For ENC, we found that increasing age was associated with reduced activity in the ventral temporal lobes and hippocampus. Our analysis of risk factors suggested that FH and age exerted independent effects, but APOE interacted with age such that APOE e4 carriers exhibit age-related increases in activity in the hippocampus. For the metacognifive SA task, increasing age was found to be associated with reduced activity in the medial prefrontal cortex, and increased activity in the mesial temporal lobe, posterior orbital cortex and striatum. Neither AD risk factor significantly modified age-related changes in brain activity during SA. These results suggest that FH and aging are exerting independent effects in both tasks while APOE affected the relationship with age in the hippocampus in one of the two tasks given. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Trivedi, Mehul A.; Schmitz, Taylor W.; Ries, Michele L.; Hess, Timothy M.; Fitzgerald, Michele E.; Atwood, Craig S.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Trivedi, Mehul A.; Schmitz, Taylor W.; Ries, Michele L.; Fitzgerald, Michele E.; Atwood, Craig S.; Asthana, Sanjay; Sager, Mark A.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Hess, Timothy M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat, Madison, WI 53705 USA. [Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. EM scj@medicine.wisc.edu OI Johnson, Sterling/0000-0002-8501-545X FU NIA NIH HHS [R01 AG021155, R01 AG021155-03, R01 AG021155-02, R01 AG021155-01A2, R01 AG021155-04]; NIMH NIH HHS [R01 MH065723, R01 MH65723, R01 MH065723-04, R01 MH065723-06, R01 MH065723-05, R01 MH065723-02, R01 MH065723-03] NR 38 TC 30 Z9 30 U1 4 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PY 2008 VL 46 IS 6 BP 1667 EP 1678 DI 10.1016/j.neuropsychologia.2007.11.035 PG 12 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 318YH UT WOS:000257128200009 PM 18241895 ER PT J AU Foerde, K Poldrack, RA Knowlton, BJ Sabb, FW Bookheirner, SY Bilder, RM Guthrie, D Granholm, E Nuechterlein, KH Marder, SR Asarnow, RF AF Foerde, Karin Poldrack, Russell A. Knowlton, Barbara J. Sabb, Fred W. Bookheirner, Susan Y. Bilder, Robert M. Guthrie, Don Granholm, Eric Nuechterlein, Keith H. Marder, Stephen R. Asarnow, Robert F. TI Selective corticostriatal dysfunction in schizophrenia: Examination of motor and cognitive skill learning SO NEUROPSYCHOLOGY LA English DT Article DE schizophrenia; corticostriatal circuits; skill learning; automaticity ID BASAL GANGLIA; MEMORY-SYSTEMS; NONDECLARATIVE MEMORY; HALOPERIDOL; NEUROLEPTICS; PERFORMANCE; OLANZAPINE; CIRCUITS; IMPLICIT; DEFICITS AB It has been suggested that patients with schizophrenia have corticostriatal circuit dysfunction (Carlsson & Carlsson. 1990). Skill learning is thought to rely on corticostriatal circuitry and different types of skill learning may be related to separable corticostriatal loops (Grafton, Hazeltine, & Ivry, 1995; Poldrack, Prabhakaran. Seger, & Gabrieli, 1999). The authors examined motor (Serial Reaction Time task, SRT) and cognitive (Probabilistic Classification task, PCT) skill learning in patients with schizophrenia and normal controls. Development of automaticity was examined, using a dual task paradigm, across three training sessions. Patients with schizophrenia were impaired at learning on the PCT compared to controls. Performance gains of controls occurred within the first session, whereas patients only improved gradually and never reached the performance level of controls. In contrast, patients were not impaired at learning on the SRT relative to controls, suggesting that patients with schizophrenia may have dysfunction in a specific corticostriatal subcircuit. C1 [Foerde, Karin; Poldrack, Russell A.; Knowlton, Barbara J.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Sabb, Fred W.; Bookheirner, Susan Y.; Bilder, Robert M.; Guthrie, Don; Nuechterlein, Keith H.; Asarnow, Robert F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90024 USA. [Granholm, Eric] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Granholm, Eric] VA San Diego Healthcare Syst, San Diego, CA USA. [Marder, Stephen R.] Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. [Marder, Stephen R.] W Los Angeles VA, Los Angeles, CA USA. RP Foerde, K (reprint author), Columbia Univ, Dept Psychol, 1190 Amsterdam Ave,MC 5501, New York, NY 10027 USA. EM kf2265@columbia.edu RI Bilder, Robert/A-8894-2008; Granholm, Eric/P-7680-2014; OI Bilder, Robert/0000-0001-5085-7852; Foerde, Karin/0000-0002-5804-9312 FU NCRR NIH HHS [RR020750]; NIMH NIH HHS [MH 37705, MH 66286, MH 72697] NR 63 TC 47 Z9 48 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 J9 NEUROPSYCHOLOGY JI Neuropsychology PD JAN PY 2008 VL 22 IS 1 BP 100 EP 109 DI 10.1037/0894-4105.22.1.100 PG 10 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA 253ZG UT WOS:000252555500011 PM 18211159 ER PT J AU Kalivas, PW O'Brien, C AF Kalivas, Peter W. O'Brien, Charles TI Drug addiction as a pathology of staged neuroplasticity SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE addiction; neuroplasticity; motivational circuitry; glutamate; dopamine ID COCAINE-INDUCED REINSTATEMENT; ELEMENT-BINDING PROTEIN; VENTRAL TEGMENTAL AREA; MESOLIMBIC DOPAMINE SYSTEM; NUCLEUS-ACCUMBENS NEURONS; MEDIAL PREFRONTAL CORTEX; D-3 RECEPTOR EXPRESSION; SEEKING BEHAVIOR; SYNAPTIC PLASTICITY; DENDRITIC SPINES AB Using addictive drugs can evolve from controlled social use into the compulsive relapsing disorder that characterizes addiction. This transition to addiction results from genetic, developmental, and sociological vulnerabilities, combined with pharmacologically induced plasticity in brain circuitry that strengthens learned drug-associated behaviors at the expense of adaptive responding for natural rewards. Advances over the last decade have identified the brain circuits most vulnerable to drug-induced changes, as well as many associated molecular and morphological underpinnings. This growing knowledge has contributed to an expanded understanding of how drugs usurp normal learning circuitry to create the pathology of addiction, as evidenced by involuntary activation of reward circuits in response to drug-associated cues and simultaneous reports of drug craving. This new understanding provides unprecedented potential opportunities for novel pharmacotherapeutic targets in treating addiction. There appears to be plasticity associated with the addiction phenomenon in general as well as changes produced by addiction to a specific class of addicting drugs. These findings also provide the basis for the current understanding of addiction as a chronic, relapsing disease of the brain with changes that persist long after the last use of the drug. Here, we describe the neuroplasticity in brain circuits and cell function induced by addictive drugs that is thought to underlie the compulsions to resume drug-taking, and discuss how this knowledge is impelling exploration and testing of novel addiction therapies. C1 Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Univ Penn, Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. RP Kalivas, PW (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 10, Charleston, SC 29425 USA. EM kalivasp@musc.edu FU NIDA NIH HHS [P50 DA015369, P60 DA01586] NR 147 TC 350 Z9 370 U1 4 U2 40 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2008 VL 33 IS 1 BP 166 EP 180 DI 10.1038/sj.npp.1301564 PG 15 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 235XH UT WOS:000251267100013 PM 17805308 ER PT J AU Moberg, PJ Rick, JH AF Moberg, Paul J. Rick, Jacqueline H. TI Decision-making capacity and competency in the elderly: A clinical and neuropsychological perspective SO NEUROREHABILITATION LA English DT Article DE Decision-making capacity; competency; geriatric; neuropsychology ID DIFFERENT LEGAL STANDARDS; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PROTOTYPE-INSTRUMENT; MEDICAL-TREATMENT; FINANCIAL SKILLS; INFORMED CONSENT; OLDER-ADULTS; DEMENTIA; MODEL AB With our ageing population, the number of older adults with cognitive impairment has also increased. There is both an acute and growing need for evidence-based assessments to identify their decision making capacity and competence. In the present article we (1) present definitions of decision-making capacity and competence, (2) review cognitive functions that are central to decision-making capacity as well as the methods and procedures commonly used to assess these domains, and (3) address the communication of assessment findings to patients and their loved ones. The importance of assessing decision-making capacity in the context of specific functions and of respecting the values and interests of older adults are emphasized. C1 [Moberg, Paul J.] Univ Penn, Sch Med, Dept Psychiat, Brain Behav Lab, Philadelphia, PA 19104 USA. [Moberg, Paul J.; Rick, Jacqueline H.] Philadelphia Vet Affairs Med Ctr, PADRECC, Philadelphia, PA USA. [Moberg, Paul J.] Univ Penn, Sch Med, ADC, Philadelphia, PA 19104 USA. RP Moberg, PJ (reprint author), Univ Penn, Sch Med, Dept Psychiat, Brain Behav Lab, 10th Floor,Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM moberg@upenn.edu NR 47 TC 15 Z9 15 U1 2 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2008 VL 23 IS 5 BP 403 EP 413 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 372PW UT WOS:000260914500004 PM 18957727 ER PT J AU Uomoto, JM AF Uomoto, Jay M. TI Older adults and neuropsychological rehabilitation following acquired brain injury SO NEUROREHABILITATION LA English DT Article DE Geriatric; brain injury; excess disability; rehabilitation ID TRANSCRANIAL MAGNETIC STIMULATION; INDUCED MOVEMENT THERAPY; STROKE REHABILITATION; ALZHEIMERS-DISEASE; DEPRESSION; OUTCOMES; TRIAL; PAIN; COMMUNITY; IMPACT AB The literature related to neurorehabilitation methods specific to older adults is now emerging, the timing of which is important given the epidemiology of acquired brain injury in this population. Examined are epidemiological characteristics of acquired brain injury, with a focus on traumatic brain injury and stroke. Principles of geriatric neurorehabilitation are proposed by using a Neo-Lurian framework, and employing the PASS model of brain-behavior relationship forwarded by J. P. Das. Discussed are specific issues and strategies of geriatric neurorehabilitation by removing excess disability that complicates acquired brain injury. These include addressing depression, sleep disturbance, chronic pain, and social support. Restorative interventions may now also appear as a part of geriatric neurorehabilitation practices. A focus on team functioning as a critical contributor to functional outcomes in those older adults with acquired brain injury is presented along with future directions that capitalize upon the ideals of primary, secondary, and tertiary prevention. C1 VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Ctr Polytrauma Care, Seattle, WA 98108 USA. RP Uomoto, JM (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Ctr Polytrauma Care, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM jay.uomoto@va.gov NR 60 TC 2 Z9 2 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2008 VL 23 IS 5 BP 415 EP 424 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 372PW UT WOS:000260914500005 PM 18957728 ER PT J AU Pawlyk, AC Morrison, AR Ross, RJ Brennan, FX AF Pawlyk, Aaron C. Morrison, Adrian R. Ross, Richard J. Brennan, Francis X. TI Stress-induced changes in sleep in rodents: Models and mechanisms SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE amygdala; corticotropin-releasing factor; stress; sleep; REM; PTSD ID CORTICOTROPIN-RELEASING HORMONE; EYE-MOVEMENT SLEEP; COMBAT-RELATED PTSD; REM-SLEEP; IMMOBILIZATION STRESS; SEROTONERGIC NEURONS; PARADOXICAL SLEEP; ALLOSTATIC LOAD; CONTEXTUAL FEAR; C57BL/6J MICE AB Psychological stressors have a prominent effect on sleep in general, and rapid eye movement (REM) sleep in particular. Disruptions in sleep are a prominent feature, and potentially even the hallmark, of posttraumatic stress disorder (PTSD) (Ross, R.J., Ball, W.A., Sullivan, K., Caroff, S., 1989. Sleep disturbance as the hallmark of posttraumatic stress disorder. American Journal of Psychiatry 146, 697-707). Animal models are critical in understanding both the causes and potential treatments of psychiatric disorders. The current review describes a number of studies that have focused on the impact of stress on sleep in rodent models. The studies are also in Table 1, summarizing the effects of stress in 4-h blocks in both the light and dark phases. Although mild stress procedures have sometimes produced increases in REM sleep, more intense stressors appear to model the human condition by leading to disruptions in sleep, particularly REM sleep. We also discuss work conducted by our group and others looking at conditioning as a factor in the temporal extension of stress-related sleep disruptions. Finally, we attempt to describe the probable neural mechanisms of the sleep disruptions. A complete understanding of the neural correlates of stress-induced sleep alterations may lead to novel treatments for a variety of debilitating sleep disorders. Published by Elsevier Ltd. C1 [Pawlyk, Aaron C.] Wyeth Res, Collegeville, PA 19426 USA. [Morrison, Adrian R.; Ross, Richard J.] Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. [Morrison, Adrian R.; Ross, Richard J.; Brennan, Francis X.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Brennan, FX (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM brennan_f@mail.trc.upenn.edu FU NIMH NIH HHS [R01 MH072897-02, R01-MH072897] NR 74 TC 61 Z9 64 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PY 2008 VL 32 IS 1 BP 99 EP 117 DI 10.1016/j.neubiorev.2007.06.001 PG 19 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 250KH UT WOS:000252298300007 PM 17764741 ER PT J AU Gale, JT Amirnovin, R Williains, ZM Flaherty, AW Eskandar, EN AF Gale, John T. Amirnovin, Ramin Williains, Ziv M. Flaherty, Alice W. Eskandar, Emad N. TI From symphony to cacophony: Pathophysiology of the human basal ganglia in Parkinson disease SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Parkinson's disease; basal ganglia; physiology; human; deep brain stimulation; intraoperative; oscillations ID DEEP-BRAIN-STIMULATION; PRIMATE SUBTHALAMIC NUCLEUS; THALAMIC NEURONAL-ACTIVITY; HIGH-FREQUENCY STIMULATION; MPTP-INDUCED PARKINSONISM; GLOBUS-PALLIDUS NEURONS; PRIMARY MOTOR CORTEX; POSTEROVENTRAL PALLIDOTOMY; FUNCTIONAL-ANATOMY; MOVEMENT-DISORDERS AB Despite remarkable advances, the relationship between abnormal neuronal activity and the clinical manifestations of Parkinson disease (PD) remains unclear. Numerous hypotheses have emerged to explain the relationship between neuronal activity and symptoms such as tremor, rigidity and akinesia. Among these are the antagonist balance hypothesis wherein increased firing rates in the indirect pathway inhibits movement; the selectivity hypothesis wherein loss of neuronal selectivity leads to an inability to select or initiate movements; the firing pattern hypothesis wherein increased oscillation and synchronization contribute to tremor and disrupt information flow; and the learning hypothesis, wherein the basal ganglia are conceived as playing an important role in learning sensory-motor associations which is disrupted by the loss of dopamine. Deep brain stimulation (DBS) surgery provides a unique opportunity to assess these different ideas since neuronal activity can be directly recorded from PD patients. The emerging data suggest that the pathophysiologic changes include derangements in the overall firing rates, decreased neuronal selectivity, and increased neuronal oscillation and synchronization. Thus, elements of all hypotheses are present, emphasizing that the loss of dopamine results in a profound and multifaceted disruption of normal information flow through the basal ganglia that ultimately leads to the signs and symptoms of PD. (c) 2006 Elsevier Ltd. All rights reserved. C1 [Eskandar, Emad N.] Massachusetts Gen Hosp, Wang Ambulatory Care Ctr, Boston, MA 02114 USA. [Gale, John T.; Amirnovin, Ramin; Williains, Ziv M.; Flaherty, Alice W.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Gale, John T.; Amirnovin, Ramin; Williains, Ziv M.; Flaherty, Alice W.; Eskandar, Emad N.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Eskandar, EN (reprint author), Massachusetts Gen Hosp, Wang Ambulatory Care Ctr, 03-331,15 Parkman St, Boston, MA 02114 USA. EM eeskandar@partners.org NR 100 TC 31 Z9 32 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PY 2008 VL 32 IS 3 BP 378 EP 387 DI 10.1016/j.neubiorev.2006.11.005 PG 10 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 265ZM UT WOS:000253400600006 PM 17466375 ER PT J AU Montgomery, EB Gale, JT AF Montgomery, Erwin B., Jr. Gale, John T. TI Mechanisms of action of deep brain stimulation (DBS) SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE basal ganglia; deep brain stimulation; movement disorders; Parkinson's disease; dystonia; neurophysiology; pathophysiology; subthalamic nucleus; globus pallidus ID HIGH-FREQUENCY STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; INTERNAL GLOBUS-PALLIDUS; NIGRA PARS RETICULATA; PARKINSONS-DISEASE; BASAL GANGLIA; NEURONAL-ACTIVITY; OSCILLATORY ACTIVITY; MOTOR CORTEX; THALAMIC-STIMULATION AB Deep brain stimulation (DBS) is remarkably effective for a range of neurological and psychiatric disorders that have failed pharmacological and cell transplant therapies. Clinical investigations are underway for a variety of other conditions. Yet, the therapeutic mechanisms of action are unknown. In addition, DBS research demonstrates the need to re-consider many hypotheses regarding basal ganglia physiology and pathophysiology such as the notion that increased activity in the globus pallidus internal segment is causal to Parkinson's disease symptoms. Studies reveal a variety of apparently discrepant results. At the least, it is unclear which DBS effects are therapeutically effective. This systematic review attempts to organize current DBS research into a series of unifying themes or issues such as whether the therapeutic effects are local or systems-wide or whether the effects are related to inhibition or excitation. A number of alternative hypotheses are offered for consideration including suppression of abnormal activity, striping basal ganglia output of misinformation, reduction of abnormal stochastic resonance effects due to increased noise in the disease state, and reinforcement of dynamic modulation of neuronal activity by resonance effects. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Montgomery, Erwin B., Jr.] Univ Wisconsin, Natl Primate Res Ctr, Dept Neurol, Madison, WI 53792 USA. [Gale, John T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Montgomery, EB (reprint author), Univ Wisconsin, Natl Primate Res Ctr, Dept Neurol, H6-538 CSC,600 Highland Ave, Madison, WI 53792 USA. EM montgomery@neurology.wisc.edu FU NCRR NIH HHS [P51 RR000167, RR020141-01, RR15459-01] NR 113 TC 158 Z9 161 U1 1 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PY 2008 VL 32 IS 3 BP 388 EP 407 DI 10.1016/j.neubiorev.2007.06.003 PG 20 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 265ZM UT WOS:000253400600007 PM 17706780 ER PT J AU Edge, A AF Edge, Albert TI Stem cells and regeneration of the inner ear SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Edge, Albert] Harvard Univ, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Edge, Albert] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S25 EP S25 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548100143 ER PT J AU Fujioka, M Hosoya, M Wakabayashi, K Jeon, SJ Okano, HJ Kanzaki, S Ogawa, K Edge, A Okano, H AF Fujioka, Masato Hosoya, Makoto Wakabayashi, Kenichiro Jeon, Sang-Jun Okano, Hirotaka James Kanzaki, Sho Ogawa, Kaoru Edge, Albert Okano, Hideyuki TI A novel gamma-secretase inhibitor, LY411575, replaced auditory hair cells and recovered hearing loss after severe acoustic trauma in mice SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Fujioka, Masato; Jeon, Sang-Jun; Edge, Albert] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Fujioka, Masato; Jeon, Sang-Jun; Edge, Albert] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Fujioka, Masato; Hosoya, Makoto; Wakabayashi, Kenichiro; Okano, Hirotaka James; Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan. [Fujioka, Masato; Wakabayashi, Kenichiro; Kanzaki, Sho; Ogawa, Kaoru] Keio Univ, Sch Med, Dept Otorhinolaryngol, Tokyo, Japan. RI Kanzaki, Sho/B-3100-2014 OI Kanzaki, Sho/0000-0001-9056-0850 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S25 EP S25 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548100147 ER PT J AU Gruen, S van Vreeswijk, C Pipa, G AF Gruen, Sonja van Vreeswijk, Carl Pipa, Gordon TI Impact of spike train autostructure on significance estimation of joint-spike events SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Gruen, Sonja] RIKEN Brain Sci Inst, Wako, Saitama, Japan. [Pipa, Gordon] MPI Brain Res, Dept Neurophysiol, Frankfurt, Germany. [Pipa, Gordon] MIT, Dept Brain & Cognit Sci, Cambridge, MA USA. [Pipa, Gordon] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [van Vreeswijk, Carl] Univ Paris 05, Lab Neurophys & Physiol, Paris, France. [Pipa, Gordon] FIAS, Frankfurt, Germany. RI Pipa, Gordon/M-1813-2014 OI Pipa, Gordon/0000-0002-3416-2652 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S280 EP S280 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548101812 ER PT J AU Iwaki, S Bonmassar, G Belliveau, JW AF Iwaki, Sunao Bonmassar, Giorgio Belliveau, John W. TI Dynamic neural substrates of the 3D structure perception from motion SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Iwaki, Sunao] Natl Inst Adv Ind Sci & Technol, Tokyo, Japan. [Bonmassar, Giorgio; Belliveau, John W.] Mass Gen Hosp, Boston, MA USA. RI Iwaki, Sunao/B-1079-2011 OI Iwaki, Sunao/0000-0002-7123-7203 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S176 EP S176 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548101192 ER PT J AU Kishi, N Macklis, J AF Kishi, Noriyuki Macklis, Jeffrey TI Identification and analysis of MeCP2 target genes in developing cerebral cortex projection neurons SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Kishi, Noriyuki; Macklis, Jeffrey] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S130 EP S130 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548100773 ER PT J AU Koizumi, A Jakobs, TC Masland, RH AF Koizumi, Amane Jakobs, Tatjana C. Masland, Richard H. TI Oarganotypic culture of adult rabbit retina with gene transfection by gene-gun SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Koizumi, Amane] Natl Inst Physiol Sci, Okazaki, Aichi 444, Japan. [Koizumi, Amane; Jakobs, Tatjana C.; Masland, Richard H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Koizumi, Amane/E-7771-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S244 EP S244 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548101596 ER PT J AU Shioda, N Kitajima, I Tokoro, T Beppu, H Fukunaga, K AF Shioda, Norifumi Kitajima, Isao Tokoro, Takashi Beppu, Hideyuki Fukunaga, Kohji TI Activation of CaMKII mediates abnormal dendritic spine formation via Rac1-GEF/PAK signaling in ATRX mutant mouse brain SO NEUROSCIENCE RESEARCH LA English DT Meeting Abstract C1 [Shioda, Norifumi; Fukunaga, Kohji] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sendai, Miyagi 980, Japan. [Kitajima, Isao; Tokoro, Takashi] Med Univ Toyama, Dept Clin & Mol Pathol, Toyama, Japan. [Beppu, Hideyuki] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-0102 J9 NEUROSCI RES JI Neurosci. Res. PY 2008 VL 61 BP S45 EP S45 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 381PJ UT WOS:000261548100264 ER PT J AU Tyler, KL Gilden, DH AF Tyler, Kenneth L. Gilden, Donald H. BE Reiss, CS TI Clinical management of viral encephalitis SO NEUROTROPIC VIRAL INFECTIONS LA English DT Article; Book Chapter ID HERPES-SIMPLEX ENCEPHALITIS; STEM-CELL TRANSPLANT; GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; HUMAN HERPESVIRUS-6 ENCEPHALITIS; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; CENTRAL-NERVOUS-SYSTEM; VIRUS-INFECTION; CEREBROSPINAL-FLUID; VIDARABINE THERAPY C1 [Tyler, Kenneth L.] Univ Colorado, Dept Neurol Microbiol & Med, Denver, CO 80202 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. [Gilden, Donald H.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Gilden, Donald H.] Univ Colorado, Sch Med, Dept Microbiol, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Dept Neurol Microbiol & Med, Denver, CO 80202 USA. NR 85 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-86964-5 PY 2008 BP 347 EP 361 DI 10.1017/CBO9780511541728.024 D2 10.1017/CBO9780511541728 PG 15 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BDI54 UT WOS:000313454600024 ER PT J AU Curry, WT Martuza, RL AF Curry, William T., Jr. Martuza, Robert L. BE Reiss, CS TI Viral oncolysis of glioblastoma SO NEUROTROPIC VIRAL INFECTIONS LA English DT Article; Book Chapter ID HERPES-SIMPLEX-VIRUS; CONDITIONALLY REPLICATIVE ADENOVIRUS; HIGH-GRADE GLIOMAS; INTERGENERIC POLIOVIRUS RECOMBINANTS; RECURRENT MALIGNANT GLIOMA; LONG-TERM SURVIVAL; TYPE-1 MUTANT G207; HUMAN TUMOR-CELLS; PHASE-II TRIAL; IONIZING-RADIATION C1 [Curry, William T., Jr.; Martuza, Robert L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. RP Curry, WT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. NR 99 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-86964-5 PY 2008 BP 407 EP 423 DI 10.1017/CBO9780511541728.027 D2 10.1017/CBO9780511541728 PG 17 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BDI54 UT WOS:000313454600027 ER PT J AU Cristofaro, V Yalla, SV Sullivan, MP AF Cristofaro, V. Yalla, S. V. Sullivan, M. P. TI Detrusor overactivity in spontaneously hypertensive rats is associated with alterations in caveolae-mediated signaling events SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-and-Female-Urology CY FEB 28-MAR 02, 2008 CL Miami, FL SP Soc Urodynam & Female Urol C1 [Cristofaro, V.; Yalla, S. V.; Sullivan, M. P.] VA Boston Healthcare Syst, Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2008 VL 27 IS 2 BP 104 EP 105 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 261YS UT WOS:000253116500008 ER PT J AU Alperin, M Abrahams-Gessel, S Wakamatsu, MM AF Alperin, Marianna Abrahams-Gessel, Shafika Wakamatsu, May M. TI Development of de novo urge incontinence in women post sling: The role of preoperative urodynamics in assessing the risk SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE de novo urge incontinence; midurethral sling; urodynamics ID STRESS URINARY-INCONTINENCE; DETRUSOR INSTABILITY; VOIDING DYSFUNCTION; COLPOSUSPENSION; COMPLICATIONS; MUSCLE AB Aims: The study was undertaken to investigate if there are specific identifiable risk factors on the preoperative history or urodynamics testing associated with an increased risk for the development of symptoms of de novo urge urinary incontinence after a minimally invasive sling procedure. Methods: Two hundred eighty-one women who had undergone minimally invasive sling surgery for stress urinary incontinence between January 2000 and December 2003 were identified. The records of 92 patients were included in this review. Results: Twenty-five patients (27%) reported urge urinary incontinence on postoperative questioning. Clinical and urodynamic parameters were correlated with the development of de novo urge urinary incontinence. Preoperative history parameters were not predictive of the increased risk of de novo urge urinary incontinence, with the exception of increased preoperative daytime frequency (OR 3.3 (1.2, 9.1)). Of 16 women whose detrusor pressure during the filling phase of cystometry exceeded 15 cm H2O, de novo urge urinary incontinence developed in 9 (56%) vs. 16 (21%) of 76 women, whose detrusor pressure was <= 15 cm H2O (OR 4.6 (1.4, 15.0)). Conclusions: Directed patient history is only minimally helpful in the identification of women at increased risk for the development of de novo urge urinary incontinence, with the exception of the complaint of increased daytime frequency. Women with elevated detrusor pressure during the filling phase of cystometry were more likely to develop urge urinary incontinence postoperatively. Therefore, we suggest that preoperative urodynamic evaluation, and specifically detrusor pressure > 15 cm H2O may help identify patients at increased risk of developing de novo urge urinary incontinence following the minimally invasive sling procedure. C1 [Alperin, Marianna] Univ Pittsburgh, Div Urogynecol, Dept Obstet & Gynecol & Reprod Sci, Magee Womens Hosp, Pittsburgh, PA 15260 USA. [Abrahams-Gessel, Shafika] Harvard Univ, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Wakamatsu, May M.] Massachusetts Gen Hosp, Div Urogynecol, Boston, MA 02114 USA. RP Alperin, M (reprint author), Magee Womens Hosp, Dept Ob Gyn RES, Div Urogynecol, 300 Halket St, Pittsburgh, PA 15213 USA. EM malperin@mail.magee.edu OI Abrahams-Gessel, Shafika/0000-0003-4954-057X NR 20 TC 18 Z9 19 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2008 VL 27 IS 5 BP 407 EP 411 DI 10.1002/nau.20526 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 318ND UT WOS:000257097800011 PM 17985373 ER PT J AU Shields, AE Levy, DE Blumenthal, D Currivan, D McGinn-Shapiro, M Weiss, KB Yucel, R Lerman, C AF Shields, Alexandra E. Levy, Douglas E. Blumenthal, David Currivan, Douglas McGinn-Shapiro, Mary Weiss, Kevin B. Yucel, Recai Lerman, Caryn TI Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID NICOTINE REPLACEMENT THERAPY; TOBACCO DEPENDENCE; RECEPTOR DRD2; SELF-REPORT; TREATMENT RESPONSE; CLINICAL-PRACTICE; CONTROLLED-TRIAL; US PHYSICIANS; CHART AUDIT; FOLLOW-UP AB Emerging pharmacogenetics research may improve clinical outcomes for common complex conditions typically treated in primary care settings. Physicians' willingness to offer genetically-tailored treatments to their patients will be critical to realizing this potential. According to recent research, it is likely that genotypes used to tailor smoking will have pleiotropic associations with other addictions and diseases, and may have different frequencies across populations. These additional features may pose an additional barrier to adoption. To assess physicians' willingness to offer a new test to individually tailor smoking treatment according to specific test characteristics, we conducted a national mailed survey of 2,000 U.S. primary care physicians (response rate: 62.3%). Physicians responded to a baseline scenario describing a new test to tailor smoking treatment, and three additional scenarios describing specific test characteristics based on published research; there was random assignment to one of two survey conditions in which the test was described as a genetic or non-genetic test. Our findings indicate physicians' self-reported likelihood (0-100 scale) that they would offer a new test to tailor smoking cessation treatment ranged from 69%-78% across all scenarios. Relative to baseline scenario responses, physicians were significantly less likely to offer the test when informed that the same genotypes assessed for treatment tailoring: (1) may also identify individuals predisposed to become addicted to nicotine (p<.001), (2) differ in frequency by race (p<.004), and (3) may have associations with other conditions (e.g., alcohol and cocaine addiction, attention deficit hyperactivity disorder ADHD and Tourette Syndrome) (p<.01). Describing a new test to individually tailor smoking treatment as a genetic versus non-genetic test significantly reduced physicians' likelihood of offering the test across all scenarios, regardless of specific test characteristics (p<.0007). Effective education of primary care physicians will be critical to successful integration of promising new pharmacogenetic treatment strategies for smoking. C1 [Shields, Alexandra E.; Blumenthal, David] Massachusetts Gen Hosp Partners Healthcare Syst, Harvard MGH Ctr Gen Vulnerable Populat & Hlth Dis, Inst HealthPolicy, Boston, MA 02111 USA. [Blumenthal, David] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Lerman, Caryn] Univ Penn, Abramson Canc Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Lerman, Caryn] Annenberg Publ Policy Ctr, Philadelphia, PA USA. [Yucel, Recai] Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA. [Blumenthal, David] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Currivan, Douglas] RTI Int, Survey Res Div, Res Triangle Pk, NC USA. [Weiss, Kevin B.] Hines VA Med Ctr, Midwest Ctr Hlth Serv & Policy Res, Hines, IL USA. [Weiss, Kevin B.] Northwestern Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL USA. [Weiss, Kevin B.] Northwestern Feinberg Sch Med, Div Gen Med, Chicago, IL USA. RP Shields, AE (reprint author), Massachusetts Gen Hosp Partners Healthcare Syst, Harvard MGH Ctr Gen Vulnerable Populat & Hlth Dis, Inst HealthPolicy, 50 Staniford St,Suite 901, Boston, MA 02111 USA. EM ashields@partners.org FU NCI NIH HHS [P50 CA/DA84718, P50 CA084718] NR 54 TC 14 Z9 14 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PY 2008 VL 10 IS 6 BP 1037 EP 1045 DI 10.1080/14622200802087580 PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 319EH UT WOS:000257146400011 PM 18584467 ER PT J AU Berg, CJ Park, ER Chang, YC Rigotti, NA AF Berg, Carla J. Park, Elyse R. Chang, Yuchiao Rigotti, Nancy A. TI Is concern about post-cessation weight gain a barrier to smoking cessation among pregnant women? SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID BIRTH-WEIGHT; POSTPARTUM; SMOKERS; RELAPSE; PREDICTORS; KNOWLEDGE; ATTITUDES; PATTERNS; ALCOHOL; TRIAL AB Women who quit smoking during pregnancy gain more weight than women who continue to smoke. Concern about weight gain is a barrier to smoking cessation in the general population, but whether attitudes about weight are associated with failure to stop smoking during pregnancy or to maintain abstinence postpartum is unknown. Thus, attitudes about weight were assessed in 412 pregnant smokers recruited from obstetric practices in Massachusetts for a smoking cessation intervention trial. Smoking cessation outcomes (7-day point-prevalence abstinence by self-report and by cotinine-validation) were assessed at end-of-pregnancy and 3 months postpartum. Bivariate and multivariable analyses assessed the relationship between attitudes about weight and smoking cessation. In bivariate analyses, a high level of concern about post-cessation weight gain was associated with older age (p=.01), smoking more cigarettes/day (p<.001), not making a quit attempt in pregnancy (p=.02), being less likely to self-report tobacco abstinence at end of pregnancy (p=.01) and postpartum (p=.02), and having less cotinine-validated abstinence at 3 months postpartum (p=.05). In multivariable analyses that adjusted for cigarettes/day, a low level of concern about post-cessation weight gain was associated with more self-reported abstinence at end-of-pregnancy (OR=1.77, 95% CI 1.01-3.09) and postpartum (OR=2.09, 95% CI 1.05-4.14), but not with cotinine-validated abstinence at end-of-pregnancy (OR=1.30, 95% CI 0.63-2.68) or postpartum (OR=2.18, 95% CI 0.93-5.10). In conclusion, women who are more concerned about post-cessation weight gain may be less likely to quit smoking during pregnancy or remain abstinent in the postpartum period. C1 [Berg, Carla J.; Park, Elyse R.; Chang, Yuchiao; Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Park, ER (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 50 Staniford St, Boston, MA 02114 USA. EM epark@partners.org RI Vollrath, Margarete/G-1297-2011 FU NHLBI NIH HHS [K24-HL04440] NR 29 TC 18 Z9 18 U1 0 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PY 2008 VL 10 IS 7 BP 1159 EP 1163 DI 10.1080/14622200802163068 PG 5 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 329DI UT WOS:000257846700006 PM 18629725 ER PT J AU Monuteaux, MC Faraone, SV Hammerness, P Wilens, TE Fraire, M Biederman, J AF Monuteaux, Michael C. Faraone, Stephen V. Hammerness, Paul Wilens, Timothy E. Fraire, Maria Biederman, Joseph TI The familial association between cigarette smoking and ADHD: A study of clinically referred girls with and without ADHD, and their families SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; LA-TOURETTES SYNDROME; GENETIC-RELATIONSHIP; MULTIPLE THRESHOLDS; YOUNG-ADULTS; DRUG-USE; CHILDREN; NICOTINE; INITIATION AB Attention-deficit/hyperactivity disorder (ADHD) is a strong risk factor for smoking. Since both ADHD and smoking are familial disorders, one way to further our understanding of this association is to examine the familial relationship between them. Our aim was to evaluate the familial association between ADHD and smoking in families ascertained from girls with and without ADHD. Subjects were derived from a longitudinal case-control family study of girls with (n=140) and without (n=122) ADHD ascertained from pediatric and psychiatric clinics, and their biological first-degree relatives. Diagnoses of ADHD and smoking (i.e., full or subthreshold nicotine dependence) were made with structured psychiatric interviews. We stratified the relatives into four groups based on probands' ADHD and smoking status: (1) relatives of controls without smoking (probands n=100, relatives n=317), (2) relatives of controls with smoking (probands n=22, relatives n=71), (3) relatives of ADHD girls without smoking (probands n=100, relatives n=320), and (4) relatives of ADHD girls with smoking (probands n=39, relatives n=133). We compared the rates of ADHD and smoking across the four relative groups using survival analysis. ADHD in the proband increased the risk for ADHD in the relatives irrespective of probands' smoking and smoking in the proband increased the risk for smoking in the relatives irrespective of probands' ADHD status. Furthermore, we found statistically significant evidence for cosegregation of smoking and ADHD, suggesting that the two disorders are transmitted together through families more often than expected by chance. These findings support the hypothesis that the combination of ADHD and smoking comprises an etiologically distinct familial subtype of ADHD in girls. C1 [Monuteaux, Michael C.; Hammerness, Paul; Wilens, Timothy E.; Fraire, Maria; Biederman, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA. RP Monuteaux, MC (reprint author), Clin & Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM mmonuteaux@partners.org OI Faraone, Stephen/0000-0002-9217-3982 FU Lilly Foundation; National Institutes of Health (NIH) [MH079954-01]; Abbott,; McNeil; Lilly; NIH (National Institute on Drug Abuse, NIDA); Merck; Shire; Alza; Bristol Myers Squibb; Eli Lilly and Co.; Janssen Pharmaceuticals Inc.; Merk; Otsuka; National Institute of Mental Health; National Institute of Child Health and Human Development; Abbott; AstraZeneca; Celltech; Cephalon; Esai; Forest; Glaxo; Gliatech; NARSAD; NIDA; New River; Novartis; Noven; Neurosearch; Pfizer; Pharmacia; The Prechter Foundation; The Stanley Foundation; Wyeth FX This work is from the Clinical and Research Program in Pediatric Psychopharmacology, Department of Psychiatry, Massachusetts General Hospital, Boston, MA. It was supported, in part, by a grant from the Lilly Foundation and National Institutes of Health (NIH) grant MH079954-01 (Dr. Biederman). Dr. Faraone receives research support from, and is on the speakers' bureaus of McNeill Pediatrics and Shire Laboratories and has had an advisory or consulting relationship with both companies; Dr. Faraone also has had an advisory or consulting relationship with Novartis and Eli Lilly. Dr. Hammerness receives research support from Shire and is on the Shire speakers' bureau. Dr. Wilens receives grant support from the following sources: Abbott, McNeil, Lilly, NIH (National Institute on Drug Abuse, NIDA), Merck, and Shire. He is a speaker for the following speaker's bureaus: McNeil, Novartis, and Shire; he also is a consultant for Abbott, Cephalon, McNeil, Lilly, NIH (NIDA), Novartis, Merck, and Shire. Dr. Biederman receives research support from the following sources: Alza, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merk, Otsuka, Shire, National Institute of Mental Health, and National Institute of Child Health and Human Development. He is a consultant or advisory board member for pharmaceutical companies Janssen, McNeil, Novartis, and Shire. He is a speaker for the following speaker's bureaus: Janssen, McNeil, Novartis, Shire, and UCB Pharma, Inc. In previous years, he received research support, consultation fees, or speaker's fees from Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, NARSAD, NIDA, New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth. The other authors report no competing interests. Dr Monuteaux was a speaker in a symposia sponsored by Shire, Inc. NR 60 TC 11 Z9 11 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PY 2008 VL 10 IS 10 BP 1549 EP 1558 DI 10.1080/14622200802326137 PG 10 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 363IA UT WOS:000260259800004 PM 18946774 ER PT J AU Evgenov, OV Egorina, EM Stasch, JP Sovershaev, MA AF Evgenov, Olej V. Egorina, Elena M. Stasch, Johannes-PeteF Sovershaev, Mikhail A. TI Inhibition of expression and procoagulant activity of tissue factor by soluble guanylate cyclase agonists in monocytes and endothelial cells SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Meeting Abstract CT 5th International Conference on Biology, Chemistry, and Therapeutic Applications of Nitric Oxide CY AUG 24-28, 2008 CL Bregenz, AUSTRIA C1 [Evgenov, Olej V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Cambridge, MA 02138 USA. [Egorina, Elena M.; Sovershaev, Mikhail A.] Univ Tromso, Dept Biochem, N-9001 Tromso, Norway. NR 0 TC 0 Z9 2 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PY 2008 VL 19 SU S BP S61 EP S61 DI 10.1016/j.niox.2008.06.178 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 334WY UT WOS:000258253500173 ER PT J AU Schleicher, M Yu, J Murata, T Harrisson, KD Huang, PL Sessa, WC AF Schleicher, Michael Yu, Jun Murata, Takahisa Harrisson, Kenneth D. Huang, Paul L. Sessa, William C. TI Phosphorylation of eNOS on Serine 1176 by Akt1 is indispensable for pathophysiological angiogenesis SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Meeting Abstract CT 5th International Conference on Biology, Chemistry, and Therapeutic Applications of Nitric Oxide CY AUG 24-28, 2008 CL Bregenz, AUSTRIA C1 [Schleicher, Michael; Yu, Jun; Harrisson, Kenneth D.; Sessa, William C.] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA. [Murata, Takahisa] Univ Tokyo, Tokyo 1138654, Japan. [Huang, Paul L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PY 2008 VL 19 SU S BP S31 EP S31 DI 10.1016/j.niox.2008.06.049 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 334WY UT WOS:000258253500049 ER PT J AU Thoonen, R Buys, M Sips, P Rogge, E Hochepied, T Nimmegeers, S de Voorde, JV Brouckaer, P AF Thoonen, Robrecht Buys, Manu Sips, Patrick Rogge, Elke Hochepied, Tino Nimmegeers, Sofie de Voorde, Johan Van Brouckaer, Peter TI Targeting the NO-cGMP pathway: Phenotyping of NO-insensitive sGC beta 1 H105F knockin mice SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY LA English DT Meeting Abstract CT 5th International Conference on Biology, Chemistry, and Therapeutic Applications of Nitric Oxide CY AUG 24-28, 2008 CL Bregenz, AUSTRIA C1 [Thoonen, Robrecht; Rogge, Elke; Brouckaer, Peter] Univ Ghent, Dept Mol Biol, Fac Sci, Ghent, Belgium. [Buys, Manu; Sips, Patrick] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Cambridge, MA 02138 USA. [Nimmegeers, Sofie; de Voorde, Johan Van] Univ Ghent, Dept Gen Physiol & Human Physiol & Pathophysiol, Ghent, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1089-8603 J9 NITRIC OXIDE-BIOL CH JI Nitric Oxide-Biol. Chem. PY 2008 VL 19 SU S BP S32 EP S32 DI 10.1016/j.niox.2008.06.055 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 334WY UT WOS:000258253500055 ER PT B AU McMahan, MA Blacktnore, E Cascio, EW Castaneda, C von Przewoski, B Eisen, H AF McMahan, Margaret A. Blacktnore, Ewart Cascio, Ethan W. Castaneda, Carlos von Przewoski, Barbara Eisen, Harvey GP IEEE TI Standard Practice for Dosimetry of Proton Beams for use in Radiation Effects Testing of Electronics SO NSRE: 2008 IEEE RADIATION EFFECTS DATA WORKSHOP, WORKSHOP RECORD LA English DT Proceedings Paper CT IEEE Radiation Effects Data Workshop 2008 CY JUL 14-18, 2008 CL Tucson, AZ SP IEEE ID SLIT SCATTERING; PARTICLES AB Representatives of facilities that routinely deliver protons for radiation effect testing are collaborating to establish a set of standard best practices for proton dosimetry. These best practices will be submitted to the ASTM International for adoption. C1 [McMahan, Margaret A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA. [Blacktnore, Ewart] TRIUMF, Vancouver, BC V6T2A3, Canada. [Cascio, Ethan W.] Massachusetts Gen Hosp, Cambridge, MA USA. [Castaneda, Carlos] Univ Calif Davis, Davis, CA 95616 USA. [von Przewoski, Barbara] Indiana Univ, Cyclotron Facil, Bloomington, IN USA. [Eisen, Harvey] Chair Space Parts Working Grp Hardness Assurance, Bloomington, IN USA. RP McMahan, MA (reprint author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA. EM p_mcmahan@lbl.gov; blackmore@triumf.ca; ecascio@partners.org; Castaneda@crocker.ucdavis.edu; bvonprze@indiana.edu; harveyeisen@aol.com NR 21 TC 2 Z9 2 U1 0 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4244-2545-7 PY 2008 BP 135 EP + DI 10.1109/REDW.2008.31 PG 4 WC Engineering, Electrical & Electronic; Physics, Fluids & Plasmas; Physics, Nuclear SC Engineering; Physics GA BIM83 UT WOS:000260931600024 ER PT J AU Bois, F Baldwin, RM Amici, L Al-Tikriti, MS Kula, N Baldessarini, R Innis, RB Staley, JK Tamagnan, GD AF Bois, Frederic Baldwin, Ronald M. Amici, Louis Al-Tikriti, Mohammed S. Kula, Nora Baldessarini, Ross Innis, Robert B. Staley, Julie K. Tamagnan, Gilles D. TI Synthesis, radiolabeling and baboon SPECT imaging of 2 beta-carbomethoxy-3 beta-(3 '- [I-123]iodophenyl)tropane ([I-123]YP256) as a serotonin transporter radiotracer SO NUCLEAR MEDICINE AND BIOLOGY LA English DT Review DE radiolabeling; serotonin transporter; monkey study; brain imaging; SPECT ID POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; DOPAMINE TRANSPORTER; BINDING AFFINITIES; NONHUMAN-PRIMATES; PET RADIOLIGAND; REUPTAKE SITES; BRAIN; PHARMACOKINETICS; STRIATUM AB To develop a potential SPECT probe to evaluate the integrity of the serotoninergic system (5-HTT) whose dysfunction is linked to several disease conditions such as Parkinson's disease, Alzheimer's disease and depression, we report the synthesis, radiolabeling and in vivo baboon imaging of 2 beta-carbomethoxy-3 beta-(3'-[I-123]iodophenyl) tropane (YP256, 6). The radiolabeling was performed by iododestannylation using sodium [I-123] iodide and peracetic acid. Although the ligand displayed high selectivity for 5-HTT over dopamine transporter in vitro, SPECT imaging in baboons did not reveal selective 5-HTT accumulation in brain in vivo. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bois, Frederic; Baldwin, Ronald M.; Amici, Louis; Innis, Robert B.; Staley, Julie K.; Tamagnan, Gilles D.] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Kula, Nora; Baldessarini, Ross] Harvard Univ, Sch Med, Dept Psychiat & Neurosci Program, Massachusetts Gen Hosp,Mailman Res Ctr,Mclean Div, Belmont, MA 02478 USA. [Tamagnan, Gilles D.] Inst Neurodegenerat Disorders, New Haven, CT 06510 USA. RP Tamagnan, GD (reprint author), Yale Univ, Sch Med, VA Connecticut HCS 116A2, West Haven, CT 06516 USA. EM gtamagnan@indd.org FU NIMH NIH HHS [MH-34006, R43 MH071022-01, R21 MH067066-01A1, MH-47370] NR 33 TC 5 Z9 5 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0969-8051 J9 NUCL MED BIOL JI Nucl. Med. Biol. PD JAN PY 2008 VL 35 IS 1 BP 53 EP 59 DI 10.1016/j.nucmedbio.2007.09.002 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 250YR UT WOS:000252337800008 PM 18158943 ER PT J AU Tabatadze, D Zamecnik, P Yanachkov, I Wright, G Pierson, K Zhang, S Bogdanov, A Metelev, V AF Tabatadze, David Zamecnik, Paul Yanachkov, Ivan Wright, George Pierson, Katherine Zhang, Surong Bogdanov, Alexei, Jr. Metelev, Valeri TI A novel thymidine phosphoramidite synthon for incorporation of internucleoside phosphate linkers during automated oligodeoxynucleotide synthesis SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS LA English DT Article DE thymidine phosphoramidite synthon; sequence-specific attachment; single ligand; multiple ligands; reporter molecules ID LOCKED NUCLEIC-ACIDS; REPORTER GROUPS; OLIGONUCLEOTIDE DENDRIMERS; HYBRIDIZATION PROPERTIES; POLY(ETHYLENE GLYCOL); CHEMICAL SYNTHESIS; DNA; ANTISENSE; LINKAGES; OLIGODEOXYRIBONUCLEOTIDES AB A novel thymidine phosphoramidite synthon was synthesized and successfully used for incorporation of primary amino groups, attached through a triethylene glycol linker to the internucleoside phosphates, at desired locations during automated oligodeoxynucleotide synthesis. The synthesized amino-linker bearing oligonucleotides are stable under deprotection conditions and exhibit Watson-Crick base-pairing properties. Covalent labeling of oligonucleotides with carbocyanine near-infrared fluorochromes resulted in 2.5 times higher labeling yields when compared with oligonucleotides containing base-attached aminolinkers. We anticipate that the developed synthetic approach will be useful for nucleotide sequence-specific attachment of single or multiple ligands or reporter molecules. C1 [Tabatadze, David; Zamecnik, Paul; Pierson, Katherine] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Yanachkov, Ivan; Wright, George] GL Synthesis Inc, Worcester, MA USA. [Zhang, Surong; Bogdanov, Alexei, Jr.; Metelev, Valeri] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01605 USA. [Metelev, Valeri] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia. RP Zamecnik, P (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA. EM paul_zamecnik@hms.harvard.edu RI Metelev, Valeri/I-3238-2012 FU NCI NIH HHS [R21 CA116144]; NIAID NIH HHS [5 R01 AI060872-02] NR 36 TC 7 Z9 7 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1525-7770 J9 NUCLEOS NUCLEOT NUCL JI Nucleosides Nucleotides Nucleic Acids PY 2008 VL 27 IS 2 BP 157 EP 172 DI 10.1080/15257770701795938 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 253KG UT WOS:000252516500006 PM 18205070 ER PT J AU Lindgren, TG Fukuoka, Y Rankin, SH Cooper, BA Carroll, D Munn, YL AF Lindgren, Teri G. Fukuoka, Yoshimi Rankin, Sally H. Cooper, Bruce A. Carroll, Diane Munn, Yvonne L. TI Cluster analysis of elderly cardiac patients' prehospital symptomatology SO NURSING RESEARCH LA English DT Article DE cardiac symptoms; cluster analysis; elderly ID ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; CHRONIC PAIN; RISK-FACTOR; DEPRESSION; SYMPTOMS; OLDER; PREVALENCE; MORBIDITY AB Background: Chest pain routinely brings patients into the healthcare system, and elderly patients may present with more complex symptoms presaging ischemic heart I changes than do younger patients. Objective: To examine, using cluster analysis, how elderly I patients experiencing an ischemic coronary heart disease cluster based on presenting symptoms in the week before hospitalization and how they vary in terms of their general physical and mental health, mood states, and quality of life. Methods: Elderly (age >= 65 years), unpartnered patients (N = 247) admitted with ischemic coronary heart disease to one of I five university medical centers were inducted into a clinical trial; only baseline data are reported. Interviews assessed cardiac symptoms, medical history, general physical and mental health, mood states, and quality of life. Patients were clustered (grouped) using squared Euclidean distances and weighted average linkage. Characteristics of patients were examined using analysis of variance and chi-squared analyses. Results: Three clusters (groups) were identified: (a) Classic Acute Coronary Syndrome (severe ischemic pain; 22%), (b) Weary (severe fatigue, sleep disturbance, and shortness of breath; 29%), and (c) Diffuse Symptoms (mild symptomatology; 49%). Post hoc tests revealed that the Weary group was more likely to have a history of heart failure; they also exhibited significantly more psychological distress and lower quality of life than the other subgroups. Conclusion: Cluster analysis proved useful in grouping patients based on their symptom experience, but further research is needed to clarify the relationships among identified symptoms, psychological distress, and health outcomes; develop interventions for Weary patients; and extend the findings of this study. C1 [Lindgren, Teri G.; Fukuoka, Yoshimi; Rankin, Sally H.; Cooper, Bruce A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Munn, Yvonne L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lindgren, TG (reprint author), Univ Calif San Francisco, Box 0606,2 Koret Way,Nursing 431 M, San Francisco, CA 94143 USA. EM teri.lindgren@nursing.ucsfedu FU NICHD NIH HHS [9K12 HD052163-06]; NINR NIH HHS [R01 NR005205, T32 NR07088] NR 39 TC 24 Z9 24 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD JAN-FEB PY 2008 VL 57 IS 1 BP 14 EP 23 PG 10 WC Nursing SC Nursing GA 249PQ UT WOS:000252241600003 PM 18091288 ER PT J AU Gottardo, L De Cosmo, S Zhang, YY Powers, C Prudente, S Marescotti, MC Trischitta, V Avogaro, A Doria, A AF Gottardo, Lucia De Cosmo, Salvatore Zhang, Yuan-Yuan Powers, Christine Prudente, Sabrina Marescotti, Maria C. Trischitta, Vincenzo Avogaro, Angelo Doria, Alessandro TI A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndrome SO OBESITY LA English DT Article ID INTERLEUKIN-6 RECEPTOR GENE; INSULIN-RESISTANCE; HAPLOTYPE; VARIANTS; OBESITY AB The interleukin 6 signal transducer (IL6ST, also known as gp130) is a ubiquitously expressed intermediate of the interleukin-6 signaling pathway. We investigated whether genetic variability at the IL6ST locus is involved in the modulation of metabolic traits and the etiology of the metabolic syndrome (MS). Four haplotype-tagging single nucleotide polymorphisms were typed in two populations of non-diabetic subjects, one from Northern Italy (Padua (PD), n = 630), the other from Southern Italy (San Giovanni Rotondo (SGR), n = 553). In the PD population, a nominally significant association was observed between fasting glucose and rs715180 (P = 0.02), rs3729960 (P 0.02), and rs10940495 (P = 0.05), between homeostasis model assessment index (HOMA(IR)) and rs715180 (P = 0.04), and between triglycerides and rs3729960 (P = 0.03). In the SGR population, high-density lipoprotein (HDL) levels were associated with rs715180 (P = 0.01), systolic blood pressure and waist circumference with rs3729960 (P = 0.005 and 0.02, respectively). The frequency of rs715180 minor allele carriers progressively decreased from individuals with no MS components to those with three or more components (P for trend = 0.006 in the two populations combined). Compared to major allele homozygotes, minor allele carriers had 40% lower odds of having at least one MS component (Odds ratio = 0.6, 95% confidence interval 0.4-0.8, P = 0.005). These findings point to IL6ST variants as possible determinants of impaired glucose metabolism and other abnormalities of MS. C1 [Gottardo, Lucia; Zhang, Yuan-Yuan; Powers, Christine; Doria, Alessandro] Harvard Univ, Sch Med, Div Res, Joslin Diabet Ctr, Boston, MA 02115 USA. [Gottardo, Lucia; Zhang, Yuan-Yuan; Doria, Alessandro] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [De Cosmo, Salvatore; Trischitta, Vincenzo] IRCCS Casa Sollievo Sofferenza, Res Unit Diabetol & Endocrinol, San Giovanni Rotondo, Italy. [Prudente, Sabrina; Trischitta, Vincenzo] Casa Sollievo Sofferenza Mendel Inst, Rome, Italy. [Marescotti, Maria C.; Avogaro, Angelo] Univ Padua, Dept Clin & Expt Med, Padua, Italy. [Trischitta, Vincenzo] Univ Roma La Sapienza, Dept Clin Sci, Rome, Italy. RP Doria, A (reprint author), Harvard Univ, Sch Med, Div Res, Joslin Diabet Ctr, Boston, MA 02115 USA. EM alessandro.doria@joslin.harvard.edu RI Prudente, Sabrina/H-2886-2016; Trischitta, Vincenzo/K-1487-2016 OI De Cosmo, Salvatore/0000-0001-8787-8286; Prudente, Sabrina/0000-0001-9220-8981; Trischitta, Vincenzo/0000-0003-1174-127X FU NHLBI NIH HHS [HL73168, HL71981]; NIDDK NIH HHS [DK60837, DK36836] NR 20 TC 8 Z9 8 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD JAN PY 2008 VL 16 IS 1 BP 205 EP 210 DI 10.1038/oby.2007.28 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 253YU UT WOS:000252554300035 PM 18223637 ER PT J AU Olatunji, BO Wilhelm, S Deckersbach, T AF Olatunji, Bunmi O. Wilhelm, Sabine Deckersbach, Thilo BE Abramowitz, JS McKay, D Taylor, S TI TIC-RELATED OBSESSIVE-COMPULSIVE DISORDER SO OBSESSIVE-COMPULSIVE DISORDER: SUBTYPES AND SPECTRUM CONDITIONS LA English DT Article; Book Chapter ID CEREBRAL-BLOOD-FLOW; GLUCOSE METABOLIC RATES; RANDOMIZED CONTROLLED-TRIAL; LA-TOURETTES-SYNDROME; HABIT-REVERSAL; SYMPTOM PROVOCATION; SUPPORTIVE PSYCHOTHERAPY; PSYCHIATRIC-DISORDERS; UNMEDICATED PATIENTS; DOUBLE-BLIND C1 [Olatunji, Bunmi O.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA. [Wilhelm, Sabine; Deckersbach, Thilo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. RP Deckersbach, T (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Bldg 149,2611,13th St, Charlestown, MA 02129 USA. NR 79 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-055049-7 PY 2008 BP 94 EP 106 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BEF11 UT WOS:000316363300007 ER PT J AU Shimazaki, K Jirawuthiworavong, GV Nguyen, EV Awazu, M Levinson, RD Gordon, LK AF Shimazaki, Kaori Jirawuthiworavong, Guy V. Nguyen, Eddy V. Awazu, Midori Levinson, Ralph D. Gordon, Lynn K. TI Tubulointerstitial nephritis and uveitis syndrome: A case with an autoimmune reactivity against retinal and renal antigens SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE antiretinal reactivity; autoantibody; autoantigen; autoimmune reactivity; tubulointerstitial nephritis and uveitis (TINU) ID CELLS AB Tubulointerstitial nephritis and uveitis (TINU) generally occurs at young age and has a female preponderance. Renal biopsy reveals interstitial infiltration of inflammatory cells and edema, and the associated intraocular inflammation typically consists of an anterior, bilateral uveitis. The pathogenesis of TINU likely involves both humoral and cellular immunity and is mediated by medications, infectious agents, or other unknown causes. A previous report detected a renal antigen recognized by the serum of a TINU patient. In this report the authors extend these observations to document seroreactivity against a retinal antigen of similar size. C1 [Jirawuthiworavong, Guy V.; Nguyen, Eddy V.; Levinson, Ralph D.; Gordon, Lynn K.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Greater Los Angeles Vet Affairs Heathcare Syst, Dept Surg, Los Angeles, CA USA. [Shimazaki, Kaori] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA. [Awazu, Midori] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan. RP Gordon, LK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu NR 5 TC 6 Z9 7 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD JAN-APR PY 2008 VL 16 IS 1-2 BP 51 EP 53 DI 10.1080/09273940801899772 PG 3 WC Ophthalmology SC Ophthalmology GA 289OW UT WOS:000255064800012 PM 18379944 ER PT B AU Niederkorn, JY Dana, MR AF Niederkorn, Jerry Y. Dana, M. Reza BE Yorio, T Clark, AF Wax, MB TI Immune System and the Eye SO OCULAR THERAPEUTICS: EYE ON NEW DISCOVERIES LA English DT Article; Book Chapter ID CORNEAL ALLOGRAFT-REJECTION; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; PERIPHERAL ULCERATIVE KERATITIS; TOPICAL CYCLOSPORINE TREATMENT; ANTI-CD4 MONOCLONAL-ANTIBODY; OCULAR INFLAMMATORY DISEASE; HUMAN MAST-CELLS; DRY-EYE; SJOGRENS-SYNDROME; ANTERIOR-CHAMBER C1 [Niederkorn, Jerry Y.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA. [Dana, M. Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Dana, M. Reza] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. RP Niederkorn, JY (reprint author), Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA. NR 156 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055677-2; 978-0-12-370585-3 PY 2008 BP 199 EP 237 DI 10.1016/B978-012370585-3.50012-1 PG 39 WC Ophthalmology; Pharmacology & Pharmacy SC Ophthalmology; Pharmacology & Pharmacy GA BIB47 UT WOS:000327247300011 ER PT J AU Hultman, T Reder, EAK Dahlin, CM AF Hultman, Todd Reder, Elizabeth A. Keene Dahlin, Constance M. TI IMPROVING PSYCHOLOGICAL AND PSYCHIATRIC ASPECTS OF PALLIATIVE CARE: THE NATIONAL CONSENSUS PROJECT AND THE NATIONAL QUALITY FORUM PREFERRED PRACTICES FOR PALLIATIVE AND HOSPICE CARE SO OMEGA-JOURNAL OF DEATH AND DYING LA English DT Article ID END-OF-LIFE; CANCER-PATIENTS; BEREAVEMENT; DEPRESSION; DISORDERS; HEALTH; PREVALENCE; DIGNITY; ANXIETY AB As patients with terminal disease enter into the final stage of their illness, psychiatric symptoms and psychological responses to the disease contribute to overall suffering of both patient and family. Until recently, no nationally accepted guidelines or practices had been established to support assessment and management of this type of suffering. In 2007, the National Quality Forum published A National Framework and Preferred Practices for Palliative and Hospice Care Quality that included a list of preferred practices for assessing and treating symptoms of psychiatric illness, anticipatory grief and psychologic distress prior to death, and bereavement after the death, of the patient. While specialized care may be provided to patient and families in the context of advanced disease, all clinicians involved in palliative and end-of-life care are responsible for having a basic understanding of effectively managing psychologic and psychiatric aspects of this care. Evidence from current literature supports these best practices. C1 [Hultman, Todd] Univ Massachusetts Lowell, Dept Nursing, Lowell, MA 01854 USA. [Reder, Elizabeth A. Keene] Johns Hopkins Childrens Ctr, Baltimore, MD USA. [Dahlin, Constance M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Hultman, T (reprint author), Univ Massachusetts Lowell, Dept Nursing, 3 Solomont Way,Suite 2, Lowell, MA 01854 USA. EM todd_hultman@uml.edu NR 34 TC 10 Z9 10 U1 0 U2 8 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0030-2228 J9 OMEGA-J DEATH DYING JI Omega-J. Death Dying PY 2008 VL 57 IS 4 BP 323 EP 339 DI 10.2190/OM.57.4.a PG 17 WC Psychology, Multidisciplinary; Social Sciences, Biomedical SC Psychology; Biomedical Social Sciences GA 361OY UT WOS:000260138200001 PM 19294824 ER PT J AU Novina, CD Chabner, BA AF Novina, Carl D. Chabner, Bruce A. TI RNA-directed therapy: The next step in the miRNA revolution SO ONCOLOGIST LA English DT Editorial Material ID C-ELEGANS; MICRORNAS; LIN-14 C1 [Chabner, Bruce A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Novina, Carl D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02114 USA. RP Chabner, BA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,LRH 214, Boston, MA 02114 USA. EM bchabner@partners.org NR 6 TC 3 Z9 6 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 1 BP 1 EP 3 DI 10.1634/theoncologist.2007-0236 PG 3 WC Oncology SC Oncology GA 259IT UT WOS:000252933700001 PM 18245006 ER PT J AU Van den Abbeele, AD AF Van den Abbeele, Annick D. TI The lessons of GIST - PET and PET/CT: A new paradigm for imaging SO ONCOLOGIST LA English DT Article DE positron emission tomography; computed tomography; fluorodeoxyglucose; gastrointestinal stromal tumor; imatinib mesylate ID GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; FDG-PET; THERAPY; STI571; CT AB Traditional anatomic tumor response criteria are based on uni- or bidimensional changes in tumor size, and do not take into account changes in tumor metabolism, tumor density, or decrease in the number of intratumoral vessels. These changes are, however, all indicative of response to imatinib therapy in patients with gastrointestinal stromal tumor (GIST). In these patients, metabolic responses seen on positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose ((18)FDG) have been shown to be closely related to clinical benefit. Furthermore, these metabolic changes precede by weeks or months significant decrease in tumor size on computed tomography (CT). Conversely, lack of metabolic response on FDG-PET indicates primary resistance to the drug and may help identify patients who would benefit from another therapy, while re-emergence of metabolic activity within tumor sites following a period of therapeutic response indicates secondary resistance to the drug. Newly proposed CT criteria using either no growth in tumor size or a combination of tumor density and size criteria have shown a close correlation with the predictive value results of FDG-PET. Thus, the integration of FDG-PET and CT, as in the combined hybrid PET/CT scanners now available, will not only optimize the evaluation of patients with GIST treated with molecularly targeted drugs, but may ultimately help shorten clinical trials, and accelerate drug development in this disease and other cancers as well. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Van den Abbeele, AD (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM abbeele@dfci.harvard.edu NR 18 TC 139 Z9 143 U1 1 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 SU 2 BP 8 EP 13 DI 10.1634/theoncologist.13-S2-8 PG 6 WC Oncology SC Oncology GA 293PS UT WOS:000255347800003 PM 18434632 ER PT J AU Ryan, PD Goss, PE AF Ryan, Paula D. Goss, Paul E. TI The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer SO ONCOLOGIST LA English DT Article DE insulin-like growth factor-I; insulin-like growth factor-II; insulin-like growth factor-I receptor; breast cancer; review ID FACTOR-I-RECEPTOR; CELL LUNG-CANCER; BINDING PROTEIN-3 EXPRESSION; BREAST-CANCER; IGF-I; PROSTATE-CANCER; ANTITUMOR-ACTIVITY; COLORECTAL-CANCER; TUMOR-GROWTH; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR AB The insulin-like growth factor signaling pathway is important in many human cancers based on data from experimental models as well as epidemiological studies. Important therapies targeted at this pathway have been or are being developed, including monoclonal antibodies to the insulin-like growth factor-I receptor and small molecule inhibitors of the tyrosine kinase function of this receptor. These investigational therapies are now being studied in clinical trials. Emerging data from phase I trials are encouraging regarding the safety of the monoclonal antibodies. In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data. C1 [Ryan, Paula D.; Goss, Paul E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ryan, PD (reprint author), Massachusetts Gen Hosp, LRH 308,55 Fruit St, Boston, MA 02114 USA. EM pdryan@partners.org NR 93 TC 98 Z9 100 U1 1 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 1 BP 16 EP 24 DI 10.1634/theoncologist.2007-0199 PG 9 WC Oncology SC Oncology GA 259IT UT WOS:000252933700004 PM 18245009 ER PT J AU Zhu, AX Holalkere, NS Muzikansky, A Horgan, K Sahani, DV AF Zhu, Andrew X. Holalkere, Nagaraj S. Muzikansky, Alona Horgan, Kerry Sahani, Dushyant V. TI Early Antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma SO ONCOLOGIST LA English DT Article DE hepatocellular carcinoma; bevacizumab; angiogenesis; CT perfusion scan ID ENDOTHELIAL GROWTH-FACTOR; PROGNOSTIC-SIGNIFICANCE; CONTRAST ENHANCEMENT; TUMOR VASCULATURE; CANCER STATISTICS; RECTAL-CANCER; UNITED-STATES; CT; ANGIOGENESIS; COMBINATION AB Background. Hepatocellular carcinoma (HCC) is a highly vascularized tumor with a poor prognosis. In a phase II study that combined bevacizumab with gemcitabine and oxaliplatin in advanced HCC, we examined computed tomography perfusion (CTp) scan parameters as surrogate markers of angiogenesis after bevacizumab administration. Methods. HCC patients received bevacizumab alone i.v. at 10 mg/kg on day 1 during cycle 1. CTp scanning was performed at baseline and days 10-12 to assess changes in tissue blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface area product (PS). Results. Compared with baseline, a significant decrease in the estimated tumor perfusion parameters including BF, BV, and PS and an increase in MTT were seen on days 10-12 following bevacizumab administration alone. Patients with progressive disease had lower baseline MTT values and a higher percent increase following bevacizumab administration than those with stable disease or partial responses. Conclusions. Bevacizumab induced a significant decrease in tumor BF, BV, and PS and an increase in MTT by CTp scan in HCC. Baseline and percent change in MTT following bevacizumab administration correlated with clinical outcome, whereas BF, BV, and PS did not. C1 [Zhu, Andrew X.; Holalkere, Nagaraj S.; Muzikansky, Alona; Horgan, Kerry; Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Zhu, AX (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,LH-POB 232, Boston, MA 02114 USA. EM azhu@partners.org OI Holalkere, Nagaraj/0000-0001-6324-7682 NR 31 TC 97 Z9 100 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 2 BP 120 EP 125 DI 10.1634/theoncologist.2007-0174 PG 6 WC Oncology SC Oncology GA 268LJ UT WOS:000253581000005 PM 18305056 ER PT J AU Refaat, MM Idriss, SZ Blaszkowsky, LS AF Refaat, Marwan M. Idriss, Shereene Z. Blaszkowsky, Lawrence S. TI Case report: An unusual case of adrenal neuroblastoma in pregnancy SO ONCOLOGIST LA English DT Article DE adrenal; adult; neuroblastoma; pregnancy ID HIGH-RISK NEUROBLASTOMA; UNRESECTABLE NEUROBLASTOMA; PRIMARY CHEMOTHERAPY; PEDIATRIC-ONCOLOGY; NEURO-BLASTOMA; INFANTS; STAGE; AMPLIFICATION; DIAGNOSIS; THERAPY AB Neuroblastomas are the fourth most common malignancy of childhood and account for most adrenal tumors in children. However, they are rarely reported in adults. We present herein an extremely rare case of adrenal neuroblastoma occurring in a 25-year-old woman during her first trimester of pregnancy. She had a spontaneous abortion secondary to chorioamnionitis and she was operated on for an "incidentaloma." Her tumor was curatively resected. She presented with right lower quadrant abdominal pain 26 months after her operation and there was evidence of local tumor recurrence without metastasis. Adult adrenal neuroblastoma is an uncommon malignancy and, to our knowledge, there was no case of this tumor occurring in pregnancy ever described in the English literature. The case presentation is followed by a general discussion with an emphasis on the diagnosis, treatment, and follow-up of neuroblastoma and its association with pregnancy. C1 [Refaat, Marwan M.; Blaszkowsky, Lawrence S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Blaszkowsky, Lawrence S.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Idriss, Shereene Z.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Refaat, MM (reprint author), Massachusetts Gen Hosp, Dept Med, GRB 740,55 Fruit St, Boston, MA 02114 USA. EM rifaatmarwan@hotmail.com NR 25 TC 5 Z9 5 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 2 BP 152 EP 156 DI 10.1634/theoncologist.2006-0180 PG 5 WC Oncology SC Oncology GA 268LJ UT WOS:000253581000009 PM 18305060 ER PT J AU Chabner, BA AF Chabner, Bruce A. TI A sad week for this oncologist, and an unfinished task - Bruce A. Chabner, MD SO ONCOLOGIST LA English DT Biographical-Item C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Chabner, BA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 2 BP 207 EP 208 PG 2 WC Oncology SC Oncology GA 268LJ UT WOS:000253581000015 ER PT J AU Chan-Smutko, G Patel, D Shannon, KM Ryan, PD AF Chan-Smutko, Gayun Patel, Devanshi Shannon, Kristen M. Ryan, Paula D. TI Professional challenges in cancer genetic testing: Who is the patient? SO ONCOLOGIST LA English DT Article DE duty-to-warn; genetic testing; family dynamics; patient confidentiality ID RISK AB In the genetic counseling setting, the health care provider can be challenged by opposing duties to members of the same family: protecting the privacy of the patient identified with a gene mutation and the ethical obligation to warn at- risk relatives. In a situation of nondisclosure between members of a family with a known disease- predisposing mutation, this type of dilemma can present in acute form for the provider who cares for different members of the family. This can hinder effective medical decision making. To minimize this effect, we recommend detailed pretest genetic counseling steps to empower the patient to communicate with their at- risk relatives their intent to pursue testing and willingness to share information. In addition, post- test counseling should reiterate the implications of a positive result for at- risk relatives and conclude with a written summary that patients can share with their family. C1 [Chan-Smutko, Gayun; Patel, Devanshi; Shannon, Kristen M.; Ryan, Paula D.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Risk Assessment, Boston, MA USA. RP Chan-Smutko, G (reprint author), 55 Fruit St,YAW9A, Boston, MA 02114 USA. EM gchansmutko@partners.org NR 10 TC 7 Z9 7 U1 0 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 3 BP 232 EP 238 DI 10.1634/theoncologist.2007-0203 PG 7 WC Oncology SC Oncology GA 285UQ UT WOS:000254802100004 PM 18378533 ER PT J AU Barry, MJ AF Barry, Michael J. TI Commentary: How serious is getting a diagnosis of prostate cancer? SO ONCOLOGIST LA English DT Editorial Material ID UNITED-STATES; MORTALITY; ANTIGEN C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Med Pracitces Evaluat Ctr,Gen Med Unit, Boston, MA 02114 USA. RP Barry, MJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Med Pracitces Evaluat Ctr,Gen Med Unit, 50 Staniford St 9th Floor, Boston, MA 02114 USA. EM mbarry@partners.org NR 11 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 3 BP 306 EP 308 DI 10.1634/theoncologist.2008-0008 PG 3 WC Oncology SC Oncology GA 285UQ UT WOS:000254802100012 PM 18378541 ER PT J AU Chabner, BA AF Chabner, Bruce A. TI Smoke, then fire: Lung cancer screening studies under further scrutiny SO ONCOLOGIST LA English DT Editorial Material C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Chabner, BA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. NR 8 TC 3 Z9 4 U1 0 U2 1 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 4 BP 348 EP 349 DI 10.1634/theoncologist.2008-0079 PG 2 WC Oncology SC Oncology GA 294QU UT WOS:000255421400001 PM 18448547 ER PT J AU Hezel, AF Zhu, AX AF Hezel, Aram F. Zhu, Andrew X. TI Systemic therapy for biliary tract cancers SO ONCOLOGIST LA English DT Article DE cholangiocarcinoma; gallbladder cancer; chemotherapy; bile duct cancer ID PHASE-II TRIAL; GROWTH-FACTOR-RECEPTOR; 1ST-LINE TREATMENT; PANCREATIC-CANCER; MITOMYCIN-C; INTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; METASTATIC BILIARY; OXALIPLATIN GEMOX; PLUS LEUCOVORIN AB Biliary tract cancers (BTCs) are invasive carcinomas that arise from the epithelial lining of the gallbladder and bile ducts. These include intrahepatic, perihilar, and distal biliary tree cancers as well as carcinoma arising from the gallbladder. Complete surgical resection offers the only chance for cure; however, only 10% of patients present with early-stage disease and are considered surgical candidates. Among those patients who do undergo "curative" resection, recurrence rates are high; thus, for the majority of BTC patients, systemic chemotherapy is the mainstay of their treatment plan. Patients with unresectable or metastatic BTC have a poor prognosis, with a median overall survival time of < 1 year. Despite a paucity of randomized phase III data, a consensus on first-line systemic therapy is emerging. In this review, we discuss the clinical experience with systemic treatment of BTC, focusing on the rationale for a first-line regimen as well as future directions in the field. C1 [Hezel, Aram F.; Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med,Tucker Gosnell Ctr Gastrointestinal Canc, Boston, MA 02114 USA. RP Hezel, AF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med,Tucker Gosnell Ctr Gastrointestinal Canc, Lawrence House POB 232, Boston, MA 02114 USA. EM ahezel@partners.org; azhu@partners.org NR 70 TC 123 Z9 134 U1 0 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 4 BP 415 EP 423 DI 10.1634/theoncologist.2007-0252 PG 9 WC Oncology SC Oncology GA 294QU UT WOS:000255421400010 PM 18448556 ER PT J AU Ko, E Lee, S Goodman, A AF Ko, Emily Lee, Susanna Goodman, Annekathryn TI Gemcitabine pulmonary toxicity in ovarian cancer SO ONCOLOGIST LA English DT Article DE gemcitabine; ovarian cancer; chemotherapy; pulmonary toxicity; ARDS AB Background. A case of gemcitabine-induced lung toxicity is reported in a woman with stage IIIc ovarian papillary serous carcinoma. Case. An 83-year-old woman with stage IIIc ovarian serous papillary carcinoma diagnosed in 2001 underwent suboptimal cytoreductive surgery followed by carboplatin paclitaxel chemotherapy. Initially in remission following chemotherapy, the disease subsequently progressed over the next 5 years. The patient received gemcitabine palliative chemotherapy. She developed significant pulmonary toxicity consistent with drug-induced interstitial pneumonitis, which improved with steroid therapy. Conclusion. Gemcitabine, a second-line chemotherapy agent for the treatment of ovarian cancer, may rarely cause a serious or even fatal condition of pulmonary lung toxicity. C1 [Goodman, Annekathryn] Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Dept Gynecol Oncol, Boston, MA 02114 USA. RP Goodman, A (reprint author), Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Dept Gynecol Oncol, Yawkey 9E-9050,32 Fruit St, Boston, MA 02114 USA. EM Agoodman@partners.org NR 12 TC 7 Z9 7 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 7 BP 807 EP 811 DI 10.1634/theoncologist.2008-0049 PG 5 WC Oncology SC Oncology GA 338JT UT WOS:000258504700007 PM 18614588 ER PT J AU Russo, G Haddad, R Posner, M Machtay, M AF Russo, Gregory Haddad, Robert Posner, Marshall Machtay, Mitchell TI Radiation treatment breaks and ulcerative mucositis in head and neck cancer SO ONCOLOGIST LA English DT Article DE head and neck cancer; concurrent chemoradiation; radiation mucositis; radiation treatment breaks; radiation toxicity ID SQUAMOUS-CELL CARCINOMA; STAGE OROPHARYNX CARCINOMA; RANDOMIZED CLINICAL-TRIAL; LOCALLY ADVANCED HEAD; PHASE-III; ORAL MUCOSITIS; TREATMENT TIME; TUMOR-CONTROL; ACCELERATED RADIOTHERAPY; POSTOPERATIVE IRRADIATION AB Unplanned radiation treatment breaks and prolongation of the radiation treatment time are associated with lower survival and locoregional control rates when radiotherapy or concurrent chemoradiotherapy is used in the curative treatment of head and neck cancer. Treatment of head and neck cancer is intense, involving high-dose, continuous radiotherapy, and often adding chemotherapy to radiotherapy. As the intensity of treatment regimens has escalated in recent years, clinical outcomes generally have improved. However, more intensive therapy also increases the incidence of treatment-related toxicities, particularly those impacting the mucosal lining of the oral cavity, pharynx, and cervical esophagus, and results in varying degrees of ulcerative mucositis. Ulcerative mucositis is a root cause of unscheduled radiation treatment breaks, which prolongs the total radiation treatment time. Alterations in radiotherapy and chemotherapy, including the use of continuous (i.e., 7 days/week) radiotherapy to ensure constant negative proliferative pressure, may improve efficacy outcomes. However, these approaches also increase the incidence of ulcerative mucositis, thereby increasing the incidence of unplanned radiation treatment breaks. Conversely, the reduction of ulcerative mucositis to minimize unplanned breaks in radiotherapy may enhance not only tolerability, but also efficacy outcomes. Several strategies to prevent ulcerative mucositis in radiotherapy for head and neck cancer have been evaluated, but none have demonstrated strong efficacy. Continued investigation is needed to identify superior radiation treatment regimens, technology, and supportive care that reduce unplanned radiation treatment breaks with the goal of improving clinical outcomes in head and neck cancer. C1 [Russo, Gregory; Machtay, Mitchell] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA. [Haddad, Robert; Posner, Marshall] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Machtay, M (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, 111 S 11th St, Philadelphia, PA 19107 USA. EM Mitchell.machtay@jeffersonhospital.org FU Amgen FX The authors take full responsibility for the content of the paper but thank Jonathan Latham, PharmD, and Roberta Connelly, MS, ELS, supported by Amgen, for their assistance in organizing the published literature, writing the first draft of the manuscript, and collating the authors' comments. NR 67 TC 64 Z9 71 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 8 BP 886 EP 898 DI 10.1634/theoncologist.2008-0024 PG 13 WC Oncology SC Oncology GA 346DY UT WOS:000259049800006 PM 18701763 ER PT J AU Schapira, L Gordon-Rowe, L Martignetti, R Washington, D Bartholomay, M Greenberg, D Lathan, C LaFrancesca, J Lynch, T Chabner, B AF Schapira, Lidia Gordon-Rowe, Leah Martignetti, Rosalba Washington, Deborah Bartholomay, Mimi Greenberg, Donna Lathan, Christopher LaFrancesca, Joanne Lynch, Thomas Chabner, Bruce TI Racism in the Chemotherapy Infusion Unit: A Nurse's Story SO ONCOLOGIST LA English DT Article AB Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery that provides hope to the patient and support to caregivers, and encourages the healing process. The Center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. In this article a nurse relates her experience as care-giver for a patient who made repeated racially motivated comments. She reflects on her response and the support she received from her colleagues. The Oncologist 2008; 13: 1177-1180 C1 [Schapira, Lidia] Massachusetts Gen Hosp, Ctr Canc, Gillette Ctr Breast Canc, Dept Med Oncol, Boston, MA 02114 USA. [Gordon-Rowe, Leah; Martignetti, Rosalba; Washington, Deborah; Bartholomay, Mimi; LaFrancesca, Joanne] Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA. [Greenberg, Donna] Massachusetts Gen Hosp, Dept Social Serv, Boston, MA 02114 USA. [Lathan, Christopher] Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA. RP Schapira, L (reprint author), Massachusetts Gen Hosp, Ctr Canc, Gillette Ctr Breast Canc, Dept Med Oncol, 55 Fruit St,YAW 9, Boston, MA 02114 USA. EM lschapira@partners.org NR 8 TC 0 Z9 0 U1 2 U2 4 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 11 BP 1177 EP 1180 DI 10.1634/theoncologist.2008-0210 PG 4 WC Oncology SC Oncology GA 380UO UT WOS:000261491100007 PM 18984873 ER PT J AU Dietrich, J Monje, M Wefel, J Meyers, C AF Dietrich, Joerg Monje, Michelle Wefel, Jeffrey Meyers, Christina TI Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy SO ONCOLOGIST LA English DT Review DE Neurotoxicity; Cognitive dysfunction; Chemotherapy; Radiation therapy; Progenitor cells; Neural stem cells ID CENTRAL-NERVOUS-SYSTEM; HIGH-DOSE CHEMOTHERAPY; RECEIVING ADJUVANT CHEMOTHERAPY; ADULT HIPPOCAMPAL NEUROGENESIS; TEMPORAL-LOBE NECROSIS; BRAIN-TUMOR PATIENTS; LONG-TERM SURVIVORS; BREAST-CANCER; RADIATION-THERAPY; CRANIAL IRRADIATION AB Standard oncological therapies, such as chemotherapy and cranial radiotherapy, frequently result in a spectrum of neurocognitive deficits that includes impaired learning, memory, attention, and speed of information processing. In addition to classical mechanisms of neurotoxicity associated with chemo- and radiotherapy, such as radiation necrosis and leukoencephalopathy, damage to dynamic progenitor cell populations in the brain is emerging as an important etiologic factor. Radiation- and chemotherapy-induced damage to progenitor populations responsible for maintenance of white matter integrity and adult hippocampal neurogenesis is now believed to play a major role in the neurocognitive impairment many cancer survivors experience. The Oncologist 2008; 13: 1285-1295 C1 [Dietrich, Joerg] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Div Neurooncol,Stephen E & Catherine, Boston, MA 02114 USA. [Monje, Michelle] Stanford Univ, Stanford Inst Med, Dept Neurol, Palo Alto, CA 94304 USA. [Monje, Michelle] Stanford Univ, Stanford Inst Med, Dept Dev Biol, Palo Alto, CA 94304 USA. [Wefel, Jeffrey; Meyers, Christina] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. RP Dietrich, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Div Neurooncol,Stephen E & Catherine, 55 Fruit St, Boston, MA 02114 USA. EM jdietrich1@partners.org NR 106 TC 130 Z9 133 U1 1 U2 18 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PY 2008 VL 13 IS 12 BP 1285 EP 1295 DI 10.1634/theoncologist.2008-0130 PG 11 WC Oncology SC Oncology GA 388BZ UT WOS:000261996600008 PM 19019972 ER PT J AU Kunisaki, SM Jennings, RW AF Kunisaki, Shaun M. Jennings, Russell W. BE OGrady, JP Gimovsky, ML TI FETAL SURGERY SO OPERATIVE OBSTETRICS, 2ND EDITION LA English DT Article; Book Chapter ID CONGENITAL DIAPHRAGMATIC-HERNIA; TWIN TRANSFUSION SYNDROME; LEFT-HEART SYNDROME; CYSTIC ADENOMATOID MALFORMATION; INTRAUTERINE MYELOMENINGOCELE REPAIR; UTERO INTRAPARTUM TREATMENT; SHUNT-DEPENDENT HYDROCEPHALUS; INITIAL CLINICAL-EXPERIENCE; AIRWAY-OBSTRUCTION SYNDROME; POSTERIOR URETHRAL VALVES C1 [Kunisaki, Shaun M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Kunisaki, Shaun M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Jennings, Russell W.] Childrens Hosp, Adv Fetal Care Ctr, Boston, MA 02115 USA. RP Kunisaki, SM (reprint author), Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. NR 164 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-86248-6 PY 2008 BP 638 EP 662 D2 10.1017/CBO9780511580987 PG 25 WC Obstetrics & Gynecology; Surgery SC Obstetrics & Gynecology; Surgery GA BBU60 UT WOS:000308236500022 ER PT J AU Dawson, CK Rolf, RH Holovacs, TF AF Dawson, Courtney K. Rolf, Robert H. Holovacs, Thomas F. TI The Management of Localized Articular Cartilage Lesions of the Humeral Head in the Athlete SO OPERATIVE TECHNIQUES IN SPORTS MEDICINE LA English DT Article DE articular cartilage; humeral resurfacing; localized lesions ID REPLACEMENT SHOULDER ARTHROPLASTY; SURFACE REPLACEMENT; ANATOMY AB Localized articular cartilage lesions of the humeral head can be a source of persistent pain and functional decline in patients who have failed conservative treatment measures. Many are younger, active patients who pose a challenging management decision for surgeons. The goals of treatment should focus on maintaining humeral bone stock, restoring the contour of the articular surface, minimizing soft-tissue disruption, and relieving symptoms. There has been a trend toward humeral resurfacing arthroplasty and away from stemmed components over the past few decades for younger patients potentially requiring future revision surgery. More recently, the HemiCAP resurfacing system (Arthrosurface, Franklin, MA) has been used for localized defects in patients with Hill-Sachs and reverse Hill-Sachs lesions, avascular necrosis, focal chondral defects, and humeral head osteoarthritis. Early, short-term outcome results of the HemiCAP system are encouraging. In this article, we describe our technique for management of localized articular cartilage defects of the humeral head using the HemiCAP resurfacing system. C1 [Dawson, Courtney K.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA. [Dawson, Courtney K.] Massachusetts Gen Hosp, Harvard Combined Orthopaed Residency Program, Boston, MA 02114 USA. RP Dawson, CK (reprint author), Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Ctr Outpatient Care, 55 Fruit St,Suite 3200, Boston, MA 02114 USA. EM ckdawson@partners.org NR 18 TC 3 Z9 3 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1060-1872 J9 OPER TECHN SPORT MED JI Oper. Tech. Sports Med. PD JAN PY 2008 VL 16 IS 1 BP 14 EP 20 DI 10.1053/j.otsm.2008.08.004 PG 7 WC Sport Sciences; Surgery SC Sport Sciences; Surgery GA 374DE UT WOS:000261021900004 ER PT B AU Borba, CPC Henderson, DC AF Borba, Christina P. C. Henderson, David C. BE Thompson, LU Ward, WE TI Depression and Psychiatric Disorders SO OPTIMIZING WOMENS HEALTH THROUGH NUTRITION LA English DT Article; Book Chapter ID STRUCTURAL BRAIN CHANGES; ESSENTIAL FATTY-ACIDS; EICOSAPENTAENOIC ACID; DOUBLE-BLIND; VITAMIN SUPPLEMENTATION; SCHIZOPHRENIC-PATIENTS; PHOSPHOLIPID TURNOVER; SEAFOOD CONSUMPTION; ECOLOGICAL ANALYSIS; SYMPTOM REMISSION C1 [Borba, Christina P. C.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Henderson, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Freedom Trail Clin, Boston, MA USA. RP Borba, CPC (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. NR 71 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-4300-6 PY 2008 BP 383 EP 394 PG 12 WC Public, Environmental & Occupational Health; Nutrition & Dietetics; Women's Studies SC Public, Environmental & Occupational Health; Nutrition & Dietetics; Women's Studies GA BKU55 UT WOS:000269272700016 ER PT J AU Smullin, SE Faquin, W Susarla, SM Kaban, LB AF Smullin, Steven E. Faquin, William Susarla, Srinivas M. Kaban, Leonard B. TI Peripheral desmoplastic ameloblastoma: report of a case and literature review SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY LA English DT Review AB The desmoplastic variant of ameloblastoma is a rare, locally invasive, benign tumor of the jaws, typically found in the anterior regions of the maxilla and mandible. This ameloblastoma variant has been described as an intraosseous tumor; to our knowledge, there have been no published cases of a peripheral desmoplastic ameloblastoma. The purpose of this case report is to describe a patient with a desmoplastic ameloblastoma localized to the soft tissue of the palate with no osseous involvement. C1 [Kaban, Leonard B.] Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA. [Faquin, William] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Kaban, LB (reprint author), Harvard Univ, Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,Warren 1201, Boston, MA 02115 USA. EM lkaban@partners.org OI Susarla, Srinivas/0000-0003-0155-8260 NR 14 TC 8 Z9 10 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD JAN PY 2008 VL 105 IS 1 BP 37 EP 40 DI 10.1016/j.tripleo.2007.04.012 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 248ZY UT WOS:000252197200008 PM 17764981 ER PT B AU Delmonico, FL AF Delmonico, Francis L. BE Weimar, W Bos, MA Busschbach, JJ TI Transplant tourism and organ trafficking, an American perspective SO ORGAN TRANSPLANTATION: ETHICAL, LEGAL AND PSYCHOSOCIAL ASPECTS - TOWARDS A COMMON EUROPEAN POLICY LA English DT Proceedings Paper CT International Congress on Organ Transplantation - Ethical, Legal and Psychosocial Aspects CY APR 01-04, 2007 CL Rotterdam, NETHERLANDS SP European Commiss, Dutch Transplant Fdn, Hlth Council Netherlands, Erasmus Med Ctr AB The extent of organ sales from living vendors has now become apparent to the international transplant community. Despite the growing market for body parts and products, there remains a strong societal taboo not only against buying solid organs from living people but also against buying and selling dead bodies or certain parts of dead bodies, including solid organs. These reasons hold even though a few analysts argue that it would be cost effective to pay individuals as much as $90,000 to provide a kidney for transplantation. This article argues against such a regulated market for organ sales. Instead, The Transplantation Society in partnership with the International Society of Nephrology now seeks to convene an international conference that would derive a consensus of practice that employs acceptable incentives for organ donation and yet sustains the dignity of the human person. These incentives would prohibit cash payments but provide benefits that address donor needs and improve the quality of life of the living donor. C1 [Delmonico, Francis L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PABST SCIENCE PUBLISHERS PI D-49525 LENGERICH PA EICHENGRUND 28, D-49525 LENGERICH, GERMANY BN 978-3-89967-415-6 PY 2008 BP 29 EP 31 PG 3 WC Health Policy & Services; Law; Medicine, Research & Experimental; Social Sciences, Biomedical SC Health Care Sciences & Services; Government & Law; Research & Experimental Medicine; Biomedical Social Sciences GA BHT50 UT WOS:000256225000002 ER PT B AU Myaskovsky, L Switzer, GE Mor, MK Ramkumar, M Shapiro, R Dew, MA AF Myaskovsky, Larissa Switzer, Galen E. Mor, Maria K. Ramkumar, Mohan Shapiro, Ron Dew, Mary Amanda BE Weimar, W Bos, MA Busschbach, JJ TI Cultural factors related to race differences in preference for living donor kidney transplantation SO ORGAN TRANSPLANTATION: ETHICAL, LEGAL AND PSYCHOSOCIAL ASPECTS - TOWARDS A COMMON EUROPEAN POLICY LA English DT Proceedings Paper CT International Congress on Organ Transplantation - Ethical, Legal and Psychosocial Aspects CY APR 01-04, 2007 CL Rotterdam, NETHERLANDS SP European Commiss, Dutch Transplant Fdn, Hlth Council Netherlands, Erasmus Med Ctr ID RENAL-TRANSPLANTATION; AFRICAN-AMERICANS; CONSPIRACY BELIEFS; RACIAL-DIFFERENCES; ORGAN DONATION; HEALTH; DISPARITIES; ATTITUDES; ACCESS; CARE AB Living donor kidney transplantation (LDKT) is the optimum treatment for patients with end-stage renal disease (ESRD). In the United States, African Americans (AAs) are less than half as likely to be referred for or undergo LDKT as white patients. This study examined how cultural factors (perceptions of discrimination and racism, medical mistrust) and transplant knowledge are related to race differences in transplant preference. Questionnaires were completed by 36 patients awaiting kidney transplantation. Results indicated that AA patients in this sample had less transplant knowledge than white patients. AAs reported more experiences of discrimination and perceived more racism in health-care settings than whites. AA and white patients did not differ on medical mistrust. Patients who experienced more discrimination in health-care settings were less willing to ask someone to be a living donor for them. Results indicate that previous experience of discrimination may contribute to race disparities in kidney transplantation. C1 [Myaskovsky, Larissa; Switzer, Galen E.; Mor, Maria K.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 38 TC 1 Z9 1 U1 0 U2 0 PU PABST SCIENCE PUBLISHERS PI D-49525 LENGERICH PA EICHENGRUND 28, D-49525 LENGERICH, GERMANY BN 978-3-89967-415-6 PY 2008 BP 366 EP 376 PG 11 WC Health Policy & Services; Law; Medicine, Research & Experimental; Social Sciences, Biomedical SC Health Care Sciences & Services; Government & Law; Research & Experimental Medicine; Biomedical Social Sciences GA BHT50 UT WOS:000256225000047 ER PT J AU Merchant, SN Durand, ML Adams, JC AF Merchant, Saumil N. Durand, Marlene L. Adams, Joe C. TI Sudden deafness: Is it viral? SO ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES LA English DT Article DE sudden deafness; sensorineural hearing loss; etiology; pathology; pathogenesis; viral infection ID SENSORINEURAL HEARING-LOSS; VIRUS-INDUCED LABYRINTHITIS; BLIND CLINICAL-TRIAL; INNER-EAR DISORDERS; HUMAN TEMPORAL BONE; ASYMPTOMATIC MUMPS; MEMBRANE RUPTURES; GUINEA-PIGS; INFECTION; COCHLEAR AB A number of theories have been proposed to explain the etiopathogenesis of idiopathic sudden sensorineural hearing loss (ISSHL), including viral infection, vascular occlusion, breaks of labyrinthine membranes, immune-mediated mechanisms and abnormal cellular stress responses within the cochlea. In the present paper, we provide a critical review of the viral hypothesis of ISSHL. The evidence reviewed includes published reports of epidemiological and serological studies, clinical observations and results of antiviral therapy, morphological and histopathological studies, as well as results of animal experiments. The published evidence does not satisfy the majority of the Henle-Koch postulates for viral causation of an infectious disease. Possible explanations as to why these postulates remain unfulfilled are reviewed, and future studies that may provide more insight are described. We also discuss other mechanisms that have been postulated to explain ISSHL. Our review indicates that vascular occlusion, labyrinthine membrane breaks and immune-mediated mechanisms are unlikely to be common causes of ISSHL. Finally, we review our recently proposed theory that abnormal cellular stress responses within the cochlea may be responsible for ISSHL. Copyright (c) 2008 S. Karger AG, Basel. C1 [Merchant, Saumil N.; Adams, Joe C.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Eye & Ear Infirm, Infect Dis Unit, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Adams, Joe C.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Durand, Marlene L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Merchant, SN (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM saumil_merchant@meei.harvard.edu FU NIDCD NIH HHS [U24 DC008559, U24 DC008559-02] NR 76 TC 71 Z9 80 U1 1 U2 11 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-1569 J9 ORL J OTO-RHINO-LARY JI ORL-J. Oto-Rhino-Laryngol. Relat. Spec. PY 2008 VL 70 IS 1 BP 52 EP 60 DI 10.1159/000111048 PG 9 WC Otorhinolaryngology SC Otorhinolaryngology GA 262SD UT WOS:000253167400014 PM 18235206 ER PT J AU Provot, S Schipani, E Wu, J Kronenberg, H AF Provot, Sylvain Schipani, Ernestina Wu, Joy Kronenberg, Henry BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Development of the Skeleton SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID COLONY-STIMULATING FACTOR; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; GROWTH-FACTOR RECEPTOR; ENDOCHONDRAL BONE-FORMATION; TRANSCRIPTION FACTOR PU.1; SAETHRE-CHOTZEN SYNDROME; NECROSIS-FACTOR RECEPTOR; HORMONE-RELATED PEPTIDE; TGF-BETA-SUPERFAMILY; NF-KAPPA-B C1 [Provot, Sylvain; Schipani, Ernestina; Wu, Joy; Kronenberg, Henry] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Provot, Sylvain; Schipani, Ernestina; Wu, Joy; Kronenberg, Henry] Harvard Univ, Sch Med, Boston, MA USA. RP Provot, S (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. NR 216 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 241 EP 269 PG 29 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400011 ER PT J AU Nissenson, RA AF Nissenson, Robert A. BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Parathyroid Hormone and Parathyroid Hormone-Related Protein SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID (PTH)/PTH-RELATED PEPTIDE RECEPTOR; OSTEOBLAST-LIKE CELLS; OPOSSUM KIDNEY-CELLS; PTH-RELATED-PROTEIN; VASCULAR SMOOTH-MUSCLE; KAPPA-B LIGAND; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; MESSENGER-RIBONUCLEIC-ACID; CARBOXYL-TERMINAL REGION; 25-HYDROXYVITAMIN D-3 1-ALPHA-HYDROXYLASE C1 [Nissenson, Robert A.] Univ Calif San Francisco, Endocrine Unit, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Nissenson, Robert A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Nissenson, Robert A.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA. RP Nissenson, RA (reprint author), Univ Calif San Francisco, Endocrine Unit, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. NR 488 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 283 EP 316 PG 34 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400013 ER PT J AU Wiren, KM AF Wiren, Kristine M. BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Androgens and Skeletal Biology: Basic Mechanisms SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID BONE-MINERAL DENSITY; OSTEOBLAST-LIKE CELLS; GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; MESSENGER-RIBONUCLEIC-ACID; THYROID-HORMONE RECEPTOR; GENITAL SKIN FIBROBLASTS; AGED MALE-RATS; OVARIECTOMIZED RATS; CORTICAL BONE C1 [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Wiren, Kristine M.] Portland VA Med Ctr, Portland, OR USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. OI Wiren, Kristine/0000-0002-6159-4450 NR 197 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 425 EP 449 PG 25 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400016 ER PT J AU Orwoll, ES Klein, RF AF Orwoll, Eric S. Klein, Robert F. BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID BONE-MINERAL DENSITY; AGE-RELATED-CHANGES; HIP FRACTURE INCIDENCE; GROWTH-FACTOR-I; EUROPEAN VERTEBRAL OSTEOPOROSIS; ANDROGEN-INSENSITIVITY SYNDROME; MEDULLARY SPONGE KIDNEY; X-RAY ABSORPTIOMETRY; LEAN BODY-MASS; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM C1 [Orwoll, Eric S.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA. [Orwoll, Eric S.; Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA. RP Orwoll, ES (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA. NR 484 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 1055 EP 1094 PG 40 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400043 ER PT J AU Halloran, B Bikle, DD AF Halloran, Bernard Bikle, Daniel D. BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Mechanisms of Immobilization-Induced Bone Loss SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID GROWTH-FACTOR-I; SIGNAL-TRANSDUCTION PATHWAYS; FLUID-FLOW; INTEGRIN EXPRESSION; PARATHYROID-HORMONE; GENE-EXPRESSION; SIMULATED WEIGHTLESSNESS; OSTEOPROGENITOR CELLS; STRAIN MAGNITUDE; GROWING RATS C1 [Halloran, Bernard] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Bikle, Daniel D.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. RP Halloran, B (reprint author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA. NR 69 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 1177 EP 1185 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400047 ER PT J AU Bikle, DD AF Bikle, Daniel D. BE Marcus, R Feldman, D Nelson, DA Rosen, CJ TI Osteoporosis in Gastrointestinal, Pancreatic, and Hepatic Diseases SO OSTEOPOROSIS, VOLS I AND II, 3RD EDITION LA English DT Article; Book Chapter ID PRIMARY BILIARY-CIRRHOSIS; METABOLIC BONE-DISEASE; TOTAL PARENTERAL-NUTRITION; VITAMIN-D METABOLITES; INFLAMMATORY-BOWEL-DISEASE; INTESTINAL CALCIUM-ABSORPTION; CHOLESTATIC LIVER-DISEASE; GLUTEN-FREE DIET; LACTASE-DEFICIENT SUBJECTS; ADULT CELIAC-DISEASE C1 San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. RP Bikle, DD (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. NR 255 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055347-4 PY 2008 BP 1203 EP 1226 PG 24 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BDH03 UT WOS:000313195400050 ER PT J AU Goldstein, NA Stewart, MG Witsell, DL Hannley, MT Weaver, EM Yueh, B Smith, TL Orvidas, LJ AF Goldstein, Nira A. Stewart, Michael G. Witsell, David L. Hannley, Maureen T. Weaver, Edward M. Yueh, Bevan Smith, Timothy L. Orvidas, Laura J. CA Treat Study Investigators TI Quality of life after tonsillectomy in children with recurrent tonsillitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT 110th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation CY SEP 17-20, 2006 CL Toronto, CANADA SP Amer Acad Otolaryngol Head & Neck Surg Fdn ID OBSTRUCTIVE SLEEP-APNEA; ADENOID DISEASE; ADENOTONSILLECTOMY; DISORDERS; BEHAVIOR; HEALTH AB OBJECTIVE: To describe changes in disease-specific and global quality of life (QOL) for children with recurrent or chronic tonsillitis at 6 months and 1 year after tonsillectomy using two validated instruments, the Tonsil and Adenoid Health Status Instrument (TAHSI) and the Child Health Questionaire-PF28 (CHQ-PF28). STUDY DESIGN AND SETTING: A multicenter, prospective observational outcomes study. RESULTS: Ninety-two children, mean age (SD) 10.6 (3.4) years, enrolled with follow-up available for 58 children at 6 months and 38 children at 1 year. The children showed significant improvements in all subscales of the TAHSI including airway and breathing, infection, health care utilization, cost of care, eating and swallowing (all P < 0.001), and behavior (P = 0.01). Significant improvements were also found on several subscales of the CHQ-PF28, such as general health perceptions, physical functioning, parental impact, and family activities (all P < 0.001). CONCLUSION/SIGNIFICANCE: This uncontrolled study provides prospective evidence of improved disease-specific and global QOL in children after tonsillectomy. (c) 2008 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Goldstein, Nira A.] Suny Downstate Med Ctr, Dept Otolaryngol, Div Pediatr Otolaryngol, Brooklyn, NY 11203 USA. [Stewart, Michael G.] Weill Cornell Med Coll, Dept Otorhinolaryngol, New York, NY USA. [Witsell, David L.] Duke Univ, Sch Med, Dept Surg, Div Otolaryngol Head & Neck Surg, Durham, NC 27706 USA. [Weaver, Edward M.; Yueh, Bevan] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Witsell, David L.; Hannley, Maureen T.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Orvidas, Laura J.] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN USA. RP Goldstein, NA (reprint author), Suny Downstate Med Ctr, Dept Otolaryngol, Div Pediatr Otolaryngol, 450 Clarkson Ave,Box 126, Brooklyn, NY 11203 USA. EM ngoldstein@downstate.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NHLBI NIH HHS [R01 HL084139, K23 HL068849] NR 20 TC 25 Z9 27 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2008 VL 138 IS 1 SU S BP S9 EP S16 DI 10.1016/j.otohns.2006.12.029 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 251RW UT WOS:000252392600002 PM 18164376 ER PT J AU Witsell, DL Orvidas, LJ Stewart, MG Hannley, MT Weaver, EM Yueh, B Smith, TL Goldstein, NA AF Witsell, David L. Orvidas, Laura J. Stewart, Michael G. Hannley, Maureen T. Weaver, Edward M. Yueh, Bevan Smith, Timothy L. Goldstein, Nira A. CA Treat Study Investigators TI Quality of life after tonsillectomy in adults with recurrent or chronic tonsillitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT 110th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation CY SEP 17-20, 2006 CL Toronto, CANADA SP Amer Acad Otolaryngol Head & Neck Surg Fdn ID VALIDATION; EFFICACY; BENEFIT; THROAT; NOSE AB OBJECTIVE: To describe changes in disease-specific and global quality of life (QOL) for adults with recurrent or chronic tonsillitis at 6 months and I year after tonsillectomy using two instruments: the Tonsil and Adenoid Health Status Instrument (TAHSI) and the SF-12 Health Survey (12-item short form of SF-36 Health Survey). STUDY DESIGN AND SETTING: Multicenter, prospective observational outcomes study. RESULTS: Seventy-two adults, mean age 28.0 years (SD 7.2 years), were enrolled with follow-up available for 42 adults at 6 months and for 40 adults at 1 year. Patients showed significant improvements in all six subscales of the TAHSI: airway and breathing, infection, health care utilization, cost of care, eating and swallowing, and behavior (all P < 0.0001). Significant improvements were also found in the physical functioning subscale of the SF-12 at 1 year. CONCLUSION: After tonsillectomy for recurrent and chronic tonsillitis, we found large improvements in disease-specific and global QOL. SIGNIFICANCE: Most prior studies on tonsillectomy for recurrent tonsillitis have assessed only the frequency of infections as an outcome measure. This study describes the changes in QOL measured in our cohort of reporting adults after tonsillectomy for chronic or recurrent tonsillitis. This study provides prospective evidence of the effectiveness of tonsillectomy on adult QOL. (c) 2008 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Witsell, David L.] Duke Univ, Sch Med, Dept Surg, Div Otolaryngol Head & Neck Surg, Durham, NC 27706 USA. [Witsell, David L.; Hannley, Maureen T.] Amer Acad Otolaryngol Head & Neck Surg Fdn, Alexandria, VA USA. [Orvidas, Laura J.] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN USA. [Stewart, Michael G.] Weill Cornell Med Coll, Dept Otorhinolaryngol, New York, NY USA. [Weaver, Edward M.; Yueh, Bevan] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Goldstein, Nira A.] Suny Downstate Med Ctr, Div Pediat Otolaryngol, New York, NY USA. [Weaver, Edward M.; Yueh, Bevan] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Witsell, DL (reprint author), Duke Univ, Sch Med, Dept Surg, Div Otolaryngol Head & Neck Surg, Durham, NC 27706 USA. EM david.witsell@duke.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NHLBI NIH HHS [K23 HL068849, R01 HL084139] NR 11 TC 18 Z9 18 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2008 VL 138 IS 1 SU S BP S1 EP S8 DI 10.1016/j.otohns.2007.08.015 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 251RW UT WOS:000252392600001 PM 18164373 ER PT J AU Grant, PE Gallagher, J Gonzalez, RG Borsook, D AF Grant, P. Ellen Gallagher, Joan Gonzalez, R. Gilberto Borsook, David TI Adriamycin injection into the medial cord of the brachial plexus: Computed tomography-guided targeted pain therapy SO PAIN MEDICINE LA English Estonian DT Editorial Material DE cancer pain; neuropathic pain; treatment; interventional therapy ID DORSAL-ROOT-GANGLIA; SUBSTANCE-P RECEPTOR; SENSORY GANGLIONECTOMY; NEURONS; RATS AB Recent advances in radiographic imaging technology allow for therapeutic agents to be placed within the subepineurium of peripheral nerve tissue. Adriamycin, a chemotherapeutic agent, is retrogradely transported by nerves to their cell bodies residing in the dorsal root ganglia. The combined process of radiological approach, an understanding of the anatomy of the brachial nerve plexus, and the use of agents that are retrogradely transported by nerves allows for targeted neuroablation of nerves. Advantages of this allow for the use of very small volumes of even toxic drugs, the volume of which allows for safe administration. Here, we report on the transcutaneous computed tomography (CT)-guided injection of adriamycin into specific branches of the brachial plexus in a patient with metastatic cervical cancer involving the lower plexus whose pain was untreatable by aggressive medical therapy that included epidural trials of opioids. Identification of the medial brachial cord was achieved using CT-guided techniques that included accurate localization with intra-neural dye injection, followed by injection of 0.5 mg of adriamycin. The patient reported complete pain relief within 12 h of the injection. C1 [Grant, P. Ellen; Gonzalez, R. Gilberto; Borsook, David] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Gallagher, Joan] Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA. RP Borsook, D (reprint author), McLean Hosp, Brain Imaging Ctr, PAIN Grp, 115 Mill St, Belmont, MA 02478 USA. EM dborsook@mclean.harvard.edu NR 24 TC 3 Z9 9 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD JAN-FEB PY 2008 VL 9 IS 1 BP 83 EP 87 DI 10.1111/j.1526-4637.2006.00139.x PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 257QR UT WOS:000252814100012 PM 18254771 ER PT J AU Shear, T Ahmed, SU AF Shear, Torin Ahmed, Shihab U. TI Epidural Blood Patch for Chronic Daily Headache with Postural Component: A Case Report and the Review of Published Cases SO PAIN PHYSICIAN LA English DT Article DE Post-dural puncture headache; postural headache; chronic daily headache; epidural blood patch ID POSTDURAL PUNCTURE HEADACHE; NEVER TOO LATE; INTRACRANIAL HYPOTENSION AB Post dural puncture headache (PDPH) can be observed after any trauma to the dura. The hallmark of PDPH is an increasing headache when assuming the upright position and improvement with the supine position. Diagnosis of PDPH is essentially based on history of dural puncture and clinical presentation. In most cases, if initial conservative therapies fail to provide the relief of symptoms, an epidural blood patch is the therapy of choice. Epidural blood patch is a safe and effective treatment for PDPH and routinely done for acute onset of postural headache after spinal or epidural anesthesia or analgesia. Here, we report the successful treatment of chronic daily headache with a postural component via an epidural blood patch one year after the onset. We also review the literature pertinent to the use of epidural blood patch in chronic daily headache patients with postural component. C1 [Shear, Torin; Ahmed, Shihab U.] Massachusetts Gen Hosp, MGH Pain Ctr, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Shear, T (reprint author), Massachusetts Gen Hosp, MGH Pain Ctr, Dept Anesthesia & Crit Care, WACC 324,15 Parkman St, Boston, MA 02114 USA. EM sahmed@partners.org NR 15 TC 3 Z9 5 U1 0 U2 0 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD JAN PY 2008 VL 11 IS 1 BP 77 EP 80 PG 4 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 374OI UT WOS:000261053200007 PM 18196172 ER PT J AU Hara, H Lin, YJ Zhu, XC Tai, HC Ezzelarab, M Balamurugan, AN Bottino, R Houser, SL Cooper, DKC AF Hara, Hidetaka Lin, Yih Jyh Zhu, Xiaocheng Tai, Hao-Chih Ezzelarab, Mohamed Balamurugan, A. N. Bottino, Rita Houser, Stuart L. Cooper, David K. C. TI Safe induction of diabetes by high-dose streptozotocin in pigs SO PANCREAS LA English DT Article DE diabetes induction; porcine C-peptide; streptozotocin; pig ID ISLET TRANSPLANTATION; CYNOMOLGUS MONKEYS; CELLS; MELLITUS; MODEL AB Objectives: Streptozotocin (STZ) has been widely used to induce diabetes in rodents and nonhuman primates, but it has been found difficult to achieve a completely diabetic state in pigs in the absence of detrimental side effects. As a result, pancreatectomy has been advocated in this species. We have investigated the effects of 2 dosages of STZ to safely induce diabetes in pigs. Methods: Three pigs received Zanosar STZ at 150 mg/kg (group 1). Four pigs received Zanosar STZ at 200 mg/kg ( group 2). The levels of glucose, insulin, and C-peptide when (a) fasting, (b) 30 minutes after eating, and (c) during intravenous glucose tolerance tests (IVGTTs) were measured in all pigs for 4 weeks after STZ injection. To confirm how long the diabetic state can be maintained after induction with STZ, levels were measured for 20 weeks in group 2. Results: One to 4 weeks after STZ administration, in group 1 (150 mg/kg) pigs, insulin and C-peptide levels were detected up to 7 mu IU/mL and 0.4 ng/mL, respectively, both when fasting and after a meal test or IVGTT, indicating that the pigs had failed to become fully diabetic. In group 2 (200 mg/kg) pigs, insulin and C-peptide levels were less than the 2 mu IU/mL and 0.25 ng/mL respective detection levels and did not increase after a meal test or IVGTT. Group 2 remained completely diabetic for the entire 20-week period of follow-up, without STZ-related hepatic or renal dysfunction. Conclusions: High-dose (200 mg/kg) Zanosar STZ induces diabetes safely and completely in pigs without side effects. Pancreatectomy can, therefore, be avoided. C1 [Hara, Hidetaka; Lin, Yih Jyh; Zhu, Xiaocheng; Tai, Hao-Chih; Ezzelarab, Mohamed; Balamurugan, A. N.; Cooper, David K. C.] Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA 15261 USA. [Balamurugan, A. N.; Bottino, Rita] Univ Pittsburgh, Med Ctr, Dept Pediat, Div Immunogenet, Pittsburgh, PA 15261 USA. [Houser, Stuart L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. RP Cooper, DKC (reprint author), Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Surg, Starzl Biomed Sci Tower,W1540,200 Lothrop St, Pittsburgh, PA 15261 USA. EM cooperdk@upmc.edu OI Ezzelarab, Mohamed/0000-0002-3919-5250 NR 25 TC 18 Z9 21 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD JAN PY 2008 VL 36 IS 1 BP 31 EP 38 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 282TH UT WOS:000254589600005 PM 18192878 ER PT J AU Pitman, MB Michaels, PJ Deshpande, V Brugge, WR Bounds, BC AF Pitman, Martha Bishop Michaels, Paul J. Deshpande, Vikram Brugge, William R. Bounds, Brenna C. TI Cytological and cyst fluid analysis of small (<= 3 cm) branch duct intraductal papillary mucinous neoplasms adds value to patient management decisions SO PANCREATOLOGY LA English DT Article DE endoscopic ultrasound; fine-needle aspiration biopsy; pancreas; intraductal papillary mucinous neoplasm; branch duct ID DIFFERENTIAL-DIAGNOSIS; SURGICAL-MANAGEMENT; PANCREATIC LESIONS; UPDATED EXPERIENCE; TUMORS; FEATURES; CLASSIFICATION; PREDICTOR; PROGNOSIS; SURVIVAL AB Background/Aim: Management of patients with small (1-3 cm) branch duct intraductal papillary mucinous neoplasms (IPMN) is a challenge. Symptoms, dilated duct, mural nodule or positive cytology have been proposed as parameters for resection. The aim of our study was to compare this proposed algorithm to one that incorporates cytology with less than malignant epithelial cells and cyst fluid carcinoembryonic antigen (CEA). Methods: A retrospective study was conducted. Results: There were 14 nonmalignant and 6 malignant cysts with 3 invasive IPMN. None were associated with a dilated duct and none had positive cytology. Only a mural nodule was significant by univariate analysis for the detection of malignancy (p = 0.01) and invasion (p = 0.009). The detection of atypical epithelial cells or a cyst fluid CEA of 1 2,500 ng/ml was more accurate for the detection of malignancy than using the recommended algorithm. Conclusions: The presence of a mural nodule in a small branch duct IPMN is a predictor of malignancy and invasion by univariate analysis. Recognition of an atypical epithelial cell component in contrast to positive cytology or a cyst fluid CEA of 1 2,500 ng/ml is more accurate than the recommended algorithm and adds value to the preoperative assessment of clinically diagnosed small branch duct IPMN. Copyright (c) 2008 S. Karger AG, Basel and IAP. C1 [Pitman, Martha Bishop; Deshpande, Vikram] Harvard Univ, Dept Pathol, Massachusetts Gen Hosp, Sch Med,James Homer Wright Pathol Labs, Boston, MA 02114 USA. [Pitman, Martha Bishop; Deshpande, Vikram] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cytopathol Lab, Boston, MA 02114 USA. [Brugge, William R.; Bounds, Brenna C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Michaels, Paul J.] Lab Med Consultants, Las Vegas, NV USA. RP Pitman, MB (reprint author), Harvard Univ, Dept Pathol, Massachusetts Gen Hosp, Sch Med,James Homer Wright Pathol Labs, Warren 105-D,55 Fruit St, Boston, MA 02114 USA. EM mpitman@partners.org NR 26 TC 61 Z9 61 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2008 VL 8 IS 3 BP 277 EP 284 DI 10.1159/000134276 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 335VD UT WOS:000258318700011 PM 18497541 ER PT J AU Cheng, EM Siderowf, AD Swarztrauber, K Lee, M Vassar, S Jacob, E Eisa, MS Vickrey, BG AF Cheng, E. M. Siderowf, A. D. Swarztrauber, K. Lee, M. Vassar, S. Jacob, E. Eisa, M. S. Vickrey, B. G. TI Disparities of care in veterans with Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; disparities; quality indicators; quality of care ID QUALITY-OF-LIFE; STANDARDS SUBCOMMITTEE; PRACTICE PARAMETER; OLDER PATIENTS; HEALTH; DEPRESSION; AMERICAN; VARIABLES; NEUROLOGY; ACCESS AB Background: Disparities of Parkinson's disease (PD) care have not been assessed. Methods: We examined the medical records of 309 (83%) non-Hispanic White and 65 (17%) non-White Los Angeles veterans with PD from 1998 to 2004 to determine if care quality as measured by 10 PD indicators different by race/ethnicity. Results: In multivariate modeling, adherence to indicators was higher among non-Hispanic Whites (71% vs. 65%, risk ratio 1.15, 95% CI [1.07-1.32]) compared to non-Whites. Differences in adherence by race/ethnicity were greatest for depression treatment (P<0.05). Conclusions: We detected disparities in quality of PD care, particularly in depression treatment. Future research should determine causes for these so that interventions can be designed to reduce such disparities. Published by Elsevier Ltd. C1 [Cheng, E. M.; Vassar, S.; Jacob, E.; Vickrey, B. G.] VA Greater Los Angeles Healthcare Syst, PADRECC, Los Angeles, CA 90073 USA. [Cheng, E. M.; Vassar, S.; Vickrey, B. G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Siderowf, A. D.] Philadelphia VA Med Ctr, PADRECC, Philadelphia, PA USA. [Siderowf, A. D.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Swarztrauber, K.] Providence Hlth Syst, Providence Med Grp, Newberg, OR USA. [Lee, M.] VA Greater Los Angeles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Lee, M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Eisa, M. S.] Neurol Neurosurg & Spine Clin S Georgia, Valdosta, GA USA. RP Cheng, EM (reprint author), VA Greater Los Angeles Healthcare Syst, PADRECC, 11301 Wilshire Blvd,B500,ML 127, Los Angeles, CA 90073 USA. EM Eric.Cheng@va.gov FU NIMHD NIH HHS [P20 MD000148, P20MD000182, P20MD000148] NR 33 TC 12 Z9 12 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PY 2008 VL 14 IS 1 BP 8 EP 14 DI 10.1016/j.parkreldis.2007.05.001 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 270VG UT WOS:000253747700002 PM 17702625 ER PT J AU Hecht, JL Allred, EN Kliman, HJ Zambrano, E Doss, BJ Husain, A Pflueger, SMV Chang, CH Livasy, CA Roberts, D Bhan, I Ross, DW Senagore, PK Leviton, A AF Hecht, Jonathan L. Allred, Elizabeth N. Kliman, Harvey J. Zambrano, Eduardo Doss, Barbara J. Husain, Aliya Pflueger, Solveig M. V. Chang, Chung-Ho Livasy, Chad A. Roberts, Drucilla Bhan, Ina Ross, Dennis W. Senagore, Patricia Kaman Leviton, Alan CA ELGAN Study Investigators TI Histological characteristics of singleton placentas delivered before the 28th week of gestation SO PATHOLOGY LA English DT Article DE chorioamnionitis; prematurity; placenta; histology ID LOW-BIRTH-WEIGHT; PRETERM DELIVERY; CHORIOAMNIONITIS; INFLAMMATION; INFECTION; TERM; MEMBRANES; FEATURES AB Aims: The placenta is a record of the fetal environment and its examination may provide information about the baby's subsequent growth and development. We describe the histological characteristics of 947 singleton placentas from infants born between 23 and 27 weeks gestation. Methods: Consent was obtained from mothers who delivered before 28 weeks (clinical estimate). We evaluated the gross and histopathological features of the placenta and assessed pair-wise correlations between variables. Results: Lesions of uteroplacental circulation (abruption, extensive infarction or thrombosis, marked basal or perivillous fibrin deposition, increased syncytial knots) were inversely related to those associated with inflammation of the membranes and cord. Earlier age favoured inflammatory variables, while older age favoured characteristics attributed to impaired blood flow. We observed inflammation of the chorionic plate in 43%, the cord in 19%, and of chorionic plate vessels in 30%. Of the placentas with umbilical cord inflammation, 8% had no inflammation of the chorionic plate. Conclusions: This study population is unique in its size and recruitment by gestational age rather than birth weight. Inflammation occurred frequently, but not in placentas that had characteristics of vasculopathy. The prevalence of inflammation decreased with increasing gestational age, while vasculopathy increased. Funisitis need not be accompanied by chorionic inflammation. C1 [Hecht, Jonathan L.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02118 USA. [Allred, Elizabeth N.; Leviton, Alan] Childrens Hosp, Neuroepidemiol Unit, Boston, MA 02115 USA. [Kliman, Harvey J.] Yale Univ, Sch Med, Pediat & Dev Pathol Program, Reprod & Placental Res Unit, New Haven, CT USA. [Zambrano, Eduardo] Yale Univ, Sch Med, Pediat & Dev Pathol Program, Dept Obstet & Pathol, New Haven, CT USA. [Doss, Barbara J.] Spectrum Hlth, Dept Pathol, Grand Rapids, MI USA. [Husain, Aliya] Univ Chicago, Chicago, IL 60637 USA. [Pflueger, Solveig M. V.] Baystate Med Ctr, Springfield, MA USA. [Chang, Chung-Ho] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Livasy, Chad A.] Univ N Carolina, Chapel Hill, NC USA. [Roberts, Drucilla] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bhan, Ina] Tufts Univ, Sch Med, New England Med Ctr, Boston, MA 02111 USA. [Ross, Dennis W.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Senagore, Patricia Kaman] Michigan State Univ, E Lansing, MI 48824 USA. RP Hecht, JL (reprint author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02118 USA. EM jlhecht@bidmc.harvard.edu FU NINDS NIH HHS [1 U01 NS 40069-01A2, U01 NS040069, U01 NS040069-01A2] NR 20 TC 42 Z9 42 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0031-3025 J9 PATHOLOGY JI Pathology PY 2008 VL 40 IS 4 BP 372 EP 376 DI 10.1080/00313020802035865 PG 5 WC Pathology SC Pathology GA 294WA UT WOS:000255435800006 PM 18446627 ER PT J AU Cote, CJ AF Cote, Charles J. TI Round and round we go: sedation - what is it, who does it, and have we made things safer for children? SO PEDIATRIC ANESTHESIA LA English DT Editorial Material ID THERAPEUTIC PROCEDURES; PEDIATRIC SEDATION; INTRAMUSCULAR KETAMINE; PROCEDURAL SEDATION; ADVERSE SEDATION; NITROUS-OXIDE; DEEP SEDATION; GUIDELINES; EVENTS; MANAGEMENT C1 [Cote, Charles J.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Cote, Charles J.] Massachusetts Gen Hosp, Div Pediat Anesthesia, Boston, MA 02114 USA. RP Cote, CJ (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. NR 33 TC 11 Z9 11 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1155-5645 J9 PEDIATR ANESTH JI Pediatr. Anesth. PD JAN PY 2008 VL 18 IS 1 BP 3 EP 8 DI 10.1111/j.1460-9592.2007.02403.x PG 6 WC Anesthesiology; Pediatrics SC Anesthesiology; Pediatrics GA 239YR UT WOS:000251554700002 PM 18095957 ER PT J AU Mertens, AC Sencer, S Myers, CD Recklitis, C Kadan-Lottick, N Whitton, J Marina, N Robison, LL Zeltzer, L AF Mertens, Ann C. Sencer, Susan Myers, Cynthia D. Recklitis, Christopher Kadan-Lottick, Nina Whitton, John Marina, Neyssa Robison, Leslie L. Zeltzer, Lonnie TI Complementary and alternative therapy use in adult survivors of childhood cancer: A report from the childhood cancer survivor study SO PEDIATRIC BLOOD & CANCER LA English DT Article DE alternative medicine; late effects; long-term survival ID PEDIATRIC ONCOLOGY PATIENTS; MEDICINE USE; 5-YEAR SURVIVORS; UNITED-STATES; HEALTH-CARE; PREVALENCE; CHILDREN; BEHAVIORS; LEUKEMIA AB Background. Little information is available on the use of complementary and alternative medicine (CAM) in long-term survivors of childhood and adolescent cancer. Procedure. The Childhood Cancer Survivor Study (CCSS) is a resource evaluating the long-term effects of cancer and associated therapies in 5-year survivors of childhood and adolescent cancer diagnosed between 1970 and 1986 before the age of 21 years. A survey of CAM use during the previous year was distributed in 2000-2001 and completed by 9,984 survivors and 2,474 sibling controls. Results. CAM use reporting was similar in cases (39.4%) and siblings (41.1 %). Compared to female siblings, female survivors were more likely to use biofeedback (odds ratio (OR) = 3.3; 95% CI = 1.0-10.8) and hypnosis/guided imagery (OR = 3.2; 95% CI = 1.6-6.8); male survivors were more likely than male siblings to use herbal remedies (OR = 1.3; 95% CI = 1.1 -1.6). Factors associated with CAM use in survivors included elevated scores on the brief symptom inventory (BSI)-18 (OR= 1.6; 95% Cl = 1.3-1.9), prolonged pain (OR = 1.5; 95% CI = 1.3-1.7), and having seen a physician in the past 2 years (OR=1.6; 95% CI = 1.4-1.8). Survivors reporting low alcohol intake and excellent or good general health reported lower levels of CAM use (OR=0.7; 95% CI=0.7-0.8 and OR=0.8; 95% CI=0.7-0.9, respectively). Conclusions. Survivors have a similar reported use of CAM compared to a sibling cohort. However, our data suggest that survivors turn to CAM for specific symptoms related to previous diagnosis and treatment. Future research is needed to determine whether CAM use reflects unmet health needs in this population. C1 Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. Childrens Hosp & Clin, Minneapolis, MN USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Univ, New Haven, CT USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Stanford Univ, Palo Alto, CA 94304 USA. St Jude Childrens Hosp, Memphis, TN 38105 USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. RP Mertens, AC (reprint author), Univ Minnesota, Dept Pediat, MMC 715,420 Delaware St SE, Minneapolis, MN 55455 USA. EM mertens@epi.umn.edu OI Zeltzer, Lonnie/0000-0001-9306-9450 FU NCI NIH HHS [U24 CA55727] NR 41 TC 12 Z9 14 U1 2 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD JAN PY 2008 VL 50 IS 1 BP 90 EP 97 DI 10.1002/pbc.21177 PG 8 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 237XT UT WOS:000251410400016 PM 17366533 ER PT J AU Mascarenhas, AK Nazar, H Al-Mutawaa, S Soparkar, P AF Mascarenhas, Ana Karina Nazar, Huda Al-Mutawaa, Sabiha Soparkar, Pramod TI Effectiveness of primer and bond in sealant retention and caries prevention SO PEDIATRIC DENTISTRY LA English DT Article DE sealants; bonding agent; retention; caries; effectiveness ID FISSURE SEALANTS; AGENTS AB Purpose: The purpose of this clinical trial was to test the use of a primer and bonding agent to increase the retention of a fissuresealant in a group of Kuwaiti children. Methods: In 78 6- to 9-year-old children who required sealants in all 4 permanent first molars, sealants were placed in 2 teeth using a primer and bond (3M Scotch Bond) and in 2 teeth without primer and bond. Sealant retention was evaluated I and 2 years later. Sealant retention was scored as: (1) complete retention; (2) partial loss of sealant, and (3) complete loss of sealant. Caries was scored for those teeth in which the sealant was partially or completely lost. Results. At the 2-year examination, in teeth sealed with primer and bond: (a) 64% of the sealants were completely retained,(b) 23% were partially lost, and (c) 13% were completely lost. In teeth sealed without primer and bond: (a) 68% of the sealants were completely retained, (b) 20% were partially lost; and (C) 12% were completely lost There was no difference in sealant retention (P=.22) and caries (P=.56) in teeth sealed with and without bond. In multivariete analyses after controlling for age, gender, tooth surface, and arch, no differences in sealant retention and caries were seen. Conclusion: If a proper technique is used in sealant placement, primer and bond does not enhance sealant retention. C1 [Mascarenhas, Ana Karina] Boston Univ, Sch Dent Med, Div Dent Publ Hlth, Boston, MA 02215 USA. [Nazar, Huda] Al Ahmadi Sch Oral Hlth Program, Kuwait, Al Ahmadi, Kuwait. [Soparkar, Pramod] Forsyth Inst, Boston, MA USA. RP Mascarenhas, AK (reprint author), Boston Univ, Sch Dent Med, Div Dent Publ Hlth, Boston, MA 02215 USA. EM karinam@bu.edu NR 18 TC 8 Z9 8 U1 0 U2 2 PU AMER ACAD PEDIATRIC DENTISTRY PI CHICAGO PA 211 E CHICAGO AVENUE SUITE 1036, CHICAGO, IL 60611-2616 USA SN 0164-1263 J9 PEDIATR DENT JI Pediatr. Dent. PD JAN-FEB PY 2008 VL 30 IS 1 BP 25 EP 28 PG 4 WC Dentistry, Oral Surgery & Medicine; Pediatrics SC Dentistry, Oral Surgery & Medicine; Pediatrics GA 330PH UT WOS:000257954800006 PM 18402095 ER PT J AU Feramisco, JD Casey, RL Tsao, H AF Feramisco, Jamison D. Casey, Rachael L. Tsao, Hensin TI Recent updates on genetics: Teaching old dogmas new tricks SO PEDIATRIC DERMATOLOGY LA English DT Article ID DOUBLE-STRANDED-RNA; X-CHROMOSOME; HUMAN GENOME; MICRORNA EXPRESSION; CAENORHABDITIS-ELEGANS; CUTANEOUS MOSAICISM; MOUSE DEVELOPMENT; ANIMAL MICRORNAS; BLASCHKO LINES; HEART-DISEASE C1 [Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA. [Feramisco, Jamison D.; Casey, Rachael L.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, MGH Canc Ctr, Dept Dermatol, Wellman Ctr Photomed, Bartlett 622,48 Blossom St, Boston, MA 02114 USA. EM htsao@partners.org NR 99 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0736-8046 J9 PEDIATR DERMATOL JI Pediatr. Dermatol. PD JAN-FEB PY 2008 VL 25 IS 1 BP 99 EP 108 DI 10.1111/j.1525-1470.2007.00594.x PG 10 WC Dermatology; Pediatrics SC Dermatology; Pediatrics GA 267BD UT WOS:000253482400023 PM 18304166 ER PT J AU MacDonald, SM Desai, N Heller, G Rolnitzky, L Allen, JC AF MacDonald, Shannon M. Desai, Neal Heller, Gordon Rolnitzky, Linda Allen, Jeffrey C. TI MRI changes in the "NORMAL" pineal gland following chemotherapy for suprasellar germ cell tumors SO PEDIATRIC HEMATOLOGY AND ONCOLOGY LA English DT Article DE germinoma; magnetic resonance imaging; occult disease; pineal gland ID CENTRAL-NERVOUS-SYSTEM; DIABETES-INSIPIDUS; INTRACRANIAL GERMINOMAS; RADIATION-THERAPY; RADIOTHERAPY; CHILDREN; TRIAL AB Primary CNS germ cell tumors (GCT) arise in the suprasellar and pineal regions. Suprasellar GCT may remain radiographically occult during the early symptomatic period. Although theoretically possible, it is more difficult to identify presymptomatic disease in the pineal region. Given the sensitivity of GCT to cytotoxic therapy, a decrease in size of the "normal" pineal gland following chemotherapy (CHT) could divulge preexisting disease. Such information may impact radiation treatment (RT). The authors reviewed MRIs of 15 patients with suprasellar GCT treated with pre-RT CHT. They defined a >= 50% reduction in volume of the pineal gland as a substantial decrease suspicious for preexisting occult disease. As controls, MRIs of 11 medulloblastoma patients who received cytotoxic therapy were reviewed. Pineal gland volumes could be determined for 12 of 15 patients with GCT and 7 of 11 patients with medulloblastoma. The study radiologists concurred that 2/12 GCT patients and 0/7 medulloblastoma patients had >= 50% volumetric reduction. When radiation is delivered as the sole treatment modality, the pineal region is included in at least the initial volume, but in certain clinical trials RT volume is reduced to only the suprasellar region if a complete response is achieved following pre-RT CHT. Noting changes in the "normal" pineal gland following CHT may indicate disease. CHT alone may not be sufficient to control this disease, even in cases in which a complete response is achieved. If the intent is to deliver RT to all areas of initial disease and this phenomenon can be demonstrated on a larger scale, inclusion of the pineal should be considered for patients demonstrating a substantial decrease in the size of the pineal gland after CHT. C1 [Rolnitzky, Linda; Allen, Jeffrey C.] NYU, Med Ctr, Hassenfeld Clin, Dept Pediat, New York, NY 10016 USA. [Rolnitzky, Linda; Allen, Jeffrey C.] NYU, Med Ctr, Dept Neurol & Biostat, New York, NY 10016 USA. [Desai, Neal; Heller, Gordon] Beth Israel Deaconess Med Ctr, Dept Radiol, New York, NY 10003 USA. [MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Allen, JC (reprint author), NYU, Med Ctr, Hassenfeld Clin, Dept Pediat, 160 E 32nd St, New York, NY 10016 USA. EM jeffrey.allen@NYUMC.org NR 23 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0888-0018 J9 PEDIATR HEMAT ONCOL JI Pediatr. Hematol. Oncol. PY 2008 VL 25 IS 1 BP 5 EP 15 DI 10.1080/08880010701665777 PG 11 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 256WV UT WOS:000252761500002 PM 18231950 ER PT J AU Guggenheim, MA Frost, JD Hrachovy, RA AF Guggenheim, Mary Anne Frost, James D., Jr. Hrachovy, Richard A. TI Time interval from a brain insult to the onset of infantile spasms SO PEDIATRIC NEUROLOGY LA English DT Article ID POSTTRAUMATIC EPILEPSY; WEST-SYNDROME; IMMUNIZATION; ENCEPHALITIS; PROGNOSIS; INJURY; MODEL AB The temporal latency between an encephalopathic event and the onset of infantile spasms cannot be determined in the majority of symptomatic cases (e.g. genetic conditions, cerebral malformations). However, we can measure this interval when a previously normal infant sustains brain injury followed by infantile spasms. This information has implications for understanding the underlying pathophysiologic basis for infantile spasms and, also, is germane to allegations that a close temporal relationship between vaccination and the onset of this seizure disorder establishes causation. We identified 19 published cases with sufficient information. The interval between brain injury and the onset of infantile spasms ranged from 6 weeks to 11 months (mean = 5.1 months). A similar temporal latency occurs in children with perinatal cerebral infarction and infantile spasms. We conclude that infantile spasms do not occur acutely following an encephalopathic event. This interval of weeks to months is consistent with prior studies indicating temporal latency between brain injury and the onset of other types of epilepsy, as well as with the previously proposed developmental desynchronization hypothesis. The findings refute claims that a close temporal association between an immunization and the onset of infantile spasms establishes causation. (C) 2008 by Elsevier Inc. All rights reserved. C1 [Guggenheim, Mary Anne] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA. [Frost, James D., Jr.; Hrachovy, Richard A.] Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Neurol, Houston, TX 77030 USA. [Frost, James D., Jr.; Hrachovy, Richard A.] Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Neurosci, Houston, TX 77030 USA. [Hrachovy, Richard A.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Guggenheim, MA (reprint author), 7575 Priest Pass Rd, Helena, MT 59601 USA. EM sweenycrik@wildblue.net NR 25 TC 13 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0887-8994 J9 PEDIATR NEUROL JI Pediatr. Neurol. PD JAN PY 2008 VL 38 IS 1 BP 34 EP 37 DI 10.1016/j.pediatrneurol.2007.08.005 PG 4 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 242VB UT WOS:000251753200006 PM 18054690 ER PT J AU Agarwalla, PK Dunn, IF Turner, CD Ligon, KL Schneider, KA Smith, ER AF Agarwalla, Pankaj K. Dunn, Ian F. Turner, Christopher D. Ligon, Keith L. Schneider, Katherine A. Smith, Edward R. TI A Novel TP53 Germline Mutation in a Family with a History of Multiple Malignancies: Case Report and Review of the Literature SO PEDIATRIC NEUROSURGERY LA English DT Article DE Choroid plexus carcinoma; Li-Fraumeni syndrome; TP53 protein ID LI-FRAUMENI-SYNDROME; CHOROID-PLEXUS CARCINOMA; NERVOUS-SYSTEM TUMORS; P53 GENE-MUTATIONS; BREAST-CANCER; CONSTITUTIONAL MUTATIONS; BRAIN-TUMORS; CHILDHOOD; NEOPLASMS; CHEMOTHERAPY AB Objective: Choroid plexus carcinoma (CPC) has been associated with TP53 germline mutations and Li-Fraumeni syndrome (LFS). We describe our finding of a novel germline mutation in the TP53 gene in a family with multiple malignancies and in association with a child presenting with CPC. Method: An 8-month-old male presented with seizure-like activity; imaging disclosed a 1.5-cm left ventricular mass confirmed to be CPC intra- and postoperatively. Family history was significant for a half-sister who died of a primary CNS sarcoma and a paternal grandmother negative for BRCA1, BRCA2, MLH1, and MSH2 mutations with multiple (> 6) LFS spectrum malignancies. Results: Familial TP53 testing revealed an A -> T substitution at DNA position 13071, creating a deleterious Asn -> Ile substitution at amino acid 131 in exon 5. Conclusion: Physicians treating patients with CPC should be attuned to reviewing family history for risk factors suggestive of genetic cancer syndromes such as LFS. These syndromes markedly influence both the patient and family members and may alter postoperative treatment regimens. Copyright (C) 2009 S. Karger AG, Basel C1 [Agarwalla, Pankaj K.; Dunn, Ian F.; Smith, Edward R.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Ligon, Keith L.] Childrens Hosp, Div Neuropathol, Boston, MA 02115 USA. [Turner, Christopher D.; Schneider, Katherine A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Smith, ER (reprint author), Childrens Hosp, Dept Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA. EM edward.smith@childrens.harvard.edu NR 64 TC 3 Z9 3 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1016-2291 J9 PEDIATR NEUROSURG JI Pediatr. Neurosurg. PY 2008 VL 44 IS 6 BP 501 EP 508 DI 10.1159/000187125 PG 8 WC Clinical Neurology; Pediatrics; Surgery SC Neurosciences & Neurology; Pediatrics; Surgery GA 394CP UT WOS:000262423300013 PM 19127094 ER PT S AU Dinkin, M Banks, M Rizzo, JF AF Dinkin, Marc Banks, Michelle Rizzo, Joseph F., III BE Lorenz, B Borruat, FX TI Imaging the Nerve Fiber Layer and Optic Disc SO PEDIATRIC OPHTHALMOLOGY, NEURO-OPHTHALMOLOGY, GENETICS SE Essentials in Ophthalmology LA English DT Article; Book Chapter ID SCANNING LASER POLARIMETRY; HEAD TOPOGRAPHIC MEASUREMENTS; RETINAL VEIN OCCLUSION; OPEN-ANGLE GLAUCOMA; VISUAL-FIELD LOSS; COHERENCE TOMOGRAPHY; AXONAL LOSS; THICKNESS MEASUREMENTS; ALZHEIMERS-DISEASE; CORNEAL POLARIZATION C1 [Dinkin, Marc] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rizzo, Joseph F., III] Massachusetts Eye & Ear Infirm, Dept Neuroophthalmol, Boston, MA 02114 USA. RP Dinkin, M (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 86 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1612-3212 BN 978-3-540-33679-2 J9 ESSENT OPHTHALMOL PY 2008 BP 99 EP 118 DI 10.1007/978-3-540-33679-2_7 D2 10.1007/978-3-540-33679-2 PG 20 WC Neurosciences; Ophthalmology; Pediatrics SC Neurosciences & Neurology; Ophthalmology; Pediatrics GA BMM20 UT WOS:000272789100007 ER EF